最終報告書

表　　題：2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのラットにおける反復投与毒性・生殖発生毒性併合試験

試験番号：SR17140

株式会社化合物安全性研究所

試験責任者の署名

表題　　：2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのラットにおける反復投与毒性・生殖発生毒性併合試験

試験番号：SR17140

株式会社化合物安全性研究所

試験責任者 [redacted] 2018 年 3 月 22 日

陳述書

表　　題：2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのラットにおける反復投与毒性･生殖発生毒性併合試験

試験番号：SR17140

本試験は，GLP 基準「新規化学物質等に係る試験を実施する試験施設に関する基準について」(平成 23 年 3 月 31 日 薬食発 0331 第 8 号・平成 23･03･29 製局第 6 号・環保企発第 110331010 号 厚生労働省医薬食品局長・経済産業省製造産業局長・環境省総合環境政策局長連名通知) を遵守して実施した.

本試験に用いた試験方法は，試験法ガイドライン「新規化学物質等に係る試験の方法について」(平成 23 年 3 月 31 日薬食発 0331 第 7 号･平成 23･03･29 製局第 5 号･環保企発第 110331009 号) ならびに「新規化学物質等に係る試験の方法について」の一部改正について (平成 27 年 12 月 21 日 薬生発 1221 第 1 号・20151209 製局第 1 号・環保企発第 1512211 号 厚生労働省医薬・生活衛生局長・経済産業省製造産業局長・環境省総合環境政策局長連名通知) に準拠した.

株式会社化合物安全性研究所

試験責任者 [redacted] 2018 年 3 月 22 日

信頼性保証書

表題　　：2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのラットにおける反復投与毒性・生殖発生毒性併合試験

試験番号　：SR17140

本試験は，株式会社化合物安全性研究所 QAU によって，下記のとおり査察された．

査察段階	査察日	試験責任者への報告日	運営管理者への報告日
試験計画書	2017 年 8 月 29 日	2017 年 8 月 29 日	2017 年 8 月 29 日
コンピュータプロトコール	2017 年 9 月 5 日	2017 年 9 月 5 日	2017 年 9 月 5 日
被験物質の管理	2017 年 9 月 11 日	2017 年 9 月 12 日	2017 年 9 月 12 日
投与液の調製	2017 年 9 月 11 日	2017 年 9 月 12 日	2017 年 9 月 12 日
群分け	2017 年 9 月 19 日	2017 年 9 月 19 日	2017 年 9 月 19 日
投与	2017 年 9 月 20 日	2017 年 9 月 20 日	2017 年 9 月 20 日
一般状態観察	2017 年 9 月 20 日	2017 年 9 月 20 日	2017 年 9 月 20 日
体重測定	2017 年 9 月 20 日	2017 年 9 月 20 日	2017 年 9 月 20 日
摂餌量測定	2017 年 9 月 20 日	2017 年 9 月 20 日	2017 年 9 月 20 日
性周期検査	2017 年 9 月 20 日	2017 年 9 月 20 日	2017 年 9 月 20 日
詳細な状態観察	2017 年 9 月 26 日	2017 年 9 月 26 日	2017 年 9 月 26 日
生殖能検査 (交配)	2017 年10 月 3 日 2017 年10 月 4 日	2017 年10 月 4 日	2017 年10 月 4 日
尿検査	2017 年10 月 11 日 2017 年10 月 12 日	2017 年10 月 12 日	2017 年10 月 12 日
機能検査	2017 年10 月 13 日	2017 年10 月 13 日	2017 年10 月 13 日
採血	2017 年10 月 18 日	2017 年10 月 18 日	2017 年10 月 18 日
血液学的検査	2017 年10 月 18 日	2017 年10 月 18 日	2017 年10 月 18 日
血液化学的検査	2017 年10 月 18 日	2017 年10 月 18 日	2017 年10 月 18 日
剖検・器官重量測定	2017 年10 月 18 日	2017 年10 月 18 日	2017 年10 月 18 日
病理組織学的検査 (標本作製)	2017 年10 月 20 日 2017 年10 月 24 日 2017 年10 月 25 日	2017 年10 月 25 日	2017 年10 月 25 日
分娩および哺育状態観察	2017 年10 月 26 日	2017 年10 月 26 日	2017 年10 月 26 日
新生児の一般状態観察	2017 年10 月 26 日	2017 年10 月 26 日	2017 年10 月 26 日
新生児の体重測定	2017 年10 月 26 日	2017 年10 月 26 日	2017 年10 月 26 日
新生児の剖検	2017 年10 月 30 日	2017 年10 月 30 日	2017 年10 月 30 日
病理組織学的検査 (鏡検)	2017 年11 月 17 日	2017 年11 月 17 日	2017 年11 月 17 日
試験計画書変更書 (No.1)	2017 年11 月 30 日	2017 年11 月 30 日	2017 年11 月 30 日
試験計画書変更書 (No.2)	2017 年12 月 13 日	2017 年12 月 13 日	2017 年12 月 13 日
試験計画書変更書 (No.2)*	2017 年12 月 14 日	2017 年12 月 14 日	2017 年12 月 14 日

査察段階	査察日	試験責任者への報告日	運営管理者への報告日
コンピュータプロトコール	2017年12月14日	2017年12月14日	2017年12月14日
被験物質のサンプリング	2017年12月19日	2017年12月19日	2017年12月19日
生データ	2018年 1月24日 2018年 1月25日 2018年 1月26日 2018年 1月30日 2018年 1月31日	2018年 1月31日	2018年 1月31日
最終報告書 (草案)：図表	2018年 1月24日 2018年 1月25日 2018年 1月26日 2018年 1月30日 2018年 1月31日	2018年 1月31日	2018年 1月31日
最終報告書 (草案)：本文	2018年 1月30日 2018年 1月31日	2018年 1月31日	2018年 1月31日
最終報告書	2018年 3月22日	2018年 3月22日	2018年 3月22日

*：改善内容の確認

プロセス調査による査察段階	査察日	試験責任者への報告日	運営管理者への報告日
動物受入・検疫・馴化	2017年 8月29日	2017年 8月29日	2017年 8月29日

本試験は，「新規化学物質等に係る試験を実施する試験施設に関する基準について」(平成23年3月31日 薬食発0331第8号・平成23･03･29製局第6号・環保企発第110331010号 厚生労働省医薬食品局長・経済産業省製造産業局長・環境省総合環境政策局長連名通知) に従い実施された.

本試験は，試験計画書に従って実施され，また，本報告書には当該試験に使用した方法および手順が正確に記載されており，試験成績には当該試験の実施過程において得られた生データが正確に反映していることを確認した.

株式会社化合物安全性研究所

QAU 責任者

[redacted] 2018年 3月 22日

目次

頁

表紙 ……1
試験責任者の署名 ……2
陳述書 ……3
信頼性保証書 ……4
目次 ……6
表題 ……9
試験番号 ……9
試験目的 ……9
試験実施基準および試験法ガイドライン ……9
動物愛護 ……9
試験委託者 ……10
試験施設 ……10
試験責任者 ……10
試験従事者およびその業務分担 ……10
試験日程 ……11
1 要約 ……12
2 緒言 ……13
3 材料および方法 ……13
4 成績 ……30
5 考察 ……39
6 試験成績の信頼性に影響を及ぼしたと思われる環境要因 ……41
7 資料の保存 ……42
8 参考資料 ……42

Figures

1-1 ~ 1-3 Body weight ……44
2-1 ~ 2-3 Food consumption ……47
3 Body weight of offspring ……50

Tables

1-1 ~ 1-9 Clinical sign ……51
2-1 ~ 2-5 Detailed clinical observation (in the cage) ……60
3-1 ~ 3-5 Detailed clinical observation (on the hand) ……65
4-1 ~ 4-5 Detailed clinical observation (in the open-field) ……70

5-1 ~ 5-3	Functional observations (on the desk)	75
6-1 ~ 6-3	Grip strength	78
7-1 ~ 7-3	Motor activity measurements	81
8-1 ~ 8-7	Body weight	84
9-1 ~ 9-7	Food consumption	91
10-1 ~ 10-22	Urinary findings	98
11-1 ~ 11-5	Hematological findings	120
12-1 ~ 12-7	Biochemical findings	125
13-1 ~ 13-7	Necropsy findings	132
14-1 ~ 14-7	Organ weight	139
15-1 ~ 15-23	Histopathological findings	146
16	Estrous cycles	169
17-1, 17-2	Reproductive performance	170
18-1 ~ 18-3	Delivery data	172
19	Clinical sign of offspring	175
20	Litter size and viability index of offspring	176
21	Body weight of offspring	177
22	Necropsy findings of offspring	178
Appendices		
1-1 ~ 1-29	Clinical sign	179
2-1 ~ 2-66	Detailed clinical observation (in the cage)	208
3-1 ~ 3-66	Detailed clinical observation (on the hand)	274
4-1 ~ 4-66	Detailed clinical observation (in the open-field)	340
5-1 ~ 5-10	Functional observations (on the desk)	406
6-1 ~ 6-10	Grip strength	416
7-1 ~ 7-10	Motor activity measurements	426
8-1 ~ 8-22	Body weight	436
9-1 ~ 9-22	Food consumption	458
10-1 ~ 10-40	Urinary findings	480
11-1 ~ 11-14	Hematological findings	520
12-1 ~ 12-14	Biochemical findings	534
13-1 ~ 13-15	Necropsy findings	548
14-1 ~ 14-20	Organ weight	563

15-1 ~ 15-30 Histopathological findings ····· 583
16-1 ~ 16-8 Estrous cycles and copulation ····· 613
17-1 ~ 17-8 Reproductive performance ····· 621
18-1 ~ 18-12 Delivery data ····· 629
19-1 ~ 19-8 Clinical sign of offspring ····· 641
20-1 ~ 20-4 Litter size and viability index of offspring ····· 649
21-1 ~ 21-4 Body weight of offspring ····· 653
22-1 ~ 22-4 Necropsy findings of offspring ····· 657
Annexes
1 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験 最終報告書 ····· 661
2 Photo 1, Photo 2 (病理組織写真) ····· 694

最終頁 694

表題

2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのラットにおける反復投与毒性・生殖発生毒性併合試験

試験番号

SR17140

試験目的

2-[(2-エチルヘキサン-1-イル)オキシ]エタノールを雌雄ラットに反復経口投与してその毒性ならびに性腺機能，交尾行動，受胎および分娩等の生殖に及ぼす毒性を検討した.

試験実施基準および試験法ガイドライン

試験実施基準 (GLP) :「新規化学物質等に係る試験を実施する試験施設に関する基準について」(平成 23 年 3 月 31 日 薬食発 0331 第 8 号・平成 23・03・29 製局第 6 号・環保企発第 110331010 号 厚生労働省医薬食品局長・経済産業省製造産業局長・環境省総合環境政策局長連名通知)

試験法ガイドライン :「新規化学物質等に係る試験の方法について」(平成 23 年 3 月 31 日薬食発 0331 第 7 号・平成 23・03・29 製局第 5 号・環保企発第 110331009 号) ならびに「新規化学物質等に係る試験の方法について」の一部改正について (平成 27 年 12 月 21 日薬生発 1221 第 1 号・20151209 製局第 1 号・環保企発第 1512211 号 厚生労働省医薬・生活衛生局長・経済産業省製造産業局長・環境省総合環境政策局長連名通知)

動物愛護

法規および基準等 :「動物の愛護及び管理に関する法律」(昭和 48 年 10 月 1 日 法律第 105 号，最終改正 平成 26 年 5 月 30 日 法律第 46 号)

「実験動物の飼養及び保管並びに苦痛の軽減に関する基準」(平成 18 年 4 月 28 日 環境省告示第 88 号，最終改正 平成 25 年 8 月 30 日 環境省告示第 84 号)

「動物実験に関する指針」(昭和 62 年 5 月 22 日承認 社団法人日本実験動物学会)

「厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針について」(平成 27 年 2 月 20 日科発 0220 第 1 号)

動物実験倫理　：本試験は，動物実験の必要性および苦痛の軽減等について試験施設の動物実験倫理委員会により審議され，運営管理者の承認を得ており，試験施設の動物実験倫理規程に準拠して実施した．

試験委託者

名称　：厚生労働省 医薬・生活衛生局

所在地　：東京都千代田区霞が関 1-2-2 (〒100-8916)

連絡先　：医薬品審査管理課 化学物質安全対策室

試験施設

名称　：株式会社化合物安全性研究所

所在地　：札幌市清田区真栄 363 番 24 (〒004-0839)

運営管理者　：[redacted]

試験責任者

氏名　：[redacted]

所属　：株式会社化合物安全性研究所 安全性研究部

試験従事者およびその業務分担

被験物質の調製　：[redacted]

動物管理　：

検疫・馴化　：

投与・観察・測定　：

臨床検査　：

病理検査　：

試験日程

試験開始日　　：2017 年　8 月 29 日

動物受入　　：2017 年　9 月　6 日

群分け　　：2017 年　9 月 19 日

実験開始日　　：2017 年　9 月 20 日

投与開始　　：2017 年　9 月 20 日

交配開始　　：2017 年 10 月 3 日

雄動物およびサテライト群雌動物投与終了

：2017 年 10 月 17 日

雄動物およびサテライト群雌動物(投与終了時剖検例)投与終了時剖検

：2017 年 10 月 18 日

新生児剖検開始　　：2017 年 10 月 30 日

母動物剖検開始　　：2017 年 10 月 31 日

サテライト群雄および雌動物(回復終了時剖検例)剖検

：2017 年 11 月　1 日

実験終了日　　：2017 年 12 月 31 日

試験終了日　　：2018 年　3 月 22 日

1 要約

2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの 0 (対照，トウモロコシ油)，100，300 および 1000 mg/kg を 1 群雌雄各 12 匹の Crl:CD(SD) ラットに，雄に対しては交配前，交配期間および交配後を含む計 28 日間，雌に対しては交配前，交配および妊娠期間，ならびに分娩後 4 日までの期間経口投与し，雌雄動物への反復投与による影響，雌雄動物の生殖および新生児の発生に及ぼす影響について検討した．また，0 (対照) および 1000 mg/kg について，雄動物は各 5 匹を選抜して 28 日間の投与終了後 14 日間の回復性を検討し，雌動物は各 10 匹の非交配群を別に設け，5 匹は 28 日間の投与終了時に剖検し，5 匹はさらに 14 日間の回復性についても検討した．

1.1 反復投与毒性

100 および 300 mg/kg 群では，一般状態，詳細な状態観察，機能検査，体重，摂餌量，尿検査，血液学的検査，血液化学的検査，器官重量，剖検および病理組織学的検査の各検査項目に，雌雄とも被験物質投与の影響は認められなかった．

1000 mg/kg 群では，投与期間中および投与終了時に被験物質投与に関連する毒性として，雌雄に外尿道口周囲被毛汚染，主試験群 (交配群) の雌に自発運動の低下，呼吸緩徐および前肢の握力の低値が認められた．また，雌雄に体重または体重増加量の低値，雄に摂餌量に低値がみられた．血液学的検査では，雄で赤血球数およびヘモグロビン濃度に有意な低値がみられた．また，雌雄に器官重量で肝臓重量の高値，剖検で肝臓の暗褐色化，病理組織学的検査で小葉中心性肝細胞肥大がみられた．これらの変化には，いずれも回復性がみられた．

したがって，本試験条件下における 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの反復投与毒性に関する無影響量 (NOEL) および無毒性量 (NOAEL) は雌雄ともに 300 mg/kg/day であると考えられた．

1.2 生殖発生毒性

生殖能検査では，1000 mg/kg 群まで，いずれの項目にも被験物質投与に関連する変化はみられなかった．

新生児の検査では，1000 mg/kg 群で生後 0 日の雌雄の体重に低値がみられた．出生児の外表，一般状態，生存率，剖検および性比では被験物質投与に関連する変化はみられなかった．

したがって，本試験条件下における 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの親動物の生殖に対する無影響量 (NOEL) および無毒性量 (NOAEL) は 1000 mg/kg/day，新生児の発生に対する無影響量 (NOEL) および無毒性量 (NOAEL) は 300 mg/kg/day と考えられた．

2 緒言

2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの 0 (対照，トウモロコシ油)，100，300 および 1000 mg/kg を 1 群雌雄各 12 匹の Crl:CD(SD) ラットに，雄に対しては交配前，交配期間および交配後を含む計 28 日間，雌に対しては交配前，交配および妊娠期間，ならびに分娩後 4 日までの期間経口投与し，雌雄動物への反復投与による影響，雌雄動物の生殖および新生児の発生に及ぼす影響について検討した．また，0 (対照) および 1000 mg/kg について，雄動物は各 5 匹を選抜して 28 日間の投与終了後 14 日間の回復性を検討し，雌動物は各 10 匹を別に設け，5 匹は 28 日間の投与終了時に剖検し，5 匹はさらに 14 日間の回復性についても検討した．

3 材料および方法

3.1 被験物質

名称　：2-[(2-エチルヘキサン-1-イル)オキシ]エタノール

別名　：2-(2-エチルヘキシルオキシ)エタノール [1)]

Ethylene Glycol 2-Ethylhexyl Ether[2)]

略称 [2)]　：EGEHE

CAS 番号　：1559-35-9

官報公示整理番号(化審法) [1)]：(2)-2424，(7)-97

化学式 [1)]　：$CH_3(CH_2)_3CH(C_2H_5)CH_2OCH_2CH_2OH$

構造式 [2)]　：

分子量 [1)]　：174.28

物理化学的性質 [1)]　：外観；澄明液体，無色 ～ わずかにうすい黄色

沸点，初留点及び沸騰範囲；229°C

引火点；106°C

比重・密度；0.88

ロット番号　： DSR0115 および ECP4663

含量　： DSR0115；99.7%，ECP4663；99.5%

製造業者　：[redacted]

被験物質管理責任者からの移管量：DSR0115；866.45 g，ECP4663；300.20 g

使用量　：DSR0115；860.83574 g，ECP4663；67.36681 g

試験施設受領日　：2017 年 6 月 26 日

ただし，株式会社日曹分析センターへ分析用サンプルとして送付した残余は2017年11月29日に受領

安定性　：投与操作終了後，各ロットの安定性を確認した．分析は株式会社日曹分析センターが実施し，分析結果を入手した．分析の結果，投与期間中被験物質は安定であったことが確認された (Annex 1).

保存条件　：冷蔵 (実測範囲 5.5～7.5°C)，気密，遮光.

保存場所および保存期間：被験物質保存室；2017年6月26日 (試験施設受領)～2017年11月3日 (最終調製)

取扱上の注意　：ゴム手袋，マスクおよび保護メガネを着用した．被験物質を分取する場合は，ガラス製の器具を用い，ガラス容器に分取した.

サンプリング　：ロット No. DSR0115 の 5.00004 g およびロット No. ECP4663 の 5.00001 g を採取し，試験施設の資料保存室に保存した.

3.2 対照物質 (媒体)

名称　：トウモロコシ油

ロット番号　：V7G1095

製造者　：ナカライテスク株式会社

被験物質管理責任者からの移管量：15000 g

保存場所および保存期間：被験物質保存室；2017年8月28日 (試験施設受領)～2017年11月8日 (最終投与)

保存条件　：室温 (実測範囲 20.9～23.2°C)

取扱上の注意　：特になし.

3.3 投与液の調製

調製方法　：投与量毎に被験物質を正確に秤量した．所定の濃度となるように媒体 (対照物質) を加えてメスアップし，スターラーを用いて溶解させた.

調製頻度　：投与用の調製液は1～9日の間隔で調製し，9日以内に使用した.

保存場所および保存期間：被験物質保存室；2017年9月11日 (初回調製)～2017年11月10日 (最終投与)

保存条件　：ガラス製の遮光気密容器に入れ，室温保存 (実測範囲 20.9～23.2°C)

調製上の注意　：被験物質はクリーンベンチ内で取扱い，調製の際にはマスク，ゴム手袋，保護メガネ等を着用し，吸入，眼，皮膚および衣類等との接触を避けた．調製および分取の際は，ガラス製の器具を使用した.

残余投与液の処置　：焼却処分するために産業廃棄物として回収した.

投与液の安定性の確認：20 および 200 mg/mL の濃度の調製液について，安定性を確認した. 調製および安定性の分析は株式会社日曹分析センターが実施し，分析結果を入手した. 分析の結果，室温保存 9 日 (調製日を 0 日として起算) の安定性が確認された (Annex 1).

投与液の濃度確認　：被験物質の全濃度に関する投与液中の濃度を，初回および雄の最終回投与に使用する調製液について確認した. 投与液の濃度分析は株式会社日曹分析センターが実施し，分析結果を入手した. 分析の結果，いずれの濃度も適切であることが確認された (Annex 1).

3.4 試験系

種・系統　：ラット，Crl:CD(SD)

微生物統御　：SPF

生産業者　：日本チャールス・リバー株式会社

微生物モニタリング　：動物生産業者よりデータを入手した.

動物選定理由　：ラットはこの種の試験で通常用いられている動物種であり，繁殖成績が安定していることと試験施設における背景対照データが利用できることからこの系統を選定した.

受入動物数　：雄 50 匹，雌 70 匹

受入動物週齢　：雌雄とも 8 週齢

出荷体重基準　：雄 240 ~ 330 g，雌 160 ~ 230 g

受入時体重範囲　：雄 261 ~ 296 g，雌 169 ~ 223 g

投与開始時週齢　：雌雄とも 10 週齢

群数　：雄 6 群，雌 8 群 (主試験群 雌雄各 4 群，サテライト群 雄 2 群，雌 非交配群 4 群)

各群動物数　：主試験群 雌雄各 12 匹，サテライト群 雌雄各 5 匹

3.5 検疫および馴化

期間　：検疫期間は受入日 (検疫 1 日) から検疫 6 日までの期間.
馴化期間は検疫期間を含めた群分け日までの期間.

方法　：一般状態を 1 日 1 回観察し，体重を受入時，検疫 6 日および群分け日に測定した. 馴化期間中の一般状態および体重には，いずれの動物にも異常は認められなかった.

性周期検査　：雌動物について，性周期検査を膣垢スメア塗抹法により群分け日までの9日間に行った．検査の結果，いずれの動物にも異常は認められなかった．

3.6 群分け

馴化期間中に実施した一般状態観察および体重測定，さらに雌については性周期検査の結果，異常がみられなかったすべての動物を群分けに用いた．コンピュータシステム (MiTOX，三井造船システム技研株式会社) を使用し，群分け日 (投与開始前日) の体重に基づいて層化無作為抽出法により各群の平均体重が均一になるように群分けを行った．ただし，雌については主試験群，サテライト群それぞれの平均体重が均一になるようにした．選抜した動物の体重範囲は，雄で 345 ~ 414 g，雌で 205 ~ 255 g であり，平均体重 (雄 379.6 g，雌 232.5 g) の ± 20%以内であった．群分けから外れた動物は，投与開始日に試験から除外し，試験施設の標準操作手順書に従って取り扱った．

3.7 動物およびケージの識別

動物　：群分け前は受入時に油性フェルトペンで尾部に印を付け，個体識別を行った．
群分け後は耳介に動物番号を入れ墨し，個体識別を行った．

飼育ケージ　：群分け前は試験 No.，識別 No.，性別，ケージ No.および種 / 系統を印字したラベルを各ケージの前面に標示した．
群分け後は試験 No.，動物 No.，性別，被験物質，用量 (経路) および種 / 系統を印字したラベルを各ケージの前面に標示した．交尾成立雌動物は上記と同様の項目を記載した新たなラベルに交換し，交尾成立日ならびに交尾成立日毎のグループ名を明記して表示した．分娩終了した雌は群分け後のラベルに交換して哺育 0 日ならびに哺育 0 日毎のグループ名を明記した．

3.8 動物飼育

3.8.1 飼育環境

飼育室番号　：306 号室

温度・湿度　：22 ± 3°C (実測範囲 19 ~ 24°C)，50 ± 20% (実測範囲 41 ~ 55%)

換気回数　：10 ~ 15 回/時間

照明時間　：人工照明 12 時間 (8:00 ~ 20:00)

3.8.2 飼育器材および飼育方法

ケージの種類　：ブラケット式金属製金網床ケージ (260W×380D×180H, mm)
ただし，交尾成立雌動物については妊娠 17 日から哺育 4 日まで同ケージの金網床を小型受皿に代えて実験動物用床敷 (ホワイトフレーク，日本チャールス・リバー株式会社) を使用した.

1 ケージあたりの収容動物数：検疫および馴化期間中は 2 匹ずつ，群分け後は 1 匹，交配期間中は雌雄各 1 匹，分娩後は 1 腹とした.

ケージ交換　：群分け時および投与 14 日に実施した．ただし，交尾成立雌動物については妊娠 0 日および 14 日に，交尾不成立雌動物は 2 週間ごとに実施した．回復終了時剖検例は回復 1 日に実施した.

受皿交換　：週 2 回実施した.

小型受皿の交換　：妊娠 20 日に実施した.

給餌器交換　：群分け時および投与 14 日に実施した．ただし，交尾成立雌動物については妊娠 0 日および 14 日に，交尾不成立雌動物は 2 週間ごとに実施した．回復終了時剖検例は回復 1 日に実施した.

自動給水装置の水抜き　：週 1 回実施した.

給水器　：尿検査時にのみ使用した.

室内の清掃　：1 日 1 回実施した.

室内の消毒　：塩素系消毒薬およびヨウ素系消毒薬を 1 週間単位で交互に使用する清拭消毒を 1 日 1 回実施した.

3.8.3 飼料

種類・名称　：固型飼料，CRF-1

ロット番号　：170413，170623

製造業者　：オリエンタル酵母工業株式会社

給餌方法　：金属製給餌器を用いて自由に摂取させた.
ただし，剖検前日の夕刻からは全例を絶食させた.

汚染物質等の確認　：試験に悪影響を及ぼす恐れのある汚染物質等の有無を使用した各ロットの飼料について分析した．分析はユーロフィン・フードアンドプロダクト・テスティング株式会社 (分析報告書：No. AR-17-JP-004218-01-JA，AR-17-JP-004984-01-JA) および飼料製造業者 (分析試験報告書：No. 17G03-050，17G03-077) が行い，分析データを飼料製造業者からロット毎に入手した．分析項目と許容値は試験施設の標準操作手順書に準拠した．分析の結果，いずれの項目にも許容値を超える値は認め

られなかった.

3.8.4 飲料水

種類　：札幌市水道水

給水方法　：自動給水装置あるいは給水器を用いて自由に摂取させた.

汚染物質等の確認　：試験に悪影響を及ぼす恐れのある汚染物質等について，2017 年 7 月 4 日および 2018 年 1 月 5 日に当該飼育室の配管の最末端から試料を採取して確認した．分析は日本衛生株式会社 (水質検査結果表：No. A291242，A295125) が行い，分析データを入手した．分析項目と許容値は試験施設の標準操作手順書に準拠した．分析の結果，いずれの項目にも許容値を超える値は認められなかった.

3.9 被験物質の投与

3.9.1 投与量の設定

投与量　：0 (対照)，100，300 および 1000 mg/kg/day

設定理由　：先に実施した予備試験 (SR17139)[3] (投与量 0, 30, 100, 300 および 1000 mg/kg/day，雌雄各 3 匹/群，14 日間反復経口投与) の結果，1000 mg/kg 群では，雌で摂餌量の低値，MCHC および HGB の低値，肝臓の絶対および相対重量の高値が認められたが，一般状態，体重および剖検には変化は認められなかった．300 mg/kg 以下の投与群では，被験物質投与に関連する変化は認められなかった．従って，本試験では 1000 mg/kg/day を高用量とし，以下公比約 3 として 300 および 100 mg/kg/day をそれぞれ中用量および低用量に設定した．そのほかに媒体のみを同様の方法で投与する対照群を設けた.

3.9.2 試験群の構成

試験群の構成と各群の動物番号は以下の通りとした.

試験群	投与量 (mg/kg)	濃度 (mg/mL)	投与容量 (mL/kg)	動物数(動物番号) 雄	動物数(動物番号) 雌	識別
＜主試験群＞						
対照	0	0	5.0	12 (10101~10112)	12 (50151~50162)	白
低用量	100	20	5.0	12 (10201~10212)	12 (50251~50262)	緑
中用量	300	60	5.0	12 (10301~10312)	12 (50351~50362)	青
高用量	1000	200	5.0	12 (10401~10412)	12 (50451~50462)	赤
＜サテライト群＞						

対照 (投与終了時剖検例)	0	0	5.0		5 (50551~50555)[b]	白
(回復終了時剖検例)	0	0	5.0	5 (10104, 10106, 10108, 10110, 10112)[a]	5 (50556~50560)[b]	白
高用量 (投与終了時剖検例)	1000	200	5.0		5 (50651~50655)[b]	赤
(回復終了時剖検例)	1000	200	5.0	5 (10404, 10406, 10407, 10409, 10412)[a]	5 (50656~50660)[b]	赤

対照群には，他の群と同様の方法で対照物質 (媒体) のみを投与した．

a：主試験群から投与 21 日の体重に基づいて，各群の体重の平均値に近似するように，各群から 5 匹ずつ選抜した．ただし，交配中の雄動物は選抜から除いた．

b：非交配群

3.9.3 投与

投与方法および投与経路：ディスポーザブル胃ゾンデおよびガラスシリンジを用いて強制的に胃内に経口投与した．

投与回数　：1 日 1 回，連日投与した．

投与時刻　：9：05～12：07

なお，分娩中の母動物には分娩終了後に投与した．

投与期間　：雄；交配 14 日前より 28 日間

雌；交配前 14 日間および交尾成立までの交配期間，さらに交尾成立例は妊娠期間および分娩後 4 日 (哺育 0 日を分娩後 0 日として起算) までの期間，分娩遅延例 (妊娠 25 日まで分娩が認められない交尾成立例) は妊娠 25 日まで，交尾不成立例は交配期間終了後 23 日までの期間

サテライト群については 28 日間

回復期間　：投与期間終了後 14 日間

投与液量　：各個体の投与液量は，投与日に最も近い測定日の体重に基づいて算出した．

投与方法，投与経路，投与回数および投与期間の選定理由：

試験法ガイドラインに準拠して選定した．

3.10 観察，測定および検査項目

投与開始日を投与 1 日 (Day 1)，投与 28 日の翌日を回復 1 日 (Recovery Day 1) と起算し，雄動物およびサテライト群の剖検日は投与 28 日の翌日 (Day 29) および回復 14 日の翌日 (Recovery Day 15) とした．雌動物の交配後は，交尾成立日を妊娠 0 日，分娩終了日を哺育 0 日と規定した．

3.10.1 反復投与毒性

3.10.1.1 一般状態観察

例数　：全例

期間　：投与 1 日から剖検日まで

頻度　：投与期間中は投与前および投与後の 1 日 2 回，回復期間中は午前および午後の 1 日 2 回以上，剖検日は午前中に 1 回観察した．

観察方法　：個々の動物の生死，外観，行動等について観察した．異常が認められる場合は，その症状ならびに症状の発現および消失について記録した．

3.10.1.2 詳細な状態観察

例数　：全例

時期　：投与開始前ならびに投与 7，14，21 および 28 日
主試験群の雌については，上記に加えて投与 35 および 42 日
回復期間中は，回復 7 および 14 日

観察方法　：あらかじめ定めたスコアリング基準を用いてスコア化した観察結果を記録した．

観察項目およびその方法：

[1] 体位･姿勢，呼吸状態，振戦･痙攣，常同行動 (回転・旋回)，異常行動 (自咬) をケージ外から観察した．

[2] 取り出し易さ，取扱い易さ，筋収縮性，立毛，被毛の状態，皮膚，眼･眼球および粘膜の外観，瞳孔径，流涙，流涎，その他分泌物の有無について，ケージから取り出す時に観察した．

[3] 歩行，運動協調性，環境刺激に対する反応，探索行動 (匂嗅ぎ・立上り)，排泄状態 (排尿・排糞)，常同行動 (身づくろい･くびふり)，異常行動 (後ずさり・異常発声)，攻撃性について，オープンフィールド内で観察した．

3.10.1.3 機能検査

例数　：各群の投与 21 日の体重の平均値に近似するように選抜した雄の各群 5 例およびサテライト群 (回復終了時剖検例) の雌ならびに主試験群の雌の分娩日の早いものから順に選抜した各群 5 例．

時期　：主試験群の雄およびサテライト群の雌は，投与 4 週 (投与 24 日) に実施した．投与 4 週の検査の結果，被験物質投与の影響が認められなかったことから回復 2 週の検査は実施しなかった．
主試験群の雌は哺育 4 日に実施した．

観察 / 測定方法　　：あらかじめ定めたスコアリング基準を用いてスコア化した観察結果あるいは測定機器による測定値を記録した.

観察項目およびその方法：

[1] 刺激に対する感覚運動反応：検査台上で以下を観察した.
視覚刺激，触覚刺激，聴覚刺激，痛覚刺激，固有受容器刺激，空中正向反射

[2] 握力：CPU ゲージ (アイコーエンジニアリング株式会社) を用いて前肢および後肢について各 3 回測定し，1 g 単位で記録した.

[3] 自発運動量：自発運動量測定装置 (スーパーメックスおよび CompAct，室町機械株式会社) を用いて，上記に引き続き，10 分間隔で 1 時間測定した.

3.10.1.4 体重測定

例数　　：全例

測定日　　：雄およびサテライト群の雌は，投与 1，4，7，14，21 および 28 日の投与前，回復 1，7 および 14 日ならびに剖検日.
主試験群の雌は，投与 1，4，7，14 日の投与前，妊娠 0，7，14 および 20 日の投与前，哺育 0 および 4 日の投与前ならびに分娩後 5 日の剖検日．ただし，分娩遅延例は妊娠 26 日 (剖検日) に，交尾不成立例については，投与 21，28，35，42，49 日の投与前および剖検日 (投与 51 日の翌日) にも測定した.

測定方法　　：電子式上皿天秤 (GX-2000，株式会社 エー・アンド・デイ) を用いて測定した.

体重増加量　　：以下の式により算出した.

<雄およびサテライト群の雌>

投与期間；

体重増加量 (g) = 投与 28 日体重 (g)－投与 1 日体重 (g)

回復期間；

体重増加量 (g) = 回復 14 日体重 (g)－回復 1 日体重 (g)

<主試験群の雌>

妊娠前投与期間；

体重増加量 (g)＝投与 14 日体重 (g)－投与 1 日体重 (g)

妊娠期間；

体重増加量 (g)＝妊娠 20 日体重 (g)－妊娠 0 日体重 (g)

哺育期間；

体重増加量 (g)＝哺育 4 日体重 (g)－哺育 0 日体重 (g)

3.10.1.5 摂餌量測定

例数　：全例

測定日　：雌雄とも交配中の週および剖検日を除き，体重測定と同じ日に実施した．

測定方法　：電子式上皿天秤 (GX-2000，株式会社 エー・アンド・デイ) を用いて測定した．

投与 1 日または回復 1 日に適当量を測定後ケージ毎に給餌し，その後は測定日に残餌量および給餌量を測定した．ただし，最終回の測定は残餌量のみとした．主試験群の雌については，妊娠 20 日および哺育 4 日は残餌量のみ，妊娠 0 日および哺育 0 日は給餌量のみ測定した．次に示す式により，摂餌量 (g/rat/day) を算出した．

$$\text{摂餌量 (g/rat/day)} = \frac{\text{給餌量 (g/rat)} - \text{残餌量 (g/rat)}}{\text{測定日間の日数 (day)}}$$

3.10.1.6 尿検査

例数　：雄は機能検査と同一の各群 5 例について，雌はサテライト群の回復終了時剖検例

時期　：投与 4 週 (投与 22～23 日) および回復 2 週 (回復 8～9 日).

採尿方法　：非絶食下でラット用代謝ケージ (KN-646，B-1 型，夏目製作所) を用いて採尿し，投与直後から約 3 時間 (実際の採尿時間：約 3～6 時間) の蓄尿で[1]～[9]を，また約 21 時間の蓄尿で[10]，[11]を実施した．[9] 沈渣については，遠心分離 (約 400 × *g*, 5 分, 4°C)した後に検査を行った．採取した尿は検査終了後廃棄した．

検査項目および検査方法：

[1]	pH	試験紙法
[2]	蛋白 (Protein)	試験紙法
[3]	糖 (Glucose)	試験紙法
[4]	ケトン体 (Ketone body)	試験紙法
[5]	ウロビリノーゲン (Urobilinogen)	試験紙法
[6]	ビリルビン (Bilirubin)	試験紙法
[7]	潜血反応 (Occult blood)	試験紙法
[8]	色調 (Color)	肉眼観察
[9]	尿沈渣 (Urinary sediments)	Sternheimer 染色法

[10]	尿量 (Urine Volume)	容量測定
[11]	比重 (Specific gravity)	屈折計法

[1]～[7] マルティスティックス，シーメンスヘルスケア・ダイアグノスティクス株式会社
[9] 顕微鏡 BH-2，オリンパス光学工業株式会社
[11] 尿比重屈折計ユリコン-S，株式会社アタゴ

3.10.1.7 血液学的検査

例数　：各群 5 例 (主試験群の雄は機能検査に用いた動物以外から動物番号の若い順に選抜した．主試験群の雌は機能検査と同一例，サテライト群は全例)

時期　：剖検時 [主試験群の雄およびサテライト群の雌 (投与終了時剖検例) は投与 28 日の翌日，主試験群の雌は分娩後 5 日，サテライト群の雄および雌 (回復終了時剖検例) は回復 14 日の翌日] に採血した．

検査方法　：夕刻からの一晩の絶食下 (16～21 時間) でラットをイソフルラン麻酔し，腹部大動脈より採血した．検査項目のうち [1]～[10] については EDTA・2K (ベノジェクト II 真空採血管，テルモ株式会社) で処理した血液約 1 mL を用い，[11]，[12] については 3.8%クエン酸ナトリウムで処理した血液約 1 mL (3.8%クエン酸ナトリウム溶液 0.1 mL+血液 0.9 mL) を遠心分離 (約 2000 × *g*，10 分，4°C) し，得られた血漿を用いた．主試験群の雌の血漿は，採取後凍結保存 (-80°C 設定) し，測定直前に融解して用いた．得られた血液および血漿は検査終了後廃棄した．全例の白血球分画が得られたため，白血球塗抹標本は作製しなかった．

検査項目および検査方法：

[1]	赤血球数 (RBC)	電気抵抗検出法
[2]	ヘマトクリット値 (HCT)	電気抵抗検出法
[3]	ヘモグロビン濃度 (HGB)	SLSヘモグロビン法
[4]	平均赤血球容積 (MCV)	RBC，HCT値より算出
[5]	平均赤血球ヘモグロビン量 (MCH)	RBC，HGB値より算出
[6]	平均赤血球ヘモグロビン濃度 (MCHC)	HCT，HGB値より算出
[7]	血小板数 (Platelet)	電気抵抗検出法
[8]	網赤血球数 (Reticulocyte)	フローサイトメトリー法
[9]	白血球数 (WBC)	フローサイトメトリー法
[10]	白血球分画 (Differential count of WBC)	フローサイトメトリー法
	1　好中球 (Neutrophil, $10^2/\mu L$)	
	2　好酸球 (Eosinophil, $10^2/\mu L$)	
	3　好塩基球 (Basophil, $10^2/\mu L$)	
	4　単球 (Monocyte, $10^2/\mu L$)	

	5　リンパ球 (Lymphocyte, $10^2/\mu L$)	
[11]	プロトロンビン時間 (PT)	トロンボプラスチン法
[12]	活性化部分トロンボプラスチン時間 (APTT)	エラジン酸法

[1]～[10] 自動血球分析装置 XT-2000 iV，シスメックス株式会社

[11]，[12] 全自動血液凝固測定装置 CA-620，シスメックス株式会社

3.10.1.8 血液化学的検査

例数　：血液学的検査と同一の各群 5 例

時期　：剖検時に採血した．

検査方法　：夕刻からの一晩の絶食下 (16～21 時間) でラットをイソフルラン麻酔し，腹部大動脈より採血した．検査項目のうち [1]，[5] については血液 1 mL あたりヘパリンナトリウム (ヘパリンナトリウム注 N「AY」，1000 単位/mL，エイワイファーマ株式会社) 約 20 単位で処理後，遠心分離 (約 2000 × g，10 分，4°C) して得られた血漿を用いて検査した．他の項目については分離剤入り試験管 (セパクリーン A，栄研器材株式会社) に血液を採取し，遠心分離 (約 2000 × g，10 分，4°C) して得られた血清を用いて検査した．主試験群の雌の血清および血漿は，採取後凍結保存 (-80°C 設定) し，測定直前に融解して用いた．また，血清の一部を甲状腺機能に関連するホルモン (TSH，T3 および T4) 測定用としてポリプロピレン製チューブ 4 本に約 150 μL ずつ分注して凍結保存 (−80°C 設定) した．しかし，病理検査において下垂体－甲状腺系への影響が認められなかったため，測定は実施せず，標本は廃棄した．検査終了後の血漿および血清は，−20°C 以下で凍結保存し，試験終了日までに廃棄した．

検査項目および検査方法：

[1]	AST	JSCC 法
[2]	ALT	JSCC 法
[3]	アルカリホスファターゼ (ALP)	JSCC 法
[4]	γ-GTP	L-γ-グルタミル-3-カルボキシ-4-ニトロアニリド基質法
[5]	グルコース (Glucose)	ヘキソキナーゼ法
[6]	総コレステロール (T-Cho)	酵素法
[7]	トリグリセリド (TG)	遊離グリセロール消去法
[8]	総ビリルビン (T-Bil)	酵素法
[9]	総胆汁酸 (TBA)	酵素サイクリング法
[10]	尿素窒素 (UN)	ウレアーゼ･LED 法
[11]	クレアチニン (Crea)	酵素法
[12]	ナトリウム (Na)	イオン選択電極 (ISE) 法

[13]	カリウム (K)	イオン選択電極 (ISE) 法
[14]	クロール (Cl)	イオン選択電極 (ISE) 法
[15]	カルシウム (Ca)	OCPC 法
[16]	無機リン (IP)	Fiske-Subba Row 法
[17]	総蛋白 (TP)	ビウレット法
[18]	A/G 比 (A/G ratio)	蛋白分画より算出
[19]	アルブミン (Albumin)	総蛋白と蛋白分画より算出
[20]	蛋白分画 (Protein fraction)	アガロースゲル電気泳動法
	1 アルブミン (Albumin, %)	
	2 α_1-グロブリン (α1-G, %)	
	3 α_2-グロブリン (α2-G, %)	
	4 β-グロブリン (β-G, %)	
	5 γ-グロブリン (γ-G, %)	

[1]～[17] 自動分析装置 7080 形，株式会社日立ハイテクノロジーズ

[18]，[20] 全自動電気泳動分析装置エパライザ 2 ジュニア，株式会社ヘレナ研究所

3.10.1.9 病理検査

3.10.1.9.1 剖検

例数　：全例

時期　：主試験群の雄およびサテライト群の雌 (投与終了時剖検例) は投与 28 日の翌日，主試験群の雌は分娩後 5 日 (哺育 4 日の翌日)，サテライト群の雄および雌 (回復終了時剖検例) は回復 14 日の翌日に剖検した．ただし，分娩遅延例は妊娠 26 日に，交尾不成立例は交配期間終了後 24 日 (投与 51 日の翌日) に実施した．

検査方法　：体外表を観察し，イソフルラン麻酔下で，血液検査実施例については腹部大動脈より採血後，放血により安楽死させ，全身の器官・組織を肉眼的に観察した．以下の器官・組織を 10%中性緩衝ホルマリン液に固定・保存した．眼球およびハーダー腺はデビッドソン液で固定・保存し，精巣および精巣上体はブアン液で固定，70%エタノールに保存した．肺については固定液を注入後浸漬固定した．左右のある器官については，左右とも固定・保存した．主試験群雌では，黄体数および着床数を数えた．

性周期の確認　：サテライト群の雌の全例について剖検日の剖検前に膣垢を採取し，ギムザ染色を施して，光学顕微鏡下で観察して性周期段階を確認した．このデータは器官重量または病理組織学的評価の補助とした．

器官･組織名　：脳 (大脳，小脳および脳橋)，脊髄，下垂体，胸腺，甲状腺，上皮小体，副腎，脾臓，心臓，食道，胃，肝臓，膵臓，顎下腺，十二指腸，空腸，

回腸 (パイエル板を含む), 盲腸, 結腸, 直腸, 気管, 肺, 腎臓, 膀胱, 精巣, 精巣上体, 前立腺, 精嚢 (凝固腺含む), 卵巣, 子宮 (角部および頸部), 膣, 眼球およびハーダー腺, 乳腺 (右腹部), 大腿骨 (骨髄を含む, 右), 腸間膜リンパ節, 下顎リンパ節, 骨格筋 (腓腹筋, 右) および坐骨神経.

3.10.1.9.2 器官重量測定

例数 : 全例

時期 : 剖検時

測定方法 : 電子式上皿天秤 (GR-200, 株式会社 エー・アンド・デイ) を用いて, 以下の器官の重量を測定した. 左右のある器官は左右合せて測定した.

器官・組織名 : 脳, 心臓, 肝臓, 腎臓, 精巣, 精巣上体, 精嚢 (凝固腺含む) ; 以上 (g)
下垂体, 甲状腺 (上皮小体含む), 脾臓, 胸腺, 副腎, 前立腺, 卵巣, 子宮 ; 以上 (mg)

相対重量の算出 : 絶対重量と剖検日に測定した体重から相対重量を算出した.

$$\text{相対重量 (g/100 g または mg/100 g)} = \frac{\text{絶対重量 (g または mg)}}{\text{剖検日体重 (g)}} \times 100$$

3.10.1.9.3 病理組織学的検査

例数 : 主試験群の雌雄およびサテライト群の雌 (投与終了時剖検例) は, 剖検時に固定・保存した対照群および高用量群の全器官・組織について標本作製を実施し, 全例について鏡検した. 鏡検の結果, 高用量群の雌雄で肝臓に被験物質投与の影響と考えられる変化が認められたため, 主試験群の低用量群および中用量群, 回復終了時剖検例についても雌雄の肝臓の病理組織学的検査を実施した. また, 剖検時にみられた肉眼的異常部位 (動物番号 50358 の膣, 動物番号 10104 の精巣上体) についても鏡検した.

検査方法 : パラフィン包埋後薄切し, ヘマトキシリン・エオジン染色標本を作製して鏡検した.

3.10.2 生殖発生毒性

3.10.2.1 性周期検査

例数 : 主試験群の雌の全例

期間 : 投与開始日から交尾成立まで.
交尾不成立例については交配 14 日まで.

方法 : ギムザ染色による膣垢塗抹標本を作製し, 光学顕微鏡下で性周期段階

を観察した.

判定　：性周期の各段階 (発情前期，発情期，発情後期および発情間期) を 4 日から 6 日の間隔で繰り返すものを正常とした.

投与 1 日から投与 14 日までの 14 日間について発情期間隔，発情回数および性周期異常の動物数を算出した.

3.10.2.2 生殖能検査

例数　：主試験群の雌雄の全例

時期・方法　：投与 14 日を交配開始日，交配開始日の翌日を交配 1 日とし，交配開始日の夕刻から，同試験群内の雌雄 1 対を交尾が確認されるまで 14 日間を限度として連続同居させた.

交配組み合せ　：同一群の雌雄を，雌の動物番号末尾 2 桁が雄の動物番号末尾 2 桁に 50 を足したものとなるよう組み合わせた.

交尾成立の確認方法　：膣内または受皿上に落下した膣栓，あるいは膣垢スメア標本中の精子確認により判定した. いずれかが認められた日を妊娠 0 日とした. 同居開始から交尾成立までの所要日数を計数した.

次式から群毎に交尾率を算出した.

$$\text{交尾率 (Copulation index, \%)} = \frac{\text{交尾成立動物数}}{\text{同居動物数}} \times 100$$

受胎能　：妊娠の確認を分娩の有無および剖検時に子宮内の着床痕の有無により行った. 動物番号 50151，50358，50453 および 50458 については，剖検時に子宮内に着床痕が確認されなかったため不妊と判断した.

次式から群毎に受胎率を算出した.

$$\text{受胎率 (Fertility index, \%)} = \frac{\text{受胎動物数}}{\text{交尾成立動物数}} \times 100$$

3.10.2.3 分娩および哺育状態観察

例数　：交尾成立した雌の全例

分娩観察　：交尾が確認された雌動物は全例自然分娩させた.

分娩状態を妊娠 21 日から 25 日まで，毎日少なくとも 3 回 (9：00，13：00 および 17：00) 観察した.

分娩終了の確認　：9：00 に母動物が児を巣の中に集めて腹の下に抱え込んでいるのが観察された場合に分娩終了とし，その日を哺育 0 日 (生後 0 日) とした.

次式から群毎に出産率を算出した.

$$出産率\ (\text{Gestation index},\ \%) = \frac{正常出産雌数}{妊娠雌数} \times 100$$

妊娠期間の算出　：妊娠 0 日から哺育 0 日までの期間の日数を計数した.

着床率の算出　：剖検時に各雌の子宮内の着床痕および卵巣の黄体数を計数した.
次式から腹毎に着床率を算出した.

$$着床率\ (\text{Implantation index},\ \%) = \frac{着床数}{黄体数} \times 100$$

出産児の観察　：生後 0 日のすべての出産児について生死を確認し，外表を観察した.
腹毎に生存児数と死亡児数とを計数し，それらの合計を出産児数とした. 次式から腹毎に出生率および生存児の外表異常児出現率を算出した.

$$出生率\ (\text{Birth index},\ \%) = \frac{生後\ 0\ 日の生存児数}{着床数} \times 100$$

外表異常児出現率(%) = (外表異常児数 / 出産生児数) ×100

外表異常児を持つ腹の頻度 = 外表異常児を持つ腹数 / 出産動物数

出産児の性比の算出　：生後 0 および 4 日に個々の児動物の性を肛門と生殖突起の間の長さで判定した. 死亡児を含めない生後 0 日の生存児を対象として群毎に以下を算出した.

$$生後\ 0\ 日の生存児の性比\ (\text{Sex ratio},\ \%) = \frac{雄生存児数}{雄生存児数 + 雌生存児数} \times 100$$

哺育 4 日の哺育率の算出：次式から群毎に算出した.

$$哺育率\ (\text{Nursing index},\ \%) = \frac{哺育\ 4\ 日に生存児を持つ雌数}{生児出産雌数} \times 100$$

3.10.2.4 新生児の一般状態観察

例数　：全例

頻度　：1 回／日

期間　：生後 0 日から生後 4 日 (剖検日) までとした.

観察方法　：生存または死亡の確認，一般状態を観察した.
死亡例は発見後速やかに剖検し，Whole body を 10%中性緩衝ホルマリン液で固定･保存した.

新生児生存率の算出　：生後 0 日および 4 日の新生児生存率を次式から腹毎に算出した.

$$生後0日の生存率\ (\text{Viability index, \%}) = \frac{生後0日の生存児数}{出産児数} \times 100$$

$$生後4日の生存率\ (\text{Viability index, \%}) = \frac{生後4日の生存児数}{生後0日の生存児数} \times 100$$

3.10.2.5 新生児の体重測定

例数・時期　：生存児全例について，生後0および4日に実施した．

測定方法　：電子式上皿天秤 (GX-2000，株式会社エー・アンド・デイ) を用いて個体別に測定し，0.1 g まで記録した．
雌雄毎に腹当たりの平均体重を求めた．

3.10.2.6 新生児の剖検

時期・例数　：生後4日に全例について実施した．

検査方法　：体外表 (口腔内を含む) を観察し，ペントバルビタールナトリウムの過剰投与 (腹腔内) により安楽死させ，全身の器官・組織を肉眼的に観察した．

3.11 統計学的方法

コンピュータシステム (MiTOX) を用いて実施した．

主試験群における握力 (3回の平均)，自発運動量，体重，体重増加量，摂餌量，尿量，血液学的検査，血液化学的検査，器官の絶対重量および相対重量，発情期間隔，発情回数，交尾所要日数および着床数，出産児数，出産時の生存児数および死亡児数，出生率，妊娠期間および外表異常児出現率の成績について群平均および標準偏差を算出し，Bartlett の検定法を行い，等分散性を解析した．等分散 ($p \geqq 0.05$) の場合は一元配置分散分析法で解析し，不等分散 ($p<0.05$) の場合は Kruskal-Wallis の検定法で解析した．一元配置分散分析の結果，有意差がみられた場合 ($p<0.1$) は Dunnett の検定法を用いて対照群との比較を行った．Kruskal-Wallis 法の解析の結果，有意差がみられた場合 ($p<0.1$) は Steel の検定法を用い対照群との比較を行った．なお，黄体数，着床率ならびに生後0日および4日の生存率は別途統計解析システム (三研システム株式会社) および SAS システムを用いて上記と同様の検定を実施した．

主試験群における詳細な状態観察，刺激に対する感覚運動反応，尿量を除く尿検査の成績について，Kruskal-Wallis の検定法で解析し，有意差がみられた場合 ($p<0.1$) は Steel の検定法を用いて対照群との比較を行った．

性周期の異常の発現率，交尾率，受胎率，出産率，生後0日の生存児の性比および外表異常児を持つ腹の頻度ならびに病理組織学的検査 (主試験群およびサテライト群) については，

Fisher の正確確率検定法を用いた．なお，哺育率は別途 SAS システムを用いて上記と同様の検定を実施した．

サテライト群における握力 (3 回の平均)，自発運動量，体重，体重増加量，摂餌量，尿量，血液学的検査，血液化学的検査，器官の絶対重量および相対重量の成績について，群平均および標準偏差を算出し，F 検定による等分散の解析を行った．等分散 ($p \geq 0.05$) の場合は Student の t 検定，不等分散 ($p<0.05$) の場合は Welch の検定を用いて対照群との比較を行った．

サテライト群における詳細な状態観察，刺激に対する感覚運動反応，尿量を除く尿検査の成績について，Wilcoxon の順位和検定を用いて対照群との比較を行った．

主試験群の雌で不妊が確認された動物については，妊娠期間の体重，体重増加量および摂餌量，器官重量ならびに病理組織学的検査のデータを統計検定から除外した．

対照群との比較検定については，5%未満を有意とした．

3.12 コンピュータシステムの利用

以下に示すデータの収集には MiTOX を使用した．

オンラインデータ　；親動物の一般状態，詳細な状態観察，機能検査 (刺激に対する感覚運動反応，握力)，体重，摂餌量，血液学的検査 (PT, APTT を除く)，血液化学的検査 (A/G 比，蛋白分画を除く)，器官重量，病理組織学的検査，新生児の体重

オフラインデータ　；機能検査 (自発運動量)，尿検査，血液学的検査 (PT，APTT)，血液化学的検査 (A/G 比，蛋白分画)，性周期検査，生殖能検査，着床数，生存児数，死亡児数，親動物の剖検，新生児の一般状態，外表異常および性別

コンピュータプロトコールには，データ収集の項目，日程等を登録した．

4 成績

4.1 反復投与毒性

4.1.1 一般状態

一般状態の成績を Table 1-1 ~ 1-9，Appendix 1-1 ~ 1-29 に示す．

[投与期間]

(1) 雄：主試験群

対照群，100 および 300 mg/kg 群では，いずれの動物にも異常は認められなかった．1000 mg/kg 群では，投与期間中に 7 例に外尿道口周囲被毛汚染が認められた．

(2) 雌：主試験群

対照群, 100 および 300 mg/kg 群では, いずれの動物にも異常は認められなかった. 1000 mg/kg 群では, 投与 3 日の投与後に 1 例に自発運動の低下および呼吸緩徐がみられた. この所見は翌日の投与前までに回復がみられた. また, 交配前および交配期間中に 6 例, 妊娠期間中に 4 例に外尿道口周囲被毛汚染が認められた. 哺育期間中では, いずれの動物にも異常は認められなかった.

(3) 雌：サテライト群 (非交配群)

対照群の動物には異常は認められなかった. 1000 mg/kg 群では, 投与期間中に 3 例に外尿道口周囲被毛汚染が認められた.

[回復期間]

(1) 雄：サテライト群

対照群および 1000 mg/kg 群のいずれの動物にも異常は認められなかった.

(2) 雌：サテライト群 (非交配群)

対照群および 1000 mg/kg 群のいずれの動物にも異常は認められなかった.

4.1.2 詳細な状態観察

詳細な状態観察の成績を Table 2-1 ~ 4-5, Appendix 2-1 ~ 4-66 に示す.

[投与期間]

(1) 雄：主試験群

100 および 300 mg/kg 群では, いずれの検査項目にも対照群と比較して有意な差は認められなかった. 1000 mg/kg 群では, 投与 28 日の検査で排尿に有意な高値がみられたが, 21 日までの検査に変化がみられないこと, 同群では投与開始前でもほぼ同様の頻度でみられていることから被験物質投与との関連はないと考えられた. その他の項目には被験物質投与群と対照群の間に有意な差は認められなかった.

(2) 雌：主試験群

いずれの項目にも被験物質投与群と対照群の間に有意な差は認められなかった.

(3) 雌：サテライト群 (非交配群)

1000 mg/kg 群では, いずれの項目にも対照群と比較して有意な差は認められなかった.

[回復期間]

(1) 雄：サテライト群

1000 mg/kg 群では, いずれの項目にも対照群と比較して有意な差は認められなかった.

(2) 雌：サテライト群 (非交配群)

1000 mg/kg 群では, いずれの項目にも対照群と比較して有意な差は認められなかった.

4.1.3 機能検査

刺激に対する感覚運動反応の成績を Table 5-1 ~ 5-3, Appendix 5-1 ~ 5-10, 握力の成績を Table 6-1 ~ 6-3, Appendix 6-1 ~ 6-10, 自発運動量の成績を Table 7-1 ~ 7-3, Appendix 7-1 ~ 7-10 に示す.

[投与期間]

(1) 雄：主試験群 (投与 4 週)

いずれの項目にも被験物質投与群と対照群の間に有意な差は認められなかった.

(2) 雌：主試験群 (哺育 4 日)

100 および 300 mg/kg 群では，いずれの検査項目にも対照群と比較して有意な差は認められなかった．1000 mg/kg 群では前肢の握力に有意な低値がみられた.

(3) 雌：サテライト群 (非交配群，投与 4 週)

1000 mg/kg 群では，いずれの項目にも対照群と比較して有意な差は認められなかった.

4.1.4 体重

体重の成績を Figure 1-1 ~ 1-3, Table 8-1 ~ 8-7, Appendix 8-1 ~ 8-22 に示す.

[投与期間]

(1) 雄：主試験群

100 および 300 mg/kg 群では，対照群と比較して有意な差は認められなかった．1000 mg/kg 群では，投与 21 および 28 日の体重および投与期間の体重増加量に有意な低値がみられた.

(2) 雌：主試験群

100 および 300 mg/kg 群では，対照群と比較して有意な差は認められなかった．1000 mg/kg 群では，妊娠 20 日，哺育 0 および 4 日の体重ならびに交配前期間および妊娠期間の体重増加量に有意な低値がみられた.

(3) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，投与期間の体重増加量に有意な低値がみられた.

[回復期間]

(1) 雄：サテライト群

1000 mg/kg 群では，回復 1 および 7 日に対照群と比較して有意な低値がみられたが，回復 14 日の体重と回復期間の体重増加量には変化は認められなかった.

(2) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，体重および体重増加量に対照群と比較して有意な差は認められなかった.

4.1.5 摂餌量

摂餌量の成績を Figure 2-1 ~ 2-3，Table 9-1 ~ 9-7，Appendix 9-1 ~ 9-22 に示す.

[投与期間]

(1) 雄：主試験群

100 mg/kg 群では，対照群と比較して有意な差は認められなかった．300 mg/kg 群では，投与 7 日に有意な低値が認められたが，体重に変化がなく，用量相関性もみられないことから被験物質投与との関連はないと考えられた．1000 mg/kg 群では，投与 4 日に有意な低値が認められた.

(2) 雌：主試験群

いずれの投与群においても対照群と比較して有意な差は認められなかった.

(3) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，投与 28 日に対照群と比較して有意な高値が認められたが，僅かな変化で，対照群の投与 14 日とほぼ同等の値であることから偶発的な変動と考えられた.

[回復期間]

(1) 雄：サテライト群

1000 mg/kg 群では，対照群と比較して有意な差は認められなかった.

(2) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，回復期間を通して対照群と比較して有意な高値が認められた.

4.1.6 尿検査

尿検査の成績を Table 10-1 ~ 10-22，Appendix 10-1 ~ 10-40 に示す.

[投与 4 週]

(1) 雄：主試験群

いずれの項目にも被験物質投与群と対照群の間に有意な差は認められなかった.

(2) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，いずれの項目にも対照群と比較して有意な差は認められなかった.

[回復 2 週]

(1) 雄：サテライト群

1000 mg/kg 群では，いずれの項目にも対照群と比較して有意な差は認められなかった.

(2) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，いずれの項目にも対照群と比較して有意な差は認められなかった.

4.1.7 血液学的検査

血液学的検査の成績を Table 11-1 ~ 11-5, Appendix 11-1 ~ 11-14 に示す.

[投与期間終了時]

(1) 雄：主試験群

100 mg/kg 群では，ヘモグロビン濃度および血小板数に対照群と比較して有意な低値がみられたが，用量相関性が認められないことから被験物質投与との関連はないと考えられた．300 mg/kg 群では，いずれの項目にも有意な差は認められなかった．1000 mg/kg 群では，赤血球数およびヘモグロビン濃度に有意な低値がみられた.

(2) 雌：主試験群

100 mg/kg 群では，好酸球数に対照群と比較して有意な低値がみられたが，用量相関性がみられないことから被験物質投与との関連性はないと考えられた．300 mg/kg 群では，いずれの項目にも有意な差は認められなかった．1000 mg/kg 群では，好酸球数に有意な低値がみられたが，個々の値は試験施設の背景データ [4] (平均値 ±2SD：0.88± 0.78×10^2/μL，例数：35) の範囲内であること，白血球数には変化がみられないことから毒性学的意義はないと考えられた.

(3) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，対照群と比較して平均赤血球容積に有意な高値，平均赤血球ヘモグロビン濃度に有意な低値が認められたが，赤血球数，ヘモグロビン濃度およびヘマトクリット値に変化がみられないことから毒性学的意義はないと考えられた.

[回復期間終了時]

(1) 雄：サテライト群

1000 mg/kg 群では，好中球数に対照群と比較して有意な高値が認められたが，投与終了時にはみられない変化であり，個々の値は試験施設の背景データ [5] (平均値 ±2SD：13.54± 9.90×10^2/μL，例数：40) の範囲内であることから被験物質投与との関連はないと考えられた.

(2) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，活性化部分トロンボプラスチン時間に対照群と比較して有意な延長が認められたが，投与終了時にはみられない変化であり，個々の値は試験施設の背景データ [5] (平均値 ±2SD：14.10± 4.74 sec，例数：15) の範囲内であることから被験物質投与との関連はないと考えられた.

4.1.8 血液化学的検査

血液化学的検査の成績を Table 12-1 ~ 12-7, Appendix 12-1 ~ 12-14 に示す.

[投与期間終了時]

(1) 雄：主試験群

100 mg/kg 群では，総コレステロールおよびカルシウムに対照群と比較して有意な高値がみられたが，用量相関性がみられないことから被験物質投与との関連性はないと考えられた．300 mg/kg 群では，いずれの項目にも有意な差は認められなかった．1000 mg/kg 群では，カルシウムに有意な高値がみられたが，無機リンに変化がみられないこと，個々の値は試験施設の背景データ [6] (平均値 ±2SD：9.41± 0.54 mg/dL，例数：35) の範囲内であることから被験物質投与との関連はないと考えられた．

(2) 雌：主試験群

100 mg/kg 群では対照群と比較して総ビリルビンおよび総コレステロールに有意な高値，300 mg/kg 群では総蛋白に有意な低値がみられたが，いずれも用量相関性がみられないことから被験物質投与との関連はないと考えられた．1000 mg/kg 群では，いずれの項目にも有意な差は認められなかった．

(3) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，対照群と比較して総ビリルビンに有意な低値，トリグリセリドに有意な高値がみられた．トリグリセリドについては，個々の値は試験施設の背景データ [6] (平均値 ± 2SD：13.2± 12.0 mg/dL，例数：35) の範囲内であることから毒性学的意義はないと考えられた．その他の検査項目には有意な差は認められなかった．

[回復期間終了時]

(1) 雄：サテライト群

1000 mg/kg 群では，いずれの検査項目にも対照群と比較して有意な差は認められなかった．

(2) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，総ビリルビンの低値が投与終了時に引き続きみられたが，回復終了時では個々の値は試験施設の背景データ [5] (平均値 ±2SD：0.077± 0.036 mg/dL，例数：35) の範囲内であった．その他に，グルコース，A/G 比，アルブミン分画に対照群と比較して有意な低値がみられた．これらは投与終了時にはみられない変化であり，グルコースについては個々の値は試験施設の背景データ [5] (平均値 ±2SD：136.9± 35.8 mg/dL，例数：35) の範囲内であることから，アルブミン分画および A/G 比については僅かな変化であり，総蛋白およびアルブミン量に変化がみられないことから，いずれも被験物質投与との関連はないと考えられた．

4.1.9 病理検査

4.1.9.1 剖検

剖検所見を Table 13-1 ~ 13-7，Appendix 13-1 ~ 13-15 に示す．

[投与期間終了時]

(1) 雄：主試験群

対照群，100 および 300 mg/kg 群では，異常所見は認められなかった．1000 mg/kg 群では，肝臓の暗褐色化が 4/7 例に認められた．

(2) 雌：主試験群

妊娠動物では，対照群の 1/11 例で腎臓の黄白色巣がみられたのみであり，100，300 および 1000 mg/kg 群では異常所見は認められなかった．

不妊例および交尾不成立例では，対照群および 300 mg/kg 群の不妊例各 1 例に膣の閉鎖および膣の粘稠液貯留/子宮の内腔拡張および漿液貯留が認められた．これらの肉眼所見部位の病理組織学的検査では，膣の中隔と子宮または膣の炎症性細胞浸潤がみられた．これらの変化は 1000 mg/kg 群ではみられないことから被験物質投与との関連はないと考えられた．

(3) 雌：サテライト群 (非交配群)

対照群では，異常所見は認められなかった．1000 mg/kg 群では，肝臓の暗褐色化が 2/5 例に認められた．

[回復期間終了時]

(1) 雄：サテライト群

対照群では，精巣上体尾部の黄白色巣が 1/5 例にみられた．1000 mg/kg 群では異常所見は認められなかった．

(2) 雌：サテライト群 (非交配群)

対照群および 1000 mg/kg 群ともに異常所見は認められなかった．

4.1.9.2 器官重量

器官重量の成績を Table 14-1 ~ 14-7，Appendix 14-1 ~ 14-20 に示す．

[投与期間終了時]

(1) 雄：主試験群

100 および 300 mg/kg 群では，対照群と比較して有意な差は認められなかった．1000 mg/kg 群では，肝臓および腎臓の相対重量に有意な高値がみられ，肝臓の絶対重量にも高値傾向がみられた．

(2) 雌：主試験群

100 mg/kg 群では，対照群と比較して有意な差は認められなかった．300 mg/kg 群では，肝臓および副腎の相対重量に有意な高値が認められた．その他に，脾臓の絶対および相対重量に有意な高値がみられたが，用量相関性がみられないことから被験物質投与との関連はないと考えられた．1000 mg/kg 群では，肝臓の絶対および相対重量，腎臓および副腎の相対重量の有意な高値，卵巣および子宮の絶対重量ならびに剖検日の体重の有意な低値が認められた．

(3) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，肝臓の絶対および相対重量の有意な高値，心臓の絶対重量の有意な低値が認められた．

[回復期間終了時]

(1) 雄：サテライト群

1000 mg/kg 群では，剖検時の体重に対照群と比較して有意な低値がみられた他には，いずれの器官重量にも変化は認められなかった．

(2) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，腎臓の相対重量に対照群と比較して有意な高値が認められた．しかし，僅かな変化であり，個々の値は試験施設の背景データ [5] (平均値 ±2SD：0.699± 0.104 g/100gBW，例数：35) の範囲内であること，投与終了時の腎臓の病理組織学的検査では被験物質投与の影響はみられないことから (4.1.9.3 病理組織学的検査)，毒性学的意義はないと考えられた．

4.1.9.3 病理組織学的検査

病理組織学的所見を Table 15-1 ~ 15-23，Appendix 15-1 ~ 15-30，Annex 2 に示す．

[投与期間終了時]

(1) 雄：主試験群

100 および 300 mg/kg 群では，肝臓に軽微な小肉芽腫および小葉周辺性肝細胞空胞化が散見されたが，対照群にもみられる変化であり，頻度の増加がみられないことからいずれも被験物質投与との関連はないと考えられた．

1000 mg/kg 群では，軽微な小葉中心性肝細胞肥大が 7/7 例にみられ，出現頻度に対照群と比較して有意な高値が認められた．その他には種々の所見が散見されたが，対照群あるいは試験施設の背景データ [7] に認められる所見であり，発生頻度の増加がみられないことから被験物質投与との関連はないと考えられた．

(2) 雌：主試験群

妊娠動物の 100 および 300 mg/kg 群では，肝臓に軽微な小肉芽腫および限局性壊死が散見されたが，対照群あるいは試験施設の背景データ [7] に認められる所見であり，頻度の増加がみられないことからいずれも被験物質投与との関連はないと考えられた．1000 mg/kg 群では，軽微な小葉中心性肝細胞肥大が 7/10 例にみられ，出現頻度に対照群と比較して有意な高値が認められた．その他には種々の所見が散見されたが，対照群または試験施設の背景データ [7] に認められる所見もしくは自然発生することが知られている変化 [8] であり，発生頻度の増加はみられないことから被験物質投与との関連はないと考えられた．

不妊例および交尾不成立例では，1000 mg/kg 群で軽微な小葉中心性肝細胞肥大が 1/2 例にみられた．その他には，肝臓および甲状腺の自然発生する種類の変化および肉眼異常部位の変化

がみられたのみであった.

(3) 雌：サテライト群 (非交配群)

1000 mg/kg 群では，軽微な小葉中心性肝細胞肥大が 3/5 例に認められた．その他に，種々の所見が散見されたが，対照群あるいは試験施設の背景データ [7]に認められる所見であり，発生頻度の増加はみられないことから被験物質投与と関連のない変化と考えられた.

[回復期間終了時]

(1) 雄：サテライト群

1000 mg/kg 群の肝臓では軽微な小肉芽腫が認められたが，自然発生する変化であり，頻度の増加がみられないことから被験物質投与との関連はないと考えられた.

(2) 雌：サテライト群 (非交配群)

1000 mg/kg 群の肝臓では軽微な小肉芽腫が認められたが，自然発生する変化であり，頻度の増加がみられないことから被験物質投与との関連はないと考えられた.

4.2 生殖発生毒性

4.2.1 性周期検査

性周期検査の成績を Table 16，Appendix 16-1 ~ 16-8 に示す.

交配前 14 日間の性周期観察において，性周期の異常の発現率，発情期間隔および発情回数には被験物質投与群と対照群の間に有意な差は認められなかった.

4.2.2 生殖能検査

生殖能検査の成績を Table 17-1 および 17-2，Appendix 17-1 ~ 17-8 に示す.

交尾率，受胎率および交尾所要日数には，被験物質投与群と対照群の間に有意な差は認められなかった.

4.2.3 分娩および哺育状態観察

分娩および哺育状態観察の成績を Table 18-1 ~ 18-3，Appendix 18-1 ~ 18-12 に示す.

黄体数，着床数，着床率，妊娠期間，出産率，出産児数，出産児の生存児数および死亡児数，性比ならびに哺育 4 日の哺育率には，被験物質投与群と対照群の間に有意な差は認められなかった．出生率の群平均では，1000 mg/kg 群で対照群と比較してやや低い値であったが，試験施設の背景データ [9] (試験の平均値：84.1 ~ 95.9 %，試験数：15) の範囲内の値であった．低値は 1 例 (動物番号 50452，38.5 %) によるものと考えられたが，この 1 例の値は出生率の個々の値の背景データ [10] (平均値：92.04 %，最小~最大：6.7 ~ 100.0 %，例数 253) の範囲内であった．その他の動物の平均は対照群とほぼ同じ値 (93.0 %) であることから，出生率の低値傾向

は偶発的なもので被験物質投与との関連はないと考えられた．また，いずれの出産生児にも外表異常は認められなかった．

4.2.4 新生児の一般状態および生存率

新生児の一般状態および生存率の成績を Table 19 および 20, Appendix 19-1 ~ 19-8 および 20-1 ~ 20-4 に示す．

いずれの投与群においても異常所見は認められなかった．

生後 0 日および 4 日の生存率には，被験物質投与群と対照群の間に有意な差は認められなかった．

4.2.5 新生児の体重

新生児の体重の成績を Figure 3，Table 21，Appendix 21-1 ~ 21-4 に示す．

100 および 300 mg/kg 群では，雌雄の生後 0 日および 4 日の体重に被験物質投与群と対照群の間に有意な差は認められなかった．1000 mg/kg 群では，生後 0 日に雄で有意な低値，雌で低値傾向がみられた．

4.2.6 新生児の剖検

新生児の剖検の成績を Table 22，Appendix 22-1 ~ 22-4 に示す．

生後 4 日の生存児の剖検では，対照群，100 および 300 mg/kg 群では異常は認められなかった．1000 mg/kg 群では，腎盂拡張が 2 例にみられたが，出現頻度が低いこと，対照群の死亡例 1 例にもみられる変化であることから被験物質投与との関連はないと考えられた．

生後 0-4 日の間に発見された死亡児では，被験物質投与群に異常は認められなかった．

5 考察

5.1 反復投与毒性

投与期間の一般状態では，1000 mg/kg 群の雌雄で外尿道口周囲被毛汚染が認められ，主試験群（交配群）の雌 1 例で投与 3 日に自発運動の低下および呼吸緩徐が認められた．機能検査では，1000 mg/kg 群の主試験群（交配群）の雌で前肢の握力の低値がみられた．体重または体重増加量では，1000 mg/kg 群の主試験群（交配群）の雌雄および非交配群の雌で有意な低値がみられ，摂餌量でも 1000 mg/kg 群の主試験群の雄で投与 4 日に有意な低値がみられた．これらは被験物質投与に起因する変化と考えられた．回復期間ではいずれの動物にも一般状態には異常はなく，雌雄の体重および雄の摂餌量には回復性が認められた．雌の回復期間中では摂餌量の有意な高値がみられたが，投与期間中の体重増加抑制に対する反動と考えられた．握力につ

いては，繁殖期間の雌のみにみられた変化であることから，回復性は不明であった．

投与終了時の血液学的検査では，1000 mg/kg 群の雄で赤血球数およびヘモグロビン濃度に有意な低値がみられた．これらの変化は被験物質の雄ラットへの 6 週間強制経口投与試験 (1.5-160 g/kg) でも報告されており [2]，被験物質投与の影響と考えられた．被験物質を含むエチレングリコールエーテル類のうち，アルキル基の炭素鎖が 1 または 2 のものは骨髄毒性に起因する汎血球減少症を引き起こし，アルキル基の炭素鎖がより長いものは赤血球膜の浸透圧脆弱性の増大による溶血を引き起こすことが知られている [11]．被験物質はアルキル基の最長の炭素鎖が 6 であり，網赤血球数，白血球数，血小板数および骨髄の病理組織学的検査で変化がみられないことから，赤血球数およびヘモグロビン濃度の低値は溶血によるものである可能性が考えられた．しかし，本試験でみられた変化は僅かなものであり，肝臓，脾臓のヘモジデリンの沈着，尿検査でのウロビリノーゲンの高値および血液化学的検査におけるビリルビンの高値等の溶血に伴う変化はみられず，機序は明らかではなかった．雄の回復終了時ではこれらの変化はみられず，回復性が認められた．

投与終了時の血液化学的検査では，1000 mg/kg 群の雌の非交配群でビリルビンの低値がみられ，被験物質投与に関連する変化と考えられたが，ビリルビンの低値は臨床的意義が乏しいことから，毒性学的意義はないと考えられた．この変化には，回復性が認められた．

投与終了時の病理学的検査では，1000 mg/kg 群の主試験群 (交配群) の雌雄および非交配群の雌で肝臓の絶対または相対重量の有意な高値または高値傾向，1000 mg/kg 群の主試験群の雄および非交配群の雌で肝臓の暗褐色化がみられた．これらは被験物質投与に起因する変化と考えられたが，肝臓の病理組織学的検査では 1000 mg/kg 群の雌雄に小葉中心性肝細胞肥大がみられたのみであった．血液化学的検査の肝機能に関するパラメーターにも被験物質投与の影響はみられないことから，肝臓の変化は異物に対する適応を示すものである可能性が考えられた [12]．これらの変化は，いずれも回復性が認められた．その他に，300 mg/kg 群の主試験群 (交配群) の雌の肝臓および副腎の相対重量，1000 mg/kg 群の主試験群 (交配群) の雌雄の腎臓および雌の副腎の相対重量に有意な高値，卵巣および子宮の絶対重量に有意な低値，非交配群の雌の心臓の絶対重量に有意な低値がみられたが，絶対重量または相対重量のいずれかのみの変化であること，病理組織学的検査で被験物質投与に関連する変化がみられなかったことから，剖検時の体重の低値に起因する変化または偶発的な変動と考えられた．

尿検査では，被験物質投与に関連する毒性はみられなかった．

以上のように，100 および 300 mg/kg 群では雌雄ともに被験物質投与の影響は認められなかった．1000 mg/kg 群では，雌雄に外尿道口周囲被毛汚染，体重または体重増加量の低値，雌に自発運動の低下，呼吸緩徐および前肢の握力の低値，雄に摂餌量，赤血球数およびヘモグロ

ビン濃度の低値，雌雄に肝臓重量の高値，肝臓の暗褐色化および小葉中心性肝細胞肥大がみられた．したがって，本試験条件下における 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの反復投与毒性に関する無影響量 (NOEL) および無毒性量 (NOAEL) は雌雄ともに 300 mg/kg/day であると考えられた．

5.2 生殖発生毒性

生殖能検査では，1000 mg/kg 群まで性周期の異常の発現率，発情期間隔および発情回数，交尾率，受胎率，交尾所要日数，黄体数，着床数，着床率，出生率，妊娠期間，出産率，出産児数，出産児の生存児数および死亡児数ならびに哺育 4 日の哺育率には，被験物質投与に関連する変化はみられなかった．

新生児では，1000 mg/kg 群で生後 0 日の雌雄の体重に有意な低値または低値傾向がみられ，被験物質投与による胎児の発育抑制と考えられた．出生児の外形検査，一般状態，剖検，性比および生存率では被験物質投与の影響は認められなかった．

以上のように，100 および 300 mg/kg 群では，親動物の生殖能および新生児の発生に被験物質投与に関連した変化は認められなかった．1000 mg/kg 群では，親動物の生殖能には被験物質投与の影響はみられなかったが，新生児では雌雄の体重に低値が認められた．したがって，本試験条件下における 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの親動物の生殖に対する無影響量 (NOEL) および無毒性量 (NOAEL) は 1000 mg/kg/day, 新生児の発生に対する無影響量 (NOEL) および無毒性量 (NOAEL) は 300 mg/kg/day と考えられた．

6 試験成績の信頼性に影響を及ぼしたと思われる環境要因

標準操作手順書からの逸脱：2017 年 11 月 3, 4, および 6 日の主試験群の雌の搬出登録の際，データ取得のために使用している 2 本の MiTOX プロトコール (生殖用および一般毒性用) の両方で搬出時の体重を取得した．再測定の必要はないことから，先に取得した値を採用とした．必要なデータは得られていることから，このことによる試験の信頼性に対する影響はないと考えられた．

尿検査の SOP では試験紙の精度管理は 2 週間を限度に実施すると規定されているが，回復群の尿検査において，精度管理を規定された期間内に実施していなかった (前回の精度管理から 15 日後に実施)．使用した試験紙は使用期限内のものであったことから，試験の信頼性に対する影響はないと考えられた．

予見することができなかった事態：雌のサテライト群の回復終了時剖検例の凝固系検査において，動物番号 50559 ではプロトロンビン時間が 160.0 秒であり，活性化部分トロンボプラス

チン時間では凝固が認められなかった．これらの値は対照群としては明らかな異常値であることから，この動物のプロトロンビン時間の値は集計から除外した．4 例のデータが得られており，統計検定は可能であることから，このことによる試験の信頼性に対する影響はないと考えられた．

その他に試験成績の信頼性に影響を及ぼしたと思われる環境要因はなかった．

7 資料の保存

7.1 資料の種類

以下を株式会社化合物安全性研究所の資料保存室に保存する．

1. 試験計画書および試験計画書変更書
2. 生データその他の記録文書
3. 最終報告書
4. 標本
5. 被験物質サンプル

7.2 保存期間

試験終了後 10 年間保存し，その後の保存については試験委託者との協議により決定する．

8 参考資料

1) 安全データシート 2-(2-エチルヘキシルオキシ)エタノール．2016.7.6.　和光純薬工業株式会社

2) National Toxicology Program. 2008. Chemical Information Profile for Ethylene Glycol 2-Ethylhexyl Ether[CAS No.1559-35-9]. Supporting Nomination for Toxicological Evaluation by the National Toxicology Program, 1-11.

3) 最終報告書：2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのラットにおける反復投与毒性・生殖発生毒性併合試験のための予備試験 (SR17139)，株式会社化合物安全性研究所 2017 年

4) 背景データ Crl:CD(SD) ラット(雌:分娩後 5 日) (2012-2017) 株式会社化合物安全性研究所 社内資料

5) 背景データ Crl:CD(SD) ラット(雌雄：15 ~ 16 週齢) (2012-2017) 株式会社化合物安全性研究所　社内資料

6) 背景データ Crl:CD(SD) ラット(雌雄：13 ~ 14 週齢) (2012-2017) 株式会社化合物安全性研究所　社内資料

7) Historical control data of Crl:CD(SD) rats: Histopathological findings (2006-2011)　株式会社化合

物安全性研究所　社内資料

8) Greaves P. 2012. Musculoskeletal System. In: Histopathology of Preclinical Toxicity Studies. Interpretation and Relevance in Drug Safety Studies. Fourth Edition. Academic Press, 157-206.

9) 背景データ Crl:CD(SD) ラット(繁殖データ) (2008-2017) 株式会社化合物安全性研究所　社内資料

10) 背景データ Crl:CD(SD) ラット(繁殖データ) (2012-2017) 株式会社化合物安全性研究所　社内資料

11) ECETOC. 2005. The Toxicology of Glycol Ethers and its Relevance to Man (Forth Edition) Volume I. Technical Report No.95. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium, 1-202.

12) Hall AP, et al. 2012. Liver Hypertrophy: A Review of Adaptive (Adverse and Non-adverse) Changes-Conclusions from the 3rd International ESTP Expert Workshop. Toxicologic Pathology, 971-994.

Figure 1 - 1

Study No. : SR17140

Body weight, Male

Period : Administration day 1-28, Recovery day 1-14

Species : Rat

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01
DT : Dunnett test (two-side), T2 : Student t-test (two-side)

Figure 1 - 2

Study No. : SR17140

Body weight, Female

Period : F0 before mating Day 1-14, F0 gestation Day 0-20, F0 lactation Day 0-4

Species : Rat

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01
DT : Dunnett test (two-side)

Figure 1 - 3

Study No. : SR17140

Body weight, Female (satellite)

Period : Administration day 1-28, Recovery day 1-14

Species : Rat

Not significantly different from EGEHE 0 mg/kg

Figure 2 - 1

Study No. : SR17140

Food consumption, Male

Period : Administration day 1-28, Recovery day 1-14

Species : Rat

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01
DT : Dunnett test (two-side)

Figure 2 - 2

Study No. : SR17140

Food consumption, Female

Period : F0 before mating Day 1-14, F0 gestation Day 0-20, F0 lactation Day 0-4

Species : Rat

Not significantly different from EGEHE 0 mg/kg

Figure 2 - 3

Study No. : SR17140

Food consumption, Female (satellite) Period : Administration day 1-28, Recovery day 1-14

Species : Rat

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01
T2 : Student t-test (two-side)

Figure 3

Study No. : SR17140

Body weight of offspring

Period : Postnatal Day 0-4

Species : Rat

Significantly different from EGEHE 0 mg/kg: * P<0.05
DT : Dunnett test (two-side)

Table 1 - 1

Study No. : SR17140

Clinical sign

Period : Administration Day 1-29

Sex : Male

Species : Rat

Test article		Day	1		2		3		4		5		6		7		8	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
0 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
100 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
300 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
1000 mg/kg	No abnormality		12	12	12	12	12	12	11	11	10	10	10	10	11	11	12	12
	Soil of perigenital fur		0	0	0	0	0	0	1	1	2	2	2	2	1	1	0	0

Test article		Day	9		10		11		12		13		14		15		16	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
0 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
100 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
300 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
1000 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	7	5	5
	Soil of perigenital fur		0	0	0	0	0	0	0	0	0	0	0	0	0	5	7	7

Test article		Day	17		18		19		20		21		22		23		24	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
0 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
100 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
300 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
1000 mg/kg	No abnormality		5	5	9	9	10	10	11	11	12	12	12	12	12	12	12	12
	Soil of perigenital fur		7	7	3	3	2	2	1	1	0	0	0	0	0	0	0	0

Test article		Day	25		26		27		28		29
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	3
EGEHE	n		12	12	12	12	12	12	12	12	7
0 mg/kg	No abnormality		12	12	12	12	12	12	12	12	7
EGEHE	n		12	12	12	12	12	12	12	12	12
100 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12
300 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	7
1000 mg/kg	No abnormality		12	12	12	12	12	12	12	12	7
	Soil of perigenital fur		0	0	0	0	0	0	0	0	0

Administration)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Table 1 - 2

Study No. : SR17140

Clinical sign

Period : F0 Day 1-52

Sex : Female

Species : Rat

Test article		Day	1		2		3		4		5		6		7		8	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
0 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
100 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
300 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
1000 mg/kg	No abnormality		12	12	12	12	12	10	11	11	11	11	10	9	9	9	10	10
	Decrease in locomotor activity		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
	Bradypnea		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
	Soil of perigenital fur		0	0	0	0	0	1	1	1	1	1	2	3	3	3	2	2

Test article		Day	9		10		11		12		13		14		15		16	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	8	8	7	7
0 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	8	8	7	7
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	8	8	7	7
100 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	8	8	7	7
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	6	6	5	5
300 mg/kg	No abnormality		12	12	12	12	12	12	12	12	12	12	12	12	6	6	5	5
EGEHE	n		12	12	12	12	12	12	12	12	12	12	12	12	8	8	4	4
1000 mg/kg	No abnormality		10	10	10	10	10	10	10	10	10	10	11	11	3	3	0	0
	Decrease in locomotor activity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Soil of perigenital fur		2	2	2	2	2	2	2	2	2	2	1	1	5	5	4	4

Test article		Day	17		18		19		20		21		22		23		24	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		4	4	2	2	2	2	2	2	1	1	1	1	1	1	0	0
0 mg/kg	No abnormality		4	4	2	2	2	2	2	2	1	1	1	1	1	1	0	0
EGEHE	n		4	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1
100 mg/kg	No abnormality		4	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EGEHE	n		4	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
300 mg/kg	No abnormality		4	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EGEHE	n		3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
1000 mg/kg	No abnormality		0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	Decrease in locomotor activity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Soil of perigenital fur		3	3	1	1	1	1	0	0	0	0	0	0	0	0	0	0

F0)1 : Pre-dosing, 2 : Post-dosing

Table 1 - 3

Study No. : SR17140

Clinical sign

Period : F0 Day 1-52

Sex : Female

Species : Rat

Test article		Day	25		26		27		28		29		30		31		32	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0 mg/kg	No abnormality		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EGEHE	n		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
100 mg/kg	No abnormality		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EGEHE	n		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
300 mg/kg	No abnormality		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EGEHE	n		1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
1000 mg/kg	No abnormality		1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	Decrease in locomotor activity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Soil of perigenital fur		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Test article		Day	33		34		35		36		37		38		39		40	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0 mg/kg	No abnormality		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EGEHE	n		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
100 mg/kg	No abnormality		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EGEHE	n		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
300 mg/kg	No abnormality		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EGEHE	n		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1000 mg/kg	No abnormality		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Decrease in locomotor activity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Soil of perigenital fur		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Test article		Day	41		42		43		44		45		46		47		48	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0 mg/kg	No abnormality		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EGEHE	n		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
100 mg/kg	No abnormality		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EGEHE	n		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
300 mg/kg	No abnormality		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EGEHE	n		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1000 mg/kg	No abnormality		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Decrease in locomotor activity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Soil of perigenital fur		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

F0)1 : Pre-dosing, 2 : Post-dosing

Table 1 - 4

Study No. : SR17140

Clinical sign

Period : F0 Day 1-52

Sex : Female

Species : Rat

Test article		Day	49		50		51		52
Dose	Clinical signs	Time	1	2	1	2	1	2	3
EGEHE	n		0	0	0	0	0	0	0
0 mg/kg	No abnormality		0	0	0	0	0	0	0
EGEHE	n		1	1	1	1	1	1	1
100 mg/kg	No abnormality		1	1	1	1	1	1	1
EGEHE	n		0	0	0	0	0	0	0
300 mg/kg	No abnormality		0	0	0	0	0	0	0
EGEHE	n		0	0	0	0	0	0	0
1000 mg/kg	No abnormality		0	0	0	0	0	0	0
	Decrease in locomotor activity		0	0	0	0	0	0	0
	Bradypnea		0	0	0	0	0	0	0
	Soil of perigenital fur		0	0	0	0	0	0	0

F0)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Table 1 - 5

Study No. : SR17140

Clinical sign

Period : F0 gestation Day 0-22

Sex : Female

Species : Rat

Test article		Day	0		1		2		3		4		5		6		7	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
0 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
100 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
300 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
1000 mg/kg	No abnormality		8	8	8	8	8	8	10	10	10	10	10	10	10	10	10	10
	Soil of perigenital fur		2	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0

Test article		Day	8		9		10		11		12		13		14		15	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
0 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
100 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
300 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
1000 mg/kg	No abnormality		10	10	10	10	10	10	9	9	9	9	9	9	9	9	10	10
	Soil of perigenital fur		0	0	0	0	0	0	1	1	1	1	1	1	1	1	0	0

Test article		Day	16		17		18		19		20		21		22	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11	11	1	1
0 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11	11	1	1
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11	11	3	3
100 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11	11	3	3
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11	11	6	6
300 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11	11	6	6
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10	10	3	3
1000 mg/kg	No abnormality		10	10	10	10	10	10	10	10	10	10	10	10	3	3
	Soil of perigenital fur		0	0	0	0	0	0	0	0	0	0	0	0	0	0

F0 gestation)1 : Pre-dosing, 2 : Post-dosing

Table 1 - 6

Study No. : SR17140

Clinical sign

Period : F0 lactation Day 0-5

Sex : Female

Species : Rat

Test article		Day	0		1		2		3		4		5
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	3
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11
0 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11
100 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11
EGEHE	n		11	11	11	11	11	11	11	11	11	11	11
300 mg/kg	No abnormality		11	11	11	11	11	11	11	11	11	11	11
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10
1000 mg/kg	No abnormality		10	10	10	10	10	10	10	10	10	10	10

F0 lactation)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Table 1 - 7

Study No. : SR17140

Clinical sign

Period : Administration Day 1-29

Sex : Female (satellite)

Species : Rat

Test article		Day	1		2		3		4		5		6		7		8	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
0 mg/kg	No abnormality		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
1000 mg/kg	No abnormality		10	10	10	10	10	9	9	9	9	9	8	8	8	8	9	8
	Soil of perigenital fur		0	0	0	0	0	1	1	1	1	1	2	2	2	2	1	2

Test article		Day	9		10		11		12		13		14		15		16	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
0 mg/kg	No abnormality		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
1000 mg/kg	No abnormality		8	8	8	8	9	9	10	10	10	10	10	10	10	10	10	10
	Soil of perigenital fur		2	2	2	2	1	1	0	0	0	0	0	0	0	0	0	0

Test article		Day	17		18		19		20		21		22		23		24	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
0 mg/kg	No abnormality		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
EGEHE	n		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
1000 mg/kg	No abnormality		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	Soil of perigenital fur		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Test article		Day	25		26		27		28		29
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	3
EGEHE	n		10	10	10	10	10	10	10	10	5
0 mg/kg	No abnormality		10	10	10	10	10	10	10	10	5
EGEHE	n		10	10	10	10	10	10	10	10	5
1000 mg/kg	No abnormality		10	10	10	10	10	10	10	10	5
	Soil of perigenital fur		0	0	0	0	0	0	0	0	0

Administration)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Table 1 - 8

Study No. : SR17140

Clinical sign

Period : Recovery Day 1-15

Sex : Male

Species : Rat

Test article			Day	1		2		3		4		5		6		7		8	
Dose		Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n			5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
0 mg/kg	No abnormality			5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EGEHE	n			5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	No abnormality			5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

Test article			Day	9		10		11		12		13		14		15
Dose		Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	3
EGEHE	n			5	5	5	5	5	5	5	5	5	5	5	5	5
0 mg/kg	No abnormality			5	5	5	5	5	5	5	5	5	5	5	5	5
EGEHE	n			5	5	5	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	No abnormality			5	5	5	5	5	5	5	5	5	5	5	5	5

Recovery)1 : AM, 2 : PM, 3 : Necropsy day

Table 1 - 9

Study No. : SR17140

Clinical sign

Period : Recovery Day 1-15

Sex : Female (satellite)

Species : Rat

Test article		Day	1		2		3		4		5		6		7		8	
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
EGEHE	n		5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
0 mg/kg	No abnormality		5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EGEHE	n		5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	No abnormality		5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

Test article		Day	9		10		11		12		13		14		15
Dose	Clinical signs	Time	1	2	1	2	1	2	1	2	1	2	1	2	3
EGEHE	n		5	5	5	5	5	5	5	5	5	5	5	5	5
0 mg/kg	No abnormality		5	5	5	5	5	5	5	5	5	5	5	5	5
EGEHE	n		5	5	5	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	No abnormality		5	5	5	5	5	5	5	5	5	5	5	5	5

Recovery)1 : AM, 2 : PM, 3 : Necropsy day

Table 2 - 1

Study No. : SR17140

Detailed clinical observation (in the cage)

Sex : Male

Species : Rat

Stage	Group		Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Stereotype		Bizarre behavior
						Rolling	Repetitive circling	Self biting
			1	1	1	0	0	1
Pre	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 7	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 14	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 21	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 28	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.
Not significantly different from EGEHE 0 mg/kg

Table 2 - 2

Study No. : SR17140

Detailed clinical observation (in the cage)

Sex : Female

Species : Rat

Stage	Group		Body position/ Posture 1	Respiratory pattern 1	Tremor/ Convulsion 1	Stereotype Rolling 0	Stereotype Repetitive circling 0	Bizarre behavior Self biting 1
Pre	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 7	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 14	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 21	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 28	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 35	0 mg/kg	n	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12
Day 42	0 mg/kg	n	8	8	8	8	8	8
	100 mg/kg	n	9	9	9	9	9	9
	300 mg/kg	n	8	8	8	8	8	8
	1000 mg/kg	n	8	8	8	8	8	8

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.
Not significantly different from EGEHE 0 mg/kg

Table 2 - 3

Study No. : SR17140

Detailed clinical observation (in the cage)
Sex : Female (satellite)

Species : Rat

Stage	Group		Body position/ Posture 1	Respiratory pattern 1	Tremor/ Convulsion 1	Stereotype Rolling 0	Stereotype Repetitive circling 0	Bizarre behavior Self biting 1
Pre	0 mg/kg	n	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10
Day 7	0 mg/kg	n	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10
Day 14	0 mg/kg	n	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10
Day 21	0 mg/kg	n	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10
Day 28	0 mg/kg	n	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.
Not significantly different from EGEHE 0 mg/kg

Table 2 - 4

Study No. : SR17140

Detailed clinical observation (in the cage)

Sex : Male

Species : Rat

Stage	Group		Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Stereotype		Bizarre behavior
						Rolling	Repetitive circling	Self biting
			1	1	1	0	0	1
Recovery Day 7	0 mg/kg	n	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	5	5
Recovery Day 14	0 mg/kg	n	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.
Not significantly different from EGEHE 0 mg/kg

Table 2 - 5

Study No. : SR17140

Detailed clinical observation (in the cage)
Sex : Female (satellite)

Species : Rat

Stage	Group		Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Stereotype		Bizarre behavior
						Rolling	Repetitive circling	Self biting
			1	1	1	0	0	1
Recovery Day 7	0 mg/kg	n	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	5	5
Recovery Day 14	0 mg/kg	n	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.
Not significantly different from EGEHE 0 mg/kg

Table 3 - 1

Study No. : SR17140

Detailed clinical observation (on the hand)

Sex : Male

Species : Rat

Stage	Group		Ease of Removal 1	Ease of Handling 1	Muscle tone 2	Piloerection 1	Fur 1	Eyes 1	Mucous membranes 0	Skin 1	Pupil size 1	Lacrimation 1	Salivation 1	Secretions/ Excretions 0
Pre	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 7	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 14	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 21	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 28	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.
Not significantly different from EGEHE 0 mg/kg

Table 3 - 2

Study No. : SR17140

Detailed clinical observation (on the hand)

Sex : Female

Species : Rat

Stage	Group		Ease of Removal 1	Ease of Handling 1	Muscle tone 2	Piloerection 1	Fur 1	Eyes 1	Mucous membranes 0	Skin 1	Pupil size 1	Lacrimation 1	Salivation 1	Secretions/ Excretions 0
Pre	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 7	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 14	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 21	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 28	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 35	0 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	12	12	12	12	12	12	12
Day 42	0 mg/kg	n	8	8	8	8	8	8	8	8	8	8	8	8
	100 mg/kg	n	9	9	9	9	9	9	9	9	9	9	9	9
	300 mg/kg	n	8	8	8	8	8	8	8	8	8	8	8	8
	1000 mg/kg	n	8	8	8	8	8	8	8	8	8	8	8	8

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.
Not significantly different from EGEHE 0 mg/kg

Table 3 - 3

Study No. : SR17140

Detailed clinical observation (on the hand)
Sex : Female (satellite)

Species : Rat

Stage	Group		Ease of Removal 1	Ease of Handling 1	Muscle tone 2	Piloerection 1	Fur 1	Eyes 1	Mucous membranes 0	Skin 1	Pupil size 1	Lacrimation 1	Salivation 1	Secretions/ Excretions 0
Pre	0 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10
Day 7	0 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10
Day 14	0 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10
Day 21	0 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10
Day 28	0 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	10	10	10	10	10	10	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.
Not significantly different from EGEHE 0 mg/kg

Table 3 - 4

Study No. : SR17140

Detailed clinical observation (on the hand)

Sex : Male

Species : Rat

Stage	Group		Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation	Secretions/ Excretions
			1	1	2	1	1	1	0	1	1	1	1	0
Recovery Day 7	0 mg/kg	n	5	5	5	5	5	5	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	5	5	5	5	5	5	5	5
Recovery Day 14	0 mg/kg	n	5	5	5	5	5	5	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	5	5	5	5	5	5	5	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.
Not significantly different from EGEHE 0 mg/kg

Table 3 - 5

Study No. : SR17140

Detailed clinical observation (on the hand)
Sex : Female (satellite)

Species : Rat

Stage	Group		Ease of Removal 1	Ease of Handling 1	Muscle tone 2	Piloerection 1	Fur 1	Eyes 1	Mucous membranes 0	Skin 1	Pupil size 1	Lacrimation 1	Salivation 1	Secretions/ Excretions 0
Recovery Day 7	0 mg/kg	n	5	5	5	5	5	5	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	5	5	5	5	5	5	5	5
Recovery Day 14	0 mg/kg	n	5	5	5	5	5	5	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	5	5	5	5	5	5	5	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.
Not significantly different from EGEHE 0 mg/kg

Table 4 - 1

Study No. : SR17140

Detailed clinical observation (in the open-field)

Sex : Male

Species : Rat

Stage	Group		Gait 1	Co-ordination of movement 1	Reactivity to stimuli 1	Searching 1	Urination 0	Urination 1		Defecation 0	Defecation 1	Stereotype: Excessive grooming 0	Stereotype: Unusual head movement 0	Bizarre behavior: Walking backward 1	Bizarre behavior: Vocalization 1	Aggression 1
Pre	0 mg/kg	n	12	12	12	12	9	3		10	2	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	7	5		8	4	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	5	7		5	7	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	6	6		9	3	12	12	12	12	12
Day 7	0 mg/kg	n	12	12	12	12	9	3		12	0	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	10	2		12	0	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	10	2		12	0	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	9	3		10	2	12	12	12	12	12
Day 14	0 mg/kg	n	12	12	12	12	10	2		11	1	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	9	3		12	0	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	0		9	3	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	11	1		10	2	12	12	12	12	12
Day 21	0 mg/kg	n	12	12	12	12	9	3		11	1	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	10	2		11	1	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	8	4		9	3	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	10	2		9	3	12	12	12	12	12
Day 28	0 mg/kg	n	12	12	12	12	11	1		11	1	12	12	12	12	12
	100 mg/kg	n	12	12	12	12	10	2		12	0	12	12	12	12	12
	300 mg/kg	n	12	12	12	12	10	2		11	1	12	12	12	12	12
	1000 mg/kg	n	12	12	12	12	5	7	ST $	10	2	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.
Significantly different from EGEHE 0 mg/kg: $ P<0.05
ST : Steel test (two-side)

Table 4 - 2

Study No. : SR17140

Detailed clinical observation (in the open-field)

Sex : Female

Species : Rat

Stage	Group		Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination		Defecation		Stereotype: Excessive grooming		Stereotype: Unusual head movement	Bizarre behavior: Walking backward	Bizarre behavior: Vocalization	Aggression
			1	1	1	1	0	1	0	1	0	1	0	1	1	1
Pre	0 mg/kg	n	12	12	12	12	12	0	11	1	12	0	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	0	11	1	12	0	12	12	12	12
	300 mg/kg	n	12	12	12	12	11	1	11	1	12	0	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
Day 7	0 mg/kg	n	12	12	12	12	11	1	12	0	12	0	12	12	12	12
	100 mg/kg	n	12	12	12	12	11	1	12	0	12	0	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
Day 14	0 mg/kg	n	12	12	12	12	11	1	12	0	12	0	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
Day 21	0 mg/kg	n	12	12	12	12	11	1	12	0	12	0	12	12	12	12
	100 mg/kg	n	12	12	12	12	11	1	12	0	11	1	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
Day 28	0 mg/kg	n	12	12	12	12	10	2	12	0	12	0	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
Day 35	0 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
	100 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
	300 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
	1000 mg/kg	n	12	12	12	12	12	0	12	0	12	0	12	12	12	12
Day 42	0 mg/kg	n	8	8	8	8	8	0	8	0	8	0	8	8	8	8
	100 mg/kg	n	9	9	9	9	9	0	9	0	9	0	9	9	9	9
	300 mg/kg	n	8	8	8	8	8	0	8	0	8	0	8	8	8	8
	1000 mg/kg	n	8	8	8	8	8	0	8	0	8	0	8	8	8	8

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.
Not significantly different from EGEHE 0 mg/kg

Table 4 - 3

Study No. : SR17140

Detailed clinical observation (in the open-field)
Sex : Female (satellite)

Species : Rat

Stage	Group		Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination		Defecation	Stereotype		Bizarre behavior		Aggression
										Excessive grooming	Unusual head movement	Walking backward	Vocaliza-tion	
			1	1	1	1	0	1	0	0	0	1	1	1
Pre	0 mg/kg	n	10	10	10	10	10	0	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	9	1	10	10	10	10	10	10
Day 7	0 mg/kg	n	10	10	10	10	10	0	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	9	1	10	10	10	10	10	10
Day 14	0 mg/kg	n	10	10	10	10	10	0	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	10	0	10	10	10	10	10	10
Day 21	0 mg/kg	n	10	10	10	10	10	0	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	9	1	10	10	10	10	10	10
Day 28	0 mg/kg	n	10	10	10	10	8	2	10	10	10	10	10	10
	1000 mg/kg	n	10	10	10	10	9	1	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.
Not significantly different from EGEHE 0 mg/kg

Table 4 - 4

Study No. : SR17140

Detailed clinical observation (in the open-field)

Sex : Male

Species : Rat

Stage	Group		Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination		Defecation		Stereotype: Excessive grooming	Stereotype: Unusual head movement	Bizarre behavior: Walking backward	Bizarre behavior: Vocalization	Aggression
			1	1	1	1	0	1	0	1	0	0	1	1	1
Recovery Day 7	0 mg/kg	n	5	5	5	5	3	2	5	0	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	3	2	4	1	5	5	5	5	5
Recovery Day 14	0 mg/kg	n	5	5	5	5	5	0	5	0	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	4	1	5	0	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.
Not significantly different from EGEHE 0 mg/kg

Table 4 - 5

Study No. : SR17140

Detailed clinical observation (in the open-field)
Sex : Female (satellite)

Species : Rat

Stage	Group		Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination		Defecation	Stereotype		Bizarre behavior		Aggression
										Excessive grooming	Unusual head movement	Walking backward	Vocaliza-tion	
			1	1	1	1	0	1	0	0	0	1	1	1
Recovery Day 7	0 mg/kg	n	5	5	5	5	5	0	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	4	1	5	5	5	5	5	5
Recovery Day 14	0 mg/kg	n	5	5	5	5	5	0	5	5	5	5	5	5
	1000 mg/kg	n	5	5	5	5	5	0	5	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.
Not significantly different from EGEHE 0 mg/kg

Table 5 - 1

Study No. : SR17140

Functional observations (on the desk)

Stage : Week 4

Sex : Male

Species : Rat

Group		Reactivity					Righting reflex
		Visual	Touch	Auditory	Pain	Proprioceptive	
		4	2	1	2	1	1
0 mg/kg	n	5	5	5	5	5	5
100 mg/kg	n	5	5	5	5	5	5
300 mg/kg	n	5	5	5	5	5	5
1000 mg/kg	n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.
Not significantly different from EGEHE 0 mg/kg

Table 5 - 2

Study No. : SR17140

Functional observations (on the desk)

Stage : Lactation day 4

Sex : Female

Species : Rat

Group		Reactivity					Righting reflex
		Visual	Touch	Auditory	Pain	Proprioceptive	
		4	2	1	2	1	1
0 mg/kg	n	5	5	5	5	5	5
100 mg/kg	n	5	5	5	5	5	5
300 mg/kg	n	5	5	5	5	5	5
1000 mg/kg	n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.
Not significantly different from EGEHE 0 mg/kg

Table 5 - 3

Study No. : SR17140

Functional observations (on the desk)

Stage : Week 4

Sex : Female (satellite)

Species : Rat

Group		Reactivity					Righting reflex
		Visual	Touch	Auditory	Pain	Proprioceptive	
		4	2	1	2	1	1
0 mg/kg	n	5	5	5	5	5	5
1000 mg/kg	n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.
Not significantly different from EGEHE 0 mg/kg

Table 6 - 1

Study No. : SR17140

Grip strength

Stage : Week 4

Sex : Male

Species : Rat

Test article Dose		Forelimb g	Hindlimb g
EGEHE	n	5	5
0 mg/kg	Mean	1495.86	614.58
	S.D.	90.24	103.64
EGEHE	n	5	5
100 mg/kg	Mean	1352.00	578.12
	S.D.	267.57	64.13
EGEHE	n	5	5
300 mg/kg	Mean	1392.12	575.20
	S.D.	189.13	51.18
EGEHE	n	5	5
1000 mg/kg	Mean	1341.74	562.40
	S.D.	92.33	74.27

Not significantly different from EGEHE 0 mg/kg

Table 6 - 2

Study No. : SR17140

Grip strength

Stage : Lactation Day 4

Sex : Female

Species : Rat

Test article Dose		Forelimb g	Hindlimb g
EGEHE	n	5	5
0 mg/kg	Mean	1253.86	475.08
	S.D.	198.63	59.23
EGEHE	n	5	5
100 mg/kg	Mean	1115.52	460.72
	S.D.	124.47	70.08
EGEHE	n	5	5
300 mg/kg	Mean	1182.68	439.32
	S.D.	134.05	75.37
EGEHE	n	5	5
1000 mg/kg	Mean	963.54	438.44
	S.D.	151.31	31.02
		DT *	

Significantly different from EGEHE 0 mg/kg: * P<0.05

DT : Dunnett test (two-side)

Table 6 - 3

Study No. : SR17140

Grip strength

Stage : Week 4

Sex : Female (satellite)

Species : Rat

Test article Dose		Forelimb g	Hindlimb g
EGEHE	n	5	5
0 mg/kg	Mean	1109.88	463.34
	S.D.	85.00	38.12
EGEHE	n	5	5
1000 mg/kg	Mean	1054.48	475.28
	S.D.	110.28	47.88

Not significantly different from EGEHE 0 mg/kg

Table 7 - 1

Study No. : SR17140

Motor activity measurements

Stage : Week 4

Sex : Male

Species : Rat

Test article Dose		0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
EGEHE	n	5	5	5	5	5	5	5
0 mg/kg	Mean	590.2	365.0	234.6	120.0	90.4	102.2	1502.4
	S.D.	136.7	164.6	99.2	85.6	175.6	107.8	651.1
EGEHE	n	5	5	5	5	5	5	5
100 mg/kg	Mean	609.0	468.2	388.6	250.4	129.6	87.6	1933.4
	S.D.	353.2	295.4	368.0	232.2	97.4	96.3	1224.4
EGEHE	n	5	5	5	5	5	5	5
300 mg/kg	Mean	517.2	330.2	112.2	216.0	87.4	75.4	1338.4
	S.D.	234.0	241.1	130.6	250.8	91.9	133.5	975.5
EGEHE	n	5	5	5	5	5	5	5
1000 mg/kg	Mean	718.2	478.2	236.6	251.0	108.4	75.4	1867.8
	S.D.	351.4	286.4	163.9	40.8	121.7	146.3	855.3

Not significantly different from EGEHE 0 mg/kg

Table 7 - 2

Study No. : SR17140

Motor activity measurements

Stage : Lactation Day 4

Sex : Female

Species : Rat

Test article Dose		0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
EGEHE	n	5	5	5	5	5	5	5
0 mg/kg	Mean	766.2	276.4	181.6	204.2	134.4	117.4	1680.2
	S.D.	379.4	207.2	386.5	238.6	176.3	189.6	1443.4
EGEHE	n	5	5	5	5	5	5	5
100 mg/kg	Mean	610.6	305.8	202.4	187.0	217.2	186.6	1709.6
	S.D.	312.1	365.6	255.2	163.5	274.0	239.1	1121.4
EGEHE	n	5	5	5	5	5	5	5
300 mg/kg	Mean	646.4	226.4	87.0	79.2	1.6	75.4	1116.0
	S.D.	426.3	149.9	76.2	174.3	3.6	160.9	705.7
EGEHE	n	5	5	5	5	5	5	5
1000 mg/kg	Mean	594.8	182.4	144.6	3.0	55.6	71.8	1052.2
	S.D.	300.7	258.7	164.0	6.7	61.4	106.4	578.0

Not significantly different from EGEHE 0 mg/kg

Table 7 - 3

Study No. : SR17140

Motor activity measurements

Stage : Week 4

Sex : Female (satellite)

Species : Rat

Test article Dose		0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
EGEHE	n	5	5	5	5	5	5	5
0 mg/kg	Mean	591.6	391.4	242.8	206.2	42.8	53.2	1528.0
	S.D.	273.1	122.5	98.8	188.1	62.6	119.0	691.3
EGEHE	n	5	5	5	5	5	5	5
1000 mg/kg	Mean	733.0	549.0	411.8	367.8	251.8	129.4	2442.8
	S.D.	245.7	346.7	254.5	281.8	326.4	132.5	1437.3

Not significantly different from EGEHE 0 mg/kg

Table 8 - 1

Study No. : SR17140

Body weight

Period : Administration Day 1-28

Sex : Male

Unit : g

Species : Rat

Test article		/Day						Body weight
Dose		1	4	7	14	21	28	gain
EGEHE	n	12	12	12	12	12	12	12
0 mg/kg	Mean	382.1	397.9	414.2	443.1	466.4	491.1	109.0
	S.D.	19.0	20.0	18.6	23.8	27.1	31.1	18.4
EGEHE	n	12	12	12	12	12	12	12
100 mg/kg	Mean	381.4	398.4	413.9	440.8	465.3	488.9	107.5
	S.D.	20.5	23.4	24.0	29.3	30.8	33.6	16.5
EGEHE	n	12	12	12	12	12	12	12
300 mg/kg	Mean	382.8	396.3	410.0	436.3	457.3	478.2	95.3
	S.D.	16.7	20.7	22.4	25.1	27.5	29.1	17.1
EGEHE	n	12	12	12	12	12	12	12
1000 mg/kg	Mean	381.5	387.5	399.8	421.7	438.2	459.1	77.6
	S.D.	16.7	17.8	17.6	20.3	20.7	21.6	13.0
						DT *	DT *	DT **

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01

DT : Dunnett test (two-side)

Table 8 - 2

Study No. : SR17140

Body weight

Period : F0 before mating Day 1-14

Sex : Female

Unit : g

Species : Rat

Test article Dose		/Day 1	4	7	14	Body weight gain
EGEHE	n	12	12	12	12	12
0 mg/kg	Mean	228.0	234.9	242.1	252.5	24.5
	S.D.	13.7	14.0	13.6	16.4	8.8
EGEHE	n	12	12	12	12	12
100 mg/kg	Mean	231.5	236.1	241.4	253.5	22.0
	S.D.	11.0	13.0	17.1	19.2	9.9
EGEHE	n	12	12	12	12	12
300 mg/kg	Mean	231.3	234.5	237.5	249.8	18.6
	S.D.	12.4	12.1	13.2	16.0	7.1
EGEHE	n	12	12	12	12	12
1000 mg/kg	Mean	231.8	235.3	240.5	244.9	13.2
	S.D.	14.8	17.2	22.4	18.2	8.9
						DT **

Significantly different from EGEHE 0 mg/kg: ** P<0.01

DT : Dunnett test (two-side)

Table 8 - 3

Study No. : SR17140

Body weight
Sex : Female

Period : F0 gestation Day 0-20

Unit : g

Species : Rat

Test article Dose		/Day 0	7	14	20	Body weight gain
EGEHE	n	11	11	11	11	11
0 mg/kg	Mean	264.5	300.9	341.2	429.3	164.8
	S.D.	20.7	23.1	26.1	33.6	21.8
EGEHE	n	11	11	11	11	11
100 mg/kg	Mean	261.3	297.0	340.0	421.3	160.0
	S.D.	23.3	20.0	25.0	32.6	21.5
EGEHE	n	11	11	11	11	11
300 mg/kg	Mean	257.8	292.3	330.7	411.9	154.1
	S.D.	15.9	19.8	23.7	20.6	10.0
EGEHE	n	10	10	10	10	10
1000 mg/kg	Mean	248.1	281.4	317.9	381.8	133.7
	S.D.	20.7	26.3	29.1	29.0	14.6
					DT **	DT **

Significantly different from EGEHE 0 mg/kg: ** P<0.01
DT : Dunnett test (two-side)

Table 8 - 4

Study No. : SR17140

Body weight
Sex : Female

Period : F0 lactation Day 0-4

Unit : g

Species : Rat

Test article Dose		/Day 0	 4	Body weight gain
EGEHE	n	11	11	11
0 mg/kg	Mean	326.5	339.9	13.4
	S.D.	28.8	27.2	8.8
EGEHE	n	11	11	11
100 mg/kg	Mean	322.2	335.4	13.2
	S.D.	23.6	18.1	12.1
EGEHE	n	11	11	11
300 mg/kg	Mean	313.5	329.5	16.1
	S.D.	17.7	20.5	5.9
EGEHE	n	10	10	10
1000 mg/kg	Mean	298.0	314.1	16.1
	S.D.	30.3	28.4	9.5
		DT *	DT *	

Significantly different from EGEHE 0 mg/kg: * P<0.05
DT : Dunnett test (two-side)

Table 8 - 5

Study No. : SR17140

Body weight

Period : Administration Day 1-28

Sex : Female (satellite)

Unit : g

Species : Rat

Test article		/Day						Body weight
Dose		1	4	7	14	21	28	gain
EGEHE	n	10	10	10	10	10	10	10
0 mg/kg	Mean	231.4	237.4	243.5	251.3	264.8	270.4	39.0
	S.D.	6.3	7.4	7.8	7.8	10.1	13.0	10.3
EGEHE	n	10	10	10	10	10	10	10
1000 mg/kg	Mean	234.6	237.9	242.7	249.2	254.6	262.9	28.3
	S.D.	7.5	8.4	6.6	9.7	13.2	9.0	10.1
								T2 *

Significantly different from EGEHE 0 mg/kg: * P<0.05

T2 : Student t-test (two-side)

Table 8 - 6

Study No. : SR17140

Body weight

Period : Recovery Day 1-14

Sex : Male

Unit : g

Species : Rat

Test article		/Day			Body weight
Dose		1	7	14	gain
EGEHE	n	5	5	5	5
0 mg/kg	Mean	490.2	510.2	527.4	37.2
	S.D.	16.9	13.6	12.8	7.6
EGEHE	n	5	5	5	5
1000 mg/kg	Mean	454.8	479.4	505.0	50.2
	S.D.	15.9	15.9	23.7	12.8
		T2 **	T2 *		

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01

T2 : Student t-test (two-side)

Table 8 - 7

Study No. : SR17140

Body weight

Period : Recovery Day 1-14

Sex : Female (satellite)

Unit : g

Species : Rat

Test article Dose		/Day 1	7	14	Body weight gain
EGEHE	n	5	5	5	5
0 mg/kg	Mean	268.8	276.2	286.6	17.8
	S.D.	11.4	13.3	9.6	3.6
EGEHE	n	5	5	5	5
1000 mg/kg	Mean	259.2	273.4	283.4	24.2
	S.D.	5.7	7.0	9.4	7.1

Not significantly different from EGEHE 0 mg/kg

Table 9 - 1

Study No. : SR17140

Food consumption

Period : Administration Day 1-28

Sex : Male

Unit : g

Species : Rat

Test article		/Day			
Dose		4	7	14	28
EGEHE	n	12	12	12	11
0 mg/kg	Mean	23.58	24.00	23.97	22.70
	S.D.	1.84	1.69	1.56	1.53
EGEHE	n	12	12	12	11
100 mg/kg	Mean	23.68	23.45	23.74	22.82
	S.D.	2.17	2.16	2.06	1.95
EGEHE	n	12	12	12	12
300 mg/kg	Mean	22.44	22.03	22.85	21.98
	S.D.	1.56	1.50	1.41	1.13
			DT *		
EGEHE	n	12	12	12	11
1000 mg/kg	Mean	18.88	22.75	23.22	23.95
	S.D.	1.76	1.41	1.71	2.15
		DT **			

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01

DT : Dunnett test (two-side)

Table 9 - 2

Study No. : SR17140

Food consumption

Period : F0 before mating Day 1-14

Sex : Female

Unit : g

Species : Rat

Test article		/Day		
Dose		4	7	14
EGEHE	n	12	12	12
0 mg/kg	Mean	15.43	15.97	16.88
	S.D.	2.32	1.76	2.04
EGEHE	n	12	12	12
100 mg/kg	Mean	15.32	16.10	17.06
	S.D.	2.12	1.69	1.70
EGEHE	n	12	12	12
300 mg/kg	Mean	14.78	15.34	16.60
	S.D.	1.22	1.11	1.27
EGEHE	n	12	12	12
1000 mg/kg	Mean	14.77	15.71	16.20
	S.D.	3.58	3.32	2.13

Not significantly different from EGEHE 0 mg/kg

Table 9 - 3

Study No. : SR17140

Food consumption

Period : F0 gestation Day 0-20

Sex : Female

Unit : g

Species : Rat

Test article Dose		/Day 7	14	20
EGEHE 0 mg/kg	n	11	11	11
	Mean	21.09	23.85	24.33
	S.D.	2.80	3.48	2.87
EGEHE 100 mg/kg	n	11	11	11
	Mean	21.49	23.96	23.42
	S.D.	2.66	2.79	2.09
EGEHE 300 mg/kg	n	11	11	11
	Mean	20.56	22.87	22.62
	S.D.	1.51	2.17	1.40
EGEHE 1000 mg/kg	n	10	10	10
	Mean	20.21	22.75	21.92
	S.D.	3.40	3.23	3.66

Not significantly different from EGEHE 0 mg/kg

Table 9 - 4

Study No. : SR17140

Food consumption

Period : F0 lactation Day 0-4

Sex : Female

Unit : g

Species : Rat

Test article		/Day
Dose		4
EGEHE	n	11
0 mg/kg	Mean	30.45
	S.D.	3.28
EGEHE	n	11
100 mg/kg	Mean	29.16
	S.D.	4.85
EGEHE	n	11
300 mg/kg	Mean	31.14
	S.D.	3.73
EGEHE	n	10
1000 mg/kg	Mean	31.20
	S.D.	5.22

Not significantly different from EGEHE 0 mg/kg

Table 9 - 5

Study No. : SR17140

Food consumption

Period : Administration Day 1-28

Sex : Female (satellite)

Unit : g

Species : Rat

Test article		/Day				
Dose		4	7	14	21	28
EGEHE	n	10	10	10	10	10
0 mg/kg	Mean	14.75	15.78	16.45	15.89	15.30
	S.D.	1.51	1.59	0.93	1.24	0.85
EGEHE	n	10	10	10	10	10
1000 mg/kg	Mean	14.23	15.05	15.77	16.49	16.60
	S.D.	1.97	0.98	1.71	1.34	1.28
						T2 *

Significantly different from EGEHE 0 mg/kg: * P<0.05

T2 : Student t-test (two-side)

Table 9 - 6

Study No. : SR17140

Food consumption

Period : Recovery Day 1-14

Sex : Male

Unit : g

Species : Rat

Test article		/Day	
Dose		7	14
EGEHE	n	5	5
0 mg/kg	Mean	27.36	28.24
	S.D.	1.54	0.84
EGEHE	n	5	5
1000 mg/kg	Mean	29.10	29.44
	S.D.	2.78	2.90

Not significantly different from EGEHE 0 mg/kg

Table 9 - 7

Study No. : SR17140

Food consumption

Period : Recovery Day 1-14

Sex : Female (satellite)

Unit : g

Species : Rat

Test article		/Day	
Dose		7	14
EGEHE	n	5	5
0 mg/kg	Mean	17.78	19.84
	S.D.	1.05	0.36
EGEHE	n	5	5
1000 mg/kg	Mean	21.24	21.58
	S.D.	1.15	1.00
		T2 **	T2 **

Significantly different from EGEHE 0 mg/kg: ** P<0.01

T2 : Student t-test (two-side)

Table 10 - 1

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Week 4

Species : Rat

pH

Test article Dose		5.0	6.0	6.5	7.0	7.5	8.0	8.5
EGEHE 0 mg/kg	n	0	0	0	0	0	0	5
EGEHE 100 mg/kg	n	0	0	0	0	0	0	5
EGEHE 300 mg/kg	n	0	0	0	0	0	2	3
EGEHE 1000 mg/kg	n	0	0	0	1	0	2	2

Test article Dose		Protein					Glucose			
		-	±	+	2+	3+	-	+	2+	3+
EGEHE 0 mg/kg	n	0	1	2	2	0	5	0	0	0
EGEHE 100 mg/kg	n	1	1	3	0	0	5	0	0	0
EGEHE 300 mg/kg	n	0	0	2	3	0	5	0	0	0
EGEHE 1000 mg/kg	n	0	2	1	2	0	5	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 10 - 2

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Week 4

Species : Rat

Test article Dose		Ketone body -	±	+	2+	3+	Urobilinogen EU/dL 0.1	1	2	4	8
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 100 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 300 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Test article Dose		Bilirubin -	+	2+	3+	Occult blood -	±	+	2+	3+
EGEHE 0 mg/kg	n	5	0	0	0	4	1	0	0	0
EGEHE 100 mg/kg	n	5	0	0	0	4	0	1	0	0
EGEHE 300 mg/kg	n	5	0	0	0	4	1	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	5	0	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 10 - 3

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Week 4

Species : Rat

Test article Dose		Color			
		A	B	C	D
EGEHE 0 mg/kg	n	5	0	0	0
EGEHE 100 mg/kg	n	5	0	0	0
EGEHE 300 mg/kg	n	5	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white
Not significantly different from EGEHE 0 mg/kg

Table 10 - 4

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Week 4

Species : Rat

Test article Dose		Urine volume mL/21hr
EGEHE 0 mg/kg	n	5
	Mean	11.50
	S.D.	4.85
EGEHE 100 mg/kg	n	5
	Mean	10.50
	S.D.	2.76
EGEHE 300 mg/kg	n	5
	Mean	7.90
	S.D.	2.07
EGEHE 1000 mg/kg	n	5
	Mean	15.60
	S.D.	7.14

Not significantly different from EGEHE 0 mg/kg

Table 10 - 5

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Week 4

Species : Rat

Test article Dose		Specific gravity 0	1	2	3	4	5
EGEHE 0 mg/kg	n	0	0	0	1	0	4
EGEHE 100 mg/kg	n	0	0	0	1	2	2
EGEHE 300 mg/kg	n	0	0	0	0	0	5
EGEHE 1000 mg/kg	n	0	0	0	1	2	2

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜
Not significantly different from EGEHE 0 mg/kg

Table 10 - 6

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Week 4

Species : Rat

Test article Dose		RBC -	±	+	2+	3+	WBC -	±	+	2+	3+
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 100 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 300 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Test article Dose		Squamous -	±	+	2+	3+	Round -	±	+	2+	3+
EGEHE 0 mg/kg	n	2	3	0	0	0	5	0	0	0	0
EGEHE 100 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 300 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	1	4	0	0	0	5	0	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 10 - 7

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Week 4

Species : Rat

Test article Dose		Small round					Cast				
		-	±	+	2+	3+	-	±	+	2+	3+
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 100 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 300 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 10 - 8

Study No. : SR17140

Urinary findings
Sex : Female (satellite)

Stage : Week 4

Species : Rat

pH

Test article Dose		5.0	6.0	6.5	7.0	7.5	8.0	8.5
EGEHE 0 mg/kg	n	0	0	0	0	1	0	4
EGEHE 1000 mg/kg	n	0	0	1	0	0	2	2

Test article Dose		Protein					Glucose			
		-	±	+	2+	3+	-	+	2+	3+
EGEHE 0 mg/kg	n	0	2	2	1	0	5	0	0	0
EGEHE 1000 mg/kg	n	3	0	2	0	0	5	0	0	0

Test article Dose		Ketone body					Urobilinogen EU/dL				
		-	±	+	2+	3+	0.1	1	2	4	8
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 10 - 9

Study No. : SR17140

Urinary findings

Stage : Week 4

Sex : Female (satellite)

Species : Rat

Test article Dose		Bilirubin -	 +	 2+	 3+	Occult blood -	 ±	 +	 2+	 3+
EGEHE 0 mg/kg	n	5	0	0	0	4	1	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	5	0	0	0	0

Test article Dose		Color A	 B	 C	 D
EGEHE 0 mg/kg	n	5	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Not significantly different from EGEHE 0 mg/kg

Table 10 - 10

Study No. : SR17140

Urinary findings

Stage : Week 4

Sex : Female (satellite)

Species : Rat

Test article Dose		Urine volume mL/21hr
EGEHE	n	5
0 mg/kg	Mean	9.10
	S.D.	4.79
EGEHE	n	5
1000 mg/kg	Mean	13.90
	S.D.	10.54

Not significantly different from EGEHE 0 mg/kg

Table 10 - 11

Study No. : SR17140

Urinary findings
Sex : Female (satellite)

Stage : Week 4

Species : Rat

Test article		Specific gravity					
Dose		0	1	2	3	4	5
EGEHE 0 mg/kg	n	0	0	1	1	0	3
EGEHE 1000 mg/kg	n	0	0	1	1	1	2

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜
Not significantly different from EGEHE 0 mg/kg

Table 10 - 12

Study No. : SR17140

Urinary findings
Sex : Female (satellite)

Stage : Week 4

Species : Rat

Test article Dose		RBC -	±	+	2+	3+	WBC -	±	+	2+	3+
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	4	1	0	0	0

Test article Dose		Squamous -	±	+	2+	3+	Round -	±	+	2+	3+
EGEHE 0 mg/kg	n	3	2	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	2	2	1	0	0	5	0	0	0	0

Test article Dose		Small round -	±	+	2+	3+	Cast -	±	+	2+	3+
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 10 - 13

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Recovery Week 2

Species : Rat

pH

Test article Dose		5.0	6.0	6.5	7.0	7.5	8.0	8.5
EGEHE 0 mg/kg	n	0	0	0	0	0	2	3
EGEHE 1000 mg/kg	n	0	0	0	0	0	0	5

		Protein					Glucose			
Test article Dose		-	±	+	2+	3+	-	+	2+	3+
EGEHE 0 mg/kg	n	0	0	4	1	0	5	0	0	0
EGEHE 1000 mg/kg	n	0	0	4	1	0	5	0	0	0

		Ketone body					Urobilinogen				
Test article							EU/dL				
Dose		-	±	+	2+	3+	0.1	1	2	4	8
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 10 - 14

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Recovery Week 2

Species : Rat

Test article Dose		Bilirubin -	 +	 2+	 3+	Occult blood -	 ±	 +	 2+	 3+
EGEHE 0 mg/kg	n	5	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	5	0	0	0	0

Test article Dose		Color A	 B	 C	 D
EGEHE 0 mg/kg	n	5	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white
Not significantly different from EGEHE 0 mg/kg

Table 10 - 15

Study No. : SR17140

Urinary findings

Stage : Recovery Week 2

Sex : Male

Species : Rat

Test article Dose		Urine volume mL/21hr
EGEHE 0 mg/kg	n	5
	Mean	18.00
	S.D.	13.45
EGEHE 1000 mg/kg	n	5
	Mean	16.90
	S.D.	7.43

Not significantly different from EGEHE 0 mg/kg

Table 10 - 16

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Recovery Week 2

Species : Rat

Test article		Specific gravity					
Dose		0	1	2	3	4	5
EGEHE 0 mg/kg	n	0	0	1	0	0	4
EGEHE 1000 mg/kg	n	0	0	0	2	1	2

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜
Not significantly different from EGEHE 0 mg/kg

Table 10 - 17

Study No. : SR17140

Urinary findings
Sex : Male

Stage : Recovery Week 2

Species : Rat

Test article Dose		RBC -	±	+	2+	3+	WBC -	±	+	2+	3+
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Test article Dose		Squamous -	±	+	2+	3+	Round -	±	+	2+	3+
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	3	2	0	0	0	5	0	0	0	0

Test article Dose		Small round -	±	+	2+	3+	Cast -	±	+	2+	3+
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 10 - 18

Study No. : SR17140

Urinary findings
Sex : Female (satellite)

Stage : Recovery Week 2

Species : Rat

pH

Test article Dose		5.0	6.0	6.5	7.0	7.5	8.0	8.5
EGEHE 0 mg/kg	n	0	0	0	0	0	1	4
EGEHE 1000 mg/kg	n	0	0	0	0	0	1	4

		Protein					Glucose			
Test article Dose		-	±	+	2+	3+	-	+	2+	3+
EGEHE 0 mg/kg	n	0	3	2	0	0	5	0	0	0
EGEHE 1000 mg/kg	n	0	2	3	0	0	5	0	0	0

		Ketone body					Urobilinogen				
Test article							EU/dL				
Dose		-	±	+	2+	3+	0.1	1	2	4	8
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 10 - 19

Study No. : SR17140

Urinary findings

Stage : Recovery Week 2

Sex : Female (satellite)

Species : Rat

Test article Dose		Bilirubin -	 +	 2+	 3+	Occult blood -	 ±	 +	 2+	 3+
EGEHE 0 mg/kg	n	5	0	0	0	3	2	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	5	0	0	0	0

Test article Dose		Color A	 B	 C	 D
EGEHE 0 mg/kg	n	5	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Not significantly different from EGEHE 0 mg/kg

Table 10 - 20

Study No. : SR17140

Urinary findings

Stage : Recovery Week 2

Sex : Female (satellite)

Species : Rat

Test article Dose		Urine volume mL/21hr
EGEHE	n	5
0 mg/kg	Mean	10.90
	S.D.	2.25
EGEHE	n	5
1000 mg/kg	Mean	9.00
	S.D.	2.76

Not significantly different from EGEHE 0 mg/kg

Table 10 - 21

Study No. : SR17140

Urinary findings
Sex : Female (satellite)

Stage : Recovery Week 2

Species : Rat

Test article		Specific gravity					
Dose		0	1	2	3	4	5
EGEHE 0 mg/kg	n	0	0	0	0	5	0
EGEHE 1000 mg/kg	n	0	0	0	0	2	3

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜
Not significantly different from EGEHE 0 mg/kg

Table 10 - 22

Study No. : SR17140

Urinary findings
Sex : Female (satellite)

Stage : Recovery Week 2

Species : Rat

Test article Dose		RBC -	±	+	2+	3+	WBC -	±	+	2+	3+
EGEHE 0 mg/kg	n	4	1	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Test article Dose		Squamous -	±	+	2+	3+	Round -	±	+	2+	3+
EGEHE 0 mg/kg	n	1	4	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	3	2	0	0	0	5	0	0	0	0

Test article Dose		Small round -	±	+	2+	3+	Cast -	±	+	2+	3+
EGEHE 0 mg/kg	n	5	0	0	0	0	5	0	0	0	0
EGEHE 1000 mg/kg	n	5	0	0	0	0	5	0	0	0	0

Not significantly different from EGEHE 0 mg/kg

Table 11 - 1

Study No. : SR17140

Hematological findings

Stage : Day 29

Sex : Male

Species : Rat

Test article Dose		RBC 10^4/μL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet 10^4/μL	WBC 10^2/μL	Neutrophil 10^2/μL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	870.0	15.68	44.10	50.74	18.02	35.58	3.426	112.62	100.52	18.70
	S.D.	23.2	0.11	0.94	1.91	0.44	0.68	0.319	8.30	33.10	4.92
EGEHE	n	5	5	5	5	5	5	5	5	5	5
100 mg/kg	Mean	820.4	15.10	42.82	52.22	18.40	35.24	3.290	90.44	68.62	13.98
	S.D.	27.6	0.41	0.98	1.36	0.19	0.62	0.376	12.39	13.13	2.30
			ST *						DT *		
EGEHE	n	5	5	5	5	5	5	5	5	5	5
300 mg/kg	Mean	837.4	15.10	43.16	51.56	18.02	34.98	3.484	106.08	92.80	20.24
	S.D.	34.8	0.62	1.90	1.86	0.44	0.42	0.328	14.91	12.92	5.21
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	813.4	14.64	41.80	51.42	18.00	35.04	3.256	113.06	79.00	17.22
	S.D.	45.0	0.56	2.00	1.42	0.49	0.38	0.582	12.62	11.58	4.37
		DT *	ST *								

Test article Dose		Lymphocyte 10^2/μL	Monocyte 10^2/μL	Eosinophil 10^2/μL	Basophil 10^2/μL	PT sec	APTT sec
EGEHE	n	5	5	5	5	5	5
0 mg/kg	Mean	77.32	3.16	1.32	0.02	21.04	19.66
	S.D.	31.53	0.51	0.30	0.04	3.05	2.16
EGEHE	n	5	5	5	5	5	5
100 mg/kg	Mean	51.10	2.44	1.08	0.02	18.32	17.50
	S.D.	13.57	0.55	0.33	0.04	1.17	1.29
EGEHE	n	5	5	5	5	5	5
300 mg/kg	Mean	68.34	3.08	1.12	0.02	21.54	19.18
	S.D.	7.91	0.72	0.47	0.04	3.93	2.47
EGEHE	n	5	5	5	5	5	5
1000 mg/kg	Mean	57.66	3.12	0.98	0.02	20.28	19.60
	S.D.	9.12	0.29	0.41	0.04	3.31	2.51

Significantly different from EGEHE 0 mg/kg: * $P<0.05$

DT : Dunnett test (two-side), ST : Steel test (two-side)

Table 11 - 2

Study No. : SR17140

Hematological findings
Sex : Female

Stage : Day 5 after delivery

Species : Rat

Test article Dose		RBC 10^4/μL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet 10^4/μL	WBC 10^2/μL	Neutrophil 10^2/μL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	736.6	14.14	40.72	55.40	19.22	34.74	7.998	108.30	106.38	38.04
	S.D.	44.2	0.49	1.54	3.20	0.97	0.57	2.277	9.77	17.75	6.23
EGEHE	n	5	5	5	5	5	5	5	5	5	5
100 mg/kg	Mean	732.6	14.04	40.64	55.58	19.16	34.54	7.908	113.60	84.20	31.16
	S.D.	54.0	0.97	2.44	2.75	0.74	0.46	3.721	14.08	31.05	15.19
EGEHE	n	5	5	5	5	5	5	5	5	5	5
300 mg/kg	Mean	696.0	13.62	39.98	57.42	19.56	34.10	9.410	114.84	130.58	35.72
	S.D.	12.0	0.46	1.90	2.53	0.73	0.70	1.323	4.14	35.65	12.83
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	727.4	13.78	40.16	55.32	18.98	34.30	8.240	118.60	86.26	29.78
	S.D.	59.2	0.91	2.54	2.64	0.77	0.51	2.495	10.79	30.92	11.38

Test article Dose		Lymphocyte 10^2/μL	Monocyte 10^2/μL	Eosinophil 10^2/μL	Basophil 10^2/μL	PT sec	APTT sec
EGEHE	n	5	5	5	5	5	5
0 mg/kg	Mean	62.30	4.58	1.46	0.00	16.30	15.68
	S.D.	13.16	1.03	0.40	0.00	0.42	2.04
EGEHE	n	5	5	5	5	5	5
100 mg/kg	Mean	48.82	3.50	0.70	0.02	15.88	15.70
	S.D.	15.10	1.68	0.42	0.04	0.64	0.82
				DT *			
EGEHE	n	5	5	5	5	5	5
300 mg/kg	Mean	89.74	4.20	0.88	0.04	16.00	13.10
	S.D.	23.45	0.81	0.45	0.05	0.34	2.36
EGEHE	n	5	5	5	5	5	5
1000 mg/kg	Mean	51.86	4.10	0.50	0.02	16.06	13.20
	S.D.	23.19	0.94	0.30	0.04	0.55	1.20
				DT **			

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01
DT : Dunnett test (two-side)

Table 11 - 3

Study No. : SR17140

Hematological findings
Sex : Female (satellite)

Stage : Day 29

Species : Rat

Test article Dose		RBC 10^4/μL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet 10^4/μL	WBC 10^2/μL	Neutrophil 10^2/μL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	805.4	14.96	41.50	51.66	18.60	36.04	2.722	112.72	51.00	7.78
	S.D.	53.9	0.62	1.50	2.49	0.66	0.51	1.049	11.50	12.66	2.06
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	752.2	14.20	41.12	54.68	18.88	34.54	3.732	105.22	74.32	11.44
	S.D.	25.0	0.57	1.45	1.42	0.36	0.59	0.567	11.47	37.56	5.21
					T2 *		T2 **				

Test article Dose		Lymphocyte 10^2/μL	Monocyte 10^2/μL	Eosinophil 10^2/μL	Basophil 10^2/μL	PT sec	APTT sec
EGEHE	n	5	5	5	5	5	5
0 mg/kg	Mean	41.58	1.06	0.58	0.00	14.80	12.10
	S.D.	12.75	0.45	0.23	0.00	0.34	1.29
EGEHE	n	5	5	5	5	5	5
1000 mg/kg	Mean	60.06	2.04	0.78	0.00	15.60	13.60
	S.D.	31.08	1.43	0.67	0.00	1.11	1.75

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01
T2 : Student t-test (two-side)

Table 11 - 4

Study No. : SR17140

Hematological findings
Sex : Male

Stage : Recovery Day 15

Species : Rat

Test article Dose		RBC 10^4/μL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet 10^4/μL	WBC 10^2/μL	Neutrophil 10^2/μL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	860.2	15.46	43.44	50.58	18.02	35.58	3.776	114.00	89.22	11.78
	S.D.	37.4	0.67	2.28	3.30	1.05	0.35	0.391	14.84	18.18	2.08
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	858.2	14.98	42.36	49.36	17.46	35.38	4.454	115.36	89.96	17.28
	S.D.	28.8	0.66	1.97	1.46	0.51	0.18	0.580	11.89	31.92	4.00
											T2 ＊

Test article Dose		Lymphocyte 10^2/μL	Monocyte 10^2/μL	Eosinophil 10^2/μL	Basophil 10^2/μL	PT sec	APTT sec
EGEHE	n	5	5	5	5	5	5
0 mg/kg	Mean	72.76	3.32	1.30	0.06	17.40	16.70
	S.D.	16.72	0.57	0.58	0.05	3.48	2.69
EGEHE	n	5	5	5	5	5	5
1000 mg/kg	Mean	68.50	3.00	1.14	0.04	19.72	18.08
	S.D.	28.21	0.68	0.30	0.05	2.48	1.06

Significantly different from EGEHE 0 mg/kg: ＊ $P<0.05$
T2 : Student t-test (two-side)

Table 11 - 5

Study No. : SR17140

Hematological findings
Sex : Female (satellite)

Stage : Recovery Day 15

Species : Rat

Test article Dose		RBC 10^4/μL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet 10^4/μL	WBC 10^2/μL	Neutrophil 10^2/μL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	828.8	15.06	41.86	50.56	18.18	36.00	3.246	104.04	49.02	6.76
	S.D.	34.7	0.23	1.16	1.64	0.61	0.60	0.728	12.85	20.26	1.73
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	819.6	15.30	42.60	52.02	18.64	35.92	3.086	112.06	44.32	7.74
	S.D.	35.7	0.76	2.21	2.09	0.50	0.59	0.737	7.28	12.07	2.06

Test article Dose		Lymphocyte 10^2/μL	Monocyte 10^2/μL	Eosinophil 10^2/μL	Basophil 10^2/μL	PT sec	APTT sec
EGEHE	n	5	5	5	5	4	4
0 mg/kg	Mean	40.64	1.12	0.50	0.00	15.63	11.15
	S.D.	19.32	0.31	0.20	0.00	0.64	0.66
EGEHE	n	5	5	5	5	5	5
1000 mg/kg	Mean	34.52	1.32	0.74	0.00	15.80	12.66
	S.D.	11.13	0.27	0.24	0.00	1.23	0.89
							T2 *

Significantly different from EGEHE 0 mg/kg: * P<0.05
T2 : Student t-test (two-side)

Table 12 - 1

Study No. : SR17140

Biochemical findings

Stage : Day 29

Sex : Male

Species : Rat

Test article Dose		AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	72.2	30.2	494.4	0.32	0.054	9.62	157.8	47.0	25.6	5.24
	S.D.	8.7	3.3	47.3	0.13	0.009	2.55	14.0	6.0	11.7	0.23
EGEHE	n	5	5	5	5	5	5	5	5	5	5
100 mg/kg	Mean	62.2	27.0	487.2	0.36	0.054	6.54	163.0	61.8	28.0	5.32
	S.D.	7.7	4.5	124.8	0.11	0.005	2.62	5.3	11.6	7.8	0.28
									DT *		
EGEHE	n	5	5	5	5	5	5	5	5	5	5
300 mg/kg	Mean	72.0	35.8	418.6	0.26	0.050	9.50	151.2	56.4	30.8	5.28
	S.D.	26.0	17.1	84.2	0.22	0.012	10.12	7.9	9.0	18.3	0.11
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	79.4	42.4	495.8	0.84	0.052	9.26	144.2	53.0	17.8	5.42
	S.D.	13.6	14.5	123.3	1.06	0.023	5.26	15.4	5.0	4.2	0.36

Test article Dose		UN mg/dL	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	11.98	0.290	144.8	4.640	104.4	9.30	6.82	1.060	2.678	51.18
	S.D.	1.75	0.022	0.4	0.301	0.9	0.20	0.64	0.145	0.104	3.50
EGEHE	n	5	5	5	5	5	5	5	5	5	5
100 mg/kg	Mean	11.84	0.316	145.0	4.528	104.6	9.66	6.82	0.974	2.620	49.26
	S.D.	2.20	0.031	1.6	0.133	1.5	0.30	0.41	0.085	0.134	2.09
							DT *				
EGEHE	n	5	5	5	5	5	5	5	5	5	5
300 mg/kg	Mean	10.92	0.290	145.8	4.644	104.8	9.48	6.58	0.934	2.546	48.26
	S.D.	1.55	0.016	0.8	0.315	1.3	0.11	0.55	0.040	0.081	1.17
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	11.12	0.302	145.6	4.670	104.4	9.70	6.52	1.048	2.758	51.02
	S.D.	1.63	0.032	0.5	0.199	1.1	0.16	0.73	0.154	0.135	3.49
							DT *				

Significantly different from EGEHE 0 mg/kg: * P<0.05

DT : Dunnett test (two-side)

Table 12 - 2

Study No. : SR17140

Biochemical findings

Stage : Day 29

Sex : Male

Species : Rat

Test article Dose		α1-G %	α2-G %	β-G %	γ-G %
EGEHE	n	5	5	5	5
0 mg/kg	Mean	19.94	9.46	15.08	4.34
	S.D.	2.40	1.20	0.97	1.78
EGEHE	n	5	5	5	5
100 mg/kg	Mean	21.42	9.72	15.74	3.86
	S.D.	3.51	0.83	0.57	0.79
EGEHE	n	5	5	5	5
300 mg/kg	Mean	23.42	9.36	15.32	3.64
	S.D.	1.58	0.73	1.08	0.47
EGEHE	n	5	5	5	5
1000 mg/kg	Mean	19.18	9.88	14.90	5.02
	S.D.	4.88	1.05	0.72	1.47

Not significantly different from EGEHE 0 mg/kg

Table 12 - 3

Study No. : SR17140

Biochemical findings

Stage : Day 5 after delivery

Sex : Female

Species : Rat

Test article Dose		AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	102.6	49.2	233.4	0.74	0.042	12.04	142.8	57.0	32.2	5.78
	S.D.	41.1	7.6	81.9	0.23	0.011	4.29	13.1	8.5	14.6	0.19
EGEHE	n	5	5	5	5	5	5	5	5	5	5
100 mg/kg	Mean	108.8	48.6	221.4	1.08	0.058	19.50	145.8	76.0	45.8	5.66
	S.D.	33.6	8.0	20.1	0.54	0.011	15.56	17.4	15.7	25.6	0.17
						DT *			DT *		
EGEHE	n	5	5	5	5	5	5	5	5	5	5
300 mg/kg	Mean	109.2	52.4	265.2	1.00	0.048	19.16	138.2	65.2	46.0	5.42
	S.D.	47.3	27.5	94.2	0.60	0.008	11.38	9.4	7.4	30.2	0.11
											DT *
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	86.4	53.8	319.6	1.28	0.030	11.14	152.8	68.2	40.2	5.66
	S.D.	10.2	12.1	113.7	0.51	0.007	2.48	14.5	7.0	19.3	0.23

Test article Dose		UN mg/dL	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	17.16	0.334	143.8	4.458	107.2	10.28	7.76	0.910	2.744	47.48
	S.D.	2.68	0.040	0.8	0.166	1.3	0.15	0.61	0.147	0.203	3.76
EGEHE	n	5	5	5	5	5	5	5	5	5	5
100 mg/kg	Mean	18.74	0.378	144.8	4.312	107.4	10.30	8.54	0.924	2.708	47.84
	S.D.	5.43	0.033	0.8	0.301	1.5	0.35	0.77	0.118	0.176	3.30
EGEHE	n	5	5	5	5	5	5	5	5	5	5
300 mg/kg	Mean	15.34	0.362	144.6	4.532	106.6	10.02	8.16	0.886	2.538	46.80
	S.D.	2.95	0.028	1.1	0.178	2.3	0.24	0.48	0.115	0.166	3.06
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	17.12	0.340	144.2	4.646	105.6	10.34	7.90	0.898	2.674	47.20
	S.D.	4.45	0.053	0.8	0.131	0.5	0.30	0.93	0.108	0.224	3.11

Significantly different from EGEHE 0 mg/kg: * $P<0.05$
DT : Dunnett test (two-side)

Table 12 - 4

Study No. : SR17140

Biochemical findings
Sex : Female

Stage : Day 5 after delivery

Species : Rat

Test article Dose		α1-G %	α2-G %	β-G %	γ-G %
EGEHE	n	5	5	5	5
0 mg/kg	Mean	19.44	10.08	18.24	4.76
	S.D.	3.23	1.70	0.78	1.21
EGEHE	n	5	5	5	5
100 mg/kg	Mean	20.26	9.74	17.64	4.52
	S.D.	0.86	1.28	1.50	1.84
EGEHE	n	5	5	5	5
300 mg/kg	Mean	20.66	10.04	18.00	4.50
	S.D.	2.09	0.99	1.43	0.90
EGEHE	n	5	5	5	5
1000 mg/kg	Mean	19.54	10.14	18.28	4.84
	S.D.	0.99	1.00	1.19	1.04

Not significantly different from EGEHE 0 mg/kg

Table 12 - 5

Study No. : SR17140

Biochemical findings
Sex : Female (satellite)

Stage : Day 29

Species : Rat

Test article Dose		AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	57.2	21.6	239.4	0.44	0.070	9.90	134.8	54.0	9.0	5.92
	S.D.	6.2	0.9	42.1	0.38	0.007	1.91	17.5	7.2	4.3	0.62
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	58.0	31.6	208.8	0.62	0.040	9.70	126.4	69.0	16.2	6.08
	S.D.	10.5	8.1	47.5	0.26	0.007	7.13	9.6	15.4	1.3	0.48
						T2 **				A2 *	

Test article Dose		UN mg/dL	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	14.22	0.342	145.0	4.520	105.2	10.28	7.08	1.232	3.274	55.20
	S.D.	2.15	0.032	1.2	0.671	0.4	0.36	0.58	0.076	0.417	1.50
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	15.20	0.372	144.6	4.326	104.8	10.36	6.46	1.222	3.340	54.88
	S.D.	2.07	0.034	0.5	0.214	1.1	0.23	0.69	0.118	0.327	2.44

Test article Dose		α1-G %	α2-G %	β-G %	γ-G %
EGEHE	n	5	5	5	5
0 mg/kg	Mean	17.78	7.94	13.94	5.14
	S.D.	2.12	1.71	1.24	1.16
EGEHE	n	5	5	5	5
1000 mg/kg	Mean	16.56	8.80	14.48	5.28
	S.D.	0.61	1.34	1.75	0.80

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01
A2 : Welch test (two-side), T2 : Student t-test (two-side)

Table 12 - 6

Study No. : SR17140

Biochemical findings

Stage : Recovery Day 15

Sex : Male

Species : Rat

Test article Dose		AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	72.0	29.6	346.0	0.34	0.072	15.44	157.8	61.4	28.2	5.40
	S.D.	15.8	6.1	65.5	0.21	0.016	13.68	9.5	13.0	10.6	0.16
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	64.0	28.0	368.0	0.38	0.054	5.20	165.2	56.6	22.2	5.44
	S.D.	7.7	3.9	72.2	0.15	0.011	1.56	13.6	7.6	8.9	0.17

Test article Dose		UN mg/dL	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	14.74	0.310	142.4	4.680	103.4	9.04	6.00	0.934	2.604	48.24
	S.D.	1.16	0.029	0.5	0.191	0.9	0.33	0.29	0.011	0.078	0.30
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	14.00	0.302	143.0	4.652	103.6	9.08	6.28	0.964	2.670	49.02
	S.D.	1.18	0.030	1.0	0.202	0.9	0.30	0.48	0.098	0.192	2.57

Test article Dose		α1-G %	α2-G %	β-G %	γ-G %
EGEHE	n	5	5	5	5
0 mg/kg	Mean	21.80	9.54	15.68	4.74
	S.D.	2.66	0.80	0.83	1.62
EGEHE	n	5	5	5	5
1000 mg/kg	Mean	22.28	8.80	15.26	4.64
	S.D.	1.75	0.46	1.08	1.64

Not significantly different from EGEHE 0 mg/kg

Table 12 - 7

Study No. : SR17140

Biochemical findings

Stage : Recovery Day 15

Sex : Female (satellite)

Species : Rat

Test article Dose		AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	52.6	22.0	203.6	0.78	0.090	13.94	156.6	71.4	13.2	5.94
	S.D.	1.1	1.6	61.9	0.28	0.007	4.83	18.2	11.7	4.5	0.30
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	59.0	24.6	199.2	0.46	0.070	12.30	124.8	58.6	8.4	5.92
	S.D.	8.5	3.8	65.7	0.24	0.007	7.41	9.5	14.0	2.2	0.29
						T2 **		T2 **			

Test article Dose		UN mg/dL	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	15.28	0.326	141.4	4.500	104.4	9.58	5.80	1.222	3.262	54.92
	S.D.	1.25	0.033	0.9	0.139	0.9	0.19	0.44	0.102	0.239	2.06
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	15.54	0.334	141.4	4.484	103.6	9.48	6.36	1.084	3.072	51.94
	S.D.	2.09	0.028	1.5	0.143	0.5	0.15	0.72	0.083	0.108	1.93
									T2 *		T2 *

Test article Dose		α1-G %	α2-G %	β-G %	γ-G %
EGEHE	n	5	5	5	5
0 mg/kg	Mean	17.22	8.12	14.34	5.40
	S.D.	3.25	1.33	0.82	1.29
EGEHE	n	5	5	5	5
1000 mg/kg	Mean	16.76	8.40	15.42	7.48
	S.D.	2.92	1.01	1.39	1.82

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01
T2 : Student t-test (two-side)

Table 13 - 1

Study No. : SR17140

Necropsy findings

Sex : Male | Stage : Day 29 | Species : Rat

Organ / Findings	Test article / Dose / Number of Animals		EGEHE 0 mg/kg 7	EGEHE 100 mg/kg 12	EGEHE 300 mg/kg 12	EGEHE 1000 mg/kg 7
Liver			<7/7>	<12/12>	<12/12>	<3/7>
Dark brown		P	0	0	0	4
Other organs & tissues			<7/7>	<12/12>	<12/12>	<7/7>

<> : Not remarkable/Number of animals examined

P : Non-graded change

Table 13 - 2

Study No. : SR17140

Necropsy findings
Sex : Female

Stage : Day 5 after delivery

Species : Rat

Organ / Findings		Test article	EGEHE	EGEHE	EGEHE	EGEHE
		Dose	0 mg/kg	100 mg/kg	300 mg/kg	1000 mg/kg
		Number of Animals	11	11	11	10
Kidney			<10/11>	<11/11>	<11/11>	<10/10>
Yellowish white focus, unilateral	P		1	0	0	0
Other organs & tissues			<11/11>	<11/11>	<11/11>	<10/10>

<> : Not remarkable/Number of animals examined
P : Non-graded change

Table 13 - 3

Study No. : SR17140

Necropsy findings

Sex : Female

Stage : Unsuccessful mating

Species : Rat

	Test article	EGEHE
	Dose	100 mg/kg
Organ Findings	Number of Animals	1
All organs & tissues		<1/1>

<> : Not remarkable/Number of animals examined

Table 13 - 4

Study No. : SR17140

Necropsy findings
Sex : Female

Stage : Non-pregnancy

Species : Rat

Organ / Findings		Test article / Dose / Number of Animals	EGEHE 0 mg/kg 1	EGEHE 300 mg/kg 1	EGEHE 1000 mg/kg 2
Uterus			<0/1>	<1/1>	<2/2>
Retention, fluid, colorless, serous and transparent	P		1	0	0
Dilatation, lumen	P		1	0	0
Vagina			<0/1>	<0/1>	<2/2>
Atresia	P		1	1	0
Retention, fluid, pale yellow, viscous and cloudy	P		0	1	0
Other organs & tissues			<1/1>	<1/1>	<2/2>

Table 13 - 5

Study No. : SR17140

Necropsy findings
Sex : Female (satellite)

Stage : Day 29

Species : Rat

	Test article		EGEHE	EGEHE
	Dose		0	1000
Organ			mg/kg	mg/kg
Findings	Number of Animals		5	5
Liver			<5/5>	<3/5>
Dark brown		P	0	2
Other organs & tissues			<5/5>	<5/5>

<> : Not remarkable/Number of animals examined
P : Non-graded change

Table 13 - 6

Study No. : SR17140

Necropsy findings
Sex : Male

Stage : Recovery Day 15

Species : Rat

Organ / Findings		Test article	EGEHE	EGEHE
		Dose	0 mg/kg	1000 mg/kg
		Number of Animals	5	5
Epididymis			<4/5>	<5/5>
Yellowish white focus, cauda, unilateral	P		1	0
Other organs & tissues			<5/5>	<5/5>

<> : Not remarkable/Number of animals examined
P : Non-graded change

Table 13 - 7

Study No. : SR17140

Necropsy findings

Sex : Female (satellite) | Stage : Recovery Day 15 | Species : Rat

	Test article	EGEHE	EGEHE
	Dose	0	1000
Organ		mg/kg	mg/kg
Findings	Number of Animals	5	5
All organs & tissues		<5/5>	<5/5>

<> : Not remarkable/Number of animals examined

Table 14 - 1

Study No. : SR17140

Organ weight

Stage : Day 29

Sex : Male

Species : Rat

Test article		Body weight	Liver		Kidney		Heart		Spleen	
			AB	RE	AB	RE	AB	RE	AB	RE
Dose		g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
EGEHE	n	7	7	7	7	7	7	7	7	7
0 mg/kg	Mean	464.4	12.083	2.594	3.097	0.669	1.399	0.303	764.7	164.991
	S.D.	39.4	1.845	0.263	0.310	0.033	0.107	0.023	116.5	24.075
EGEHE	n	12	12	12	12	12	12	12	12	12
100 mg/kg	Mean	462.9	12.335	2.660	3.195	0.691	1.430	0.308	714.9	154.498
	S.D.	31.6	1.456	0.195	0.274	0.068	0.156	0.019	106.5	20.512
EGEHE	n	12	12	12	12	12	12	12	12	12
300 mg/kg	Mean	453.4	12.541	2.766	3.308	0.730	1.389	0.307	731.0	161.217
	S.D.	28.3	0.938	0.097	0.322	0.049	0.083	0.015	84.5	15.047
EGEHE	n	7	7	7	7	7	7	7	7	7
1000 mg/kg	Mean	425.6	13.480	3.169	3.274	0.769	1.369	0.320	688.3	161.750
	S.D.	24.2	1.022	0.169	0.460	0.083	0.095	0.012	98.7	21.262
				ST **		DT *				

Test article		Thymus		Adrenal		Pituitary gland		Thyroid		Testis	
		AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
Dose		mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	g	g/100g
EGEHE	n	7	7	7	7	7	7	7	7	7	7
0 mg/kg	Mean	402.4	86.953	66.6	14.416	11.61	2.514	21.03	4.536	3.150	0.680
	S.D.	88.5	18.965	6.4	1.757	0.70	0.264	2.46	0.490	0.159	0.060
EGEHE	n	12	12	12	12	12	12	12	12	12	12
100 mg/kg	Mean	387.7	83.423	63.8	13.838	11.92	2.575	21.07	4.568	3.320	0.722
	S.D.	112.5	21.569	10.2	2.494	2.20	0.447	2.14	0.519	0.365	0.096
EGEHE	n	12	12	12	12	12	12	12	12	12	12
300 mg/kg	Mean	343.8	75.523	68.1	15.040	11.91	2.640	21.10	4.663	3.254	0.719
	S.D.	97.9	18.962	12.3	2.703	1.74	0.438	3.58	0.832	0.386	0.085
EGEHE	n	7	7	7	7	7	7	7	7	7	7
1000 mg/kg	Mean	291.4	68.336	65.0	15.277	11.94	2.803	19.89	4.673	3.190	0.749
	S.D.	58.0	12.146	8.4	1.802	1.21	0.225	3.80	0.827	0.295	0.056

AB : Absolute weight, RE : Relative weight by body weight

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01

DT : Dunnett test (two-side), ST : Steel test (two-side)

Table 14 - 2

Study No. : SR17140

Organ weight

Stage : Day 29

Sex : Male

Species : Rat

Test article		Epididymis		Prostate		Seminal vesicle		Brain	
		AB	RE	AB	RE	AB	RE	AB	RE
Dose		g	g/100g	mg	mg/100g	g	g/100g	g	g/100g
EGEHE	n	7	7	7	7	7	7	7	7
0 mg/kg	Mean	1.250	0.270	656.7	143.271	2.190	0.479	2.224	0.481
	S.D.	0.098	0.022	113.0	32.365	0.302	0.104	0.117	0.029
EGEHE	n	12	12	12	12	12	12	12	12
100 mg/kg	Mean	1.293	0.280	733.4	158.568	2.175	0.470	2.161	0.469
	S.D.	0.141	0.038	139.7	29.329	0.349	0.072	0.083	0.033
EGEHE	n	12	12	12	12	12	12	12	12
300 mg/kg	Mean	1.249	0.276	637.7	140.483	2.014	0.446	2.210	0.489
	S.D.	0.185	0.040	79.3	12.784	0.262	0.056	0.085	0.034
EGEHE	n	7	7	7	7	7	7	7	7
1000 mg/kg	Mean	1.200	0.281	618.4	145.716	2.036	0.479	2.186	0.516
	S.D.	0.117	0.023	136.2	33.722	0.202	0.041	0.078	0.033

AB : Absolute weight, RE : Relative weight by body weight

Not significantly different from EGEHE 0 mg/kg

Table 14 - 3

Study No. : SR17140

Organ weight

Stage : Day 5 after delivery

Sex : Female

Species : Rat

Test article		Body weight	Liver		Kidney		Heart		Spleen	
			AB	RE	AB	RE	AB	RE	AB	RE
Dose		g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
EGEHE	n	11	11	11	11	11	11	11	11	11
0 mg/kg	Mean	314.8	10.301	3.277	2.171	0.694	1.013	0.324	627.3	200.302
	S.D.	25.6	0.888	0.211	0.143	0.074	0.061	0.028	96.3	33.293
EGEHE	n	11	11	11	11	11	11	11	11	11
100 mg/kg	Mean	309.5	10.305	3.327	2.164	0.698	0.971	0.315	641.2	208.121
	S.D.	19.4	0.869	0.171	0.236	0.051	0.069	0.019	79.5	30.906
EGEHE	n	11	11	11	11	11	11	11	11	11
300 mg/kg	Mean	299.2	10.630	3.555	2.120	0.709	1.006	0.336	735.5	246.825
	S.D.	16.1	0.923	0.264	0.196	0.050	0.099	0.024	121.1	44.849
				DT *					DT *	DT **
EGEHE	n	10	10	10	10	10	10	10	10	10
1000 mg/kg	Mean	280.9	12.211	4.346	2.156	0.768	0.918	0.327	542.8	193.877
	S.D.	26.9	1.317	0.214	0.223	0.033	0.139	0.026	52.1	17.021
		DT **	DT **	DT **		DT **				

Test article		Thymus		Adrenal		Pituitary gland		Thyroid		Ovary	
		AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
Dose		mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g
EGEHE	n	11	11	11	11	11	11	11	11	11	11
0 mg/kg	Mean	227.4	71.678	69.3	22.122	16.28	5.185	17.85	5.698	112.5	35.934
	S.D.	63.1	16.104	5.3	2.266	2.13	0.648	4.56	1.491	12.6	4.538
EGEHE	n	11	11	11	11	11	11	11	11	11	11
100 mg/kg	Mean	243.2	79.025	73.8	23.868	16.35	5.290	18.82	6.076	118.3	38.112
	S.D.	69.4	23.360	12.7	3.913	2.01	0.657	2.24	0.570	17.8	4.266
EGEHE	n	11	11	11	11	11	11	11	11	11	11
300 mg/kg	Mean	265.0	89.052	75.8	25.347	16.73	5.585	16.20	5.434	118.2	39.485
	S.D.	41.1	16.434	6.3	1.703	2.25	0.634	3.43	1.210	22.2	6.760
					ST **						
EGEHE	n	10	10	10	10	10	10	10	10	10	10
1000 mg/kg	Mean	234.5	83.195	75.4	26.876	15.31	5.458	17.44	6.234	96.9	34.710
	S.D.	70.1	22.354	12.3	3.794	1.94	0.566	4.18	1.539	6.3	3.350
					ST *					ST **	

AB : Absolute weight, RE : Relative weight by body weight

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01

DT : Dunnett test (two-side), ST : Steel test (two-side)

Table 14 - 4

Study No. : SR17140

Organ weight
Sex : Female

Stage : Day 5 after delivery

Species : Rat

Test article		Uterus		Brain	
		AB	RE	AB	RE
Dose		mg	mg/100g	g	g/100g
EGEHE	n	11	11	11	11
0 mg/kg	Mean	698.0	223.027	2.024	0.648
	S.D.	80.9	30.990	0.077	0.064
EGEHE	n	11	11	11	11
100 mg/kg	Mean	695.6	225.447	2.013	0.652
	S.D.	59.6	22.960	0.066	0.043
EGEHE	n	11	11	11	11
300 mg/kg	Mean	667.2	223.539	1.994	0.667
	S.D.	47.3	19.629	0.094	0.031
EGEHE	n	10	10	10	10
1000 mg/kg	Mean	630.2	226.672	1.995	0.716
	S.D.	59.1	33.640	0.092	0.079
		DT *			

AB : Absolute weight, RE : Relative weight by body weight
Significantly different from EGEHE 0 mg/kg: * P<0.05
DT : Dunnett test (two-side)

Table 14 - 5

Study No. : SR17140

Organ weight

Stage : Day 29

Sex : Female (satellite)

Species : Rat

Test article		Body weight	Liver		Kidney		Heart		Spleen	
			AB	RE	AB	RE	AB	RE	AB	RE
Dose		g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
EGEHE	n	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	250.6	6.398	2.558	1.894	0.758	0.830	0.334	480.8	191.652
	S.D.	14.6	0.586	0.221	0.144	0.078	0.045	0.023	52.8	14.347
EGEHE	n	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	244.0	8.758	3.588	1.830	0.750	0.770	0.318	489.0	199.718
	S.D.	11.0	0.706	0.175	0.105	0.019	0.019	0.008	117.6	42.915
			T2 **	T2 **			T2 *			

Test article		Thymus		Adrenal		Pituitary gland		Thyroid		Ovary	
		AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
Dose		mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	331.4	132.674	73.6	29.304	13.16	5.288	15.18	6.058	82.8	32.862
	S.D.	67.7	29.635	8.1	1.755	1.74	0.903	4.71	1.828	21.9	8.040
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	358.0	145.904	72.4	29.704	14.90	6.136	16.94	6.964	83.6	34.224
	S.D.	77.7	25.628	10.5	4.341	3.12	1.445	1.96	0.992	8.8	2.601

Test article		Uterus		Brain	
		AB	RE	AB	RE
Dose		mg	mg/100g	g	g/100g
EGEHE	n	5	5	5	5
0 mg/kg	Mean	884.6	350.710	1.976	0.788
	S.D.	286.8	103.369	0.083	0.035
EGEHE	n	5	5	5	5
1000 mg/kg	Mean	790.2	323.256	1.958	0.806
	S.D.	214.5	82.694	0.023	0.046

AB : Absolute weight, RE : Relative weight by body weight

Significantly different from EGEHE 0 mg/kg: * P<0.05, ** P<0.01

T2 : Student t-test (two-side)

Table 14 - 6

Study No. : SR17140

Organ weight

Stage : Recovery Day 15

Sex : Male

Species : Rat

Test article		Body weight	Liver		Kidney		Heart		Spleen	
			AB	RE	AB	RE	AB	RE	AB	RE
Dose		g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
EGEHE	n	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	495.8	12.102	2.438	3.064	0.618	1.434	0.290	800.4	161.438
	S.D.	11.8	0.652	0.099	0.275	0.044	0.011	0.007	94.9	18.958
EGEHE	n	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	468.0	11.920	2.546	3.148	0.672	1.386	0.294	690.2	147.654
	S.D.	21.3	0.933	0.113	0.317	0.049	0.065	0.011	18.2	5.924
		T2 *								

Test article		Thymus		Adrenal		Pituitary gland		Thyroid		Testis	
		AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
Dose		mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	g	g/100g
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	366.6	74.112	62.2	12.530	12.96	2.612	22.06	4.452	3.250	0.656
	S.D.	88.6	18.668	9.1	1.671	1.13	0.197	4.81	0.991	0.602	0.118
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	330.0	70.436	63.8	13.596	12.78	2.734	20.38	4.364	3.064	0.658
	S.D.	54.5	10.469	8.2	1.154	0.56	0.128	1.18	0.339	0.302	0.084

Test article		Epididymis		Prostate		Seminal vesicle		Brain	
		AB	RE	AB	RE	AB	RE	AB	RE
Dose		g	g/100g	mg	mg/100g	g	g/100g	g	g/100g
EGEHE	n	5	5	5	5	5	5	5	5
0 mg/kg	Mean	1.312	0.264	903.8	182.472	2.536	0.512	2.234	0.450
	S.D.	0.168	0.034	159.3	32.817	0.230	0.037	0.128	0.022
EGEHE	n	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	1.276	0.270	701.6	151.600	2.392	0.512	2.234	0.478
	S.D.	0.134	0.032	211.6	50.211	0.281	0.080	0.118	0.031

AB : Absolute weight, RE : Relative weight by body weight

Significantly different from EGEHE 0 mg/kg: * P<0.05

T2 : Student t-test (two-side)

Table 14 - 7

Study No. : SR17140

Organ weight

Stage : Recovery Day 15

Sex : Female (satellite)

Species : Rat

Test article		Body weight	Liver		Kidney		Heart		Spleen	
			AB	RE	AB	RE	AB	RE	AB	RE
Dose		g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
EGEHE	n	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	265.6	6.774	2.548	1.832	0.690	0.880	0.332	504.0	190.212
	S.D.	12.0	0.482	0.078	0.140	0.032	0.053	0.008	100.1	38.359
EGEHE	n	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	261.8	6.898	2.636	1.962	0.750	0.876	0.334	548.4	209.566
	S.D.	5.4	0.427	0.183	0.015	0.020	0.031	0.009	82.1	31.724
						T2 **				

Test article		Thymus		Adrenal		Pituitary gland		Thyroid		Ovary	
		AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
Dose		mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g
EGEHE	n	5	5	5	5	5	5	5	5	5	5
0 mg/kg	Mean	298.2	112.680	73.6	27.848	17.28	6.508	16.92	6.356	97.2	36.264
	S.D.	32.9	15.046	13.5	5.876	3.57	1.302	5.60	2.026	29.9	9.566
EGEHE	n	5	5	5	5	5	5	5	5	5	5
1000 mg/kg	Mean	309.8	118.452	74.6	28.564	14.70	5.624	13.40	5.120	97.0	36.984
	S.D.	22.6	10.152	12.4	5.202	2.04	0.884	2.91	1.105	18.2	6.451

Test article		Uterus		Brain	
		AB	RE	AB	RE
Dose		mg	mg/100g	g	g/100g
EGEHE	n	5	5	5	5
0 mg/kg	Mean	718.0	274.086	2.036	0.768
	S.D.	254.3	109.359	0.072	0.057
EGEHE	n	5	5	5	5
1000 mg/kg	Mean	543.4	206.648	1.992	0.762
	S.D.	294.3	109.087	0.108	0.047

AB : Absolute weight, RE : Relative weight by body weight

Significantly different from EGEHE 0 mg/kg: ** P<0.01

T2 : Student t-test (two-side)

Table 15 - 1

Study No. : SR17140

Histopathological findings
Sex : Male

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	7					12					12					7				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Lung				<7>					<0>					<0>					<7>		
Aggregation, macrophage, alveolar		6	1	0	0	0	0	0	0	0	0	0	0	0	0	0	7	0	0	0	0
							ED					ED									
Trachea				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Submandibular gland				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Esophagus				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Stomach				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Duodenum				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Jejunum				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Ileum				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Cecum				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg
ED : The number of samples of a treated group is less than 2.

Table 15 - 2

Study No. : SR17140

Histopathological findings
Sex : Male

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	7					12					12					7				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Colon		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Rectum		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Pancreas		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Liver		<7>					<12>					<12>					<7>				
Hypertrophy, hepatocyte, centrilobular		7	0	0	0	0	12	0	0	0	0	12	0	0	0	0	0	7	0	0	0
																	FT $$				
Microgranuloma		4	3	0	0	0	5	7	0	0	0	5	7	0	0	0	2	3	2	0	0
Vacuolation, hepatocyte, periportal		5	2	0	0	0	12	0	0	0	0	11	1	0	0	0	7	0	0	0	0
Heart		<7>					<0>					<0>					<7>				
Inflammation, focal		4	3	0	0	0	0	0	0	0	0	0	0	0	0	0	6	1	0	0	0
							ED					ED									
Kidney		<7>					<0>					<0>					<7>				
Basophilic change, renal tubule		5	2	0	0	0	0	0	0	0	0	0	0	0	0	0	5	2	0	0	0
							ED					ED									
Urinary bladder		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Significantly different from EGEHE 0 mg/kg: $$ P<0.01
FT : Fisher's exact test (two-side)
ED : The number of samples of a treated group is less than 2.

Table 15 - 3

Study No. : SR17140

Histopathological findings
Sex : Male

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	7					12					12					7				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Testis				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Epididymis				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Prostate				<7>					<0>					<0>					<7>		
Inflammation, interstitium		4	3	0	0	0	0	0	0	0	0	0	0	0	0	0	6	1	0	0	0
							ED					ED									
Seminal vesicle				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Coagulating gland				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Cerebrum				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Cerebellum				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Pons				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									
Spinal cord				<7>					<0>					<0>					<7>		
		7					0					0					7				
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg
ED : The number of samples of a treated group is less than 2.

Table 15 - 4

Study No. : SR17140

Histopathological findings
Sex : Male

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	7					12					12					7				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Sciatic nerve		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Spleen		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Thymus		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Bone marrow, femur		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Submandibular lymph node		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Mesenteric lymph node		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Peyer's patch		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Pituitary gland		<7>					<0>					<0>					<7>				
Cyst, pars distalis		7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	2	0	0	0
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg
ED : The number of samples of a treated group is less than 2.

Table 15 - 5

Study No. : SR17140

Histopathological findings
Sex : Male

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	7					12					12					7				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Thyroid		<7>					<0>					<0>					<7>				
Ultimobranchial body		5	2	0	0	0	0	0	0	0	0	0	0	0	0	0	4	3	0	0	0
							ED					ED									
Parathyroid		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Adrenal		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Eyeball		<7>					<0>					<0>					<7>				
Rosette, retina		6	1	0	0	0	0	0	0	0	0	0	0	0	0	0	7	0	0	0	0
							ED					ED									
Harderian gland		<7>					<0>					<0>					<7>				
Infiltration, inflammatory cell, focal		5	2	0	0	0	0	0	0	0	0	0	0	0	0	0	6	1	0	0	0
							ED					ED									
Skeletal muscle		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Femur		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									
Mammary gland		<7>					<0>					<0>					<7>				
		7					0					0					7				
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg
ED : The number of samples of a treated group is less than 2.

Table 15 - 6

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Day 5 after delivery

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	11					11					11					10				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Lung		<11>					<0>					<0>					<10>				
Aggregation, macrophage, alveolar		11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	1	0	0	0
							ED					ED									
Trachea		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Submandibular gland		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Esophagus		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Stomach		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Duodenum		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Jejunum		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Ileum		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Cecum		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg
ED : The number of samples of a treated group is less than 2.

Table 15 - 7

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Day 5 after delivery

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	11					11					11					10				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Colon		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Rectum		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Pancreas		<11>					<0>					<0>					<10>				
Atrophy, acinar cell, focal		10	1	0	0	0	0	0	0	0	0	0	0	0	0	0	10	0	0	0	0
							ED					ED									
Liver		<11>					<11>					<11>					<10>				
Hypertrophy, hepatocyte, centrilobular		11	0	0	0	0	11	0	0	0	0	11	0	0	0	0	3	7	0	0	0
																	FT $$				
Necrosis, focal		11	0	0	0	0	10	1	0	0	0	10	1	0	0	0	10	0	0	0	0
Microgranuloma		8	3	0	0	0	10	1	0	0	0	8	3	0	0	0	6	4	0	0	0
Heart		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Kidney		<11>					<0>					<0>					<10>				
Infarct		10	0	1	0	0	0	0	0	0	0	0	0	0	0	0	10	0	0	0	0
							ED					ED									
Infiltration, inflammatory cell, renal pelvic mucosa		10	1	0	0	0	0	0	0	0	0	0	0	0	0	0	10	0	0	0	0
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Significantly different from EGEHE 0 mg/kg: $$ P<0.01
FT : Fisher's exact test (two-side)
ED : The number of samples of a treated group is less than 2.

Table 15 - 8

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Day 5 after delivery

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	11					11					11					10				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Urinary bladder				<11>					<0>					<0>					<10>		
		11					0					0					10				
							ED					ED									
Ovary				<11>					<0>					<0>					<10>		
		11					0					0					10				
							ED					ED									
Uterine horn				<11>					<0>					<0>					<10>		
		11					0					0					10				
							ED					ED									
Uterine cervix				<11>					<0>					<0>					<10>		
		11					0					0					10				
							ED					ED									
Vagina				<11>					<0>					<0>					<10>		
		11					0					0					10				
							ED					ED									
Cerebrum				<11>					<0>					<0>					<10>		
		11					0					0					10				
							ED					ED									
Cerebellum				<11>					<0>					<0>					<10>		
		11					0					0					10				
							ED					ED									
Pons				<11>					<0>					<0>					<10>		
		11					0					0					10				
							ED					ED									
Spinal cord				<11>					<0>					<0>					<10>		
		11					0					0					10				
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg
ED : The number of samples of a treated group is less than 2.

Table 15 - 9

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Day 5 after delivery

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	11					11					11					10				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Sciatic nerve		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Spleen		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Thymus		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Bone marrow, femur		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Submandibular lymph node		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Mesenteric lymph node		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Peyer's patch		<11>					<0>					<0>					<10>				
Mineralization		11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	3	0	0	0
							ED					ED									
Pituitary gland		<11>					<0>					<0>					<10>				
Cyst, pars distalis		10	1	0	0	0	0	0	0	0	0	0	0	0	0	0	10	0	0	0	0
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg
ED : The number of samples of a treated group is less than 2.

Table 15 - 10

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Day 5 after delivery

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					100 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	11					11					11					10				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Thyroid		<11>					<0>					<0>					<10>				
Cyst		10	1	0	0	0	0	0	0	0	0	0	0	0	0	0	10	0	0	0	0
							ED					ED									
Ultimobranchial body		9	2	0	0	0	0	0	0	0	0	0	0	0	0	0	6	4	0	0	0
							ED					ED									
Parathyroid		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Adrenal		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Eyeball		<11>					<0>					<0>					<10>				
Atrophy, retina, focal		9	2	0	0	0	0	0	0	0	0	0	0	0	0	0	10	0	0	0	0
							ED					ED									
Harderian gland		<11>					<0>					<0>					<10>				
Infiltration, inflammatory cell		11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	1	0	0	0
							ED					ED									
Skeletal muscle		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									
Femur		<11>					<0>					<0>					<10>				
Osteosclerosis		11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	0	1	0	0
							ED					ED									
Mammary gland		<11>					<0>					<0>					<10>				
		11					0					0					10				
							ED					ED									

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg
ED : The number of samples of a treated group is less than 2.

Table 15 - 11

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Unsuccessful mating

Species : Rat

Organ / Findings	Test article	EGEHE				
	Dose	100 mg/kg				
	Number of Animals	1				
	Grade	-	1+	2+	3+	4+
Liver		<1>				
Microgranuloma		0	1	0	0	0

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe

Table 15 - 12

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Non-pregnancy

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	1					1					2				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Lung				<1>					<0>					<2>		
		1					0					2				
Trachea				<1>					<0>					<2>		
		1					0					2				
Submandibular gland				<1>					<0>					<2>		
		1					0					2				
Esophagus				<1>					<0>					<2>		
		1					0					2				
Stomach				<1>					<0>					<2>		
		1					0					2				
Duodenum				<1>					<0>					<2>		
		1					0					2				
Jejunum				<1>					<0>					<2>		
		1					0					2				
Ileum				<1>					<0>					<2>		
		1					0					2				
Cecum				<1>					<0>					<2>		
		1					0					2				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe

Table 15 - 13

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Non-pregnancy

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	1					1					2				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Colon		<1>					<0>					<2>				
		1					0					2				
Rectum		<1>					<0>					<2>				
		1					0					2				
Pancreas		<1>					<0>					<2>				
		1					0					2				
Liver		<1>					<1>					<2>				
Hypertrophy, hepatocyte, centrilobular		1	0	0	0	0	1	0	0	0	0	1	1	0	0	0
Microgranuloma		0	1	0	0	0	1	0	0	0	0	1	1	0	0	0
Heart		<1>					<0>					<2>				
		1					0					2				
Kidney		<1>					<0>					<2>				
		1					0					2				
Urinary bladder		<1>					<0>					<2>				
		1					0					2				
Ovary		<1>					<0>					<2>				
		1					0					2				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe

Table 15 - 14

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Non-pregnancy

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	1					1					2				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Uterine horn		<1>					<0>					<2>				
Infiltration, inflammatory cell		0	0	1	0	0	0	0	0	0	0	2	0	0	0	0
Uterine cervix		<1>					<0>					<2>				
Infiltration, inflammatory cell		0	0	1	0	0	0	0	0	0	0	2	0	0	0	0
Vagina		<1>					<1>					<2>				
Septum		0	0	1	0	0	0	0	1	0	0	2	0	0	0	0
Infiltration, inflammatory cell		1	0	0	0	0	0	0	1	0	0	2	0	0	0	0
Cerebrum		<1>					<0>					<2>				
		1					0					2				
Cerebellum		<1>					<0>					<2>				
		1					0					2				
Pons		<1>					<0>					<2>				
		1					0					2				
Spinal cord		<1>					<0>					<2>				
		1					0					2				
Sciatic nerve		<1>					<0>					<2>				
		1					0					2				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe

Table 15 - 15

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Non-pregnancy

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	1					1					2				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Spleen				<1>					<0>					<2>		
		1					0					2				
Thymus				<1>					<0>					<2>		
		1					0					2				
Bone marrow, femur				<1>					<0>					<2>		
		1					0					2				
Submandibular lymph node				<1>					<0>					<2>		
		1					0					2				
Mesenteric lymph node				<1>					<0>					<2>		
		1					0					2				
Peyer's patch				<1>					<0>					<2>		
		1					0					2				
Pituitary gland				<1>					<0>					<2>		
		1					0					2				
Thyroid				<1>					<0>					<2>		
Ultimobranchial body		0	1	0	0	0	0	0	0	0	0	1	1	0	0	0
Parathyroid				<1>					<0>					<2>		
		1					0					2				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe

Table 15 - 16

Study No. : SR17140

Histopathological findings
Sex : Female

Stage : Non-pregnancy

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE					EGEHE				
	Dose	0 mg/kg					300 mg/kg					1000 mg/kg				
	Number of Animals	1					1					2				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Adrenal		<1>					<0>					<2>				
		1					0					2				
Eyeball		<1>					<0>					<2>				
		1					0					2				
Harderian gland		<1>					<0>					<2>				
		1					0					2				
Skeletal muscle		<1>					<0>					<2>				
		1					0					2				
Femur		<1>					<0>					<2>				
		1					0					2				
Mammary gland		<1>					<0>					<2>				
		1					0					2				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe

Table 15 - 17

Study No. : SR17140

Histopathological findings
Sex : Female (satellite)

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE				
	Dose	0 mg/kg					1000 mg/kg				
	Number of Animals	5					5				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Lung		<5>					<5>				
Aggregation, macrophage, alveolar		4	1	0	0	0	4	1	0	0	0
Trachea		<5>					<5>				
		5					5				
Submandibular gland		<5>					<5>				
		5					5				
Esophagus		<5>					<5>				
		5					5				
Stomach		<5>					<5>				
		5					5				
Duodenum		<5>					<5>				
		5					5				
Jejunum		<5>					<5>				
		5					5				
Ileum		<5>					<5>				
		5					5				
Cecum		<5>					<5>				
		5					5				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg

Table 15 - 18

Study No. : SR17140

Histopathological findings
Sex : Female (satellite)

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE				
	Dose	0 mg/kg					1000 mg/kg				
	Number of Animals	5					5				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Colon		<5>					<5>				
		5					5				
Rectum		<5>					<5>				
		5					5				
Pancreas		<5>					<5>				
		5					5				
Liver		<5>					<5>				
Hypertrophy, hepatocyte, centrilobular		5	0	0	0	0	2	3	0	0	0
Microgranuloma		4	1	0	0	0	3	2	0	0	0
Vacuolation, hepatocyte, periportal		4	1	0	0	0	5	0	0	0	0
Heart		<5>					<5>				
		5					5				
Kidney		<5>					<5>				
Cyst		5	0	0	0	0	4	1	0	0	0
Basophilic change, renal tubule		4	1	0	0	0	4	1	0	0	0

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg

Table 15 - 19

Study No. : SR17140

Histopathological findings
Sex : Female (satellite)

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE				
	Dose	0 mg/kg					1000 mg/kg				
	Number of Animals	5					5				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Urinary bladder		<5>					<5>				
		5					5				
Ovary		<5>					<5>				
		5					5				
Uterine horn		<5>					<5>				
		5					5				
Uterine cervix		<5>					<5>				
		5					5				
Vagina		<5>					<5>				
		5					5				
Cerebrum		<5>					<5>				
		5					5				
Cerebellum		<5>					<5>				
		5					5				
Pons		<5>					<5>				
		5					5				
Spinal cord		<5>					<5>				
		5					5				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg

Table 15 - 20

Study No. : SR17140

Histopathological findings
Sex : Female (satellite)

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE				
	Dose	0 mg/kg					1000 mg/kg				
	Number of Animals	5					5				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Sciatic nerve		<5>					<5>				
		5					5				
Spleen		<5>					<5>				
		5					5				
Thymus		<5>					<5>				
		5					5				
Bone marrow, femur		<5>					<5>				
		5					5				
Submandibular lymph node		<5>					<5>				
		5					5				
Mesenteric lymph node		<5>					<5>				
		5					5				
Peyer's patch		<5>					<5>				
		5					5				
Pituitary gland		<5>					<5>				
		5					5				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg

Table 15 - 21

Study No. : SR17140

Histopathological findings
Sex : Female (satellite)

Stage : Day 29

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE				
	Dose	0 mg/kg					1000 mg/kg				
	Number of Animals	5					5				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Thyroid		<5>					<5>				
Ultimobranchial body		3	2	0	0	0	4	1	0	0	0
Parathyroid		<5>					<5>				
		5					5				
Adrenal		<5>					<5>				
		5					5				
Eyeball		<5>					<5>				
		5					5				
Harderian gland		<5>					<5>				
		5					5				
Skeletal muscle		<5>					<5>				
		5					5				
Femur		<5>					<5>				
		5					5				
Mammary gland		<5>					<5>				
		5					5				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg

Table 15 - 22

Study No. : SR17140

Histopathological findings
Sex : Male

Stage : Recovery Day 15

Species : Rat

Organ / Findings	Test article	EGEHE					EGEHE				
	Dose	0 mg/kg					1000 mg/kg				
	Number of Animals	5					5				
	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Liver		<5>					<5>				
Microgranuloma		2	2	1	0	0	1	4	0	0	0
Vacuolation, hepatocyte, periportal		4	1	0	0	0	5	0	0	0	0
Epididymis		<1>					<0>				
Granuloma, spermatic		0	1	0	0	0	0	0	0	0	0
							ED				

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg
ED : The number of samples of a treated group is less than 2.

Table 15 - 23

Study No. : SR17140

Histopathological findings
Sex : Female (satellite)

Stage : Recovery Day 15

Species : Rat

Organ	Test article	EGEHE					EGEHE				
	Dose	0 mg/kg					1000 mg/kg				
	Number of Animals	5					5				
Findings	Grade	-	1+	2+	3+	4+	-	1+	2+	3+	4+
Liver		<5>					<5>				
Microgranuloma		3	2	0	0	0	2	3	0	0	0

<> : Number of animals examined
- : Not remarkable
1+ : Slight, 2+ : Mild, 3+ : Moderate, 4+ : Severe
Not significantly different from EGEHE 0 mg/kg

Table 16

Study No. : SR17140

Estrous cycles
Generation : F0

Species : Rat

Test article Dose		/Before mating Mean length of estrous cycle (Days)	Number of estrus	Number of animals with acyclic or irregular cycle
EGEHE 0 mg/kg	n	12	12	12 (0)
	Mean	4.03	3.7	
	S.D.	0.09	0.5	
EGEHE 100 mg/kg	n	12	12	12 (0)
	Mean	4.13	3.4	
	S.D.	0.31	0.5	
EGEHE 300 mg/kg	n	12	12	12 (0)
	Mean	4.08	3.4	
	S.D.	0.29	0.5	
EGEHE 1000 mg/kg	n	12	12	12 (0)
	Mean	4.04	3.4	
	S.D.	0.14	0.5	

() : Values in brackets represent number of animals with acyclic or irregular cycle.
Not significantly different from EGEHE 0 mg/kg

Table 17 - 1

Study No. : SR17140

Reproductive performance
Generation : F0 Sex : Male

Species : Rat

Test article Dose		Number of pairs	Day of conceiving	1st mating Copulation index (%)	1st mating Fertility index (%)	2nd mating Copulation index (%)	2nd mating Fertility index (%)	Total Copulation index (%)	Total Fertility index (%)
EGEHE	n	12	12	(12/12)	(11/12)			(12/12)	(11/12)
0 mg/kg	Mean		3.3	100.0	91.7			100.0	91.7
	S.D.		2.7						
EGEHE	n	12	11	(11/12)	(11/11)			(11/12)	(11/11)
100 mg/kg	Mean		2.5	91.7	100.0			91.7	100.0
	S.D.		1.3						
EGEHE	n	12	12	(12/12)	(11/12)			(12/12)	(11/12)
300 mg/kg	Mean		2.3	100.0	91.7			100.0	91.7
	S.D.		1.4						
EGEHE	n	12	12	(12/12)	(10/12)			(12/12)	(10/12)
1000 mg/kg	Mean		3.0	100.0	83.3			100.0	83.3
	S.D.		3.3						

Not significantly different from EGEHE 0 mg/kg

Table 17 - 2

Study No. : SR17140

Reproductive performance
Generation : F0 Sex : Female

Species : Rat

Test article Dose		Number of pairs	Day of conceiving	1st mating Copulation index (%)	1st mating Fertility index (%)	2nd mating Copulation index (%)	2nd mating Fertility index (%)	Total Copulation index (%)	Total Fertility index (%)
EGEHE	n	12	12	(12/12)	(11/12)			(12/12)	(11/12)
0 mg/kg	Mean		3.3	100.0	91.7			100.0	91.7
	S.D.		2.7						
EGEHE	n	12	11	(11/12)	(11/11)			(11/12)	(11/11)
100 mg/kg	Mean		2.5	91.7	100.0			91.7	100.0
	S.D.		1.3						
EGEHE	n	12	12	(12/12)	(11/12)			(12/12)	(11/12)
300 mg/kg	Mean		2.3	100.0	91.7			100.0	91.7
	S.D.		1.4						
EGEHE	n	12	12	(12/12)	(10/12)			(12/12)	(10/12)
1000 mg/kg	Mean		3.0	100.0	83.3			100.0	83.3
	S.D.		3.3						

Not significantly different from EGEHE 0 mg/kg

Table 18 - 1

Study No. : SR17140

Delivery data
Generation : F0

Species : Rat

Test article Dose		Gestation period (day)	Number of implantation	Birth index (%)	Number of offspring	Number of live newborns M	F	Total	Sex ratio (offspring) (%)	Number of dead newborns Dead	Cannibalism	Total	Gestation index (%)
EGEHE	n	11	11	11	11	11	11	11	90/164	11	11	11	11/11
0 mg/kg	Mean	22.09	15.9	93.69	15.1	8.2	6.7	14.9	54.9	0.2	0.0	0.2	100.0
	S.D.	0.30	1.7	5.57	1.8	2.1	2.5	1.9		0.6	0.0	0.6	0.00
EGEHE	n	11	11	11	11	11	11	11	71/151	11	11	11	11/11
100 mg/kg	Mean	22.27	14.7	92.97	13.7	6.5	7.3	13.7	47.0	0.0	0.0	0.0	100.0
	S.D.	0.47	1.6	8.35	2.1	1.9	2.1	2.1		0.0	0.0	0.0	0.00
EGEHE	n	11	11	11	11	11	11	11	71/157	11	11	11	11/11
300 mg/kg	Mean	22.55	15.5	92.45	14.5	6.5	7.8	14.3	45.2	0.2	0.0	0.2	100.0
	S.D.	0.52	1.6	15.08	2.0	1.4	2.5	2.4		0.6	0.0	0.6	0.00
EGEHE	n	10	10	10	10	10	10	10	62/127	10	10	10	10/10
1000 mg/kg	Mean	22.30	14.4	87.55	13.5	6.2	6.5	12.7	48.8	0.8	0.0	0.8	100.0
	S.D.	0.48	2.1	18.15	2.5	2.5	2.6	3.5		1.9	0.0	1.9	0.00

M : Male, F : Female
Not significantly different from EGEHE 0 mg/kg

Table 18 - 2

Study No. : SR17140

Delivery data
Generation : F0

Species : Rat

Test article Dose		Number of corpora lutea	Implantation index (%)	Nursing index (%)
EGEHE	n	11	11	11/11
0 mg/kg	Mean	16.4	97.38	100.0
	S.D.	1.8	4.71	
EGEHE	n	11	11	11/11
100 mg/kg	Mean	15.1	97.83	100.0
	S.D.	1.8	4.01	
EGEHE	n	11	11	11/11
300 mg/kg	Mean	16.4	95.32	100.0
	S.D.	2.0	5.06	
EGEHE	n	10	10	10/10
1000 mg/kg	Mean	14.7	98.20	100.0
	S.D.	2.3	4.02	

Not significantly different from EGEHE 0 mg/kg

Table 18 - 3

Study No. : SR17140

Delivery data (external examination of offspring)

Generation : F0

Day after birth : 0

Species : Rat

Test article	EGEHE	EGEHE	EGEHE	EGEHE
Dose	0	100	300	1000
Dose unit	mg/kg	mg/kg	mg/kg	mg/kg
Number of dams	11	11	11	10
Number of offspring	164	151	157	127
Number of dams with anomalous offspring (incidence %)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
Number of offspring with any anomaly (incidence %)	0(0.00)	0(0.00)	0(0.00)	0(0.00)

Not significantly different from EGEHE 0 mg/kg

Table 19

Study No. : SR17140

Clinical sign of offspring
Generation : F0

Species : Rat

Test article Dose	Clinical signs	Day after birth	0	1	2	3	4
EGEHE 0 mg/kg	Number of dams examined		11	11	11	11	11
	Number of offspring		164	164	164	164	162
	Number of dams with anomalous offspring		0	0	0	0	0
EGEHE 100 mg/kg	Number of dams examined		11	11	11	11	11
	Number of offspring		151	151	151	151	151
	Number of dams with anomalous offspring		0	0	0	0	0
EGEHE 300 mg/kg	Number of dams examined		11	11	11	11	11
	Number of offspring		157	157	157	157	156
	Number of dams with anomalous offspring		0	0	0	0	0
EGEHE 1000 mg/kg	Number of dams examined		10	10	10	10	10
	Number of offspring		127	127	127	127	122
	Number of dams with anomalous offspring		0	0	0	0	0

Table 20

Study No. : SR17140

Litter size and viability index of offspring
Generation : F0

Species : Rat

Test article Dose		/Day after birth 0 All pups	0 Live pups	0 Viability index (%)	4 Live pups	4 Viability index (%)
EGEHE	Total	166	164		162	
0 mg/kg	n	11	11	11	11	11
	Mean			98.79		98.75
	S.D.			4.01		2.79
EGEHE	Total	151	151		151	
100 mg/kg	n	11	11	11	11	11
	Mean			100.00		100.00
	S.D.			0.00		0.00
EGEHE	Total	159	157		156	
300 mg/kg	n	11	11	11	11	11
	Mean			98.35		99.49
	S.D.			5.49		1.69
EGEHE	Total	135	127		122	
1000 mg/kg	n	10	10	10	10	10
	Mean			93.30		95.12
	S.D.			17.25		6.45

Not significantly different from EGEHE 0 mg/kg

Table 21

Study No. : SR17140

Body weight of offspring
Generation : F0

Unit : g

Species : Rat

Test article Dose			/Day after birth 0	 4
EGEHE 0 mg/kg	Male	n	11	11
		Mean	6.495	10.608
		S.D.	0.398	0.788
	Female	n	11	11
		Mean	6.065	10.055
		S.D.	0.427	0.931
EGEHE 100 mg/kg	Male	n	11	11
		Mean	6.964	11.132
		S.D.	0.575	1.050
	Female	n	11	11
		Mean	6.542	10.746
		S.D.	0.629	1.093
EGEHE 300 mg/kg	Male	n	11	11
		Mean	6.783	11.101
		S.D.	0.717	1.903
	Female	n	11	11
		Mean	6.383	10.463
		S.D.	0.735	1.855
EGEHE 1000 mg/kg	Male	n	10	10
		Mean	5.852	10.036
		S.D.	0.664	1.493
			DT *	
	Female	n	10	10
		Mean	5.687	9.554
		S.D.	0.718	1.454

Significantly different from EGEHE 0 mg/kg: * P<0.05
DT : Dunnett test (two-side)

Table 22

Study No. : SR17140

Necropsy findings of offspring
Generation : F0

Species : Rat

Test article	EGEHE	EGEHE	EGEHE	EGEHE
Dose	0	100	300	1000
Dose unit	mg/kg	mg/kg	mg/kg	mg/kg
Number of dams	11	11	11	10
Number of live offspring examined on Day 4 of birth	162	151	156	122
Finding absent	162	151	156	120
Kidney: Dilatation, renal pelvis	0	0	0	2
Number of dead offspring examined on Day 0-4 of birth	4	0	2	9
Finding absent	3	0	2	9
Kidney: Dilatation, renal pelvis	1	0	0	0

Clinical sign
Sex : Male

Period : Administration Day 1-29
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10101	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10102	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10103	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10104	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10105	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10106	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10107	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10108	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10109	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10110	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10111	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10112	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17		18	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10101	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10102	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10103	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10104	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10105	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10106	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10107	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10108	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10109	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10110	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10111	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10112	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	19		20		21		22		23		24		25		26		27	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10101	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10102	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10103	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10104	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10105	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10106	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10107	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10108	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10109	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10110	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10111	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10112	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Administration)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Male

Period : Administration Day 1-29
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Clinical signs	Day	28		29
		Time	1	2	3
10101	No abnormality		-	-	-
10102	No abnormality		-	-	-
10103	No abnormality		-	-	-
10104	No abnormality		-	-	
10105	No abnormality		-	-	-
10106	No abnormality		-	-	
10107	No abnormality		-	-	-
10108	No abnormality		-	-	
10109	No abnormality		-	-	-
10110	No abnormality		-	-	
10111	No abnormality		-	-	-
10112	No abnormality		-	-	

Administration)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Male

Period : Administration Day 1-29
Dose : EGEHE 100 mg/kg
Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10201	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10202	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10203	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10204	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10205	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10206	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10207	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10208	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10209	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10210	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10211	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10212	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17		18	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10201	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10202	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10203	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10204	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10205	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10206	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10207	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10208	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10209	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10210	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10211	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10212	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	19		20		21		22		23		24		25		26		27	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10201	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10202	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10203	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10204	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10205	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10206	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10207	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10208	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10209	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10210	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10211	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10212	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Administration)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Male

Period : Administration Day 1-29
Dose : EGEHE 100 mg/kg
Species : Rat

Animal No.	Clinical signs	Day	28		29
		Time	1	2	3
10201	No abnormality		-	-	-
10202	No abnormality		-	-	-
10203	No abnormality		-	-	-
10204	No abnormality		-	-	-
10205	No abnormality		-	-	-
10206	No abnormality		-	-	-
10207	No abnormality		-	-	-
10208	No abnormality		-	-	-
10209	No abnormality		-	-	-
10210	No abnormality		-	-	-
10211	No abnormality		-	-	-
10212	No abnormality		-	-	-

Administration)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Male

Period : Administration Day 1-29
Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10301	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10302	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10303	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10304	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10305	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10306	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10307	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10308	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10309	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10310	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10311	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10312	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17		18	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10301	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10302	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10303	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10304	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10305	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10306	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10307	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10308	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10309	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10310	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10311	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10312	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	19		20		21		22		23		24		25		26		27	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10301	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10302	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10303	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10304	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10305	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10306	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10307	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10308	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10309	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10310	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10311	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10312	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Administration)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Male

Period : Administration Day 1-29
Dose : EGEHE 300 mg/kg
Species : Rat

Animal No.	Clinical signs	Day 28		29
		Time 1	2	3
10301	No abnormality	-	-	-
10302	No abnormality	-	-	-
10303	No abnormality	-	-	-
10304	No abnormality	-	-	-
10305	No abnormality	-	-	-
10306	No abnormality	-	-	-
10307	No abnormality	-	-	-
10308	No abnormality	-	-	-
10309	No abnormality	-	-	-
10310	No abnormality	-	-	-
10311	No abnormality	-	-	-
10312	No abnormality	-	-	-

Administration)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Male

Period : Administration Day 1-29
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10401	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10402	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10403	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10404	Soil of perigenital fur		-	-	-	-	-	-	-	-	+	+	+	+	+	+	-	-	-	-
10405	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10406	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10407	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10408	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10409	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10410	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10411	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10412	Soil of perigenital fur		-	-	-	-	-	-	+	+	+	+	+	+	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17		18	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10401	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10402	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
10403	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10404	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	-	-
10405	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	-	-
10406	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-
10407	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-
10408	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10409	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10410	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10411	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
10412	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+

Animal No.	Clinical signs	Day	19		20		21		22		23		24		25		26		27	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10401	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10402	Soil of perigenital fur		+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10403	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10404	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10405	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10406	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10407	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10408	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10409	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10410	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10411	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10412	Soil of perigenital fur		+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Administration)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Male

Period : Administration Day 1-29
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Clinical signs	Day 28 Time 1	2	29 3
10401	No abnormality	-	-	-
10402	Soil of perigenital fur	-	-	-
10403	No abnormality	-	-	-
10404	Soil of perigenital fur	-	-	
10405	Soil of perigenital fur	-	-	-
10406	Soil of perigenital fur	-	-	
10407	Soil of perigenital fur	-	-	
10408	No abnormality	-	-	-
10409	No abnormality	-	-	
10410	No abnormality	-	-	-
10411	Soil of perigenital fur	-	-	-
10412	Soil of perigenital fur	-	-	

Administration)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Female

Period : F0 Day 1-23
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50151	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50152	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50153	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50154	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50155	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50156	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50157	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50158	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50159	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50160	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50161	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50162	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17		18	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50151	No abnormality		-	-	-	-	-	-	-	-	-	-								
50152	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50153	No abnormality		-	-	-	-	-	-	-	-	-	-								
50154	No abnormality		-	-	-	-	-	-	-	-	-	-								
50155	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-				
50156	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-						
50157	No abnormality		-	-	-	-	-	-	-	-	-	-								
50158	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50159	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-				
50160	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
50161	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-				
50162	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		

Animal No.	Clinical signs	Day	19		20		21		22		23	
		Time	1	2	1	2	1	2	1	2	1	2
50151	No abnormality											
50152	No abnormality		-	-	-	-	-	-	-	-	-	-
50153	No abnormality											
50154	No abnormality											
50155	No abnormality											
50156	No abnormality											
50157	No abnormality											
50158	No abnormality		-	-	-	-						
50159	No abnormality											
50160	No abnormality											
50161	No abnormality											
50162	No abnormality											

F0)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Female

Period : F0 gestation Day 0-26
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Clinical signs	Day	0		1		2		3		4		5		6		7		8	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50151	No abnormality		-	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ - $
50152	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50153	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50154	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50155	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50156	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50157	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50158	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50159	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50160	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50161	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50162	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	9		10		11		12		13		14		15		16		17	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50151	No abnormality		-	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ - $
50152	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50153	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50154	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50155	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50156	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50157	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50158	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50159	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50160	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50161	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50162	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	18		19		20		21		22		23		24		25		26	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	3	
50151	No abnormality		-	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$
50152	No abnormality		-	-	-	-	-	-	-	-										
50153	No abnormality		-	-	-	-	-	-	-	-										
50154	No abnormality		-	-	-	-	-	-	-	-										
50155	No abnormality		-	-	-	-	-	-	-	-										
50156	No abnormality		-	-	-	-	-	-	-	-										
50157	No abnormality		-	-	-	-	-	-	-	-										
50158	No abnormality		-	-	-	-	-	-	-	-										
50159	No abnormality		-	-	-	-	-	-	-	-										
50160	No abnormality		-	-	-	-	-	-	-	-	-	-								
50161	No abnormality		-	-	-	-	-	-	-	-										
50162	No abnormality		-	-	-	-	-	-	-	-										

F0 gestation)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day
Animal No. 50151 : Non-pregnancy
$: Excepted data from calculation

Clinical sign
Sex : Female

Period : F0 lactation Day 0-5
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	0		1		2		3		4		5
		Time	1	2	1	2	1	2	1	2	1	2	3
50152	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50153	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50154	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50155	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50156	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50157	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50158	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50159	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50160	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50161	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50162	No abnormality		-	-	-	-	-	-	-	-	-	-	-

F0 lactation)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Female

Period : F0 Day 1-52
Dose : EGEHE 100 mg/kg
Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50251	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50252	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50253	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50254	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50255	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50256	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50257	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50258	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50259	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50260	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50261	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50262	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17		18	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50251	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50252	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
50253	No abnormality		-	-	-	-	-	-	-	-	-	-								
50254	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
50255	No abnormality		-	-	-	-	-	-	-	-	-	-								
50256	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-				
50257	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-				
50258	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
50259	No abnormality		-	-	-	-	-	-	-	-	-	-								
50260	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-						
50261	No abnormality		-	-	-	-	-	-	-	-	-	-								
50262	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-				

Animal No.	Clinical signs	Day	19		20		21		22		23		24		25		26		27	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50251	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50252	No abnormality																			
50253	No abnormality																			
50254	No abnormality																			
50255	No abnormality																			
50256	No abnormality																			
50257	No abnormality																			
50258	No abnormality																			
50259	No abnormality																			
50260	No abnormality																			
50261	No abnormality																			
50262	No abnormality																			

F0)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Female

Period : F0 Day 1-52
Dose : EGEHE 100 mg/kg
Species : Rat

Animal No.	Clinical signs	Day	28		29		30		31		32		33		34		35		36	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50251	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50252	No abnormality																			
50253	No abnormality																			
50254	No abnormality																			
50255	No abnormality																			
50256	No abnormality																			
50257	No abnormality																			
50258	No abnormality																			
50259	No abnormality																			
50260	No abnormality																			
50261	No abnormality																			
50262	No abnormality																			

Animal No.	Clinical signs	Day	37		38		39		40		41		42		43		44		45	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50251	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50252	No abnormality																			
50253	No abnormality																			
50254	No abnormality																			
50255	No abnormality																			
50256	No abnormality																			
50257	No abnormality																			
50258	No abnormality																			
50259	No abnormality																			
50260	No abnormality																			
50261	No abnormality																			
50262	No abnormality																			

Animal No.	Clinical signs	Day	46		47		48		49		50		51		52
		Time	1	2	1	2	1	2	1	2	1	2	1	2	3
50251	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-
50252	No abnormality														
50253	No abnormality														
50254	No abnormality														
50255	No abnormality														
50256	No abnormality														
50257	No abnormality														
50258	No abnormality														
50259	No abnormality														
50260	No abnormality														
50261	No abnormality														
50262	No abnormality														

F0)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Female

Period : F0 gestation Day 0-22
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	0		1		2		3		4		5		6		7		8	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50252	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50253	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50254	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50255	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50256	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50257	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50258	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50259	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50260	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50261	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50262	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	9		10		11		12		13		14		15		16		17	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50252	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50253	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50254	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50255	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50256	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50257	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50258	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50259	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50260	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50261	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50262	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	18		19		20		21		22	
		Time	1	2	1	2	1	2	1	2	1	2
50252	No abnormality		-	-	-	-	-	-	-	-		
50253	No abnormality		-	-	-	-	-	-	-	-		
50254	No abnormality		-	-	-	-	-	-	-	-		
50255	No abnormality		-	-	-	-	-	-	-	-		
50256	No abnormality		-	-	-	-	-	-	-	-		
50257	No abnormality		-	-	-	-	-	-	-	-	-	-
50258	No abnormality		-	-	-	-	-	-	-	-	-	-
50259	No abnormality		-	-	-	-	-	-	-	-		
50260	No abnormality		-	-	-	-	-	-	-	-		
50261	No abnormality		-	-	-	-	-	-	-	-	-	-
50262	No abnormality		-	-	-	-	-	-	-	-		

F0 gestation)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Female

Period : F0 lactation Day 0-5
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	0		1		2		3		4		5
		Time	1	2	1	2	1	2	1	2	1	2	3
50252	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50253	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50254	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50255	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50256	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50257	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50258	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50259	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50260	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50261	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50262	No abnormality		-	-	-	-	-	-	-	-	-	-	-

F0 lactation)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Female

Period : F0 Day 1-17
Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50351	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50352	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50353	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50354	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50355	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50356	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50357	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50358	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50359	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50360	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50361	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50362	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50351	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50352	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50353	No abnormality		-	-	-	-	-	-	-	-	-	-						
50354	No abnormality		-	-	-	-	-	-	-	-	-	-						
50355	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-				
50356	No abnormality		-	-	-	-	-	-	-	-	-	-						
50357	No abnormality		-	-	-	-	-	-	-	-	-	-						
50358	No abnormality		-	-	-	-	-	-	-	-	-	-						
50359	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50360	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50361	No abnormality		-	-	-	-	-	-	-	-	-	-						
50362	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-		

F0)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Female

Period : F0 gestation Day 0-26
Dose : EGEHE 300 mg/kg
Species : Rat

Animal No.	Clinical signs	Day	0		1		2		3		4		5		6		7		8	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50351	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50352	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50353	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50354	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50355	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50356	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50357	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50358	No abnormality		-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$
50359	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50360	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50361	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50362	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	9		10		11		12		13		14		15		16		17	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50351	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50352	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50353	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50354	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50355	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50356	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50357	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50358	No abnormality		-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$
50359	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50360	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50361	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50362	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	18		19		20		21		22		23		24		25		26	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	3	
50351	No abnormality		-	-	-	-	-	-	-	-	-	-								
50352	No abnormality		-	-	-	-	-	-	-	-										
50353	No abnormality		-	-	-	-	-	-	-	-	-	-								
50354	No abnormality		-	-	-	-	-	-	-	-										
50355	No abnormality		-	-	-	-	-	-	-	-	-	-								
50356	No abnormality		-	-	-	-	-	-	-	-										
50357	No abnormality		-	-	-	-	-	-	-	-										
50358	No abnormality		-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$
50359	No abnormality		-	-	-	-	-	-	-	-	-	-								
50360	No abnormality		-	-	-	-	-	-	-	-										
50361	No abnormality		-	-	-	-	-	-	-	-	-	-								
50362	No abnormality		-	-	-	-	-	-	-	-	-	-								

F0 gestation)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day
Animal No. 50358 : Non-pregnancy
$: Excepted data from calculation

Clinical sign
Sex : Female

Period : F0 lactation Day 0-5
Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	0		1		2		3		4		5
		Time	1	2	1	2	1	2	1	2	1	2	3
50351	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50352	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50353	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50354	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50355	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50356	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50357	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50359	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50360	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50361	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50362	No abnormality		-	-	-	-	-	-	-	-	-	-	-

F0 lactation)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Female

Period : F0 Day 1-26
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50451	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
50452	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50453	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50454	Decrease in locomotor activity		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	Bradypnea		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50455	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50456	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50457	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50458	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-	-	-
50459	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50460	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50461	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+
50462	Soil of perigenital fur		-	-	-	-	-	+	+	+	+	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17		18	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50451	Soil of perigenital fur		+	+	+	+	+	+	+	+	+	+								
50452	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-						
50453	No abnormality		-	-	-	-	-	-	-	-	-	-								
50454	Decrease in locomotor activity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Bradypnea		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+		
50455	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+		
50456	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-						
50457	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-						
50458	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+
50459	No abnormality		-	-	-	-	-	-	-	-	-	-								
50460	No abnormality		-	-	-	-	-	-	-	-	-	-								
50461	Soil of perigenital fur		+	+	+	+	+	+	+	+	-	-	+	+						
50462	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	+	+	+	+				

Animal No.	Clinical signs	Day	19		20		21		22		23		24		25		26	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50451	Soil of perigenital fur																	
50452	No abnormality																	
50453	No abnormality																	
50454	Decrease in locomotor activity																	
	Bradypnea																	
	Soil of perigenital fur																	
50455	Soil of perigenital fur																	
50456	No abnormality																	
50457	No abnormality																	
50458	Soil of perigenital fur		+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50459	No abnormality																	
50460	No abnormality																	
50461	Soil of perigenital fur																	
50462	Soil of perigenital fur																	

F0)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Female

Period : F0 gestation Day 0-26
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	0		1		2		3		4		5		6		7		8	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50451	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50452	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50453	No abnormality		-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$
50454	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50455	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50456	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50457	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50458	Soil of perigenital fur		-	$	-	$	-	$	-	$	-	$	+	$	+	$	+	$	+	$	+	$	+	$	+	$	-	$	-	$	-	$	-	$
50459	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50460	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50461	Soil of perigenital fur		+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
50462	Soil of perigenital fur		+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	9		10		11		12		13		14		15		16		17	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50451	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50452	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50453	No abnormality		-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$
50454	Soil of perigenital fur		-	-	-	-	+	+	+	+	+	+	+	+	-	-	-	-	-	-
50455	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50456	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50457	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50458	Soil of perigenital fur		-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$
50459	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50460	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50461	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50462	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	18		19		20		21		22		23		24		25		26	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	3	
50451	No abnormality		-	-	-	-	-	-	-	-										
50452	No abnormality		-	-	-	-	-	-	-	-	-	-								
50453	No abnormality		-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$
50454	Soil of perigenital fur		-	-	-	-	-	-	-	-										
50455	No abnormality		-	-	-	-	-	-	-	-										
50456	No abnormality		-	-	-	-	-	-	-	-	-	-								
50457	No abnormality		-	-	-	-	-	-	-	-										
50458	Soil of perigenital fur		-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$	-	$
50459	No abnormality		-	-	-	-	-	-	-	-										
50460	No abnormality		-	-	-	-	-	-	-	-										
50461	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-								
50462	Soil of perigenital fur		-	-	-	-	-	-	-	-										

F0 gestation)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day
Animal Nos. 50453 and 50458 : Non-pregnancy
$: Excepted data from calculation

Clinical sign
Sex : Female

Period : F0 lactation Day 0-5
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	0		1		2		3		4		5
		Time	1	2	1	2	1	2	1	2	1	2	3
50451	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50452	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50454	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50455	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50456	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50457	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50459	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50460	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50461	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50462	No abnormality		-	-	-	-	-	-	-	-	-	-	-

F0 lactation)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Female (satellite)

Period : Administration Day 1-29
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50551	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50552	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50553	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50554	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50555	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50556	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50557	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50558	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50559	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50560	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17		18	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50551	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50552	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50553	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50554	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50555	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50556	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50557	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50558	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50559	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50560	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	19		20		21		22		23		24		25		26		27	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50551	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50552	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50553	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50554	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50555	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50556	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50557	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50558	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50559	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50560	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Administration)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Female (satellite)

Period : Administration Day 1-29
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Clinical signs	Day 28 Time 1	2	29 3
50551	No abnormality	-	-	-
50552	No abnormality	-	-	-
50553	No abnormality	-	-	-
50554	No abnormality	-	-	-
50555	No abnormality	-	-	-
50556	No abnormality	-	-	
50557	No abnormality	-	-	
50558	No abnormality	-	-	
50559	No abnormality	-	-	
50560	No abnormality	-	-	

Administration)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Female (satellite)

Period : Administration Day 1-29
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50651	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50652	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
50653	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50654	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50655	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50656	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50657	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50658	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50659	Soil of perigenital fur		-	-	-	-	-	+	+	+	+	+	+	+	+	+	-	-	-	-
50660	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+

Animal No.	Clinical signs	Day	10		11		12		13		14		15		16		17		18	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50651	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50652	Soil of perigenital fur		+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50653	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50654	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50655	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50656	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50657	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50658	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50659	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50660	Soil of perigenital fur		+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	19		20		21		22		23		24		25		26		27	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50651	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50652	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50653	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50654	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50655	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50656	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50657	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50658	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50659	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50660	Soil of perigenital fur		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Administration)1 : Pre-dosing, 2 : Post-dosing

Clinical sign
Sex : Female (satellite)

Period : Administration Day 1-29
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Clinical signs	Day 28 Time 1	28 2	29 3
50651	No abnormality	-	-	-
50652	Soil of perigenital fur	-	-	-
50653	No abnormality	-	-	-
50654	No abnormality	-	-	-
50655	No abnormality	-	-	-
50656	No abnormality	-	-	
50657	No abnormality	-	-	
50658	No abnormality	-	-	
50659	Soil of perigenital fur	-	-	
50660	Soil of perigenital fur	-	-	

Administration)1 : Pre-dosing, 2 : Post-dosing, 3 : Necropsy day

Clinical sign
Sex : Male

Period : Recovery Day 1-15
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10104	No abnormality		-*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10106	No abnormality		-*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10108	No abnormality		-*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10110	No abnormality		-*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10112	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15
		Time	1	2	1	2	1	2	1	2	1	2	3
10104	No abnormality		-	-	-	-	-	-	-	-	-	-	-
10106	No abnormality		-	-	-	-	-	-	-	-	-	-	-
10108	No abnormality		-	-	-	-	-	-	-	-	-	-	-
10110	No abnormality		-	-	-	-	-	-	-	-	-	-	-
10112	No abnormality		-	-	-	-	-	-	-	-	-	-	-

Recovery)1 : AM, 2 : PM, 3 : Necropsy day
* : Animal was observed two times.

Clinical sign
Sex : Male

Period : Recovery Day 1-15
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
10404	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10406	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10407	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10409	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10412	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15
		Time	1	2	1	2	1	2	1	2	1	2	3
10404	No abnormality		-	-	-	-	-	-	-	-	-	-	-
10406	No abnormality		-	-	-	-	-	-	-	-	-	-	-
10407	No abnormality		-	-	-	-	-	-	-	-	-	-	-
10409	No abnormality		-	-	-	-	-	-	-	-	-	-	-
10412	No abnormality		-	-	-	-	-	-	-	-	-	-	-

Recovery)1 : AM, 2 : PM, 3 : Necropsy day

Clinical sign
Sex : Female (satellite)

Period : Recovery Day 1-15
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50556	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50557	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50558	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50559	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50560	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15
		Time	1	2	1	2	1	2	1	2	1	2	3
50556	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50557	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50558	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50559	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50560	No abnormality		-	-	-	-	-	-	-	-	-	-	-

Recovery)1 : AM, 2 : PM, 3 : Necropsy day

Clinical sign
Sex : Female (satellite)

Period : Recovery Day 1-15
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Clinical signs	Day	1		2		3		4		5		6		7		8		9	
		Time	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
50656	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50657	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50658	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50659	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50660	No abnormality		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Animal No.	Clinical signs	Day	10		11		12		13		14		15
		Time	1	2	1	2	1	2	1	2	1	2	3
50656	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50657	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50658	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50659	No abnormality		-	-	-	-	-	-	-	-	-	-	-
50660	No abnormality		-	-	-	-	-	-	-	-	-	-	-

Recovery)1 : AM, 2 : PM, 3 : Necropsy day

Detailed clinical observation (in the cage) Stage : Pre
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10101	1	1	1	0	0	1
10102	1	1	1	0	0	1
10103	1	1	1	0	0	1
10104	1	1	1	0	0	1
10105	1	1	1	0	0	1
10106	1	1	1	0	0	1
10107	1	1	1	0	0	1
10108	1	1	1	0	0	1
10109	1	1	1	0	0	1
10110	1	1	1	0	0	1
10111	1	1	1	0	0	1
10112	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Pre
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10201	1	1	1	0	0	1
10202	1	1	1	0	0	1
10203	1	1	1	0	0	1
10204	1	1	1	0	0	1
10205	1	1	1	0	0	1
10206	1	1	1	0	0	1
10207	1	1	1	0	0	1
10208	1	1	1	0	0	1
10209	1	1	1	0	0	1
10210	1	1	1	0	0	1
10211	1	1	1	0	0	1
10212	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Pre
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10301	1	1	1	0	0	1
10302	1	1	1	0	0	1
10303	1	1	1	0	0	1
10304	1	1	1	0	0	1
10305	1	1	1	0	0	1
10306	1	1	1	0	0	1
10307	1	1	1	0	0	1
10308	1	1	1	0	0	1
10309	1	1	1	0	0	1
10310	1	1	1	0	0	1
10311	1	1	1	0	0	1
10312	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Pre
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10401	1	1	1	0	0	1
10402	1	1	1	0	0	1
10403	1	1	1	0	0	1
10404	1	1	1	0	0	1
10405	1	1	1	0	0	1
10406	1	1	1	0	0	1
10407	1	1	1	0	0	1
10408	1	1	1	0	0	1
10409	1	1	1	0	0	1
10410	1	1	1	0	0	1
10411	1	1	1	0	0	1
10412	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10101	1	1	1	0	0	1
10102	1	1	1	0	0	1
10103	1	1	1	0	0	1
10104	1	1	1	0	0	1
10105	1	1	1	0	0	1
10106	1	1	1	0	0	1
10107	1	1	1	0	0	1
10108	1	1	1	0	0	1
10109	1	1	1	0	0	1
10110	1	1	1	0	0	1
10111	1	1	1	0	0	1
10112	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10201	1	1	1	0	0	1
10202	1	1	1	0	0	1
10203	1	1	1	0	0	1
10204	1	1	1	0	0	1
10205	1	1	1	0	0	1
10206	1	1	1	0	0	1
10207	1	1	1	0	0	1
10208	1	1	1	0	0	1
10209	1	1	1	0	0	1
10210	1	1	1	0	0	1
10211	1	1	1	0	0	1
10212	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10301	1	1	1	0	0	1
10302	1	1	1	0	0	1
10303	1	1	1	0	0	1
10304	1	1	1	0	0	1
10305	1	1	1	0	0	1
10306	1	1	1	0	0	1
10307	1	1	1	0	0	1
10308	1	1	1	0	0	1
10309	1	1	1	0	0	1
10310	1	1	1	0	0	1
10311	1	1	1	0	0	1
10312	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10401	1	1	1	0	0	1
10402	1	1	1	0	0	1
10403	1	1	1	0	0	1
10404	1	1	1	0	0	1
10405	1	1	1	0	0	1
10406	1	1	1	0	0	1
10407	1	1	1	0	0	1
10408	1	1	1	0	0	1
10409	1	1	1	0	0	1
10410	1	1	1	0	0	1
10411	1	1	1	0	0	1
10412	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10101	1	1	1	0	0	1
10102	1	1	1	0	0	1
10103	1	1	1	0	0	1
10104	1	1	1	0	0	1
10105	1	1	1	0	0	1
10106	1	1	1	0	0	1
10107	1	1	1	0	0	1
10108	1	1	1	0	0	1
10109	1	1	1	0	0	1
10110	1	1	1	0	0	1
10111	1	1	1	0	0	1
10112	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10201	1	1	1	0	0	1
10202	1	1	1	0	0	1
10203	1	1	1	0	0	1
10204	1	1	1	0	0	1
10205	1	1	1	0	0	1
10206	1	1	1	0	0	1
10207	1	1	1	0	0	1
10208	1	1	1	0	0	1
10209	1	1	1	0	0	1
10210	1	1	1	0	0	1
10211	1	1	1	0	0	1
10212	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10301	1	1	1	0	0	1
10302	1	1	1	0	0	1
10303	1	1	1	0	0	1
10304	1	1	1	0	0	1
10305	1	1	1	0	0	1
10306	1	1	1	0	0	1
10307	1	1	1	0	0	1
10308	1	1	1	0	0	1
10309	1	1	1	0	0	1
10310	1	1	1	0	0	1
10311	1	1	1	0	0	1
10312	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10401	1	1	1	0	0	1
10402	1	1	1	0	0	1
10403	1	1	1	0	0	1
10404	1	1	1	0	0	1
10405	1	1	1	0	0	1
10406	1	1	1	0	0	1
10407	1	1	1	0	0	1
10408	1	1	1	0	0	1
10409	1	1	1	0	0	1
10410	1	1	1	0	0	1
10411	1	1	1	0	0	1
10412	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 21
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10101	1	1	1	0	0	1
10102	1	1	1	0	0	1
10103	1	1	1	0	0	1
10104	1	1	1	0	0	1
10105	1	1	1	0	0	1
10106	1	1	1	0	0	1
10107	1	1	1	0	0	1
10108	1	1	1	0	0	1
10109	1	1	1	0	0	1
10110	1	1	1	0	0	1
10111	1	1	1	0	0	1
10112	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 21
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10201	1	1	1	0	0	1
10202	1	1	1	0	0	1
10203	1	1	1	0	0	1
10204	1	1	1	0	0	1
10205	1	1	1	0	0	1
10206	1	1	1	0	0	1
10207	1	1	1	0	0	1
10208	1	1	1	0	0	1
10209	1	1	1	0	0	1
10210	1	1	1	0	0	1
10211	1	1	1	0	0	1
10212	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 21
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10301	1	1	1	0	0	1
10302	1	1	1	0	0	1
10303	1	1	1	0	0	1
10304	1	1	1	0	0	1
10305	1	1	1	0	0	1
10306	1	1	1	0	0	1
10307	1	1	1	0	0	1
10308	1	1	1	0	0	1
10309	1	1	1	0	0	1
10310	1	1	1	0	0	1
10311	1	1	1	0	0	1
10312	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 21
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10401	1	1	1	0	0	1
10402	1	1	1	0	0	1
10403	1	1	1	0	0	1
10404	1	1	1	0	0	1
10405	1	1	1	0	0	1
10406	1	1	1	0	0	1
10407	1	1	1	0	0	1
10408	1	1	1	0	0	1
10409	1	1	1	0	0	1
10410	1	1	1	0	0	1
10411	1	1	1	0	0	1
10412	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 28
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10101	1	1	1	0	0	1
10102	1	1	1	0	0	1
10103	1	1	1	0	0	1
10104	1	1	1	0	0	1
10105	1	1	1	0	0	1
10106	1	1	1	0	0	1
10107	1	1	1	0	0	1
10108	1	1	1	0	0	1
10109	1	1	1	0	0	1
10110	1	1	1	0	0	1
10111	1	1	1	0	0	1
10112	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 28
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10201	1	1	1	0	0	1
10202	1	1	1	0	0	1
10203	1	1	1	0	0	1
10204	1	1	1	0	0	1
10205	1	1	1	0	0	1
10206	1	1	1	0	0	1
10207	1	1	1	0	0	1
10208	1	1	1	0	0	1
10209	1	1	1	0	0	1
10210	1	1	1	0	0	1
10211	1	1	1	0	0	1
10212	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 28
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10301	1	1	1	0	0	1
10302	1	1	1	0	0	1
10303	1	1	1	0	0	1
10304	1	1	1	0	0	1
10305	1	1	1	0	0	1
10306	1	1	1	0	0	1
10307	1	1	1	0	0	1
10308	1	1	1	0	0	1
10309	1	1	1	0	0	1
10310	1	1	1	0	0	1
10311	1	1	1	0	0	1
10312	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 28
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10401	1	1	1	0	0	1
10402	1	1	1	0	0	1
10403	1	1	1	0	0	1
10404	1	1	1	0	0	1
10405	1	1	1	0	0	1
10406	1	1	1	0	0	1
10407	1	1	1	0	0	1
10408	1	1	1	0	0	1
10409	1	1	1	0	0	1
10410	1	1	1	0	0	1
10411	1	1	1	0	0	1
10412	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Pre
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50151	1	1	1	0	0	1
50152	1	1	1	0	0	1
50153	1	1	1	0	0	1
50154	1	1	1	0	0	1
50155	1	1	1	0	0	1
50156	1	1	1	0	0	1
50157	1	1	1	0	0	1
50158	1	1	1	0	0	1
50159	1	1	1	0	0	1
50160	1	1	1	0	0	1
50161	1	1	1	0	0	1
50162	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Pre
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50251	1	1	1	0	0	1
50252	1	1	1	0	0	1
50253	1	1	1	0	0	1
50254	1	1	1	0	0	1
50255	1	1	1	0	0	1
50256	1	1	1	0	0	1
50257	1	1	1	0	0	1
50258	1	1	1	0	0	1
50259	1	1	1	0	0	1
50260	1	1	1	0	0	1
50261	1	1	1	0	0	1
50262	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Pre
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50351	1	1	1	0	0	1
50352	1	1	1	0	0	1
50353	1	1	1	0	0	1
50354	1	1	1	0	0	1
50355	1	1	1	0	0	1
50356	1	1	1	0	0	1
50357	1	1	1	0	0	1
50358	1	1	1	0	0	1
50359	1	1	1	0	0	1
50360	1	1	1	0	0	1
50361	1	1	1	0	0	1
50362	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Pre
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50451	1	1	1	0	0	1
50452	1	1	1	0	0	1
50453	1	1	1	0	0	1
50454	1	1	1	0	0	1
50455	1	1	1	0	0	1
50456	1	1	1	0	0	1
50457	1	1	1	0	0	1
50458	1	1	1	0	0	1
50459	1	1	1	0	0	1
50460	1	1	1	0	0	1
50461	1	1	1	0	0	1
50462	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50151	1	1	1	0	0	1
50152	1	1	1	0	0	1
50153	1	1	1	0	0	1
50154	1	1	1	0	0	1
50155	1	1	1	0	0	1
50156	1	1	1	0	0	1
50157	1	1	1	0	0	1
50158	1	1	1	0	0	1
50159	1	1	1	0	0	1
50160	1	1	1	0	0	1
50161	1	1	1	0	0	1
50162	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50251	1	1	1	0	0	1
50252	1	1	1	0	0	1
50253	1	1	1	0	0	1
50254	1	1	1	0	0	1
50255	1	1	1	0	0	1
50256	1	1	1	0	0	1
50257	1	1	1	0	0	1
50258	1	1	1	0	0	1
50259	1	1	1	0	0	1
50260	1	1	1	0	0	1
50261	1	1	1	0	0	1
50262	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50351	1	1	1	0	0	1
50352	1	1	1	0	0	1
50353	1	1	1	0	0	1
50354	1	1	1	0	0	1
50355	1	1	1	0	0	1
50356	1	1	1	0	0	1
50357	1	1	1	0	0	1
50358	1	1	1	0	0	1
50359	1	1	1	0	0	1
50360	1	1	1	0	0	1
50361	1	1	1	0	0	1
50362	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50451	1	1	1	0	0	1
50452	1	1	1	0	0	1
50453	1	1	1	0	0	1
50454	1	1	1	0	0	1
50455	1	1	1	0	0	1
50456	1	1	1	0	0	1
50457	1	1	1	0	0	1
50458	1	1	1	0	0	1
50459	1	1	1	0	0	1
50460	1	1	1	0	0	1
50461	1	1	1	0	0	1
50462	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50151	1	1	1	0	0	1
50152	1	1	1	0	0	1
50153	1	1	1	0	0	1
50154	1	1	1	0	0	1
50155	1	1	1	0	0	1
50156	1	1	1	0	0	1
50157	1	1	1	0	0	1
50158	1	1	1	0	0	1
50159	1	1	1	0	0	1
50160	1	1	1	0	0	1
50161	1	1	1	0	0	1
50162	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50251	1	1	1	0	0	1
50252	1	1	1	0	0	1
50253	1	1	1	0	0	1
50254	1	1	1	0	0	1
50255	1	1	1	0	0	1
50256	1	1	1	0	0	1
50257	1	1	1	0	0	1
50258	1	1	1	0	0	1
50259	1	1	1	0	0	1
50260	1	1	1	0	0	1
50261	1	1	1	0	0	1
50262	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50351	1	1	1	0	0	1
50352	1	1	1	0	0	1
50353	1	1	1	0	0	1
50354	1	1	1	0	0	1
50355	1	1	1	0	0	1
50356	1	1	1	0	0	1
50357	1	1	1	0	0	1
50358	1	1	1	0	0	1
50359	1	1	1	0	0	1
50360	1	1	1	0	0	1
50361	1	1	1	0	0	1
50362	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50451	1	1	1	0	0	1
50452	1	1	1	0	0	1
50453	1	1	1	0	0	1
50454	1	1	1	0	0	1
50455	1	1	1	0	0	1
50456	1	1	1	0	0	1
50457	1	1	1	0	0	1
50458	1	1	1	0	0	1
50459	1	1	1	0	0	1
50460	1	1	1	0	0	1
50461	1	1	1	0	0	1
50462	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 21
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50151	1	1	1	0	0	1
50152	1	1	1	0	0	1
50153	1	1	1	0	0	1
50154	1	1	1	0	0	1
50155	1	1	1	0	0	1
50156	1	1	1	0	0	1
50157	1	1	1	0	0	1
50158	1	1	1	0	0	1
50159	1	1	1	0	0	1
50160	1	1	1	0	0	1
50161	1	1	1	0	0	1
50162	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 21
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50251	1	1	1	0	0	1
50252	1	1	1	0	0	1
50253	1	1	1	0	0	1
50254	1	1	1	0	0	1
50255	1	1	1	0	0	1
50256	1	1	1	0	0	1
50257	1	1	1	0	0	1
50258	1	1	1	0	0	1
50259	1	1	1	0	0	1
50260	1	1	1	0	0	1
50261	1	1	1	0	0	1
50262	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 21
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50351	1	1	1	0	0	1
50352	1	1	1	0	0	1
50353	1	1	1	0	0	1
50354	1	1	1	0	0	1
50355	1	1	1	0	0	1
50356	1	1	1	0	0	1
50357	1	1	1	0	0	1
50358	1	1	1	0	0	1
50359	1	1	1	0	0	1
50360	1	1	1	0	0	1
50361	1	1	1	0	0	1
50362	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage)
Sex : Female

Stage : Day 21
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50451	1	1	1	0	0	1
50452	1	1	1	0	0	1
50453	1	1	1	0	0	1
50454	1	1	1	0	0	1
50455	1	1	1	0	0	1
50456	1	1	1	0	0	1
50457	1	1	1	0	0	1
50458	1	1	1	0	0	1
50459	1	1	1	0	0	1
50460	1	1	1	0	0	1
50461	1	1	1	0	0	1
50462	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage)
Sex : Female

Stage : Day 28
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50151	1	1	1	0	0	1
50152	1	1	1	0	0	1
50153	1	1	1	0	0	1
50154	1	1	1	0	0	1
50155	1	1	1	0	0	1
50156	1	1	1	0	0	1
50157	1	1	1	0	0	1
50158	1	1	1	0	0	1
50159	1	1	1	0	0	1
50160	1	1	1	0	0	1
50161	1	1	1	0	0	1
50162	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 28
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50251	1	1	1	0	0	1
50252	1	1	1	0	0	1
50253	1	1	1	0	0	1
50254	1	1	1	0	0	1
50255	1	1	1	0	0	1
50256	1	1	1	0	0	1
50257	1	1	1	0	0	1
50258	1	1	1	0	0	1
50259	1	1	1	0	0	1
50260	1	1	1	0	0	1
50261	1	1	1	0	0	1
50262	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 28
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50351	1	1	1	0	0	1
50352	1	1	1	0	0	1
50353	1	1	1	0	0	1
50354	1	1	1	0	0	1
50355	1	1	1	0	0	1
50356	1	1	1	0	0	1
50357	1	1	1	0	0	1
50358	1	1	1	0	0	1
50359	1	1	1	0	0	1
50360	1	1	1	0	0	1
50361	1	1	1	0	0	1
50362	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 28
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50451	1	1	1	0	0	1
50452	1	1	1	0	0	1
50453	1	1	1	0	0	1
50454	1	1	1	0	0	1
50455	1	1	1	0	0	1
50456	1	1	1	0	0	1
50457	1	1	1	0	0	1
50458	1	1	1	0	0	1
50459	1	1	1	0	0	1
50460	1	1	1	0	0	1
50461	1	1	1	0	0	1
50462	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 35
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50151	1	1	1	0	0	1
50152	1	1	1	0	0	1
50153	1	1	1	0	0	1
50154	1	1	1	0	0	1
50155	1	1	1	0	0	1
50156	1	1	1	0	0	1
50157	1	1	1	0	0	1
50158	1	1	1	0	0	1
50159	1	1	1	0	0	1
50160	1	1	1	0	0	1
50161	1	1	1	0	0	1
50162	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 35
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50251	1	1	1	0	0	1
50252	1	1	1	0	0	1
50253	1	1	1	0	0	1
50254	1	1	1	0	0	1
50255	1	1	1	0	0	1
50256	1	1	1	0	0	1
50257	1	1	1	0	0	1
50258	1	1	1	0	0	1
50259	1	1	1	0	0	1
50260	1	1	1	0	0	1
50261	1	1	1	0	0	1
50262	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 35
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50351	1	1	1	0	0	1
50352	1	1	1	0	0	1
50353	1	1	1	0	0	1
50354	1	1	1	0	0	1
50355	1	1	1	0	0	1
50356	1	1	1	0	0	1
50357	1	1	1	0	0	1
50358	1	1	1	0	0	1
50359	1	1	1	0	0	1
50360	1	1	1	0	0	1
50361	1	1	1	0	0	1
50362	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 35
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50451	1	1	1	0	0	1
50452	1	1	1	0	0	1
50453	1	1	1	0	0	1
50454	1	1	1	0	0	1
50455	1	1	1	0	0	1
50456	1	1	1	0	0	1
50457	1	1	1	0	0	1
50458	1	1	1	0	0	1
50459	1	1	1	0	0	1
50460	1	1	1	0	0	1
50461	1	1	1	0	0	1
50462	1	1	1	0	0	1
n	12	12	12	12	12	12

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 42
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50152	1	1	1	0	0	1
50155	1	1	1	0	0	1
50156	1	1	1	0	0	1
50158	1	1	1	0	0	1
50159	1	1	1	0	0	1
50160	1	1	1	0	0	1
50161	1	1	1	0	0	1
50162	1	1	1	0	0	1
n	8	8	8	8	8	8

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 42
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50251	1	1	1	0	0	1
50252	1	1	1	0	0	1
50254	1	1	1	0	0	1
50256	1	1	1	0	0	1
50257	1	1	1	0	0	1
50258	1	1	1	0	0	1
50260	1	1	1	0	0	1
50261	1	1	1	0	0	1
50262	1	1	1	0	0	1
n	9	9	9	9	9	9

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 42
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50351	1	1	1	0	0	1
50352	1	1	1	0	0	1
50353	1	1	1	0	0	1
50355	1	1	1	0	0	1
50359	1	1	1	0	0	1
50360	1	1	1	0	0	1
50361	1	1	1	0	0	1
50362	1	1	1	0	0	1
n	8	8	8	8	8	8

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 42
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50452	1	1	1	0	0	1
50454	1	1	1	0	0	1
50455	1	1	1	0	0	1
50456	1	1	1	0	0	1
50457	1	1	1	0	0	1
50458	1	1	1	0	0	1
50461	1	1	1	0	0	1
50462	1	1	1	0	0	1
n	8	8	8	8	8	8

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Pre
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50551	1	1	1	0	0	1
50552	1	1	1	0	0	1
50553	1	1	1	0	0	1
50554	1	1	1	0	0	1
50555	1	1	1	0	0	1
50556	1	1	1	0	0	1
50557	1	1	1	0	0	1
50558	1	1	1	0	0	1
50559	1	1	1	0	0	1
50560	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Pre
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50651	1	1	1	0	0	1
50652	1	1	1	0	0	1
50653	1	1	1	0	0	1
50654	1	1	1	0	0	1
50655	1	1	1	0	0	1
50656	1	1	1	0	0	1
50657	1	1	1	0	0	1
50658	1	1	1	0	0	1
50659	1	1	1	0	0	1
50660	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50551	1	1	1	0	0	1
50552	1	1	1	0	0	1
50553	1	1	1	0	0	1
50554	1	1	1	0	0	1
50555	1	1	1	0	0	1
50556	1	1	1	0	0	1
50557	1	1	1	0	0	1
50558	1	1	1	0	0	1
50559	1	1	1	0	0	1
50560	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 7
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50651	1	1	1	0	0	1
50652	1	1	1	0	0	1
50653	1	1	1	0	0	1
50654	1	1	1	0	0	1
50655	1	1	1	0	0	1
50656	1	1	1	0	0	1
50657	1	1	1	0	0	1
50658	1	1	1	0	0	1
50659	1	1	1	0	0	1
50660	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50551	1	1	1	0	0	1
50552	1	1	1	0	0	1
50553	1	1	1	0	0	1
50554	1	1	1	0	0	1
50555	1	1	1	0	0	1
50556	1	1	1	0	0	1
50557	1	1	1	0	0	1
50558	1	1	1	0	0	1
50559	1	1	1	0	0	1
50560	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 14
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50651	1	1	1	0	0	1
50652	1	1	1	0	0	1
50653	1	1	1	0	0	1
50654	1	1	1	0	0	1
50655	1	1	1	0	0	1
50656	1	1	1	0	0	1
50657	1	1	1	0	0	1
50658	1	1	1	0	0	1
50659	1	1	1	0	0	1
50660	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 21
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50551	1	1	1	0	0	1
50552	1	1	1	0	0	1
50553	1	1	1	0	0	1
50554	1	1	1	0	0	1
50555	1	1	1	0	0	1
50556	1	1	1	0	0	1
50557	1	1	1	0	0	1
50558	1	1	1	0	0	1
50559	1	1	1	0	0	1
50560	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 21
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50651	1	1	1	0	0	1
50652	1	1	1	0	0	1
50653	1	1	1	0	0	1
50654	1	1	1	0	0	1
50655	1	1	1	0	0	1
50656	1	1	1	0	0	1
50657	1	1	1	0	0	1
50658	1	1	1	0	0	1
50659	1	1	1	0	0	1
50660	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 28
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50551	1	1	1	0	0	1
50552	1	1	1	0	0	1
50553	1	1	1	0	0	1
50554	1	1	1	0	0	1
50555	1	1	1	0	0	1
50556	1	1	1	0	0	1
50557	1	1	1	0	0	1
50558	1	1	1	0	0	1
50559	1	1	1	0	0	1
50560	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Day 28
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50651	1	1	1	0	0	1
50652	1	1	1	0	0	1
50653	1	1	1	0	0	1
50654	1	1	1	0	0	1
50655	1	1	1	0	0	1
50656	1	1	1	0	0	1
50657	1	1	1	0	0	1
50658	1	1	1	0	0	1
50659	1	1	1	0	0	1
50660	1	1	1	0	0	1
n	10	10	10	10	10	10

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Recovery Day 7
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10104	1	1	1	0	0	1
10106	1	1	1	0	0	1
10108	1	1	1	0	0	1
10110	1	1	1	0	0	1
10112	1	1	1	0	0	1
n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Recovery Day 7
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10404	1	1	1	0	0	1
10406	1	1	1	0	0	1
10407	1	1	1	0	0	1
10409	1	1	1	0	0	1
10412	1	1	1	0	0	1
n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Recovery Day 14
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10104	1	1	1	0	0	1
10106	1	1	1	0	0	1
10108	1	1	1	0	0	1
10110	1	1	1	0	0	1
10112	1	1	1	0	0	1
n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Recovery Day 14
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
10404	1	1	1	0	0	1
10406	1	1	1	0	0	1
10407	1	1	1	0	0	1
10409	1	1	1	0	0	1
10412	1	1	1	0	0	1
n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Recovery Day 7
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50556	1	1	1	0	0	1
50557	1	1	1	0	0	1
50558	1	1	1	0	0	1
50559	1	1	1	0	0	1
50560	1	1	1	0	0	1
n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Recovery Day 7
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50656	1	1	1	0	0	1
50657	1	1	1	0	0	1
50658	1	1	1	0	0	1
50659	1	1	1	0	0	1
50660	1	1	1	0	0	1
n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Recovery Day 14
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50556	1	1	1	0	0	1
50557	1	1	1	0	0	1
50558	1	1	1	0	0	1
50559	1	1	1	0	0	1
50560	1	1	1	0	0	1
n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (in the cage) Stage : Recovery Day 14
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Body position/ Posture	Respiratory pattern	Tremor/ Convulsion	Rolling	Repetitive circling	Self biting
50656	1	1	1	0	0	1
50657	1	1	1	0	0	1
50658	1	1	1	0	0	1
50659	1	1	1	0	0	1
50660	1	1	1	0	0	1
n	5	5	5	5	5	5

Body position/Posture) 1;Normal (sitting, etc.), 2;Sleeping, 3;Crouching, 4;Prone, lateral, 5;Standing, jumping, 6;Cataleptic.
Respiratory pattern) 1;Normal, 2;Slightly abnormal,rapid or slow, 3;Moderately abnormal, difficult to breath, 4;Severe abnormal, labored, 5;Dyspnea.
Tremor/Convulsion) 1;Not present, 2;Irregularly only the legs, 3;Durable only the legs, 4;Clonic,systemic, 5;Tonic, systemic.
Stereotype/Rolling) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Repetitive circling) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Self biting) 1;Not present, 2;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10101	1	1	2	1	1	1	0	1	1	1	1
10102	1	1	2	1	1	1	0	1	1	1	1
10103	1	1	2	1	1	1	0	1	1	1	1
10104	1	1	2	1	1	1	0	1	1	1	1
10105	1	1	2	1	1	1	0	1	1	1	1
10106	1	1	2	1	1	1	0	1	1	1	1
10107	1	1	2	1	1	1	0	1	1	1	1
10108	1	1	2	1	1	1	0	1	1	1	1
10109	1	1	2	1	1	1	0	1	1	1	1
10110	1	1	2	1	1	1	0	1	1	1	1
10111	1	1	2	1	1	1	0	1	1	1	1
10112	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10101	0
10102	0
10103	0
10104	0
10105	0
10106	0
10107	0
10108	0
10109	0
10110	0
10111	0
10112	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10201	1	1	2	1	1	1	0	1	1	1	1
10202	1	1	2	1	1	1	0	1	1	1	1
10203	1	1	2	1	1	1	0	1	1	1	1
10204	1	1	2	1	1	1	0	1	1	1	1
10205	1	1	2	1	1	1	0	1	1	1	1
10206	1	1	2	1	1	1	0	1	1	1	1
10207	1	1	2	1	1	1	0	1	1	1	1
10208	1	1	2	1	1	1	0	1	1	1	1
10209	1	1	2	1	1	1	0	1	1	1	1
10210	1	1	2	1	1	1	0	1	1	1	1
10211	1	1	2	1	1	1	0	1	1	1	1
10212	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10201	0
10202	0
10203	0
10204	0
10205	0
10206	0
10207	0
10208	0
10209	0
10210	0
10211	0
10212	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10301	1	1	2	1	1	1	0	1	1	1	1
10302	1	1	2	1	1	1	0	1	1	1	1
10303	1	1	2	1	1	1	0	1	1	1	1
10304	1	1	2	1	1	1	0	1	1	1	1
10305	1	1	2	1	1	1	0	1	1	1	1
10306	1	1	2	1	1	1	0	1	1	1	1
10307	1	1	2	1	1	1	0	1	1	1	1
10308	1	1	2	1	1	1	0	1	1	1	1
10309	1	1	2	1	1	1	0	1	1	1	1
10310	1	1	2	1	1	1	0	1	1	1	1
10311	1	1	2	1	1	1	0	1	1	1	1
10312	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10301	0
10302	0
10303	0
10304	0
10305	0
10306	0
10307	0
10308	0
10309	0
10310	0
10311	0
10312	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10401	1	1	2	1	1	1	0	1	1	1	1
10402	1	1	2	1	1	1	0	1	1	1	1
10403	1	1	2	1	1	1	0	1	1	1	1
10404	1	1	2	1	1	1	0	1	1	1	1
10405	1	1	2	1	1	1	0	1	1	1	1
10406	1	1	2	1	1	1	0	1	1	1	1
10407	1	1	2	1	1	1	0	1	1	1	1
10408	1	1	2	1	1	1	0	1	1	1	1
10409	1	1	2	1	1	1	0	1	1	1	1
10410	1	1	2	1	1	1	0	1	1	1	1
10411	1	1	2	1	1	1	0	1	1	1	1
10412	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10401	0
10402	0
10403	0
10404	0
10405	0
10406	0
10407	0
10408	0
10409	0
10410	0
10411	0
10412	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10101	1	1	2	1	1	1	0	1	1	1	1
10102	1	1	2	1	1	1	0	1	1	1	1
10103	1	1	2	1	1	1	0	1	1	1	1
10104	1	1	2	1	1	1	0	1	1	1	1
10105	1	1	2	1	1	1	0	1	1	1	1
10106	1	1	2	1	1	1	0	1	1	1	1
10107	1	1	2	1	1	1	0	1	1	1	1
10108	1	1	2	1	1	1	0	1	1	1	1
10109	1	1	2	1	1	1	0	1	1	1	1
10110	1	1	2	1	1	1	0	1	1	1	1
10111	1	1	2	1	1	1	0	1	1	1	1
10112	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10101	0
10102	0
10103	0
10104	0
10105	0
10106	0
10107	0
10108	0
10109	0
10110	0
10111	0
10112	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10201	1	1	2	1	1	1	0	1	1	1	1
10202	1	1	2	1	1	1	0	1	1	1	1
10203	1	1	2	1	1	1	0	1	1	1	1
10204	1	1	2	1	1	1	0	1	1	1	1
10205	1	1	2	1	1	1	0	1	1	1	1
10206	1	1	2	1	1	1	0	1	1	1	1
10207	1	1	2	1	1	1	0	1	1	1	1
10208	1	1	2	1	1	1	0	1	1	1	1
10209	1	1	2	1	1	1	0	1	1	1	1
10210	1	1	2	1	1	1	0	1	1	1	1
10211	1	1	2	1	1	1	0	1	1	1	1
10212	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10201	0
10202	0
10203	0
10204	0
10205	0
10206	0
10207	0
10208	0
10209	0
10210	0
10211	0
10212	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10301	1	1	2	1	1	1	0	1	1	1	1
10302	1	1	2	1	1	1	0	1	1	1	1
10303	1	1	2	1	1	1	0	1	1	1	1
10304	1	1	2	1	1	1	0	1	1	1	1
10305	1	1	2	1	1	1	0	1	1	1	1
10306	1	1	2	1	1	1	0	1	1	1	1
10307	1	1	2	1	1	1	0	1	1	1	1
10308	1	1	2	1	1	1	0	1	1	1	1
10309	1	1	2	1	1	1	0	1	1	1	1
10310	1	1	2	1	1	1	0	1	1	1	1
10311	1	1	2	1	1	1	0	1	1	1	1
10312	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10301	0
10302	0
10303	0
10304	0
10305	0
10306	0
10307	0
10308	0
10309	0
10310	0
10311	0
10312	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10401	1	1	2	1	1	1	0	1	1	1	1
10402	1	1	2	1	1	1	0	1	1	1	1
10403	1	1	2	1	1	1	0	1	1	1	1
10404	1	1	2	1	1	1	0	1	1	1	1
10405	1	1	2	1	1	1	0	1	1	1	1
10406	1	1	2	1	1	1	0	1	1	1	1
10407	1	1	2	1	1	1	0	1	1	1	1
10408	1	1	2	1	1	1	0	1	1	1	1
10409	1	1	2	1	1	1	0	1	1	1	1
10410	1	1	2	1	1	1	0	1	1	1	1
10411	1	1	2	1	1	1	0	1	1	1	1
10412	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10401	0
10402	0
10403	0
10404	0
10405	0
10406	0
10407	0
10408	0
10409	0
10410	0
10411	0
10412	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10101	1	1	2	1	1	1	0	1	1	1	1
10102	1	1	2	1	1	1	0	1	1	1	1
10103	1	1	2	1	1	1	0	1	1	1	1
10104	1	1	2	1	1	1	0	1	1	1	1
10105	1	1	2	1	1	1	0	1	1	1	1
10106	1	1	2	1	1	1	0	1	1	1	1
10107	1	1	2	1	1	1	0	1	1	1	1
10108	1	1	2	1	1	1	0	1	1	1	1
10109	1	1	2	1	1	1	0	1	1	1	1
10110	1	1	2	1	1	1	0	1	1	1	1
10111	1	1	2	1	1	1	0	1	1	1	1
10112	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10101	0
10102	0
10103	0
10104	0
10105	0
10106	0
10107	0
10108	0
10109	0
10110	0
10111	0
10112	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10201	1	1	2	1	1	1	0	1	1	1	1
10202	1	1	2	1	1	1	0	1	1	1	1
10203	1	1	2	1	1	1	0	1	1	1	1
10204	1	1	2	1	1	1	0	1	1	1	1
10205	1	1	2	1	1	1	0	1	1	1	1
10206	1	1	2	1	1	1	0	1	1	1	1
10207	1	1	2	1	1	1	0	1	1	1	1
10208	1	1	2	1	1	1	0	1	1	1	1
10209	1	1	2	1	1	1	0	1	1	1	1
10210	1	1	2	1	1	1	0	1	1	1	1
10211	1	1	2	1	1	1	0	1	1	1	1
10212	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10201	0
10202	0
10203	0
10204	0
10205	0
10206	0
10207	0
10208	0
10209	0
10210	0
10211	0
10212	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10301	1	1	2	1	1	1	0	1	1	1	1
10302	1	1	2	1	1	1	0	1	1	1	1
10303	1	1	2	1	1	1	0	1	1	1	1
10304	1	1	2	1	1	1	0	1	1	1	1
10305	1	1	2	1	1	1	0	1	1	1	1
10306	1	1	2	1	1	1	0	1	1	1	1
10307	1	1	2	1	1	1	0	1	1	1	1
10308	1	1	2	1	1	1	0	1	1	1	1
10309	1	1	2	1	1	1	0	1	1	1	1
10310	1	1	2	1	1	1	0	1	1	1	1
10311	1	1	2	1	1	1	0	1	1	1	1
10312	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10301	0
10302	0
10303	0
10304	0
10305	0
10306	0
10307	0
10308	0
10309	0
10310	0
10311	0
10312	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10401	1	1	2	1	1	1	0	1	1	1	1
10402	1	1	2	1	1	1	0	1	1	1	1
10403	1	1	2	1	1	1	0	1	1	1	1
10404	1	1	2	1	1	1	0	1	1	1	1
10405	1	1	2	1	1	1	0	1	1	1	1
10406	1	1	2	1	1	1	0	1	1	1	1
10407	1	1	2	1	1	1	0	1	1	1	1
10408	1	1	2	1	1	1	0	1	1	1	1
10409	1	1	2	1	1	1	0	1	1	1	1
10410	1	1	2	1	1	1	0	1	1	1	1
10411	1	1	2	1	1	1	0	1	1	1	1
10412	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10401	0
10402	0
10403	0
10404	0
10405	0
10406	0
10407	0
10408	0
10409	0
10410	0
10411	0
10412	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10101	1	1	2	1	1	1	0	1	1	1	1
10102	1	1	2	1	1	1	0	1	1	1	1
10103	1	1	2	1	1	1	0	1	1	1	1
10104	1	1	2	1	1	1	0	1	1	1	1
10105	1	1	2	1	1	1	0	1	1	1	1
10106	1	1	2	1	1	1	0	1	1	1	1
10107	1	1	2	1	1	1	0	1	1	1	1
10108	1	1	2	1	1	1	0	1	1	1	1
10109	1	1	2	1	1	1	0	1	1	1	1
10110	1	1	2	1	1	1	0	1	1	1	1
10111	1	1	2	1	1	1	0	1	1	1	1
10112	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10101	0
10102	0
10103	0
10104	0
10105	0
10106	0
10107	0
10108	0
10109	0
10110	0
10111	0
10112	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10201	1	1	2	1	1	1	0	1	1	1	1
10202	1	1	2	1	1	1	0	1	1	1	1
10203	1	1	2	1	1	1	0	1	1	1	1
10204	1	1	2	1	1	1	0	1	1	1	1
10205	1	1	2	1	1	1	0	1	1	1	1
10206	1	1	2	1	1	1	0	1	1	1	1
10207	1	1	2	1	1	1	0	1	1	1	1
10208	1	1	2	1	1	1	0	1	1	1	1
10209	1	1	2	1	1	1	0	1	1	1	1
10210	1	1	2	1	1	1	0	1	1	1	1
10211	1	1	2	1	1	1	0	1	1	1	1
10212	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10201	0
10202	0
10203	0
10204	0
10205	0
10206	0
10207	0
10208	0
10209	0
10210	0
10211	0
10212	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10301	1	1	2	1	1	1	0	1	1	1	1
10302	1	1	2	1	1	1	0	1	1	1	1
10303	1	1	2	1	1	1	0	1	1	1	1
10304	1	1	2	1	1	1	0	1	1	1	1
10305	1	1	2	1	1	1	0	1	1	1	1
10306	1	1	2	1	1	1	0	1	1	1	1
10307	1	1	2	1	1	1	0	1	1	1	1
10308	1	1	2	1	1	1	0	1	1	1	1
10309	1	1	2	1	1	1	0	1	1	1	1
10310	1	1	2	1	1	1	0	1	1	1	1
10311	1	1	2	1	1	1	0	1	1	1	1
10312	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10301	0
10302	0
10303	0
10304	0
10305	0
10306	0
10307	0
10308	0
10309	0
10310	0
10311	0
10312	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10401	1	1	2	1	1	1	0	1	1	1	1
10402	1	1	2	1	1	1	0	1	1	1	1
10403	1	1	2	1	1	1	0	1	1	1	1
10404	1	1	2	1	1	1	0	1	1	1	1
10405	1	1	2	1	1	1	0	1	1	1	1
10406	1	1	2	1	1	1	0	1	1	1	1
10407	1	1	2	1	1	1	0	1	1	1	1
10408	1	1	2	1	1	1	0	1	1	1	1
10409	1	1	2	1	1	1	0	1	1	1	1
10410	1	1	2	1	1	1	0	1	1	1	1
10411	1	1	2	1	1	1	0	1	1	1	1
10412	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10401	0
10402	0
10403	0
10404	0
10405	0
10406	0
10407	0
10408	0
10409	0
10410	0
10411	0
10412	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10101	1	1	2	1	1	1	0	1	1	1	1
10102	1	1	2	1	1	1	0	1	1	1	1
10103	1	1	2	1	1	1	0	1	1	1	1
10104	1	1	2	1	1	1	0	1	1	1	1
10105	1	1	2	1	1	1	0	1	1	1	1
10106	1	1	2	1	1	1	0	1	1	1	1
10107	1	1	2	1	1	1	0	1	1	1	1
10108	1	1	2	1	1	1	0	1	1	1	1
10109	1	1	2	1	1	1	0	1	1	1	1
10110	1	1	2	1	1	1	0	1	1	1	1
10111	1	1	2	1	1	1	0	1	1	1	1
10112	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10101	0
10102	0
10103	0
10104	0
10105	0
10106	0
10107	0
10108	0
10109	0
10110	0
10111	0
10112	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10201	1	1	2	1	1	1	0	1	1	1	1
10202	1	1	2	1	1	1	0	1	1	1	1
10203	1	1	2	1	1	1	0	1	1	1	1
10204	1	1	2	1	1	1	0	1	1	1	1
10205	1	1	2	1	1	1	0	1	1	1	1
10206	1	1	2	1	1	1	0	1	1	1	1
10207	1	1	2	1	1	1	0	1	1	1	1
10208	1	1	2	1	1	1	0	1	1	1	1
10209	1	1	2	1	1	1	0	1	1	1	1
10210	1	1	2	1	1	1	0	1	1	1	1
10211	1	1	2	1	1	1	0	1	1	1	1
10212	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10201	0
10202	0
10203	0
10204	0
10205	0
10206	0
10207	0
10208	0
10209	0
10210	0
10211	0
10212	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10301	1	1	2	1	1	1	0	1	1	1	1
10302	1	1	2	1	1	1	0	1	1	1	1
10303	1	1	2	1	1	1	0	1	1	1	1
10304	1	1	2	1	1	1	0	1	1	1	1
10305	1	1	2	1	1	1	0	1	1	1	1
10306	1	1	2	1	1	1	0	1	1	1	1
10307	1	1	2	1	1	1	0	1	1	1	1
10308	1	1	2	1	1	1	0	1	1	1	1
10309	1	1	2	1	1	1	0	1	1	1	1
10310	1	1	2	1	1	1	0	1	1	1	1
10311	1	1	2	1	1	1	0	1	1	1	1
10312	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10301	0
10302	0
10303	0
10304	0
10305	0
10306	0
10307	0
10308	0
10309	0
10310	0
10311	0
10312	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10401	1	1	2	1	1	1	0	1	1	1	1
10402	1	1	2	1	1	1	0	1	1	1	1
10403	1	1	2	1	1	1	0	1	1	1	1
10404	1	1	2	1	1	1	0	1	1	1	1
10405	1	1	2	1	1	1	0	1	1	1	1
10406	1	1	2	1	1	1	0	1	1	1	1
10407	1	1	2	1	1	1	0	1	1	1	1
10408	1	1	2	1	1	1	0	1	1	1	1
10409	1	1	2	1	1	1	0	1	1	1	1
10410	1	1	2	1	1	1	0	1	1	1	1
10411	1	1	2	1	1	1	0	1	1	1	1
10412	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
10401	0
10402	0
10403	0
10404	0
10405	0
10406	0
10407	0
10408	0
10409	0
10410	0
10411	0
10412	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50151	1	1	2	1	1	1	0	1	1	1	1
50152	1	1	2	1	1	1	0	1	1	1	1
50153	1	1	2	1	1	1	0	1	1	1	1
50154	1	1	2	1	1	1	0	1	1	1	1
50155	1	1	2	1	1	1	0	1	1	1	1
50156	1	1	2	1	1	1	0	1	1	1	1
50157	1	1	2	1	1	1	0	1	1	1	1
50158	1	1	2	1	1	1	0	1	1	1	1
50159	1	1	2	1	1	1	0	1	1	1	1
50160	1	1	2	1	1	1	0	1	1	1	1
50161	1	1	2	1	1	1	0	1	1	1	1
50162	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50151	0
50152	0
50153	0
50154	0
50155	0
50156	0
50157	0
50158	0
50159	0
50160	0
50161	0
50162	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50251	1	1	2	1	1	1	0	1	1	1	1
50252	1	1	2	1	1	1	0	1	1	1	1
50253	1	1	2	1	1	1	0	1	1	1	1
50254	1	1	2	1	1	1	0	1	1	1	1
50255	1	1	2	1	1	1	0	1	1	1	1
50256	1	1	2	1	1	1	0	1	1	1	1
50257	1	1	2	1	1	1	0	1	1	1	1
50258	1	1	2	1	1	1	0	1	1	1	1
50259	1	1	2	1	1	1	0	1	1	1	1
50260	1	1	2	1	1	1	0	1	1	1	1
50261	1	1	2	1	1	1	0	1	1	1	1
50262	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50251	0
50252	0
50253	0
50254	0
50255	0
50256	0
50257	0
50258	0
50259	0
50260	0
50261	0
50262	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50351	1	1	2	1	1	1	0	1	1	1	1
50352	1	1	2	1	1	1	0	1	1	1	1
50353	1	1	2	1	1	1	0	1	1	1	1
50354	1	1	2	1	1	1	0	1	1	1	1
50355	1	1	2	1	1	1	0	1	1	1	1
50356	1	1	2	1	1	1	0	1	1	1	1
50357	1	1	2	1	1	1	0	1	1	1	1
50358	1	1	2	1	1	1	0	1	1	1	1
50359	1	1	2	1	1	1	0	1	1	1	1
50360	1	1	2	1	1	1	0	1	1	1	1
50361	1	1	2	1	1	1	0	1	1	1	1
50362	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50351	0
50352	0
50353	0
50354	0
50355	0
50356	0
50357	0
50358	0
50359	0
50360	0
50361	0
50362	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50451	1	1	2	1	1	1	0	1	1	1	1
50452	1	1	2	1	1	1	0	1	1	1	1
50453	1	1	2	1	1	1	0	1	1	1	1
50454	1	1	2	1	1	1	0	1	1	1	1
50455	1	1	2	1	1	1	0	1	1	1	1
50456	1	1	2	1	1	1	0	1	1	1	1
50457	1	1	2	1	1	1	0	1	1	1	1
50458	1	1	2	1	1	1	0	1	1	1	1
50459	1	1	2	1	1	1	0	1	1	1	1
50460	1	1	2	1	1	1	0	1	1	1	1
50461	1	1	2	1	1	1	0	1	1	1	1
50462	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50451	0
50452	0
50453	0
50454	0
50455	0
50456	0
50457	0
50458	0
50459	0
50460	0
50461	0
50462	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50151	1	1	2	1	1	1	0	1	1	1	1
50152	1	1	2	1	1	1	0	1	1	1	1
50153	1	1	2	1	1	1	0	1	1	1	1
50154	1	1	2	1	1	1	0	1	1	1	1
50155	1	1	2	1	1	1	0	1	1	1	1
50156	1	1	2	1	1	1	0	1	1	1	1
50157	1	1	2	1	1	1	0	1	1	1	1
50158	1	1	2	1	1	1	0	1	1	1	1
50159	1	1	2	1	1	1	0	1	1	1	1
50160	1	1	2	1	1	1	0	1	1	1	1
50161	1	1	2	1	1	1	0	1	1	1	1
50162	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50151	0
50152	0
50153	0
50154	0
50155	0
50156	0
50157	0
50158	0
50159	0
50160	0
50161	0
50162	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50251	1	1	2	1	1	1	0	1	1	1	1
50252	1	1	2	1	1	1	0	1	1	1	1
50253	1	1	2	1	1	1	0	1	1	1	1
50254	1	1	2	1	1	1	0	1	1	1	1
50255	1	1	2	1	1	1	0	1	1	1	1
50256	1	1	2	1	1	1	0	1	1	1	1
50257	1	1	2	1	1	1	0	1	1	1	1
50258	1	1	2	1	1	1	0	1	1	1	1
50259	1	1	2	1	1	1	0	1	1	1	1
50260	1	1	2	1	1	1	0	1	1	1	1
50261	1	1	2	1	1	1	0	1	1	1	1
50262	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50251	0
50252	0
50253	0
50254	0
50255	0
50256	0
50257	0
50258	0
50259	0
50260	0
50261	0
50262	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50351	1	1	2	1	1	1	0	1	1	1	1
50352	1	1	2	1	1	1	0	1	1	1	1
50353	1	1	2	1	1	1	0	1	1	1	1
50354	1	1	2	1	1	1	0	1	1	1	1
50355	1	1	2	1	1	1	0	1	1	1	1
50356	1	1	2	1	1	1	0	1	1	1	1
50357	1	1	2	1	1	1	0	1	1	1	1
50358	1	1	2	1	1	1	0	1	1	1	1
50359	1	1	2	1	1	1	0	1	1	1	1
50360	1	1	2	1	1	1	0	1	1	1	1
50361	1	1	2	1	1	1	0	1	1	1	1
50362	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50351	0
50352	0
50353	0
50354	0
50355	0
50356	0
50357	0
50358	0
50359	0
50360	0
50361	0
50362	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50451	1	1	2	1	1	1	0	1	1	1	1
50452	1	1	2	1	1	1	0	1	1	1	1
50453	1	1	2	1	1	1	0	1	1	1	1
50454	1	1	2	1	1	1	0	1	1	1	1
50455	1	1	2	1	1	1	0	1	1	1	1
50456	1	1	2	1	1	1	0	1	1	1	1
50457	1	1	2	1	1	1	0	1	1	1	1
50458	1	1	2	1	1	1	0	1	1	1	1
50459	1	1	2	1	1	1	0	1	1	1	1
50460	1	1	2	1	1	1	0	1	1	1	1
50461	1	1	2	1	1	1	0	1	1	1	1
50462	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50451	0
50452	0
50453	0
50454	0
50455	0
50456	0
50457	0
50458	0
50459	0
50460	0
50461	0
50462	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50151	1	1	2	1	1	1	0	1	1	1	1
50152	1	1	2	1	1	1	0	1	1	1	1
50153	1	1	2	1	1	1	0	1	1	1	1
50154	1	1	2	1	1	1	0	1	1	1	1
50155	1	1	2	1	1	1	0	1	1	1	1
50156	1	1	2	1	1	1	0	1	1	1	1
50157	1	1	2	1	1	1	0	1	1	1	1
50158	1	1	2	1	1	1	0	1	1	1	1
50159	1	1	2	1	1	1	0	1	1	1	1
50160	1	1	2	1	1	1	0	1	1	1	1
50161	1	1	2	1	1	1	0	1	1	1	1
50162	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50151	0
50152	0
50153	0
50154	0
50155	0
50156	0
50157	0
50158	0
50159	0
50160	0
50161	0
50162	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50251	1	1	2	1	1	1	0	1	1	1	1
50252	1	1	2	1	1	1	0	1	1	1	1
50253	1	1	2	1	1	1	0	1	1	1	1
50254	1	1	2	1	1	1	0	1	1	1	1
50255	1	1	2	1	1	1	0	1	1	1	1
50256	1	1	2	1	1	1	0	1	1	1	1
50257	1	1	2	1	1	1	0	1	1	1	1
50258	1	1	2	1	1	1	0	1	1	1	1
50259	1	1	2	1	1	1	0	1	1	1	1
50260	1	1	2	1	1	1	0	1	1	1	1
50261	1	1	2	1	1	1	0	1	1	1	1
50262	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50251	0
50252	0
50253	0
50254	0
50255	0
50256	0
50257	0
50258	0
50259	0
50260	0
50261	0
50262	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50351	1	1	2	1	1	1	0	1	1	1	1
50352	1	1	2	1	1	1	0	1	1	1	1
50353	1	1	2	1	1	1	0	1	1	1	1
50354	1	1	2	1	1	1	0	1	1	1	1
50355	1	1	2	1	1	1	0	1	1	1	1
50356	1	1	2	1	1	1	0	1	1	1	1
50357	1	1	2	1	1	1	0	1	1	1	1
50358	1	1	2	1	1	1	0	1	1	1	1
50359	1	1	2	1	1	1	0	1	1	1	1
50360	1	1	2	1	1	1	0	1	1	1	1
50361	1	1	2	1	1	1	0	1	1	1	1
50362	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50351	0
50352	0
50353	0
50354	0
50355	0
50356	0
50357	0
50358	0
50359	0
50360	0
50361	0
50362	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50451	1	1	2	1	1	1	0	1	1	1	1
50452	1	1	2	1	1	1	0	1	1	1	1
50453	1	1	2	1	1	1	0	1	1	1	1
50454	1	1	2	1	1	1	0	1	1	1	1
50455	1	1	2	1	1	1	0	1	1	1	1
50456	1	1	2	1	1	1	0	1	1	1	1
50457	1	1	2	1	1	1	0	1	1	1	1
50458	1	1	2	1	1	1	0	1	1	1	1
50459	1	1	2	1	1	1	0	1	1	1	1
50460	1	1	2	1	1	1	0	1	1	1	1
50461	1	1	2	1	1	1	0	1	1	1	1
50462	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50451	0
50452	0
50453	0
50454	0
50455	0
50456	0
50457	0
50458	0
50459	0
50460	0
50461	0
50462	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50151	1	1	2	1	1	1	0	1	1	1	1
50152	1	1	2	1	1	1	0	1	1	1	1
50153	1	1	2	1	1	1	0	1	1	1	1
50154	1	1	2	1	1	1	0	1	1	1	1
50155	1	1	2	1	1	1	0	1	1	1	1
50156	1	1	2	1	1	1	0	1	1	1	1
50157	1	1	2	1	1	1	0	1	1	1	1
50158	1	1	2	1	1	1	0	1	1	1	1
50159	1	1	2	1	1	1	0	1	1	1	1
50160	1	1	2	1	1	1	0	1	1	1	1
50161	1	1	2	1	1	1	0	1	1	1	1
50162	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50151	0
50152	0
50153	0
50154	0
50155	0
50156	0
50157	0
50158	0
50159	0
50160	0
50161	0
50162	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50251	1	1	2	1	1	1	0	1	1	1	1
50252	1	1	2	1	1	1	0	1	1	1	1
50253	1	1	2	1	1	1	0	1	1	1	1
50254	1	1	2	1	1	1	0	1	1	1	1
50255	1	1	2	1	1	1	0	1	1	1	1
50256	1	1	2	1	1	1	0	1	1	1	1
50257	1	1	2	1	1	1	0	1	1	1	1
50258	1	1	2	1	1	1	0	1	1	1	1
50259	1	1	2	1	1	1	0	1	1	1	1
50260	1	1	2	1	1	1	0	1	1	1	1
50261	1	1	2	1	1	1	0	1	1	1	1
50262	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50251	0
50252	0
50253	0
50254	0
50255	0
50256	0
50257	0
50258	0
50259	0
50260	0
50261	0
50262	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50351	1	1	2	1	1	1	0	1	1	1	1
50352	1	1	2	1	1	1	0	1	1	1	1
50353	1	1	2	1	1	1	0	1	1	1	1
50354	1	1	2	1	1	1	0	1	1	1	1
50355	1	1	2	1	1	1	0	1	1	1	1
50356	1	1	2	1	1	1	0	1	1	1	1
50357	1	1	2	1	1	1	0	1	1	1	1
50358	1	1	2	1	1	1	0	1	1	1	1
50359	1	1	2	1	1	1	0	1	1	1	1
50360	1	1	2	1	1	1	0	1	1	1	1
50361	1	1	2	1	1	1	0	1	1	1	1
50362	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50351	0
50352	0
50353	0
50354	0
50355	0
50356	0
50357	0
50358	0
50359	0
50360	0
50361	0
50362	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50451	1	1	2	1	1	1	0	1	1	1	1
50452	1	1	2	1	1	1	0	1	1	1	1
50453	1	1	2	1	1	1	0	1	1	1	1
50454	1	1	2	1	1	1	0	1	1	1	1
50455	1	1	2	1	1	1	0	1	1	1	1
50456	1	1	2	1	1	1	0	1	1	1	1
50457	1	1	2	1	1	1	0	1	1	1	1
50458	1	1	2	1	1	1	0	1	1	1	1
50459	1	1	2	1	1	1	0	1	1	1	1
50460	1	1	2	1	1	1	0	1	1	1	1
50461	1	1	2	1	1	1	0	1	1	1	1
50462	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50451	0
50452	0
50453	0
50454	0
50455	0
50456	0
50457	0
50458	0
50459	0
50460	0
50461	0
50462	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50151	1	1	2	1	1	1	0	1	1	1	1
50152	1	1	2	1	1	1	0	1	1	1	1
50153	1	1	2	1	1	1	0	1	1	1	1
50154	1	1	2	1	1	1	0	1	1	1	1
50155	1	1	2	1	1	1	0	1	1	1	1
50156	1	1	2	1	1	1	0	1	1	1	1
50157	1	1	2	1	1	1	0	1	1	1	1
50158	1	1	2	1	1	1	0	1	1	1	1
50159	1	1	2	1	1	1	0	1	1	1	1
50160	1	1	2	1	1	1	0	1	1	1	1
50161	1	1	2	1	1	1	0	1	1	1	1
50162	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50151	0
50152	0
50153	0
50154	0
50155	0
50156	0
50157	0
50158	0
50159	0
50160	0
50161	0
50162	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50251	1	1	2	1	1	1	0	1	1	1	1
50252	1	1	2	1	1	1	0	1	1	1	1
50253	1	1	2	1	1	1	0	1	1	1	1
50254	1	1	2	1	1	1	0	1	1	1	1
50255	1	1	2	1	1	1	0	1	1	1	1
50256	1	1	2	1	1	1	0	1	1	1	1
50257	1	1	2	1	1	1	0	1	1	1	1
50258	1	1	2	1	1	1	0	1	1	1	1
50259	1	1	2	1	1	1	0	1	1	1	1
50260	1	1	2	1	1	1	0	1	1	1	1
50261	1	1	2	1	1	1	0	1	1	1	1
50262	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50251	0
50252	0
50253	0
50254	0
50255	0
50256	0
50257	0
50258	0
50259	0
50260	0
50261	0
50262	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50351	1	1	2	1	1	1	0	1	1	1	1
50352	1	1	2	1	1	1	0	1	1	1	1
50353	1	1	2	1	1	1	0	1	1	1	1
50354	1	1	2	1	1	1	0	1	1	1	1
50355	1	1	2	1	1	1	0	1	1	1	1
50356	1	1	2	1	1	1	0	1	1	1	1
50357	1	1	2	1	1	1	0	1	1	1	1
50358	1	1	2	1	1	1	0	1	1	1	1
50359	1	1	2	1	1	1	0	1	1	1	1
50360	1	1	2	1	1	1	0	1	1	1	1
50361	1	1	2	1	1	1	0	1	1	1	1
50362	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50351	0
50352	0
50353	0
50354	0
50355	0
50356	0
50357	0
50358	0
50359	0
50360	0
50361	0
50362	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50451	1	1	2	1	1	1	0	1	1	1	1
50452	1	1	2	1	1	1	0	1	1	1	1
50453	1	1	2	1	1	1	0	1	1	1	1
50454	1	1	2	1	1	1	0	1	1	1	1
50455	1	1	2	1	1	1	0	1	1	1	1
50456	1	1	2	1	1	1	0	1	1	1	1
50457	1	1	2	1	1	1	0	1	1	1	1
50458	1	1	2	1	1	1	0	1	1	1	1
50459	1	1	2	1	1	1	0	1	1	1	1
50460	1	1	2	1	1	1	0	1	1	1	1
50461	1	1	2	1	1	1	0	1	1	1	1
50462	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50451	0
50452	0
50453	0
50454	0
50455	0
50456	0
50457	0
50458	0
50459	0
50460	0
50461	0
50462	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 35
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50151	1	1	2	1	1	1	0	1	1	1	1
50152	1	1	2	1	1	1	0	1	1	1	1
50153	1	1	2	1	1	1	0	1	1	1	1
50154	1	1	2	1	1	1	0	1	1	1	1
50155	1	1	2	1	1	1	0	1	1	1	1
50156	1	1	2	1	1	1	0	1	1	1	1
50157	1	1	2	1	1	1	0	1	1	1	1
50158	1	1	2	1	1	1	0	1	1	1	1
50159	1	1	2	1	1	1	0	1	1	1	1
50160	1	1	2	1	1	1	0	1	1	1	1
50161	1	1	2	1	1	1	0	1	1	1	1
50162	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50151	0
50152	0
50153	0
50154	0
50155	0
50156	0
50157	0
50158	0
50159	0
50160	0
50161	0
50162	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 35
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50251	1	1	2	1	1	1	0	1	1	1	1
50252	1	1	2	1	1	1	0	1	1	1	1
50253	1	1	2	1	1	1	0	1	1	1	1
50254	1	1	2	1	1	1	0	1	1	1	1
50255	1	1	2	1	1	1	0	1	1	1	1
50256	1	1	2	1	1	1	0	1	1	1	1
50257	1	1	2	1	1	1	0	1	1	1	1
50258	1	1	2	1	1	1	0	1	1	1	1
50259	1	1	2	1	1	1	0	1	1	1	1
50260	1	1	2	1	1	1	0	1	1	1	1
50261	1	1	2	1	1	1	0	1	1	1	1
50262	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50251	0
50252	0
50253	0
50254	0
50255	0
50256	0
50257	0
50258	0
50259	0
50260	0
50261	0
50262	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 35
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50351	1	1	2	1	1	1	0	1	1	1	1
50352	1	1	2	1	1	1	0	1	1	1	1
50353	1	1	2	1	1	1	0	1	1	1	1
50354	1	1	2	1	1	1	0	1	1	1	1
50355	1	1	2	1	1	1	0	1	1	1	1
50356	1	1	2	1	1	1	0	1	1	1	1
50357	1	1	2	1	1	1	0	1	1	1	1
50358	1	1	2	1	1	1	0	1	1	1	1
50359	1	1	2	1	1	1	0	1	1	1	1
50360	1	1	2	1	1	1	0	1	1	1	1
50361	1	1	2	1	1	1	0	1	1	1	1
50362	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50351	0
50352	0
50353	0
50354	0
50355	0
50356	0
50357	0
50358	0
50359	0
50360	0
50361	0
50362	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 35
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50451	1	1	2	1	1	1	0	1	1	1	1
50452	1	1	2	1	1	1	0	1	1	1	1
50453	1	1	2	1	1	1	0	1	1	1	1
50454	1	1	2	1	1	1	0	1	1	1	1
50455	1	1	2	1	1	1	0	1	1	1	1
50456	1	1	2	1	1	1	0	1	1	1	1
50457	1	1	2	1	1	1	0	1	1	1	1
50458	1	1	2	1	1	1	0	1	1	1	1
50459	1	1	2	1	1	1	0	1	1	1	1
50460	1	1	2	1	1	1	0	1	1	1	1
50461	1	1	2	1	1	1	0	1	1	1	1
50462	1	1	2	1	1	1	0	1	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Animal No.	Secretions/ Excretions
50451	0
50452	0
50453	0
50454	0
50455	0
50456	0
50457	0
50458	0
50459	0
50460	0
50461	0
50462	0
n	12

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 42
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50152	1	1	2	1	1	1	0	1	1	1	1
50155	1	1	2	1	1	1	0	1	1	1	1
50156	1	1	2	1	1	1	0	1	1	1	1
50158	1	1	2	1	1	1	0	1	1	1	1
50159	1	1	2	1	1	1	0	1	1	1	1
50160	1	1	2	1	1	1	0	1	1	1	1
50161	1	1	2	1	1	1	0	1	1	1	1
50162	1	1	2	1	1	1	0	1	1	1	1
n	8	8	8	8	8	8	8	8	8	8	8

Animal No.	Secretions/ Excretions
50152	0
50155	0
50156	0
50158	0
50159	0
50160	0
50161	0
50162	0
n	8

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 42
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50251	1	1	2	1	1	1	0	1	1	1	1
50252	1	1	2	1	1	1	0	1	1	1	1
50254	1	1	2	1	1	1	0	1	1	1	1
50256	1	1	2	1	1	1	0	1	1	1	1
50257	1	1	2	1	1	1	0	1	1	1	1
50258	1	1	2	1	1	1	0	1	1	1	1
50260	1	1	2	1	1	1	0	1	1	1	1
50261	1	1	2	1	1	1	0	1	1	1	1
50262	1	1	2	1	1	1	0	1	1	1	1
n	9	9	9	9	9	9	9	9	9	9	9

Animal No.	Secretions/ Excretions
50251	0
50252	0
50254	0
50256	0
50257	0
50258	0
50260	0
50261	0
50262	0
n	9

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 42
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50351	1	1	2	1	1	1	0	1	1	1	1
50352	1	1	2	1	1	1	0	1	1	1	1
50353	1	1	2	1	1	1	0	1	1	1	1
50355	1	1	2	1	1	1	0	1	1	1	1
50359	1	1	2	1	1	1	0	1	1	1	1
50360	1	1	2	1	1	1	0	1	1	1	1
50361	1	1	2	1	1	1	0	1	1	1	1
50362	1	1	2	1	1	1	0	1	1	1	1
n	8	8	8	8	8	8	8	8	8	8	8

Animal No.	Secretions/ Excretions
50351	0
50352	0
50353	0
50355	0
50359	0
50360	0
50361	0
50362	0
n	8

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 42
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50452	1	1	2	1	1	1	0	1	1	1	1
50454	1	1	2	1	1	1	0	1	1	1	1
50455	1	1	2	1	1	1	0	1	1	1	1
50456	1	1	2	1	1	1	0	1	1	1	1
50457	1	1	2	1	1	1	0	1	1	1	1
50458	1	1	2	1	1	1	0	1	1	1	1
50461	1	1	2	1	1	1	0	1	1	1	1
50462	1	1	2	1	1	1	0	1	1	1	1
n	8	8	8	8	8	8	8	8	8	8	8

Animal No.	Secretions/ Excretions
50452	0
50454	0
50455	0
50456	0
50457	0
50458	0
50461	0
50462	0
n	8

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50551	1	1	2	1	1	1	0	1	1	1	1
50552	1	1	2	1	1	1	0	1	1	1	1
50553	1	1	2	1	1	1	0	1	1	1	1
50554	1	1	2	1	1	1	0	1	1	1	1
50555	1	1	2	1	1	1	0	1	1	1	1
50556	1	1	2	1	1	1	0	1	1	1	1
50557	1	1	2	1	1	1	0	1	1	1	1
50558	1	1	2	1	1	1	0	1	1	1	1
50559	1	1	2	1	1	1	0	1	1	1	1
50560	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50551	0
50552	0
50553	0
50554	0
50555	0
50556	0
50557	0
50558	0
50559	0
50560	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Pre
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50651	1	1	2	1	1	1	0	1	1	1	1
50652	1	1	2	1	1	1	0	1	1	1	1
50653	1	1	2	1	1	1	0	1	1	1	1
50654	1	1	2	1	1	1	0	1	1	1	1
50655	1	1	2	1	1	1	0	1	1	1	1
50656	1	1	2	1	1	1	0	1	1	1	1
50657	1	1	2	1	1	1	0	1	1	1	1
50658	1	1	2	1	1	1	0	1	1	1	1
50659	1	1	2	1	1	1	0	1	1	1	1
50660	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50651	0
50652	0
50653	0
50654	0
50655	0
50656	0
50657	0
50658	0
50659	0
50660	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50551	1	1	2	1	1	1	0	1	1	1	1
50552	1	1	2	1	1	1	0	1	1	1	1
50553	1	1	2	1	1	1	0	1	1	1	1
50554	1	1	2	1	1	1	0	1	1	1	1
50555	1	1	2	1	1	1	0	1	1	1	1
50556	1	1	2	1	1	1	0	1	1	1	1
50557	1	1	2	1	1	1	0	1	1	1	1
50558	1	1	2	1	1	1	0	1	1	1	1
50559	1	1	2	1	1	1	0	1	1	1	1
50560	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50551	0
50552	0
50553	0
50554	0
50555	0
50556	0
50557	0
50558	0
50559	0
50560	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 7
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50651	1	1	2	1	1	1	0	1	1	1	1
50652	1	1	2	1	1	1	0	1	1	1	1
50653	1	1	2	1	1	1	0	1	1	1	1
50654	1	1	2	1	1	1	0	1	1	1	1
50655	1	1	2	1	1	1	0	1	1	1	1
50656	1	1	2	1	1	1	0	1	1	1	1
50657	1	1	2	1	1	1	0	1	1	1	1
50658	1	1	2	1	1	1	0	1	1	1	1
50659	1	1	2	1	1	1	0	1	1	1	1
50660	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50651	0
50652	0
50653	0
50654	0
50655	0
50656	0
50657	0
50658	0
50659	0
50660	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50551	1	1	2	1	1	1	0	1	1	1	1
50552	1	1	2	1	1	1	0	1	1	1	1
50553	1	1	2	1	1	1	0	1	1	1	1
50554	1	1	2	1	1	1	0	1	1	1	1
50555	1	1	2	1	1	1	0	1	1	1	1
50556	1	1	2	1	1	1	0	1	1	1	1
50557	1	1	2	1	1	1	0	1	1	1	1
50558	1	1	2	1	1	1	0	1	1	1	1
50559	1	1	2	1	1	1	0	1	1	1	1
50560	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50551	0
50552	0
50553	0
50554	0
50555	0
50556	0
50557	0
50558	0
50559	0
50560	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 14
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50651	1	1	2	1	1	1	0	1	1	1	1
50652	1	1	2	1	1	1	0	1	1	1	1
50653	1	1	2	1	1	1	0	1	1	1	1
50654	1	1	2	1	1	1	0	1	1	1	1
50655	1	1	2	1	1	1	0	1	1	1	1
50656	1	1	2	1	1	1	0	1	1	1	1
50657	1	1	2	1	1	1	0	1	1	1	1
50658	1	1	2	1	1	1	0	1	1	1	1
50659	1	1	2	1	1	1	0	1	1	1	1
50660	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50651	0
50652	0
50653	0
50654	0
50655	0
50656	0
50657	0
50658	0
50659	0
50660	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50551	1	1	2	1	1	1	0	1	1	1	1
50552	1	1	2	1	1	1	0	1	1	1	1
50553	1	1	2	1	1	1	0	1	1	1	1
50554	1	1	2	1	1	1	0	1	1	1	1
50555	1	1	2	1	1	1	0	1	1	1	1
50556	1	1	2	1	1	1	0	1	1	1	1
50557	1	1	2	1	1	1	0	1	1	1	1
50558	1	1	2	1	1	1	0	1	1	1	1
50559	1	1	2	1	1	1	0	1	1	1	1
50560	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50551	0
50552	0
50553	0
50554	0
50555	0
50556	0
50557	0
50558	0
50559	0
50560	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 21
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50651	1	1	2	1	1	1	0	1	1	1	1
50652	1	1	2	1	1	1	0	1	1	1	1
50653	1	1	2	1	1	1	0	1	1	1	1
50654	1	1	2	1	1	1	0	1	1	1	1
50655	1	1	2	1	1	1	0	1	1	1	1
50656	1	1	2	1	1	1	0	1	1	1	1
50657	1	1	2	1	1	1	0	1	1	1	1
50658	1	1	2	1	1	1	0	1	1	1	1
50659	1	1	2	1	1	1	0	1	1	1	1
50660	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50651	0
50652	0
50653	0
50654	0
50655	0
50656	0
50657	0
50658	0
50659	0
50660	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50551	1	1	2	1	1	1	0	1	1	1	1
50552	1	1	2	1	1	1	0	1	1	1	1
50553	1	1	2	1	1	1	0	1	1	1	1
50554	1	1	2	1	1	1	0	1	1	1	1
50555	1	1	2	1	1	1	0	1	1	1	1
50556	1	1	2	1	1	1	0	1	1	1	1
50557	1	1	2	1	1	1	0	1	1	1	1
50558	1	1	2	1	1	1	0	1	1	1	1
50559	1	1	2	1	1	1	0	1	1	1	1
50560	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50551	0
50552	0
50553	0
50554	0
50555	0
50556	0
50557	0
50558	0
50559	0
50560	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Day 28
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50651	1	1	2	1	1	1	0	1	1	1	1
50652	1	1	2	1	1	1	0	1	1	1	1
50653	1	1	2	1	1	1	0	1	1	1	1
50654	1	1	2	1	1	1	0	1	1	1	1
50655	1	1	2	1	1	1	0	1	1	1	1
50656	1	1	2	1	1	1	0	1	1	1	1
50657	1	1	2	1	1	1	0	1	1	1	1
50658	1	1	2	1	1	1	0	1	1	1	1
50659	1	1	2	1	1	1	0	1	1	1	1
50660	1	1	2	1	1	1	0	1	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Animal No.	Secretions/ Excretions
50651	0
50652	0
50653	0
50654	0
50655	0
50656	0
50657	0
50658	0
50659	0
50660	0
n	10

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Recovery Day 7
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10104	1	1	2	1	1	1	0	1	1	1	1
10106	1	1	2	1	1	1	0	1	1	1	1
10108	1	1	2	1	1	1	0	1	1	1	1
10110	1	1	2	1	1	1	0	1	1	1	1
10112	1	1	2	1	1	1	0	1	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Animal No.	Secretions/ Excretions
10104	0
10106	0
10108	0
10110	0
10112	0
n	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Recovery Day 7
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10404	1	1	2	1	1	1	0	1	1	1	1
10406	1	1	2	1	1	1	0	1	1	1	1
10407	1	1	2	1	1	1	0	1	1	1	1
10409	1	1	2	1	1	1	0	1	1	1	1
10412	1	1	2	1	1	1	0	1	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Animal No.	Secretions/ Excretions
10404	0
10406	0
10407	0
10409	0
10412	0
n	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Recovery Day 14
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10104	1	1	2	1	1	1	0	1	1	1	1
10106	1	1	2	1	1	1	0	1	1	1	1
10108	1	1	2	1	1	1	0	1	1	1	1
10110	1	1	2	1	1	1	0	1	1	1	1
10112	1	1	2	1	1	1	0	1	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Animal No.	Secretions/ Excretions
10104	0
10106	0
10108	0
10110	0
10112	0
n	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Recovery Day 14
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
10404	1	1	2	1	1	1	0	1	1	1	1
10406	1	1	2	1	1	1	0	1	1	1	1
10407	1	1	2	1	1	1	0	1	1	1	1
10409	1	1	2	1	1	1	0	1	1	1	1
10412	1	1	2	1	1	1	0	1	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Animal No.	Secretions/ Excretions
10404	0
10406	0
10407	0
10409	0
10412	0
n	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Recovery Day 7
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50556	1	1	2	1	1	1	0	1	1	1	1
50557	1	1	2	1	1	1	0	1	1	1	1
50558	1	1	2	1	1	1	0	1	1	1	1
50559	1	1	2	1	1	1	0	1	1	1	1
50560	1	1	2	1	1	1	0	1	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Animal No.	Secretions/ Excretions
50556	0
50557	0
50558	0
50559	0
50560	0
n	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Recovery Day 7
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50656	1	1	2	1	1	1	0	1	1	1	1
50657	1	1	2	1	1	1	0	1	1	1	1
50658	1	1	2	1	1	1	0	1	1	1	1
50659	1	1	2	1	1	1	0	1	1	1	1
50660	1	1	2	1	1	1	0	1	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Animal No.	Secretions/ Excretions
50656	0
50657	0
50658	0
50659	0
50660	0
n	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Recovery Day 14
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50556	1	1	2	1	1	1	0	1	1	1	1
50557	1	1	2	1	1	1	0	1	1	1	1
50558	1	1	2	1	1	1	0	1	1	1	1
50559	1	1	2	1	1	1	0	1	1	1	1
50560	1	1	2	1	1	1	0	1	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Animal No.	Secretions/ Excretions
50556	0
50557	0
50558	0
50559	0
50560	0
n	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (on the hand) Stage : Recovery Day 14
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Ease of Removal	Ease of Handling	Muscle tone	Piloerection	Fur	Eyes	Mucous membranes	Skin	Pupil size	Lacrimation	Salivation
50656	1	1	2	1	1	1	0	1	1	1	1
50657	1	1	2	1	1	1	0	1	1	1	1
50658	1	1	2	1	1	1	0	1	1	1	1
50659	1	1	2	1	1	1	0	1	1	1	1
50660	1	1	2	1	1	1	0	1	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Animal No.	Secretions/ Excretions
50656	0
50657	0
50658	0
50659	0
50660	0
n	5

Ease of Removal) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Ease of Handling) 1;Very easy, 2;Easy, 3;Slightly difficult, 4;Difficult, 5;Very difficult.
Muscle tone) 1;Low, 2;Normal, 3;High.
Piloerection) 1;Normal, 2;Slightly present, around head and back, 3;Slightly present, systemic, 4;Severely present, systemic.
Fur) 1;Normal, 2;Slightly stained, 3;Stained.
Eyes) 1;Not present, normal, 2;Slight ptosis, half closed, 3;Ptosis, 4;Closed.
Mucous membranes) -1;Dark purplish appearance, cyanosis, 0;Normal, 1;Red appearance.
Skin) 0;Pale appearance, cyanosis, 1;Normal, 2;Red appearance.
Pupil size) 1;Normal, 2;Slightly mydriatic, 3;Mydriatic.
Lacrimation) 1;Not present, 2;Wet around the eye, 3;Wet, 4;Severely wet.
Salivation) 1;Not present, 2;Wet around the mouth, 3;Wet, 4;Severely wet.
Secretions/Excretions) 0;Not present, 1;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10101	1	1	1	1	1	1	0	0	1	1	1
10102	1	1	1	1	0	0	0	0	1	1	1
10103	1	1	1	1	0	1	0	0	1	1	1
10104	1	1	1	1	0	0	0	0	1	1	1
10105	1	1	1	1	0	0	0	0	1	1	1
10106	1	1	1	1	0	0	0	0	1	1	1
10107	1	1	1	1	1	0	0	0	1	1	1
10108	1	1	1	1	0	0	0	0	1	1	1
10109	1	1	1	1	0	0	0	0	1	1	1
10110	1	1	1	1	0	0	0	0	1	1	1
10111	1	1	1	1	1	0	0	0	1	1	1
10112	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10201	1	1	1	1	0	0	0	0	1	1	1
10202	1	1	1	1	1	1	0	0	1	1	1
10203	1	1	1	1	1	1	0	0	1	1	1
10204	1	1	1	1	1	0	0	0	1	1	1
10205	1	1	1	1	0	1	0	0	1	1	1
10206	1	1	1	1	0	0	0	0	1	1	1
10207	1	1	1	1	1	0	0	0	1	1	1
10208	1	1	1	1	0	0	0	0	1	1	1
10209	1	1	1	1	0	0	0	0	1	1	1
10210	1	1	1	1	1	1	0	0	1	1	1
10211	1	1	1	1	0	0	0	0	1	1	1
10212	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10301	1	1	1	1	1	1	0	0	1	1	1
10302	1	1	1	1	0	1	0	0	1	1	1
10303	1	1	1	1	0	0	0	0	1	1	1
10304	1	1	1	1	1	0	0	0	1	1	1
10305	1	1	1	1	1	1	0	0	1	1	1
10306	1	1	1	1	1	1	0	0	1	1	1
10307	1	1	1	1	0	0	0	0	1	1	1
10308	1	1	1	1	1	1	0	0	1	1	1
10309	1	1	1	1	0	0	0	0	1	1	1
10310	1	1	1	1	1	0	0	0	1	1	1
10311	1	1	1	1	1	1	0	0	1	1	1
10312	1	1	1	1	0	1	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10401	1	1	1	1	1	0	0	0	1	1	1
10402	1	1	1	1	0	0	0	0	1	1	1
10403	1	1	1	1	0	0	0	0	1	1	1
10404	1	1	1	1	0	0	0	0	1	1	1
10405	1	1	1	1	1	0	0	0	1	1	1
10406	1	1	1	1	1	0	0	0	1	1	1
10407	1	1	1	1	0	0	0	0	1	1	1
10408	1	1	1	1	1	1	0	0	1	1	1
10409	1	1	1	1	1	1	0	0	1	1	1
10410	1	1	1	1	0	0	0	0	1	1	1
10411	1	1	1	1	1	1	0	0	1	1	1
10412	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10101	1	1	1	1	1	0	0	0	1	1	1
10102	1	1	1	1	0	0	0	0	1	1	1
10103	1	1	1	1	0	0	0	0	1	1	1
10104	1	1	1	1	0	0	0	0	1	1	1
10105	1	1	1	1	1	0	0	0	1	1	1
10106	1	1	1	1	0	0	0	0	1	1	1
10107	1	1	1	1	0	0	0	0	1	1	1
10108	1	1	1	1	0	0	0	0	1	1	1
10109	1	1	1	1	1	0	0	0	1	1	1
10110	1	1	1	1	0	0	0	0	1	1	1
10111	1	1	1	1	0	0	0	0	1	1	1
10112	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10201	1	1	1	1	0	0	0	0	1	1	1
10202	1	1	1	1	0	0	0	0	1	1	1
10203	1	1	1	1	1	0	0	0	1	1	1
10204	1	1	1	1	0	0	0	0	1	1	1
10205	1	1	1	1	0	0	0	0	1	1	1
10206	1	1	1	1	0	0	0	0	1	1	1
10207	1	1	1	1	0	0	0	0	1	1	1
10208	1	1	1	1	0	0	0	0	1	1	1
10209	1	1	1	1	0	0	0	0	1	1	1
10210	1	1	1	1	1	0	0	0	1	1	1
10211	1	1	1	1	0	0	0	0	1	1	1
10212	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10301	1	1	1	1	0	0	0	0	1	1	1
10302	1	1	1	1	0	0	0	0	1	1	1
10303	1	1	1	1	0	0	0	0	1	1	1
10304	1	1	1	1	0	0	0	0	1	1	1
10305	1	1	1	1	0	0	0	0	1	1	1
10306	1	1	1	1	1	0	0	0	1	1	1
10307	1	1	1	1	0	0	0	0	1	1	1
10308	1	1	1	1	0	0	0	0	1	1	1
10309	1	1	1	1	0	0	0	0	1	1	1
10310	1	1	1	1	1	0	0	0	1	1	1
10311	1	1	1	1	0	0	0	0	1	1	1
10312	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10401	1	1	1	1	0	0	0	0	1	1	1
10402	1	1	1	1	0	0	0	0	1	1	1
10403	1	1	1	1	0	0	0	0	1	1	1
10404	1	1	1	1	0	0	0	0	1	1	1
10405	1	1	1	1	0	0	0	0	1	1	1
10406	1	1	1	1	0	0	0	0	1	1	1
10407	1	1	1	1	0	0	0	0	1	1	1
10408	1	1	1	1	1	1	0	0	1	1	1
10409	1	1	1	1	1	1	0	0	1	1	1
10410	1	1	1	1	1	0	0	0	1	1	1
10411	1	1	1	1	0	0	0	0	1	1	1
10412	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10101	1	1	1	1	1	1	0	0	1	1	1
10102	1	1	1	1	0	0	0	0	1	1	1
10103	1	1	1	1	0	0	0	0	1	1	1
10104	1	1	1	1	0	0	0	0	1	1	1
10105	1	1	1	1	1	0	0	0	1	1	1
10106	1	1	1	1	0	0	0	0	1	1	1
10107	1	1	1	1	0	0	0	0	1	1	1
10108	1	1	1	1	0	0	0	0	1	1	1
10109	1	1	1	1	0	0	0	0	1	1	1
10110	1	1	1	1	0	0	0	0	1	1	1
10111	1	1	1	1	0	0	0	0	1	1	1
10112	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10201	1	1	1	1	0	0	0	0	1	1	1
10202	1	1	1	1	0	0	0	0	1	1	1
10203	1	1	1	1	1	0	0	0	1	1	1
10204	1	1	1	1	0	0	0	0	1	1	1
10205	1	1	1	1	0	0	0	0	1	1	1
10206	1	1	1	1	0	0	0	0	1	1	1
10207	1	1	1	1	0	0	0	0	1	1	1
10208	1	1	1	1	1	0	0	0	1	1	1
10209	1	1	1	1	0	0	0	0	1	1	1
10210	1	1	1	1	1	0	0	0	1	1	1
10211	1	1	1	1	0	0	0	0	1	1	1
10212	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10301	1	1	1	1	0	1	0	0	1	1	1
10302	1	1	1	1	0	1	0	0	1	1	1
10303	1	1	1	1	0	0	0	0	1	1	1
10304	1	1	1	1	0	0	0	0	1	1	1
10305	1	1	1	1	0	0	0	0	1	1	1
10306	1	1	1	1	0	0	0	0	1	1	1
10307	1	1	1	1	0	0	0	0	1	1	1
10308	1	1	1	1	0	1	0	0	1	1	1
10309	1	1	1	1	0	0	0	0	1	1	1
10310	1	1	1	1	0	0	0	0	1	1	1
10311	1	1	1	1	0	0	0	0	1	1	1
10312	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10401	1	1	1	1	0	0	0	0	1	1	1
10402	1	1	1	1	0	0	0	0	1	1	1
10403	1	1	1	1	0	0	0	0	1	1	1
10404	1	1	1	1	0	0	0	0	1	1	1
10405	1	1	1	1	0	0	0	0	1	1	1
10406	1	1	1	1	0	0	0	0	1	1	1
10407	1	1	1	1	0	0	0	0	1	1	1
10408	1	1	1	1	0	1	0	0	1	1	1
10409	1	1	1	1	1	1	0	0	1	1	1
10410	1	1	1	1	0	0	0	0	1	1	1
10411	1	1	1	1	0	0	0	0	1	1	1
10412	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10101	1	1	1	1	1	1	0	0	1	1	1
10102	1	1	1	1	0	0	0	0	1	1	1
10103	1	1	1	1	0	0	0	0	1	1	1
10104	1	1	1	1	1	0	0	0	1	1	1
10105	1	1	1	1	1	0	0	0	1	1	1
10106	1	1	1	1	0	0	0	0	1	1	1
10107	1	1	1	1	0	0	0	0	1	1	1
10108	1	1	1	1	0	0	0	0	1	1	1
10109	1	1	1	1	0	0	0	0	1	1	1
10110	1	1	1	1	0	0	0	0	1	1	1
10111	1	1	1	1	0	0	0	0	1	1	1
10112	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10201	1	1	1	1	0	0	0	0	1	1	1
10202	1	1	1	1	0	1	0	0	1	1	1
10203	1	1	1	1	0	0	0	0	1	1	1
10204	1	1	1	1	0	0	0	0	1	1	1
10205	1	1	1	1	1	0	0	0	1	1	1
10206	1	1	1	1	0	0	0	0	1	1	1
10207	1	1	1	1	0	0	0	0	1	1	1
10208	1	1	1	1	1	0	0	0	1	1	1
10209	1	1	1	1	0	0	0	0	1	1	1
10210	1	1	1	1	0	0	0	0	1	1	1
10211	1	1	1	1	0	0	0	0	1	1	1
10212	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10301	1	1	1	1	1	1	0	0	1	1	1
10302	1	1	1	1	0	1	0	0	1	1	1
10303	1	1	1	1	0	0	0	0	1	1	1
10304	1	1	1	1	1	0	0	0	1	1	1
10305	1	1	1	1	0	0	0	0	1	1	1
10306	1	1	1	1	1	0	0	0	1	1	1
10307	1	1	1	1	0	0	0	0	1	1	1
10308	1	1	1	1	0	0	0	0	1	1	1
10309	1	1	1	1	0	1	0	0	1	1	1
10310	1	1	1	1	1	0	0	0	1	1	1
10311	1	1	1	1	0	0	0	0	1	1	1
10312	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10401	1	1	1	1	0	0	0	0	1	1	1
10402	1	1	1	1	0	0	0	0	1	1	1
10403	1	1	1	1	0	0	0	0	1	1	1
10404	1	1	1	1	0	0	0	0	1	1	1
10405	1	1	1	1	0	0	0	0	1	1	1
10406	1	1	1	1	0	0	0	0	1	1	1
10407	1	1	1	1	0	0	0	0	1	1	1
10408	1	1	1	1	0	1	0	0	1	1	1
10409	1	1	1	1	1	1	0	0	1	1	1
10410	1	1	1	1	0	0	0	0	1	1	1
10411	1	1	1	1	1	1	0	0	1	1	1
10412	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10101	1	1	1	1	1	0	0	0	1	1	1
10102	1	1	1	1	0	0	0	0	1	1	1
10103	1	1	1	1	0	0	0	0	1	1	1
10104	1	1	1	1	0	0	0	0	1	1	1
10105	1	1	1	1	0	0	0	0	1	1	1
10106	1	1	1	1	0	0	0	0	1	1	1
10107	1	1	1	1	0	0	0	0	1	1	1
10108	1	1	1	1	0	1	0	0	1	1	1
10109	1	1	1	1	0	0	0	0	1	1	1
10110	1	1	1	1	0	0	0	0	1	1	1
10111	1	1	1	1	0	0	0	0	1	1	1
10112	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10201	1	1	1	1	0	0	0	0	1	1	1
10202	1	1	1	1	0	0	0	0	1	1	1
10203	1	1	1	1	0	0	0	0	1	1	1
10204	1	1	1	1	0	0	0	0	1	1	1
10205	1	1	1	1	1	0	0	0	1	1	1
10206	1	1	1	1	0	0	0	0	1	1	1
10207	1	1	1	1	0	0	0	0	1	1	1
10208	1	1	1	1	0	0	0	0	1	1	1
10209	1	1	1	1	0	0	0	0	1	1	1
10210	1	1	1	1	1	0	0	0	1	1	1
10211	1	1	1	1	0	0	0	0	1	1	1
10212	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10301	1	1	1	1	0	1	0	0	1	1	1
10302	1	1	1	1	1	0	0	0	1	1	1
10303	1	1	1	1	0	0	0	0	1	1	1
10304	1	1	1	1	0	0	0	0	1	1	1
10305	1	1	1	1	1	0	0	0	1	1	1
10306	1	1	1	1	0	0	0	0	1	1	1
10307	1	1	1	1	0	0	0	0	1	1	1
10308	1	1	1	1	0	0	0	0	1	1	1
10309	1	1	1	1	0	0	0	0	1	1	1
10310	1	1	1	1	0	0	0	0	1	1	1
10311	1	1	1	1	0	0	0	0	1	1	1
10312	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10401	1	1	1	1	0	0	0	0	1	1	1
10402	1	1	1	1	0	0	0	0	1	1	1
10403	1	1	1	1	1	0	0	0	1	1	1
10404	1	1	1	1	0	0	0	0	1	1	1
10405	1	1	1	1	1	0	0	0	1	1	1
10406	1	1	1	1	0	0	0	0	1	1	1
10407	1	1	1	1	1	0	0	0	1	1	1
10408	1	1	1	1	1	1	0	0	1	1	1
10409	1	1	1	1	1	1	0	0	1	1	1
10410	1	1	1	1	0	0	0	0	1	1	1
10411	1	1	1	1	1	0	0	0	1	1	1
10412	1	1	1	1	1	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50151	1	1	1	1	0	1	0	0	1	1	1
50152	1	1	1	1	0	0	0	0	1	1	1
50153	1	1	1	1	0	0	0	0	1	1	1
50154	1	1	1	1	0	0	0	0	1	1	1
50155	1	1	1	1	0	0	0	0	1	1	1
50156	1	1	1	1	0	0	0	0	1	1	1
50157	1	1	1	1	0	0	0	0	1	1	1
50158	1	1	1	1	0	0	0	0	1	1	1
50159	1	1	1	1	0	0	0	0	1	1	1
50160	1	1	1	1	0	0	0	0	1	1	1
50161	1	1	1	1	0	0	0	0	1	1	1
50162	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50251	1	1	1	1	0	0	0	0	1	1	1
50252	1	1	1	1	0	0	0	0	1	1	1
50253	1	1	1	1	0	0	0	0	1	1	1
50254	1	1	1	1	0	0	0	0	1	1	1
50255	1	1	1	1	0	1	0	0	1	1	1
50256	1	1	1	1	0	0	0	0	1	1	1
50257	1	1	1	1	0	0	0	0	1	1	1
50258	1	1	1	1	0	0	0	0	1	1	1
50259	1	1	1	1	0	0	0	0	1	1	1
50260	1	1	1	1	0	0	0	0	1	1	1
50261	1	1	1	1	0	0	0	0	1	1	1
50262	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50351	1	1	1	1	0	0	0	0	1	1	1
50352	1	1	1	1	0	0	0	0	1	1	1
50353	1	1	1	1	1	1	0	0	1	1	1
50354	1	1	1	1	0	0	0	0	1	1	1
50355	1	1	1	1	0	0	0	0	1	1	1
50356	1	1	1	1	0	0	0	0	1	1	1
50357	1	1	1	1	0	0	0	0	1	1	1
50358	1	1	1	1	0	0	0	0	1	1	1
50359	1	1	1	1	0	0	0	0	1	1	1
50360	1	1	1	1	0	0	0	0	1	1	1
50361	1	1	1	1	0	0	0	0	1	1	1
50362	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50451	1	1	1	1	0	0	0	0	1	1	1
50452	1	1	1	1	0	0	0	0	1	1	1
50453	1	1	1	1	0	0	0	0	1	1	1
50454	1	1	1	1	0	0	0	0	1	1	1
50455	1	1	1	1	0	0	0	0	1	1	1
50456	1	1	1	1	0	0	0	0	1	1	1
50457	1	1	1	1	0	0	0	0	1	1	1
50458	1	1	1	1	0	0	0	0	1	1	1
50459	1	1	1	1	0	0	0	0	1	1	1
50460	1	1	1	1	0	0	0	0	1	1	1
50461	1	1	1	1	0	0	0	0	1	1	1
50462	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50151	1	1	1	1	1	0	0	0	1	1	1
50152	1	1	1	1	0	0	0	0	1	1	1
50153	1	1	1	1	0	0	0	0	1	1	1
50154	1	1	1	1	0	0	0	0	1	1	1
50155	1	1	1	1	0	0	0	0	1	1	1
50156	1	1	1	1	0	0	0	0	1	1	1
50157	1	1	1	1	0	0	0	0	1	1	1
50158	1	1	1	1	0	0	0	0	1	1	1
50159	1	1	1	1	0	0	0	0	1	1	1
50160	1	1	1	1	0	0	0	0	1	1	1
50161	1	1	1	1	0	0	0	0	1	1	1
50162	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50251	1	1	1	1	1	0	0	0	1	1	1
50252	1	1	1	1	0	0	0	0	1	1	1
50253	1	1	1	1	0	0	0	0	1	1	1
50254	1	1	1	1	0	0	0	0	1	1	1
50255	1	1	1	1	0	0	0	0	1	1	1
50256	1	1	1	1	0	0	0	0	1	1	1
50257	1	1	1	1	0	0	0	0	1	1	1
50258	1	1	1	1	0	0	0	0	1	1	1
50259	1	1	1	1	0	0	0	0	1	1	1
50260	1	1	1	1	0	0	0	0	1	1	1
50261	1	1	1	1	0	0	0	0	1	1	1
50262	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50351	1	1	1	1	0	0	0	0	1	1	1
50352	1	1	1	1	0	0	0	0	1	1	1
50353	1	1	1	1	0	0	0	0	1	1	1
50354	1	1	1	1	0	0	0	0	1	1	1
50355	1	1	1	1	0	0	0	0	1	1	1
50356	1	1	1	1	0	0	0	0	1	1	1
50357	1	1	1	1	0	0	0	0	1	1	1
50358	1	1	1	1	0	0	0	0	1	1	1
50359	1	1	1	1	0	0	0	0	1	1	1
50360	1	1	1	1	0	0	0	0	1	1	1
50361	1	1	1	1	0	0	0	0	1	1	1
50362	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50451	1	1	1	1	0	0	0	0	1	1	1
50452	1	1	1	1	0	0	0	0	1	1	1
50453	1	1	1	1	0	0	0	0	1	1	1
50454	1	1	1	1	0	0	0	0	1	1	1
50455	1	1	1	1	0	0	0	0	1	1	1
50456	1	1	1	1	0	0	0	0	1	1	1
50457	1	1	1	1	0	0	0	0	1	1	1
50458	1	1	1	1	0	0	0	0	1	1	1
50459	1	1	1	1	0	0	0	0	1	1	1
50460	1	1	1	1	0	0	0	0	1	1	1
50461	1	1	1	1	0	0	0	0	1	1	1
50462	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50151	1	1	1	1	1	0	0	0	1	1	1
50152	1	1	1	1	0	0	0	0	1	1	1
50153	1	1	1	1	0	0	0	0	1	1	1
50154	1	1	1	1	0	0	0	0	1	1	1
50155	1	1	1	1	0	0	0	0	1	1	1
50156	1	1	1	1	0	0	0	0	1	1	1
50157	1	1	1	1	0	0	0	0	1	1	1
50158	1	1	1	1	0	0	0	0	1	1	1
50159	1	1	1	1	0	0	0	0	1	1	1
50160	1	1	1	1	0	0	0	0	1	1	1
50161	1	1	1	1	0	0	0	0	1	1	1
50162	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50251	1	1	1	1	0	0	0	0	1	1	1
50252	1	1	1	1	0	0	0	0	1	1	1
50253	1	1	1	1	0	0	0	0	1	1	1
50254	1	1	1	1	0	0	0	0	1	1	1
50255	1	1	1	1	0	0	0	0	1	1	1
50256	1	1	1	1	0	0	0	0	1	1	1
50257	1	1	1	1	0	0	0	0	1	1	1
50258	1	1	1	1	0	0	0	0	1	1	1
50259	1	1	1	1	0	0	0	0	1	1	1
50260	1	1	1	1	0	0	0	0	1	1	1
50261	1	1	1	1	0	0	0	0	1	1	1
50262	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50351	1	1	1	1	0	0	0	0	1	1	1
50352	1	1	1	1	0	0	0	0	1	1	1
50353	1	1	1	1	0	0	0	0	1	1	1
50354	1	1	1	1	0	0	0	0	1	1	1
50355	1	1	1	1	0	0	0	0	1	1	1
50356	1	1	1	1	0	0	0	0	1	1	1
50357	1	1	1	1	0	0	0	0	1	1	1
50358	1	1	1	1	0	0	0	0	1	1	1
50359	1	1	1	1	0	0	0	0	1	1	1
50360	1	1	1	1	0	0	0	0	1	1	1
50361	1	1	1	1	0	0	0	0	1	1	1
50362	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50451	1	1	1	1	0	0	0	0	1	1	1
50452	1	1	1	1	0	0	0	0	1	1	1
50453	1	1	1	1	0	0	0	0	1	1	1
50454	1	1	1	1	0	0	0	0	1	1	1
50455	1	1	1	1	0	0	0	0	1	1	1
50456	1	1	1	1	0	0	0	0	1	1	1
50457	1	1	1	1	0	0	0	0	1	1	1
50458	1	1	1	1	0	0	0	0	1	1	1
50459	1	1	1	1	0	0	0	0	1	1	1
50460	1	1	1	1	0	0	0	0	1	1	1
50461	1	1	1	1	0	0	0	0	1	1	1
50462	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50151	1	1	1	1	1	0	0	0	1	1	1
50152	1	1	1	1	0	0	0	0	1	1	1
50153	1	1	1	1	0	0	0	0	1	1	1
50154	1	1	1	1	0	0	0	0	1	1	1
50155	1	1	1	1	0	0	0	0	1	1	1
50156	1	1	1	1	0	0	0	0	1	1	1
50157	1	1	1	1	0	0	0	0	1	1	1
50158	1	1	1	1	0	0	0	0	1	1	1
50159	1	1	1	1	0	0	0	0	1	1	1
50160	1	1	1	1	0	0	0	0	1	1	1
50161	1	1	1	1	0	0	0	0	1	1	1
50162	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50251	1	1	1	1	0	0	0	0	1	1	1
50252	1	1	1	1	0	0	0	0	1	1	1
50253	1	1	1	1	1	0	0	0	1	1	1
50254	1	1	1	1	0	0	1	0	1	1	1
50255	1	1	1	1	0	0	0	0	1	1	1
50256	1	1	1	1	0	0	0	0	1	1	1
50257	1	1	1	1	0	0	0	0	1	1	1
50258	1	1	1	1	0	0	0	0	1	1	1
50259	1	1	1	1	0	0	0	0	1	1	1
50260	1	1	1	1	0	0	0	0	1	1	1
50261	1	1	1	1	0	0	0	0	1	1	1
50262	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50351	1	1	1	1	0	0	0	0	1	1	1
50352	1	1	1	1	0	0	0	0	1	1	1
50353	1	1	1	1	0	0	0	0	1	1	1
50354	1	1	1	1	0	0	0	0	1	1	1
50355	1	1	1	1	0	0	0	0	1	1	1
50356	1	1	1	1	0	0	0	0	1	1	1
50357	1	1	1	1	0	0	0	0	1	1	1
50358	1	1	1	1	0	0	0	0	1	1	1
50359	1	1	1	1	0	0	0	0	1	1	1
50360	1	1	1	1	0	0	0	0	1	1	1
50361	1	1	1	1	0	0	0	0	1	1	1
50362	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50451	1	1	1	1	0	0	0	0	1	1	1
50452	1	1	1	1	0	0	0	0	1	1	1
50453	1	1	1	1	0	0	0	0	1	1	1
50454	1	1	1	1	0	0	0	0	1	1	1
50455	1	1	1	1	0	0	0	0	1	1	1
50456	1	1	1	1	0	0	0	0	1	1	1
50457	1	1	1	1	0	0	0	0	1	1	1
50458	1	1	1	1	0	0	0	0	1	1	1
50459	1	1	1	1	0	0	0	0	1	1	1
50460	1	1	1	1	0	0	0	0	1	1	1
50461	1	1	1	1	0	0	0	0	1	1	1
50462	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50151	1	1	1	1	1	0	0	0	1	1	1
50152	1	1	1	1	0	0	0	0	1	1	1
50153	1	1	1	1	1	0	0	0	1	1	1
50154	1	1	1	1	0	0	0	0	1	1	1
50155	1	1	1	1	0	0	0	0	1	1	1
50156	1	1	1	1	0	0	0	0	1	1	1
50157	1	1	1	1	0	0	0	0	1	1	1
50158	1	1	1	1	0	0	0	0	1	1	1
50159	1	1	1	1	0	0	0	0	1	1	1
50160	1	1	1	1	0	0	0	0	1	1	1
50161	1	1	1	1	0	0	0	0	1	1	1
50162	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50251	1	1	1	1	0	0	0	0	1	1	1
50252	1	1	1	1	0	0	0	0	1	1	1
50253	1	1	1	1	0	0	0	0	1	1	1
50254	1	1	1	1	0	0	0	0	1	1	1
50255	1	1	1	1	0	0	0	0	1	1	1
50256	1	1	1	1	0	0	0	0	1	1	1
50257	1	1	1	1	0	0	0	0	1	1	1
50258	1	1	1	1	0	0	0	0	1	1	1
50259	1	1	1	1	0	0	0	0	1	1	1
50260	1	1	1	1	0	0	0	0	1	1	1
50261	1	1	1	1	0	0	0	0	1	1	1
50262	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50351	1	1	1	1	0	0	0	0	1	1	1
50352	1	1	1	1	0	0	0	0	1	1	1
50353	1	1	1	1	0	0	0	0	1	1	1
50354	1	1	1	1	0	0	0	0	1	1	1
50355	1	1	1	1	0	0	0	0	1	1	1
50356	1	1	1	1	0	0	0	0	1	1	1
50357	1	1	1	1	0	0	0	0	1	1	1
50358	1	1	1	1	0	0	0	0	1	1	1
50359	1	1	1	1	0	0	0	0	1	1	1
50360	1	1	1	1	0	0	0	0	1	1	1
50361	1	1	1	1	0	0	0	0	1	1	1
50362	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50451	1	1	1	1	0	0	0	0	1	1	1
50452	1	1	1	1	0	0	0	0	1	1	1
50453	1	1	1	1	0	0	0	0	1	1	1
50454	1	1	1	1	0	0	0	0	1	1	1
50455	1	1	1	1	0	0	0	0	1	1	1
50456	1	1	1	1	0	0	0	0	1	1	1
50457	1	1	1	1	0	0	0	0	1	1	1
50458	1	1	1	1	0	0	0	0	1	1	1
50459	1	1	1	1	0	0	0	0	1	1	1
50460	1	1	1	1	0	0	0	0	1	1	1
50461	1	1	1	1	0	0	0	0	1	1	1
50462	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 35
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50151	1	1	1	1	0	0	0	0	1	1	1
50152	1	1	1	1	0	0	0	0	1	1	1
50153	1	1	1	1	0	0	0	0	1	1	1
50154	1	1	1	1	0	0	0	0	1	1	1
50155	1	1	1	1	0	0	0	0	1	1	1
50156	1	1	1	1	0	0	0	0	1	1	1
50157	1	1	1	1	0	0	0	0	1	1	1
50158	1	1	1	1	0	0	0	0	1	1	1
50159	1	1	1	1	0	0	0	0	1	1	1
50160	1	1	1	1	0	0	0	0	1	1	1
50161	1	1	1	1	0	0	0	0	1	1	1
50162	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 35
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50251	1	1	1	1	0	0	0	0	1	1	1
50252	1	1	1	1	0	0	0	0	1	1	1
50253	1	1	1	1	0	0	0	0	1	1	1
50254	1	1	1	1	0	0	0	0	1	1	1
50255	1	1	1	1	0	0	0	0	1	1	1
50256	1	1	1	1	0	0	0	0	1	1	1
50257	1	1	1	1	0	0	0	0	1	1	1
50258	1	1	1	1	0	0	0	0	1	1	1
50259	1	1	1	1	0	0	0	0	1	1	1
50260	1	1	1	1	0	0	0	0	1	1	1
50261	1	1	1	1	0	0	0	0	1	1	1
50262	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 35
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50351	1	1	1	1	0	0	0	0	1	1	1
50352	1	1	1	1	0	0	0	0	1	1	1
50353	1	1	1	1	0	0	0	0	1	1	1
50354	1	1	1	1	0	0	0	0	1	1	1
50355	1	1	1	1	0	0	0	0	1	1	1
50356	1	1	1	1	0	0	0	0	1	1	1
50357	1	1	1	1	0	0	0	0	1	1	1
50358	1	1	1	1	0	0	0	0	1	1	1
50359	1	1	1	1	0	0	0	0	1	1	1
50360	1	1	1	1	0	0	0	0	1	1	1
50361	1	1	1	1	0	0	0	0	1	1	1
50362	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 35
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50451	1	1	1	1	0	0	0	0	1	1	1
50452	1	1	1	1	0	0	0	0	1	1	1
50453	1	1	1	1	0	0	0	0	1	1	1
50454	1	1	1	1	0	0	0	0	1	1	1
50455	1	1	1	1	0	0	0	0	1	1	1
50456	1	1	1	1	0	0	0	0	1	1	1
50457	1	1	1	1	0	0	0	0	1	1	1
50458	1	1	1	1	0	0	0	0	1	1	1
50459	1	1	1	1	0	0	0	0	1	1	1
50460	1	1	1	1	0	0	0	0	1	1	1
50461	1	1	1	1	0	0	0	0	1	1	1
50462	1	1	1	1	0	0	0	0	1	1	1
n	12	12	12	12	12	12	12	12	12	12	12

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 42
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50152	1	1	1	1	0	0	0	0	1	1	1
50155	1	1	1	1	0	0	0	0	1	1	1
50156	1	1	1	1	0	0	0	0	1	1	1
50158	1	1	1	1	0	0	0	0	1	1	1
50159	1	1	1	1	0	0	0	0	1	1	1
50160	1	1	1	1	0	0	0	0	1	1	1
50161	1	1	1	1	0	0	0	0	1	1	1
50162	1	1	1	1	0	0	0	0	1	1	1
n	8	8	8	8	8	8	8	8	8	8	8

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 42
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50251	1	1	1	1	0	0	0	0	1	1	1
50252	1	1	1	1	0	0	0	0	1	1	1
50254	1	1	1	1	0	0	0	0	1	1	1
50256	1	1	1	1	0	0	0	0	1	1	1
50257	1	1	1	1	0	0	0	0	1	1	1
50258	1	1	1	1	0	0	0	0	1	1	1
50260	1	1	1	1	0	0	0	0	1	1	1
50261	1	1	1	1	0	0	0	0	1	1	1
50262	1	1	1	1	0	0	0	0	1	1	1
n	9	9	9	9	9	9	9	9	9	9	9

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 42
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50351	1	1	1	1	0	0	0	0	1	1	1
50352	1	1	1	1	0	0	0	0	1	1	1
50353	1	1	1	1	0	0	0	0	1	1	1
50355	1	1	1	1	0	0	0	0	1	1	1
50359	1	1	1	1	0	0	0	0	1	1	1
50360	1	1	1	1	0	0	0	0	1	1	1
50361	1	1	1	1	0	0	0	0	1	1	1
50362	1	1	1	1	0	0	0	0	1	1	1
n	8	8	8	8	8	8	8	8	8	8	8

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 42
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50452	1	1	1	1	0	0	0	0	1	1	1
50454	1	1	1	1	0	0	0	0	1	1	1
50455	1	1	1	1	0	0	0	0	1	1	1
50456	1	1	1	1	0	0	0	0	1	1	1
50457	1	1	1	1	0	0	0	0	1	1	1
50458	1	1	1	1	0	0	0	0	1	1	1
50461	1	1	1	1	0	0	0	0	1	1	1
50462	1	1	1	1	0	0	0	0	1	1	1
n	8	8	8	8	8	8	8	8	8	8	8

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50551	1	1	1	1	0	0	0	0	1	1	1
50552	1	1	1	1	0	0	0	0	1	1	1
50553	1	1	1	1	0	0	0	0	1	1	1
50554	1	1	1	1	0	0	0	0	1	1	1
50555	1	1	1	1	0	0	0	0	1	1	1
50556	1	1	1	1	0	0	0	0	1	1	1
50557	1	1	1	1	0	0	0	0	1	1	1
50558	1	1	1	1	0	0	0	0	1	1	1
50559	1	1	1	1	0	0	0	0	1	1	1
50560	1	1	1	1	0	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Pre
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50651	1	1	1	1	0	0	0	0	1	1	1
50652	1	1	1	1	0	0	0	0	1	1	1
50653	1	1	1	1	0	0	0	0	1	1	1
50654	1	1	1	1	1	0	0	0	1	1	1
50655	1	1	1	1	0	0	0	0	1	1	1
50656	1	1	1	1	0	0	0	0	1	1	1
50657	1	1	1	1	0	0	0	0	1	1	1
50658	1	1	1	1	0	0	0	0	1	1	1
50659	1	1	1	1	0	0	0	0	1	1	1
50660	1	1	1	1	0	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50551	1	1	1	1	0	0	0	0	1	1	1
50552	1	1	1	1	0	0	0	0	1	1	1
50553	1	1	1	1	0	0	0	0	1	1	1
50554	1	1	1	1	0	0	0	0	1	1	1
50555	1	1	1	1	0	0	0	0	1	1	1
50556	1	1	1	1	0	0	0	0	1	1	1
50557	1	1	1	1	0	0	0	0	1	1	1
50558	1	1	1	1	0	0	0	0	1	1	1
50559	1	1	1	1	0	0	0	0	1	1	1
50560	1	1	1	1	0	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 7
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50651	1	1	1	1	0	0	0	0	1	1	1
50652	1	1	1	1	0	0	0	0	1	1	1
50653	1	1	1	1	1	0	0	0	1	1	1
50654	1	1	1	1	0	0	0	0	1	1	1
50655	1	1	1	1	0	0	0	0	1	1	1
50656	1	1	1	1	0	0	0	0	1	1	1
50657	1	1	1	1	0	0	0	0	1	1	1
50658	1	1	1	1	0	0	0	0	1	1	1
50659	1	1	1	1	0	0	0	0	1	1	1
50660	1	1	1	1	0	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50551	1	1	1	1	0	0	0	0	1	1	1
50552	1	1	1	1	0	0	0	0	1	1	1
50553	1	1	1	1	0	0	0	0	1	1	1
50554	1	1	1	1	0	0	0	0	1	1	1
50555	1	1	1	1	0	0	0	0	1	1	1
50556	1	1	1	1	0	0	0	0	1	1	1
50557	1	1	1	1	0	0	0	0	1	1	1
50558	1	1	1	1	0	0	0	0	1	1	1
50559	1	1	1	1	0	0	0	0	1	1	1
50560	1	1	1	1	0	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 14
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50651	1	1	1	1	0	0	0	0	1	1	1
50652	1	1	1	1	0	0	0	0	1	1	1
50653	1	1	1	1	0	0	0	0	1	1	1
50654	1	1	1	1	0	0	0	0	1	1	1
50655	1	1	1	1	0	0	0	0	1	1	1
50656	1	1	1	1	0	0	0	0	1	1	1
50657	1	1	1	1	0	0	0	0	1	1	1
50658	1	1	1	1	0	0	0	0	1	1	1
50659	1	1	1	1	0	0	0	0	1	1	1
50660	1	1	1	1	0	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50551	1	1	1	1	0	0	0	0	1	1	1
50552	1	1	1	1	0	0	0	0	1	1	1
50553	1	1	1	1	0	0	0	0	1	1	1
50554	1	1	1	1	0	0	0	0	1	1	1
50555	1	1	1	1	0	0	0	0	1	1	1
50556	1	1	1	1	0	0	0	0	1	1	1
50557	1	1	1	1	0	0	0	0	1	1	1
50558	1	1	1	1	0	0	0	0	1	1	1
50559	1	1	1	1	0	0	0	0	1	1	1
50560	1	1	1	1	0	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 21
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50651	1	1	1	1	0	0	0	0	1	1	1
50652	1	1	1	1	0	0	0	0	1	1	1
50653	1	1	1	1	0	0	0	0	1	1	1
50654	1	1	1	1	0	0	0	0	1	1	1
50655	1	1	1	1	0	0	0	0	1	1	1
50656	1	1	1	1	0	0	0	0	1	1	1
50657	1	1	1	1	0	0	0	0	1	1	1
50658	1	1	1	1	1	0	0	0	1	1	1
50659	1	1	1	1	0	0	0	0	1	1	1
50660	1	1	1	1	0	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50551	1	1	1	1	0	0	0	0	1	1	1
50552	1	1	1	1	0	0	0	0	1	1	1
50553	1	1	1	1	0	0	0	0	1	1	1
50554	1	1	1	1	0	0	0	0	1	1	1
50555	1	1	1	1	0	0	0	0	1	1	1
50556	1	1	1	1	0	0	0	0	1	1	1
50557	1	1	1	1	0	0	0	0	1	1	1
50558	1	1	1	1	0	0	0	0	1	1	1
50559	1	1	1	1	1	0	0	0	1	1	1
50560	1	1	1	1	1	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Day 28
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50651	1	1	1	1	0	0	0	0	1	1	1
50652	1	1	1	1	0	0	0	0	1	1	1
50653	1	1	1	1	0	0	0	0	1	1	1
50654	1	1	1	1	0	0	0	0	1	1	1
50655	1	1	1	1	0	0	0	0	1	1	1
50656	1	1	1	1	0	0	0	0	1	1	1
50657	1	1	1	1	0	0	0	0	1	1	1
50658	1	1	1	1	0	0	0	0	1	1	1
50659	1	1	1	1	0	0	0	0	1	1	1
50660	1	1	1	1	1	0	0	0	1	1	1
n	10	10	10	10	10	10	10	10	10	10	10

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Recovery Day 7
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10104	1	1	1	1	0	0	0	0	1	1	1
10106	1	1	1	1	0	0	0	0	1	1	1
10108	1	1	1	1	1	0	0	0	1	1	1
10110	1	1	1	1	1	0	0	0	1	1	1
10112	1	1	1	1	0	0	0	0	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Recovery Day 7
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10404	1	1	1	1	0	0	0	0	1	1	1
10406	1	1	1	1	0	0	0	0	1	1	1
10407	1	1	1	1	1	0	0	0	1	1	1
10409	1	1	1	1	1	1	0	0	1	1	1
10412	1	1	1	1	0	0	0	0	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Recovery Day 14
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10104	1	1	1	1	0	0	0	0	1	1	1
10106	1	1	1	1	0	0	0	0	1	1	1
10108	1	1	1	1	0	0	0	0	1	1	1
10110	1	1	1	1	0	0	0	0	1	1	1
10112	1	1	1	1	0	0	0	0	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field)
Sex : Male

Stage : Recovery Day 14
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
10404	1	1	1	1	0	0	0	0	1	1	1
10406	1	1	1	1	0	0	0	0	1	1	1
10407	1	1	1	1	0	0	0	0	1	1	1
10409	1	1	1	1	0	0	0	0	1	1	1
10412	1	1	1	1	1	0	0	0	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Recovery Day 7
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50556	1	1	1	1	0	0	0	0	1	1	1
50557	1	1	1	1	0	0	0	0	1	1	1
50558	1	1	1	1	0	0	0	0	1	1	1
50559	1	1	1	1	0	0	0	0	1	1	1
50560	1	1	1	1	0	0	0	0	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Recovery Day 7
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50656	1	1	1	1	0	0	0	0	1	1	1
50657	1	1	1	1	1	0	0	0	1	1	1
50658	1	1	1	1	0	0	0	0	1	1	1
50659	1	1	1	1	0	0	0	0	1	1	1
50660	1	1	1	1	0	0	0	0	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Recovery Day 14
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50556	1	1	1	1	0	0	0	0	1	1	1
50557	1	1	1	1	0	0	0	0	1	1	1
50558	1	1	1	1	0	0	0	0	1	1	1
50559	1	1	1	1	0	0	0	0	1	1	1
50560	1	1	1	1	0	0	0	0	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Detailed clinical observation (in the open-field) Stage : Recovery Day 14
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Gait	Co-ordination of movement	Reactivity to stimuli	Searching	Urination	Defecation	Excessive grooming	Unusual head movement	Walking backward	Vocalization	Aggression
50656	1	1	1	1	0	0	0	0	1	1	1
50657	1	1	1	1	0	0	0	0	1	1	1
50658	1	1	1	1	0	0	0	0	1	1	1
50659	1	1	1	1	0	0	0	0	1	1	1
50660	1	1	1	1	0	0	0	0	1	1	1
n	5	5	5	5	5	5	5	5	5	5	5

Gait) 0;Not moved, 1;Normal, 2; Difficult to walk, 3;Unable to walk, paralytic.
Co-ordination of movement) 0;Staggering (ataxic), 1;Normal.
Reactivity to stimuli) 0;Not present, 1;Present (to noise, etc.).
Searching) 0;Not present, 1;Present (sniffing, standing, etc.).
Urination) 0;Not present, 1;Present.
Defecation) 0;Not present, 1;Present.
Stereotype/Excessive grooming) 0;Not present, 1;Sometimes, 2;Frequently.
Stereotype/Unusual head movement) 0;Not present, 1;Sometimes, 2;Frequently.
Bizarre behavior/Walking backward) 1;Not present, 2;Present.
Bizarre behavior/Vocalization) 1;Not present, sometimes, 2;Present, frequently.
Aggression) 1;Not present, 2;Present.

Functional observations (on the desk) Stage : Week 4
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
10104	4	2	1	2	1	1
10106	4	2	1	2	1	1
10108	4	2	1	2	1	1
10110	4	2	1	2	1	1
10112	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Functional observations (on the desk) Stage : Week 4
Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
10205	4	2	1	2	1	1
10206	4	2	1	2	1	1
10207	4	2	1	2	1	1
10209	4	2	1	2	1	1
10211	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Functional observations (on the desk) Stage : Week 4
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
10302	4	2	1	2	1	1
10304	4	2	1	2	1	1
10305	4	2	1	2	1	1
10309	4	2	1	2	1	1
10310	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Functional observations (on the desk) Stage : Week 4
Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
10404	4	2	1	2	1	1
10406	4	2	1	2	1	1
10407	4	2	1	2	1	1
10409	4	2	1	2	1	1
10412	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Functional observations (on the desk) Stage : Lactation Day 4
Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
50153	4	2	1	2	1	1
50154	4	2	1	2	1	1
50155	4	2	1	2	1	1
50156	4	2	1	2	1	1
50157	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Functional observations (on the desk) Stage : Lactation Day 4
Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
50253	4	2	1	2	1	1
50255	4	2	1	2	1	1
50259	4	2	1	2	1	1
50260	4	2	1	2	1	1
50261	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Functional observations (on the desk) Stage : Lactation Day 4
Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
50353	4	2	1	2	1	1
50354	4	2	1	2	1	1
50356	4	2	1	2	1	1
50357	4	2	1	2	1	1
50361	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Functional observations (on the desk) Stage : Lactation Day 4
Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
50451	4	2	1	2	1	1
50452	4	2	1	2	1	1
50457	4	2	1	2	1	1
50459	4	2	1	2	1	1
50460	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Functional observations (on the desk) Stage : Week 4
Sex : Female (satellite) Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
50556	4	2	1	2	1	1
50557	4	2	1	2	1	1
50558	4	2	1	2	1	1
50559	4	2	1	2	1	1
50560	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Functional observations (on the desk) Stage : Week 4
Sex : Female (satellite) Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Visual reactivity	Touch reactivity	Auditory reactivity	Pain reactivity	Proprioceptive reactivity	Righting reflex
50656	4	2	1	2	1	1
50657	4	2	1	2	1	1
50658	4	2	1	2	1	1
50659	4	2	1	2	1	1
50660	4	2	1	2	1	1
n	5	5	5	5	5	5

Visual reactivity) 1;Jumping, 2;Turning away, 3;No reaction, 4;Approach, 5;Attack.
Touch reactivity) 1;Hyposensitive, 2;Turning away, 3;Hypersensitive.
Auditory reactivity) 0;No reaction, 1;Normal, moving the auricle, 2;Sensitive, moving the body, 3;Hypersensitive, surprising and jumping.
Pain reactivity) 0;No reaction, 1;Dull, vocalizing, 2;Normal, vocalizing and turning back, 3;Hypersensitive, attacking or jumping.
Proprioceptive reactivity) 0;No returning, 1;Returning.
Righting reflex) 1;Normal, landing by foot, 2;Abnormal, landing by body.

Grip strength
Sex : Male
Stage : Week 4
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
10104	1493	1175	1373	1347.0	584	580	576	580.0
10106	1460	1543	1464	1489.0	581	415	429	475.0
10108	1621	1490	1435	1515.3	867	727	693	762.3
10110	1689	1523	1424	1545.3	624	664	573	620.3
10112	1793	1550	1405	1582.7	646	670	590	635.3
n	5	5	5	5	5	5	5	5
Mean	1611.2	1456.2	1420.2	1495.86	660.4	611.2	572.2	614.58
S.D.	137.9	158.9	34.0	90.24	118.7	121.6	94.1	103.64

Grip strength
Sex : Male
Stage : Week 4
Dose : EGEHE 100 mg/kg
Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
10205	1016	1154	1361	1177.0	576	491	499	522.0
10206	1895	1699	1840	1811.3	502	564	551	539.0
10207	1254	1292	1140	1228.7	748	545	481	591.3
10209	1284	1239	1018	1180.3	778	616	656	683.3
10211	1369	1344	1375	1362.7	486	579	600	555.0
n	5	5	5	5	5	5	5	5
Mean	1363.6	1345.6	1346.8	1352.00	618.0	559.0	557.4	578.12
S.D.	324.6	209.7	314.3	267.57	137.1	46.1	72.2	64.13

Grip strength
Sex : Male
Stage : Week 4
Dose : EGEHE 300 mg/kg
Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
10302	1207	1419	1427	1351.0	516	511	534	520.3
10304	1236	1229	1211	1225.3	524	698	586	602.7
10305	1640	1754	1738	1710.7	547	726	509	594.0
10309	1458	1488	1228	1391.3	641	735	531	635.7
10310	1314	1399	1134	1282.3	485	505	580	523.3
n	5	5	5	5	5	5	5	5
Mean	1371.0	1457.8	1347.6	1392.12	542.6	635.0	548.0	575.20
S.D.	179.1	191.0	243.6	189.13	59.3	116.8	33.4	51.18

Grip strength
Sex : Male

Stage : Week 4
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
10404	1492	1112	1873	1492.3	649	714	671	678.0
10406	1132	1472	1232	1278.7	420	647	610	559.0
10407	1242	1167	1382	1263.7	561	464	422	482.3
10409	1265	1221	1448	1311.3	484	561	505	516.7
10412	1197	1533	1358	1362.7	512	545	671	576.0
n	5	5	5	5	5	5	5	5
Mean	1265.6	1301.0	1458.6	1341.74	525.2	586.2	575.8	562.40
S.D.	136.4	189.2	244.5	92.33	85.9	96.6	109.5	74.27

Grip strength
Sex : Female
Stage : Lactation Day 4
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
50153	1355	1188	1361	1301.3	436	492	581	503.0
50154	1597	1386	1415	1466.0	566	531	582	559.7
50155	1295	1380	1198	1291.0	531	496	391	472.7
50156	1290	1301	1267	1286.0	416	387	447	416.7
50157	985	971	819	925.0	435	449	386	423.3
n	5	5	5	5	5	5	5	5
Mean	1304.4	1245.2	1212.0	1253.86	476.8	471.0	477.4	475.08
S.D.	218.2	172.9	235.1	198.63	67.1	55.2	98.0	59.23

Grip strength
Sex : Female

Stage : Lactation Day 4
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
50253	1171	1375	1007	1184.3	535	561	546	547.3
50255	1208	1192	1425	1275.0	499	461	568	509.3
50259	1050	1024	1236	1103.3	422	453	398	424.3
50260	1053	1074	1089	1072.0	396	453	512	453.7
50261	947	938	944	943.0	439	336	332	369.0
n	5	5	5	5	5	5	5	5
Mean	1085.8	1120.6	1140.2	1115.52	458.2	452.8	471.2	460.72
S.D.	104.7	169.3	193.1	124.47	57.3	79.7	101.7	70.08

Grip strength
Sex : Female

Stage : Lactation Day 4
Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
50353	1087	1349	1141	1192.3	536	621	553	570.0
50354	1365	1456	1408	1409.7	432	336	514	427.3
50356	1236	1084	1052	1124.0	506	345	341	397.3
50357	984	1163	1200	1115.7	461	443	359	421.0
50361	1077	1039	1099	1071.7	349	388	406	381.0
n	5	5	5	5	5	5	5	5
Mean	1149.8	1218.2	1180.0	1182.68	456.8	426.6	434.6	439.32
S.D.	150.4	178.1	138.6	134.05	72.4	116.6	94.4	75.37

Grip strength
Sex : Female

Stage : Lactation Day 4
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
50451	1007	933	903	947.7	356	527	402	428.3
50452	925	664	629	739.3	431	492	551	491.3
50457	1117	1218	1045	1126.7	470	334	424	409.3
50459	996	925	858	926.3	467	434	387	429.3
50460	958	1375	900	1077.7	443	418	441	434.0
n	5	5	5	5	5	5	5	5
Mean	1000.6	1023.0	867.0	963.54	433.4	441.0	441.0	438.44
S.D.	72.7	277.7	150.7	151.31	46.3	74.2	64.9	31.02

Grip strength
Sex : Female (satellite)
Stage : Week 4
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
50556	1040	923	975	979.3	457	437	374	422.7
50557	1042	1293	1151	1162.0	498	471	463	477.3
50558	1010	1279	1298	1195.7	553	448	439	480.0
50559	1150	1130	1127	1135.7	365	471	441	425.7
50560	1245	1049	936	1076.7	490	548	495	511.0
n	5	5	5	5	5	5	5	5
Mean	1097.4	1134.8	1097.4	1109.88	472.6	475.0	442.4	463.34
S.D.	98.2	156.6	145.8	85.00	69.3	43.4	44.4	38.12

Grip strength
Sex : Female (satellite)
Stage : Week 4
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Forelimb, 1st g	Forelimb, 2nd g	Forelimb, 3rd g	Forelimb g	Hindlimb, 1st g	Hindlimb, 2nd g	Hindlimb, 3rd g	Hindlimb g
50656	1044	1034	963	1013.7	565	454	489	502.7
50657	923	1003	837	921.0	498	505	454	485.7
50658	1099	1322	1073	1164.7	531	540	510	527.0
50659	928	932	1140	1000.0	370	389	447	402.0
50660	1053	1230	1236	1173.0	467	449	461	459.0
n	5	5	5	5	5	5	5	5
Mean	1009.4	1104.2	1049.8	1054.48	486.2	467.4	472.2	475.28
S.D.	79.4	164.4	155.1	110.28	74.5	57.8	26.5	47.88

Motor activity measurements
Sex : Male

Stage : Week 4
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
10104	721	568	405	270	403	246	2613
10106	557	349	192	70	7	89	1264
10108	500	164	150	100	42	174	1130
10110	431	257	199	99	0	0	986
10112	742	487	227	61	0	2	1519
n	5	5	5	5	5	5	5
Mean	590.2	365.0	234.6	120.0	90.4	102.2	1502.4
S.D.	136.7	164.6	99.2	85.6	175.6	107.8	651.1

Motor activity measurements

Stage : Week 4

Sex : Male

Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
10205	812	513	317	203	22	23	1890
10206	1124	953	1029	657	244	0	4007
10207	255	191	91	137	58	70	802
10209	404	383	276	178	217	100	1558
10211	450	301	230	77	107	245	1410
n	5	5	5	5	5	5	5
Mean	609.0	468.2	388.6	250.4	129.6	87.6	1933.4
S.D.	353.2	295.4	368.0	232.2	97.4	96.3	1224.4

Motor activity measurements

Stage : Week 4

Sex : Male

Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
10302	693	228	98	57	0	0	1076
10304	801	707	334	647	173	310	2972
10305	408	389	11	228	197	60	1293
10309	473	266	97	83	56	7	982
10310	211	61	21	65	11	0	369
n	5	5	5	5	5	5	5
Mean	517.2	330.2	112.2	216.0	87.4	75.4	1338.4
S.D.	234.0	241.1	130.6	250.8	91.9	133.5	975.5

Motor activity measurements

Stage : Week 4

Sex : Male

Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
10404	1139	888	466	259	0	0	2752
10406	996	645	282	284	210	42	2459
10407	462	264	42	278	0	0	1046
10409	302	195	120	182	69	0	868
10412	692	399	273	252	263	335	2214
n	5	5	5	5	5	5	5
Mean	718.2	478.2	236.6	251.0	108.4	75.4	1867.8
S.D.	351.4	286.4	163.9	40.8	121.7	146.3	855.3

Motor activity measurements
Sex : Female

Stage : Lactation Day 4
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
50153	761	84	3	0	0	0	848
50154	1218	559	873	618	406	442	4116
50155	697	337	18	143	218	131	1544
50156	193	60	5	135	0	0	393
50157	962	342	9	125	48	14	1500
n	5	5	5	5	5	5	5
Mean	766.2	276.4	181.6	204.2	134.4	117.4	1680.2
S.D.	379.4	207.2	386.5	238.6	176.3	189.6	1443.4

Motor activity measurements
Sex : Female

Stage : Lactation Day 4
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
50253	1146	909	496	289	388	53	3281
50255	467	91	27	2	70	0	657
50259	398	64	467	414	617	520	2480
50260	418	66	0	102	0	360	946
50261	624	399	22	128	11	0	1184
n	5	5	5	5	5	5	5
Mean	610.6	305.8	202.4	187.0	217.2	186.6	1709.6
S.D.	312.1	365.6	255.2	163.5	274.0	239.1	1121.4

Motor activity measurements
Sex : Female

Stage : Lactation Day 4
Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
50353	0	175	49	0	0	0	224
50354	937	470	62	0	0	363	1832
50356	1039	235	196	5	0	14	1489
50357	815	188	128	391	8	0	1530
50361	441	64	0	0	0	0	505
n	5	5	5	5	5	5	5
Mean	646.4	226.4	87.0	79.2	1.6	75.4	1116.0
S.D.	426.3	149.9	76.2	174.3	3.6	160.9	705.7

Motor activity measurements
Sex : Female

Stage : Lactation Day 4
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
50451	691	132	69	0	148	237	1277
50452	1065	630	256	0	0	0	1951
50457	435	0	376	15	0	0	826
50459	284	10	22	0	56	122	494
50460	499	140	0	0	74	0	713
n	5	5	5	5	5	5	5
Mean	594.8	182.4	144.6	3.0	55.6	71.8	1052.2
S.D.	300.7	258.7	164.0	6.7	61.4	106.4	578.0

Motor activity measurements
Sex : Female (satellite)

Stage : Week 4
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
50556	495	383	158	40	0	266	1342
50557	718	495	267	293	76	0	1849
50558	365	266	249	149	0	0	1029
50559	372	278	148	58	0	0	856
50560	1008	535	392	491	138	0	2564
n	5	5	5	5	5	5	5
Mean	591.6	391.4	242.8	206.2	42.8	53.2	1528.0
S.D.	273.1	122.5	98.8	188.1	62.6	119.0	691.3

Motor activity measurements
Sex : Female (satellite)

Stage : Week 4
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	0' - 10' No.	10' - 20' No.	20' - 30' No.	30' - 40' No.	40' - 50' No.	50' - 60' No.	0' - 60' No.
50656	679	575	343	370	49	10	2026
50657	1009	968	608	724	671	101	4081
50658	793	498	500	206	0	273	2270
50659	348	17	0	0	0	0	365
50660	836	687	608	539	539	263	3472
n	5	5	5	5	5	5	5
Mean	733.0	549.0	411.8	367.8	251.8	129.4	2442.8
S.D.	245.7	346.7	254.5	281.8	326.4	132.5	1437.3

Body weight
Sex : Male
Period : Administration Day 1-28
Dose : EGEHE 0 mg/kg
Unit : g Species : Rat

Animal No.	/Day 1	4	7	14	21	28	Body weight gain
10101	365	378	392	406	417	432	67
10102	365	377	396	419	444	471	106
10103	416	434	445	481	514	538	122
10104	380	401	417	453	481	517	137
10105	352	369	390	415	437	457	105
10106	389	395	416	442	463	478	89
10107	398	413	426	454	485	511	113
10108	369	382	395	422	444	465	96
10109	404	420	440	473	491	522	118
10110	368	390	407	441	465	488	120
10111	395	417	429	465	484	507	112
10112	384	399	417	446	472	507	123
n	12	12	12	12	12	12	12
Mean	382.1	397.9	414.2	443.1	466.4	491.1	109.0
S.D.	19.0	20.0	18.6	23.8	27.1	31.1	18.4

Body weight
Sex : Male
Period : Administration Day 1-28
Dose : EGEHE 100 mg/kg
Unit : g Species : Rat

Animal No.	/Day 1	4	7	14	21	28	Body weight gain
10201	374	383	397	411	436	457	83
10202	415	434	445	483	511	537	122
10203	408	421	439	472	495	534	126
10204	387	418	439	473	498	511	124
10205	382	399	413	447	481	510	128
10206	391	407	422	443	464	487	96
10207	377	398	414	434	457	473	96
10208	392	410	429	459	483	506	114
10209	362	383	401	430	454	477	115
10210	361	369	383	415	427	457	96
10211	387	408	420	442	470	495	108
10212	341	351	365	381	408	423	82
n	12	12	12	12	12	12	12
Mean	381.4	398.4	413.9	440.8	465.3	488.9	107.5
S.D.	20.5	23.4	24.0	29.3	30.8	33.6	16.5

Body weight
Sex : Male
Period : Administration Day 1-28
Dose : EGEHE 300 mg/kg
Unit : g Species : Rat

Animal No.	/Day 1	4	7	14	21	28	Body weight gain
10301	409	423	435	456	479	498	89
10302	378	392	409	441	466	477	99
10303	390	402	422	454	483	503	113
10304	367	379	388	422	440	468	101
10305	388	401	418	442	453	473	85
10306	361	378	393	418	438	461	100
10307	374	383	394	415	430	454	80
10308	358	359	366	382	404	428	70
10309	387	403	419	451	469	488	101
10310	378	389	401	423	441	447	69
10311	409	432	443	473	497	528	119
10312	395	415	432	459	487	513	118
n	12	12	12	12	12	12	12
Mean	382.8	396.3	410.0	436.3	457.3	478.2	95.3
S.D.	16.7	20.7	22.4	25.1	27.5	29.1	17.1

Body weight
Sex : Male
Period : Administration Day 1-28
Dose : EGEHE 1000 mg/kg
Unit : g Species : Rat

Animal No.	/Day 1	4	7	14	21	28	Body weight gain
10401	361	360	370	395	408	428	67
10402	399	409	424	450	462	482	83
10403	360	366	381	400	419	440	80
10404	398	392	400	428	450	466	68
10405	376	381	395	410	410	437	61
10406	393	389	404	426	439	454	61
10407	378	390	401	424	442	461	83
10408	369	375	387	399	423	443	74
10409	364	376	389	401	424	441	77
10410	388	398	409	436	461	486	98
10411	412	424	434	452	464	489	77
10412	380	390	404	439	456	482	102
n	12	12	12	12	12	12	12
Mean	381.5	387.5	399.8	421.7	438.2	459.1	77.6
S.D.	16.7	17.8	17.6	20.3	20.7	21.6	13.0

Body weight
Sex : Female
Period : F0 Day 1-21
Dose : EGEHE 0 mg/kg
Unit : g Species : Rat

Animal No.	/Day 1	4	7	14	Body weight gain	/Day 21
50151	232	237	243	246	14	
50152	230	231	232	256	26	295
50153	244	246	248	266	22	
50154	221	234	239	239	18	
50155	229	245	261	275	46	
50156	211	209	221	226	15	
50157	248	253	254	266	18	
50158	217	229	237	247	30	
50159	212	219	226	234	22	
50160	238	246	254	261	23	
50161	210	219	229	239	29	
50162	244	251	261	275	31	
n	12	12	12	12	12	1
Mean	228.0	234.9	242.1	252.5	24.5	295.0
S.D.	13.7	14.0	13.6	16.4	8.8	

Body weight
Sex : Female
Period : F0 gestation Day 0-20
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 0	7	14	20	Body weight gain
50151	258 $	302 $	317 $	309 $	51 $
50152	290	319	348	440	150
50153	271	308	360	453	182
50154	252	301	359	459	207
50155	279	324	362	453	174
50156	233	260	295	367	134
50157	271	303	339	427	156
50158	257	296	341	441	184
50159	240	284	322	394	154
50160	288	336	374	462	174
50161	242	268	298	379	137
50162	286	311	355	447	161
n	11	11	11	11	11
Mean	264.5	300.9	341.2	429.3	164.8
S.D.	20.7	23.1	26.1	33.6	21.8

Animal No. 50151 : Non-pregnancy
$: Excepted data from calculation

Body weight
Sex : Female
Period : F0 lactation Day 0-4
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 0	4	Body weight gain
50152	318	337	19
50153	358	366	8
50154	346	356	10
50155	356	356	0
50156	285	306	21
50157	333	339	6
50158	301	323	22
50159	293	313	20
50160	354	381	27
50161	295	298	3
50162	353	364	11
n	11	11	11
Mean	326.5	339.9	13.4
S.D.	28.8	27.2	8.8

Body weight
Sex : Female
Period : F0 Day 1-49
Dose : EGEHE 100 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 1	4	7	14	Body weight gain	/Day 21	28	35	42	49
50251	235	244	246	254	19	286	301	300	309	298
50252	227	233	236	239	12					
50253	237	233	237	251	14					
50254	227	236	238	252	25					
50255	237	236	240	258	21					
50256	238	253	263	274	36					
50257	240	248	251	268	28					
50258	225	233	238	242	17					
50259	212	213	206	218	6					
50260	226	228	245	258	32					
50261	220	219	224	236	16					
50262	254	257	273	292	38					
n	12	12	12	12	12	1	1	1	1	1
Mean	231.5	236.1	241.4	253.5	22.0	286.0	301.0	300.0	309.0	298.0
S.D.	11.0	13.0	17.1	19.2	9.9					

Body weight
Sex : Female
Period : F0 gestation Day 0-20
Dose : EGEHE 100 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 0	7	14	20	Body weight gain
50252	256	280	314	373	117
50253	253	286	327	416	163
50254	272	304	338	427	155
50255	256	294	335	425	169
50256	284	331	383	489	205
50257	275	298	353	431	156
50258	265	297	338	406	141
50259	215	274	314	381	166
50260	258	294	341	431	173
50261	237	275	313	400	163
50262	303	334	384	455	152
n	11	11	11	11	11
Mean	261.3	297.0	340.0	421.3	160.0
S.D.	23.3	20.0	25.0	32.6	21.5

Body weight
Sex : Female
Period : F0 lactation Day 0-4
Dose : EGEHE 100 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 0	4	Body weight gain
50252	305	313	8
50253	299	322	23
50254	327	333	6
50255	327	348	21
50256	370	354	-16
50257	327	349	22
50258	328	347	19
50259	292	303	11
50260	331	350	19
50261	293	319	26
50262	345	351	6
n	11	11	11
Mean	322.2	335.4	13.2
S.D.	23.6	18.1	12.1

Body weight
Sex : Female
Period : F0 before mating Day 1-14
Dose : EGEHE 300 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 1	4	7	14	Body weight gain
50351	236	240	246	247	11
50352	226	228	233	238	12
50353	245	246	250	274	29
50354	236	237	238	251	15
50355	233	228	238	254	21
50356	244	247	245	261	17
50357	222	225	223	240	18
50358	215	216	218	225	10
50359	214	222	222	234	20
50360	244	255	263	277	33
50361	245	245	245	259	14
50362	215	225	229	238	23
n	12	12	12	12	12
Mean	231.3	234.5	237.5	249.8	18.6
S.D.	12.4	12.1	13.2	16.0	7.1

Body weight
Sex : Female
Period : F0 gestation Day 0-20
Dose : EGEHE 300 mg/kg
Unit : g Species : Rat

Animal No.	/Day 0	7	14	20	Body weight gain
50351	265	301	340	413	148
50352	250	290	331	411	161
50353	273	321	359	442	169
50354	254	287	323	397	143
50355	257	290	335	406	149
50356	262	295	329	423	161
50357	239	269	301	386	147
50358	230 $	270 $	298 $	287 $	57 $
50359	239	266	309	397	158
50360	293	331	383	454	161
50361	260	287	315	396	136
50362	244	278	313	406	162
n	11	11	11	11	11
Mean	257.8	292.3	330.7	411.9	154.1
S.D.	15.9	19.8	23.7	20.6	10.0

Animal No. 50358 : Non-pregnancy
$: Excepted data from calculation

Body weight
Sex : Female
Period : F0 lactation Day 0-4
Dose : EGEHE 300 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 0	4	Body weight gain
50351	327	344	17
50352	310	325	15
50353	317	341	24
50354	314	323	9
50355	314	325	11
50356	323	341	18
50357	279	293	14
50359	301	317	16
50360	350	370	20
50361	301	308	7
50362	312	338	26
n	11	11	11
Mean	313.5	329.5	16.1
S.D.	17.7	20.5	5.9

Body weight
Sex : Female

Period : F0 Day 1-21
Dose : EGEHE 1000 mg/kg

Unit : g

Species : Rat

Animal No.	/Day 1	4	7	14	Body weight gain	/Day 21
50451	234	235	235	244	10	
50452	245	244	249	254	9	
50453	226	233	232	223	-3	
50454	239	242	247	240	1	
50455	225	230	234	239	14	
50456	247	253	263	266	19	
50457	215	214	221	234	19	
50458	243	247	249	256	13	298
50459	212	213	212	228	16	
50460	221	229	227	246	25	
50461	258	270	295	285	27	
50462	216	214	222	224	8	
n	12	12	12	12	12	1
Mean	231.8	235.3	240.5	244.9	13.2	298.0
S.D.	14.8	17.2	22.4	18.2	8.9	

Body weight
Sex : Female
Period : F0 gestation Day 0-20
Dose : EGEHE 1000 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 0	7	14	20	Body weight gain
50451	246	269	296	352	106
50452	257	299	334	386	129
50453	228 $	272 $	287 $	275 $	47 $
50454	248	292	339	400	152
50455	237	276	318	377	140
50456	263	300	339	419	156
50457	238	267	291	371	133
50458	318 $	291 $	291 $	302 $	-16 $
50459	230	256	292	359	129
50460	254	275	321	393	139
50461	292	336	372	426	134
50462	216	244	277	335	119
n	10	10	10	10	10
Mean	248.1	281.4	317.9	381.8	133.7
S.D.	20.7	26.3	29.1	29.0	14.6

Animal Nos. 50453 and 50458 : Non-pregnancy
$: Excepted data from calculation

Body weight
Sex : Female

Period : F0 lactation Day 0-4
Dose : EGEHE 1000 mg/kg

Unit : g

Species : Rat

Animal No.	/Day 0	4	Body weight gain
50451	284	295	11
50452	322	324	2
50454	310	328	18
50455	298	304	6
50456	318	336	18
50457	276	297	21
50459	264	298	34
50460	286	312	26
50461	360	375	15
50462	262	272	10
n	10	10	10
Mean	298.0	314.1	16.1
S.D.	30.3	28.4	9.5

Body weight
Sex : Female (satellite)

Period : Administration Day 1-28
Dose : EGEHE 0 mg/kg

Unit : g

Species : Rat

Animal No.	/Day 1	4	7	14	21	28	Body weight gain
50551	243	250	255	259	279	287	44
50552	231	231	232	250	258	263	32
50553	230	234	241	250	269	281	51
50554	232	236	242	241	258	265	33
50555	223	233	235	236	250	247	24
50556	235	245	252	252	276	288	53
50557	222	230	240	255	264	272	50
50558	229	229	239	252	254	257	28
50559	238	245	253	262	277	272	34
50560	231	241	246	256	263	272	41
n	10	10	10	10	10	10	10
Mean	231.4	237.4	243.5	251.3	264.8	270.4	39.0
S.D.	6.3	7.4	7.8	7.8	10.1	13.0	10.3

Body weight
Sex : Female (satellite)

Period : Administration Day 1-28
Dose : EGEHE 1000 mg/kg

Unit : g

Species : Rat

Animal No.	/Day 1	4	7	14	21	28	Body weight gain
50651	227	246	241	257	248	257	30
50652	237	245	252	256	277	280	43
50653	237	236	238	231	231	247	10
50654	233	238	237	256	263	270	37
50655	228	237	239	246	263	262	34
50656	246	243	245	259	266	269	23
50657	221	224	231	235	249	260	39
50658	240	224	247	253	257	261	21
50659	236	238	247	245	245	257	21
50660	241	248	250	254	247	266	25
n	10	10	10	10	10	10	10
Mean	234.6	237.9	242.7	249.2	254.6	262.9	28.3
S.D.	7.5	8.4	6.6	9.7	13.2	9.0	10.1

Body weight
Sex : Male
Period : Recovery Day 1-14
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 1	7	14	Body weight gain
10104	510	522	543	33
10106	481	505	525	44
10108	474	493	509	35
10110	479	505	525	46
10112	507	526	535	28
n	5	5	5	5
Mean	490.2	510.2	527.4	37.2
S.D.	16.9	13.6	12.8	7.6

Body weight
Sex : Male
Period : Recovery Day 1-14
Dose : EGEHE 1000 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 1	7	14	Body weight gain
10404	458	491	529	71
10406	453	473	496	43
10407	444	473	494	50
10409	439	460	476	37
10412	480	500	530	50
n	5	5	5	5
Mean	454.8	479.4	505.0	50.2
S.D.	15.9	15.9	23.7	12.8

Body weight
Sex : Female (satellite)
Period : Recovery Day 1-14
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 1	7	14	Body weight gain
50556	280	292	295	15
50557	271	264	288	17
50558	255	266	272	17
50559	279	289	295	16
50560	259	270	283	24
n	5	5	5	5
Mean	268.8	276.2	286.6	17.8
S.D.	11.4	13.3	9.6	3.6

Body weight
Sex : Female (satellite)

Period : Recovery Day 1-14
Dose : EGEHE 1000 mg/kg

Unit : g

Species : Rat

Animal No.	/Day 1	7	14	Body weight gain
50656	268	268	290	22
50657	255	265	268	13
50658	262	282	291	29
50659	255	278	281	26
50660	256	274	287	31
n	5	5	5	5
Mean	259.2	273.4	283.4	24.2
S.D.	5.7	7.0	9.4	7.1

Food consumption
Sex : Male
Period : Administration Day 1-28
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4	7	14	28
10101	22.7	23.0	21.9	20.9
10102	21.6	22.7	22.8	:::
10103	26.6	25.1	25.9	24.5
10104	24.9	23.9	25.6	24.9
10105	22.2	27.5	23.0	21.3
10106	23.1	23.7	23.4	21.0
10107	20.9	22.1	22.4	21.9
10108	22.1	21.1	22.3	23.1
10109	23.1	24.4	24.0	22.9
10110	24.3	24.1	24.8	21.1
10111	26.2	25.2	26.5	23.8
10112	25.2	25.2	25.0	24.3
n	12	12	12	11
Mean	23.58	24.00	23.97	22.70
S.D.	1.84	1.69	1.56	1.53

::: : During mating

Food consumption
Sex : Male
Period : Administration Day 1-28
Dose : EGEHE 100 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4	7	14	28
10201	21.2	22.2	20.9	:::
10202	24.3	22.0	24.1	24.6
10203	24.4	25.0	25.0	25.8
10204	27.8	26.3	26.2	22.3
10205	24.3	24.2	25.8	24.0
10206	25.9	25.3	24.2	23.7
10207	23.0	21.3	21.4	18.7
10208	25.0	26.8	26.3	24.3
10209	23.4	24.5	25.2	22.3
10210	20.1	20.5	21.9	22.3
10211	23.7	22.4	23.1	22.0
10212	21.0	20.9	20.8	21.0
n	12	12	12	11
Mean	23.68	23.45	23.74	22.82
S.D.	2.17	2.16	2.06	1.95

::: : During mating

Food consumption
Sex : Male
Period : Administration Day 1-28
Dose : EGEHE 300 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4	7	14	28
10301	23.2	23.5	23.2	21.8
10302	22.8	22.3	24.2	21.2
10303	23.3	23.9	24.9	22.5
10304	21.6	21.0	23.4	21.6
10305	24.7	24.5	24.3	22.8
10306	21.7	21.2	21.6	21.5
10307	19.8	19.5	20.4	21.4
10308	19.9	20.1	21.6	22.7
10309	22.1	21.6	21.5	20.3
10310	22.1	21.5	21.8	20.5
10311	23.9	22.7	23.7	23.9
10312	24.2	22.5	23.6	23.6
n	12	12	12	12
Mean	22.44	22.03	22.85	21.98
S.D.	1.56	1.50	1.41	1.13

Food consumption
Sex : Male
Period : Administration Day 1-28
Dose : EGEHE 1000 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4	7	14	28
10401	15.6	21.8	20.6	21.9
10402	21.4	24.0	25.0	24.6
10403	17.2	21.8	23.3	24.5
10404	18.3	25.3	25.2	27.3
10405	18.5	22.9	22.7	21.5
10406	16.8	21.7	22.3	21.2
10407	20.2	23.4	23.0	22.2
10408	18.3	20.3	20.8	:::
10409	20.8	22.2	21.9	23.0
10410	19.6	22.3	23.2	24.3
10411	20.5	24.7	24.7	26.4
10412	19.4	22.6	25.9	26.5
n	12	12	12	11
Mean	18.88	22.75	23.22	23.95
S.D.	1.76	1.41	1.71	2.15

::: : During mating

Food consumption
Sex : Female
Period : F0 Day 1-14
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4	7	14
50151	13.9	14.8	16.5
50152	13.1	14.5	16.1
50153	15.4	16.9	17.7
50154	15.6	15.7	15.5
50155	21.2	19.5	20.7
50156	12.9	14.4	14.4
50157	16.7	16.7	17.6
50158	15.6	16.0	17.0
50159	14.4	13.7	14.7
50160	15.9	17.7	18.3
50161	13.1	14.1	14.3
50162	17.3	17.6	19.7
n	12	12	12
Mean	15.43	15.97	16.88
S.D.	2.32	1.76	2.04

Food consumption
Sex : Female
Period : F0 gestation Day 0-20
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 7	14	20
50151	21.8 $	23.8 $	15.4 $
50152	21.4	22.4	22.9
50153	21.6	26.9	29.4
50154	24.1	29.4	27.1
50155	24.4	28.4	25.7
50156	17.1	18.9	20.6
50157	22.0	23.8	24.5
50158	20.7	21.9	22.9
50159	21.0	22.0	21.9
50160	24.5	26.6	25.3
50161	16.0	19.8	20.4
50162	19.2	22.3	26.9
n	11	11	11
Mean	21.09	23.85	24.33
S.D.	2.80	3.48	2.87

Animal No. 50151 : Non-pregnancy
$: Excepted data from calculation

Food consumption
Sex : Female
Period : F0 lactation Day 0-4
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4
50152	29.5
50153	32.6
50154	31.5
50155	25.3
50156	31.6
50157	30.9
50158	29.4
50159	26.4
50160	36.5
50161	27.6
50162	33.7
n	11
Mean	30.45
S.D.	3.28

Food consumption
Sex : Female
Period : F0 Day 1-49
Dose : EGEHE 100 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4	7	14	35	42	49
50251	18.3	17.8	18.6	22.3	19.0	19.2
50252	13.3	13.7	15.1			
50253	13.8	15.3	16.1			
50254	18.3	17.9	20.5			
50255	14.0	14.9	15.8			
50256	18.6	16.6	17.8			
50257	15.0	15.6	17.0			
50258	15.5	15.6	16.7			
50259	13.1	14.3	15.5			
50260	14.7	17.2	16.0			
50261	12.8	14.9	16.1			
50262	16.4	19.4	19.5			
n	12	12	12	1	1	1
Mean	15.32	16.10	17.06	22.30	19.00	19.20
S.D.	2.12	1.69	1.70			

Food consumption
Sex : Female
Period : F0 gestation Day 0-20
Dose : EGEHE 100 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 7	14	20
50252	17.5	19.4	18.5
50253	20.4	22.1	23.2
50254	23.4	24.7	23.6
50255	19.5	24.4	26.0
50256	25.4	28.8	25.3
50257	18.7	22.4	24.3
50258	21.1	24.0	24.0
50259	24.6	25.9	23.0
50260	20.8	22.1	23.6
50261	20.2	21.9	21.1
50262	24.8	27.9	25.0
n	11	11	11
Mean	21.49	23.96	23.42
S.D.	2.66	2.79	2.09

Food consumption
Sex : Female
Period : F0 lactation Day 0-4
Dose : EGEHE 100 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4
50252	26.8
50253	31.5
50254	28.6
50255	29.6
50256	20.8
50257	34.3
50258	34.5
50259	22.3
50260	32.6
50261	34.3
50262	25.5
n	11
Mean	29.16
S.D.	4.85

Food consumption
Sex : Female
Period : F0 Day 1-14
Dose : EGEHE 300 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4	7	14
50351	16.3	16.5	16.9
50352	14.3	14.7	15.4
50353	15.9	16.7	18.9
50354	15.4	15.8	16.7
50355	13.9	16.4	16.7
50356	13.9	13.9	16.3
50357	14.5	15.0	17.0
50358	12.8	13.6	15.8
50359	13.7	15.2	15.4
50360	16.9	16.8	18.8
50361	14.2	15.3	16.6
50362	15.6	14.2	14.7
n	12	12	12
Mean	14.78	15.34	16.60
S.D.	1.22	1.11	1.27

Food consumption
Sex : Female
Period : F0 gestation Day 0-20
Dose : EGEHE 300 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 7	14	20
50351	22.0	23.7	22.7
50352	20.4	23.0	22.6
50353	22.6	24.8	23.0
50354	20.1	21.7	22.4
50355	19.3	23.0	22.5
50356	18.7	22.4	22.9
50357	20.3	20.2	20.3
50358	20.6 $	23.7 $	16.8 $
50359	19.1	21.7	23.9
50360	23.2	28.1	25.5
50361	19.3	20.6	20.6
50362	21.2	22.4	22.4
n	11	11	11
Mean	20.56	22.87	22.62
S.D.	1.51	2.17	1.40

Animal No. 50358 : Non-pregnancy
$: Excepted data from calculation

Food consumption
Sex : Female
Period : F0 lactation Day 0-4
Dose : EGEHE 300 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4
50351	28.6
50352	33.9
50353	33.7
50354	26.8
50355	33.3
50356	29.8
50357	28.8
50359	33.2
50360	28.3
50361	27.2
50362	38.9
n	11
Mean	31.14
S.D.	3.73

Food consumption
Sex : Female
Period : F0 Day 1-14
Dose : EGEHE 1000 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4	7	14
50451	13.3	14.3	14.9
50452	18.4	19.5	19.6
50453	16.9	16.3	14.7
50454	12.9	13.8	15.0
50455	13.4	13.7	14.9
50456	16.7	17.1	16.7
50457	12.4	14.6	15.6
50458	13.9	15.4	16.9
50459	12.1	13.1	14.7
50460	13.5	14.4	17.3
50461	23.5	24.2	20.6
50462	10.2	12.1	13.5
n	12	12	12
Mean	14.77	15.71	16.20
S.D.	3.58	3.32	2.13

Food consumption
Sex : Female
Period : F0 gestation Day 0-20
Dose : EGEHE 1000 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 7	14	20
50451	16.7	19.9	17.8
50452	25.1	26.0	26.8
50453	22.4 $	25.0 $	16.5 $
50454	20.8	23.7	19.9
50455	20.8	22.7	19.9
50456	21.2	24.2	26.1
50457	19.4	18.8	19.6
50458	12.8 $	18.2 $	19.4 $
50459	18.9	21.4	19.4
50460	20.2	25.1	24.3
50461	25.1	27.8	26.9
50462	13.9	17.9	18.5
n	10	10	10
Mean	20.21	22.75	21.92
S.D.	3.40	3.23	3.66

Animal Nos. 50453 and 50458 : Non-pregnancy
$: Excepted data from calculation

Food consumption
Sex : Female
Period : F0 lactation Day 0-4
Dose : EGEHE 1000 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4
50451	24.4
50452	23.2
50454	30.6
50455	31.8
50456	39.5
50457	33.5
50459	31.7
50460	34.3
50461	36.5
50462	26.5
n	10
Mean	31.20
S.D.	5.22

Food consumption
Sex : Female (satellite)
Period : Administration Day 1-28
Dose : EGEHE 0 mg/kg
Unit : g Species : Rat

Animal No.	/Day 4	7	14	21	28
50551	15.7	14.9	15.6	16.2	15.3
50552	12.0	12.9	15.6	14.0	13.7
50553	13.9	14.8	16.0	16.7	16.1
50554	14.8	18.0	16.3	16.5	15.7
50555	17.2	15.1	16.9	17.3	15.3
50556	16.2	16.3	16.6	16.9	15.7
50557	13.6	15.4	18.6	15.3	15.4
50558	13.9	16.2	15.4	13.9	14.0
50559	15.8	18.4	16.8	17.0	15.4
50560	14.4	15.8	16.7	15.1	16.4
n	10	10	10	10	10
Mean	14.75	15.78	16.45	15.89	15.30
S.D.	1.51	1.59	0.93	1.24	0.85

Food consumption
Sex : Female (satellite)
Period : Administration Day 1-28
Dose : EGEHE 1000 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 4	7	14	21	28
50651	15.7	13.7	17.2	14.8	16.0
50652	13.4	15.8	16.5	18.5	16.5
50653	12.5	14.2	12.2	14.2	15.3
50654	17.0	17.0	18.9	17.6	18.7
50655	15.3	15.0	16.0	17.6	16.1
50656	14.4	15.2	15.5	15.4	14.3
50657	12.2	14.1	15.0	16.4	16.6
50658	11.2	15.8	15.6	17.1	17.1
50659	13.8	14.6	15.0	16.7	17.5
50660	16.8	15.1	15.8	16.6	17.9
n	10	10	10	10	10
Mean	14.23	15.05	15.77	16.49	16.60
S.D.	1.97	0.98	1.71	1.34	1.28

Food consumption
Sex : Male
Period : Recovery Day 1-14
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 7	14
10104	26.8	28.3
10106	27.4	28.6
10108	25.1	26.8
10110	28.4	28.5
10112	29.1	29.0
n	5	5
Mean	27.36	28.24
S.D.	1.54	0.84

Food consumption
Sex : Male
Period : Recovery Day 1-14
Dose : EGEHE 1000 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 7	14
10404	32.5	33.3
10406	25.3	26.6
10407	28.1	28.1
10409	28.6	27.5
10412	31.0	31.7
n	5	5
Mean	29.10	29.44
S.D.	2.78	2.90

Food consumption
Sex : Female (satellite)
Period : Recovery Day 1-14
Dose : EGEHE 0 mg/kg
Unit : g
Species : Rat

Animal No.	/Day 7	14
50556	17.4	20.1
50557	17.4	19.9
50558	16.9	20.0
50559	19.6	20.0
50560	17.6	19.2
n	5	5
Mean	17.78	19.84
S.D.	1.05	0.36

Food consumption
Sex : Female (satellite)

Period : Recovery Day 1-14
Dose : EGEHE 1000 mg/kg

Unit : g

Species : Rat

Animal No.	/Day 7	14
50656	20.6	21.6
50657	19.9	20.9
50658	22.9	20.9
50659	21.0	21.2
50660	21.8	23.3
n	5	5
Mean	21.24	21.58
S.D.	1.15	1.00

Urinary findings
Sex : Male
Stage : Week 4
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen	Bilirubin	Occult blood	Color
					EU/dL			
10104	8.5	2+	-	-	0.1	-	±	A
10106	8.5	+	-	-	0.1	-	-	A
10108	8.5	2+	-	-	0.1	-	-	A
10110	8.5	±	-	-	0.1	-	-	A
10112	8.5	+	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Male

Stage : Week 4
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	Urine volume mL/21hr
10104	10.5
10106	9.0
10108	8.0
10110	20.0
10112	10.0
n	5
Mean	11.50
S.D.	4.85

Urinary findings
Sex : Male
Stage : Week 4
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Specific gravity
10104	5
10106	5
10108	5
10110	3
10112	5
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Male

Stage : Week 4
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
10104	-	-	±	-	-	-
10106	-	-	±	-	-	-
10108	-	-	±	-	-	-
10110	-	-	-	-	-	-
10112	-	-	-	-	-	-
n	5	5	5	5	5	5

Urinary findings
Sex : Male

Stage : Week 4
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen (EU/dL)	Bilirubin	Occult blood	Color
10205	8.5	+	-	-	0.1	-	+	A
10206	8.5	-	-	-	0.1	-	-	A
10207	8.5	+	-	-	0.1	-	-	A
10209	8.5	±	-	-	0.1	-	-	A
10211	8.5	+	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Male

Stage : Week 4
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	Urine volume mL/21hr
10205	7.5
10206	12.0
10207	14.5
10209	9.0
10211	9.5
n	5
Mean	10.50
S.D.	2.76

Urinary findings
Sex : Male
Stage : Week 4
Dose : EGEHE 100 mg/kg
Species : Rat

Animal No.	Specific gravity
10205	5
10206	4
10207	3
10209	4
10211	5
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Male

Stage : Week 4
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
10205	-	-	-	-	-	-
10206	-	-	-	-	-	-
10207	-	-	-	-	-	-
10209	-	-	-	-	-	-
10211	-	-	-	-	-	-
n	5	5	5	5	5	5

Urinary findings
Sex : Male
Stage : Week 4
Dose : EGEHE 300 mg/kg
Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen	Bilirubin	Occult blood	Color
					EU/dL			
10302	8.0	2+	-	-	0.1	-	-	A
10304	8.0	+	-	-	0.1	-	±	A
10305	8.5	+	-	-	0.1	-	-	A
10309	8.5	2+	-	-	0.1	-	-	A
10310	8.5	2+	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Male

Stage : Week 4
Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	Urine volume mL/21hr
10302	5.5
10304	10.5
10305	9.5
10309	7.5
10310	6.5
n	5
Mean	7.90
S.D.	2.07

Urinary findings
Sex : Male
Stage : Week 4
Dose : EGEHE 300 mg/kg
Species : Rat

Animal No.	Specific gravity
10302	5
10304	5
10305	5
10309	5
10310	5
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Male
Stage : Week 4
Dose : EGEHE 300 mg/kg
Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
10302	-	-	-	-	-	-
10304	-	-	-	-	-	-
10305	-	-	-	-	-	-
10309	-	-	-	-	-	-
10310	-	-	-	-	-	-
n	5	5	5	5	5	5

Urinary findings
Sex : Male

Stage : Week 4
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen	Bilirubin	Occult blood	Color
					EU/dL			
10404	8.5	+	-	-	0.1	-	-	A
10406	8.0	2+	-	-	0.1	-	-	A
10407	7.0	2+	-	-	0.1	-	-	A
10409	8.5	±	-	-	0.1	-	-	A
10412	8.0	±	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Male
Stage : Week 4
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Urine volume mL/21hr
10404	11.5
10406	10.5
10407	13.0
10409	15.0
10412	28.0
n	5
Mean	15.60
S.D.	7.14

Urinary findings
Sex : Male
Stage : Week 4
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Specific gravity
10404	5
10406	5
10407	4
10409	4
10412	3
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Male
Stage : Week 4
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
10404	-	-	-	-	-	-
10406	-	-	±	-	-	-
10407	-	-	±	-	-	-
10409	-	-	±	-	-	-
10412	-	-	±	-	-	-
n	5	5	5	5	5	5

Urinary findings
Sex : Female (satellite)

Stage : Week 4
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen	Bilirubin	Occult blood	Color
					EU/dL			
50556	7.5	2+	-	-	0.1	-	±	A
50557	8.5	+	-	-	0.1	-	-	A
50558	8.5	+	-	-	0.1	-	-	A
50559	8.5	±	-	-	0.1	-	-	A
50560	8.5	±	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Female (satellite)
Stage : Week 4
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Urine volume mL/21hr
50556	6.5
50557	4.5
50558	15.0
50559	6.0
50560	13.5
n	5
Mean	9.10
S.D.	4.79

Urinary findings
Sex : Female (satellite)
Stage : Week 4
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Specific gravity
50556	5
50557	5
50558	2
50559	5
50560	3
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Female (satellite)
Stage : Week 4
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
50556	-	-	±	-	-	-
50557	-	-	-	-	-	-
50558	-	-	±	-	-	-
50559	-	-	-	-	-	-
50560	-	-	-	-	-	-
n	5	5	5	5	5	5

Urinary findings
Sex : Female (satellite)

Stage : Week 4
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen	Bilirubin	Occult blood	Color
					EU/dL			
50656	8.5	-	-	-	0.1	-	-	A
50657	8.0	+	-	-	0.1	-	-	A
50658	8.5	-	-	-	0.1	-	-	A
50659	6.5	+	-	-	0.1	-	-	A
50660	8.0	-	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Female (satellite)

Stage : Week 4
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Urine volume mL/21hr
50656	13.0
50657	5.0
50658	5.5
50659	15.0
50660	31.0
n	5
Mean	13.90
S.D.	10.54

Urinary findings
Sex : Female (satellite)
Stage : Week 4
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Specific gravity
50656	4
50657	5
50658	5
50659	3
50660	2
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Female (satellite)
Stage : Week 4
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
50656	-	-	-	-	-	-
50657	-	-	+	-	-	-
50658	-	-	±	-	-	-
50659	-	±	±	-	-	-
50660	-	-	-	-	-	-
n	5	5	5	5	5	5

Urinary findings
Sex : Male
Stage : Recovery Week 2
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen	Bilirubin	Occult blood	Color
					EU/dL			
10104	8.0	+	-	-	0.1	-	-	A
10106	8.5	2+	-	-	0.1	-	-	A
10108	8.5	+	-	-	0.1	-	-	A
10110	8.0	+	-	-	0.1	-	-	A
10112	8.5	+	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Male
Stage : Recovery Week 2
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Urine volume mL/21hr
10104	13.5
10106	11.5
10108	11.0
10110	42.0
10112	12.0
n	5
Mean	18.00
S.D.	13.45

Urinary findings
Sex : Male
Stage : Recovery Week 2
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Specific gravity
10104	5
10106	5
10108	5
10110	2
10112	5
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Male

Stage : Recovery Week 2
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
10104	-	-	-	-	-	-
10106	-	-	-	-	-	-
10108	-	-	-	-	-	-
10110	-	-	-	-	-	-
10112	-	-	-	-	-	-
n	5	5	5	5	5	5

Urinary findings
Sex : Male

Stage : Recovery Week 2
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen	Bilirubin	Occult blood	Color
					EU/dL			
10404	8.5	+	-	-	0.1	-	-	A
10406	8.5	2+	-	-	0.1	-	-	A
10407	8.5	+	-	-	0.1	-	-	A
10409	8.5	+	-	-	0.1	-	-	A
10412	8.5	+	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Male
Stage : Recovery Week 2
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Urine volume mL/21hr
10404	14.0
10406	12.0
10407	21.5
10409	9.5
10412	27.5
n	5
Mean	16.90
S.D.	7.43

Urinary findings
Sex : Male
Stage : Recovery Week 2
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Specific gravity
10404	5
10406	5
10407	3
10409	4
10412	3
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Male

Stage : Recovery Week 2
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
10404	-	-	±	-	-	-
10406	-	-	-	-	-	-
10407	-	-	-	-	-	-
10409	-	-	-	-	-	-
10412	-	-	±	-	-	-
n	5	5	5	5	5	5

Urinary findings
Sex : Female (satellite)

Stage : Recovery Week 2
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen	Bilirubin	Occult blood	Color
					EU/dL			
50556	8.5	+	-	-	0.1	-	±	A
50557	8.5	+	-	-	0.1	-	±	A
50558	8.0	±	-	-	0.1	-	-	A
50559	8.5	±	-	-	0.1	-	-	A
50560	8.5	±	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Female (satellite)

Stage : Recovery Week 2
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	Urine volume mL/21hr
50556	12.0
50557	9.0
50558	8.5
50559	14.0
50560	11.0
n	5
Mean	10.90
S.D.	2.25

Urinary findings
Sex : Female (satellite)
Stage : Recovery Week 2
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Specific gravity
50556	4
50557	4
50558	4
50559	4
50560	4
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Female (satellite)
Stage : Recovery Week 2
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
50556	-	-	±	-	-	-
50557	±	-	±	-	-	-
50558	-	-	±	-	-	-
50559	-	-	±	-	-	-
50560	-	-	-	-	-	-
n	5	5	5	5	5	5

Urinary findings
Sex : Female (satellite)

Stage : Recovery Week 2
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	pH	Protein	Glucose	Ketone body	Urobilinogen	Bilirubin	Occult blood	Color
					EU/dL			
50656	8.5	+	-	-	0.1	-	-	A
50657	8.5	+	-	-	0.1	-	-	A
50658	8.5	±	-	-	0.1	-	-	A
50659	8.5	+	-	-	0.1	-	-	A
50660	8.0	±	-	-	0.1	-	-	A
n	5	5	5	5	5	5	5	5

Color) A : Pale yellow or yellow, B : Orange yellow, C : Red brown, D : Creamy white

Urinary findings
Sex : Female (satellite)
Stage : Recovery Week 2
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Urine volume mL/21hr
50656	10.5
50657	10.0
50658	5.0
50659	7.5
50660	12.0
n	5
Mean	9.00
S.D.	2.76

Urinary findings
Sex : Female (satellite)
Stage : Recovery Week 2
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Specific gravity
50656	5
50657	4
50658	5
50659	5
50660	4
n	5

Specific gravity) 0;1.001～1.010,1;1.011～1.020,2;1.021～1.030,3;1.031～1.040,4;1.041～1.050,5;1.050＜

Urinary findings
Sex : Female (satellite)
Stage : Recovery Week 2
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	RBC	WBC	Squamous	Round	Small round	Cast
50656	-	-	-	-	-	-
50657	-	-	±	-	-	-
50658	-	-	-	-	-	-
50659	-	-	-	-	-	-
50660	-	-	±	-	-	-
n	5	5	5	5	5	5

Hematological findings
Sex : Male

Stage : Day 29
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
10101	902	15.8	43.9	48.7	17.5	36.0	3.03	113.7	68.5	14.5	50.0
10102	860	15.7	43.5	50.6	18.3	36.1	3.69	101.4	140.7	25.8	110.0
10103	844	15.7	45.5	53.9	18.6	34.5	3.77	112.2	79.0	18.9	55.8
10105	885	15.7	44.5	50.3	17.7	35.3	3.46	124.7	82.8	20.6	57.4
10107	859	15.5	43.1	50.2	18.0	36.0	3.18	111.1	131.6	13.7	113.4
n	5	5	5	5	5	5	5	5	5	5	5
Mean	870.0	15.68	44.10	50.74	18.02	35.58	3.426	112.62	100.52	18.70	77.32
S.D.	23.2	0.11	0.94	1.91	0.44	0.68	0.319	8.30	33.10	4.92	31.53

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
10101	2.8	1.2	0.0	25.7	22.2
10102	3.5	1.3	0.1	17.6	18.1
10103	2.8	1.5	0.0	21.4	21.8
10105	3.9	0.9	0.0	19.2	18.5
10107	2.8	1.7	0.0	21.3	17.7
n	5	5	5	5	5
Mean	3.16	1.32	0.02	21.04	19.66
S.D.	0.51	0.30	0.04	3.05	2.16

Hematological findings
Sex : Male

Stage : Day 29
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
10201	822	15.2	42.4	51.6	18.5	35.8	3.65	78.0	76.9	15.2	58.0
10202	788	14.5	41.3	52.4	18.4	35.1	3.37	108.4	74.6	11.0	60.6
10203	799	14.9	43.4	54.3	18.6	34.3	3.50	93.4	81.8	13.0	63.9
10204	837	15.4	43.7	52.2	18.4	35.2	3.26	79.4	59.1	17.1	38.6
10208	856	15.5	43.3	50.6	18.1	35.8	2.67	93.0	50.7	13.6	34.4
n	5	5	5	5	5	5	5	5	5	5	5
Mean	820.4	15.10	42.82	52.22	18.40	35.24	3.290	90.44	68.62	13.98	51.10
S.D.	27.6	0.41	0.98	1.36	0.19	0.62	0.376	12.39	13.13	2.30	13.57

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
10201	2.8	0.9	0.0	19.3	16.7
10202	2.2	0.8	0.0	19.0	18.8
10203	3.2	1.6	0.1	16.9	15.9
10204	2.2	1.2	0.0	17.2	17.3
10208	1.8	0.9	0.0	19.2	18.8
n	5	5	5	5	5
Mean	2.44	1.08	0.02	18.32	17.50
S.D.	0.55	0.33	0.04	1.17	1.29

Hematological findings
Sex : Male

Stage : Day 29
Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
10301	875	15.7	44.7	51.1	17.9	35.1	3.43	113.9	102.2	26.3	69.9
10303	807	15.2	44.2	54.8	18.8	34.4	3.79	100.3	71.4	13.2	54.7
10306	865	15.5	43.8	50.6	17.9	35.4	3.37	128.4	102.3	24.1	73.8
10307	844	15.0	43.2	51.2	17.8	34.7	3.02	93.6	90.3	17.5	69.4
10308	796	14.1	39.9	50.1	17.7	35.3	3.81	94.2	97.8	20.1	73.9
n	5	5	5	5	5	5	5	5	5	5	5
Mean	837.4	15.10	43.16	51.56	18.02	34.98	3.484	106.08	92.80	20.24	68.34
S.D.	34.8	0.62	1.90	1.86	0.44	0.42	0.328	14.91	12.92	5.21	7.91

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
10301	4.1	1.9	0.0	19.0	17.1
10303	2.3	1.2	0.0	22.7	21.9
10306	3.4	0.9	0.1	16.2	16.6
10307	2.5	0.9	0.0	26.1	21.6
10308	3.1	0.7	0.0	23.7	18.7
n	5	5	5	5	5
Mean	3.08	1.12	0.02	21.54	19.18
S.D.	0.72	0.47	0.04	3.93	2.47

Hematological findings
Sex : Male

Stage : Day 29
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
10401	825	14.5	41.3	50.1	17.6	35.1	2.62	116.2	76.4	11.7	60.5
10402	856	15.1	43.0	50.2	17.6	35.1	2.84	130.2	67.6	13.5	49.8
10403	765	14.4	40.9	53.5	18.8	35.2	4.03	113.9	87.7	20.2	63.3
10405	767	13.9	39.3	51.2	18.1	35.4	3.13	109.9	69.2	19.0	46.6
10408	854	15.3	44.5	52.1	17.9	34.4	3.66	95.1	94.1	21.7	68.1
n	5	5	5	5	5	5	5	5	5	5	5
Mean	813.4	14.64	41.80	51.42	18.00	35.04	3.256	113.06	79.00	17.22	57.66
S.D.	45.0	0.56	2.00	1.42	0.49	0.38	0.582	12.62	11.58	4.37	9.12

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
10401	3.4	0.8	0.0	21.6	19.5
10402	2.7	1.5	0.1	21.2	22.1
10403	3.4	0.8	0.0	18.5	18.1
10405	3.1	0.5	0.0	15.7	16.3
10408	3.0	1.3	0.0	24.4	22.0
n	5	5	5	5	5
Mean	3.12	0.98	0.02	20.28	19.60
S.D.	0.29	0.41	0.04	3.31	2.51

Hematological findings
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
50153	726	14.6	41.5	57.2	20.1	35.2	7.08	95.7	100.1	34.1	60.2
50154	713	13.4	38.0	53.3	18.8	35.3	7.74	117.8	118.1	37.2	75.7
50155	784	14.3	41.4	52.8	18.2	34.5	6.04	101.9	120.6	46.9	67.7
50156	681	13.9	41.0	60.2	20.4	33.9	11.92	108.2	115.1	41.1	67.0
50157	779	14.5	41.7	53.5	18.6	34.8	7.21	117.9	78.0	30.9	40.9
n	5	5	5	5	5	5	5	5	5	5	5
Mean	736.6	14.14	40.72	55.40	19.22	34.74	7.998	108.30	106.38	38.04	62.30
S.D.	44.2	0.49	1.54	3.20	0.97	0.57	2.277	9.77	17.75	6.23	13.16

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
50153	4.2	1.6	0.0	15.9	18.5
50154	3.1	2.1	0.0	16.0	13.8
50155	4.7	1.3	0.0	16.7	15.2
50156	5.9	1.1	0.0	16.8	13.9
50157	5.0	1.2	0.0	16.1	17.0
n	5	5	5	5	5
Mean	4.58	1.46	0.00	16.30	15.68
S.D.	1.03	0.40	0.00	0.42	2.04

Hematological findings
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
50253	662	13.4	39.7	60.0	20.2	33.8	14.24	102.0	126.9	48.1	73.4
50255	786	15.2	43.4	55.2	19.3	35.0	6.52	124.0	103.6	45.6	51.9
50259	756	14.7	42.3	56.0	19.4	34.8	4.67	96.6	71.8	24.3	43.3
50260	770	14.1	40.7	52.9	18.3	34.6	6.21	129.6	70.9	25.2	41.1
50261	689	12.8	37.1	53.8	18.6	34.5	7.90	115.8	47.8	12.6	34.4
n	5	5	5	5	5	5	5	5	5	5	5
Mean	732.6	14.04	40.64	55.58	19.16	34.54	7.908	113.60	84.20	31.16	48.82
S.D.	54.0	0.97	2.44	2.75	0.74	0.46	3.721	14.08	31.05	15.19	15.10

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
50253	4.8	0.6	0.0	15.2	16.7
50255	4.8	1.2	0.1	15.9	14.6
50259	3.6	0.6	0.0	15.9	15.8
50260	3.6	1.0	0.0	16.9	15.2
50261	0.7	0.1	0.0	15.5	16.2
n	5	5	5	5	5
Mean	3.50	0.70	0.02	15.88	15.70
S.D.	1.68	0.42	0.04	0.64	0.82

Hematological findings
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
50353	694	12.8	36.8	53.0	18.4	34.8	9.21	111.0	124.4	37.6	81.9
50354	690	13.8	41.0	59.4	20.0	33.7	9.41	109.8	178.2	50.6	120.9
50356	683	13.8	39.9	58.4	20.2	34.6	8.11	117.9	147.6	45.0	97.2
50357	715	13.8	41.7	58.3	19.3	33.1	11.60	118.8	121.1	24.7	92.2
50361	698	13.9	40.5	58.0	19.9	34.3	8.72	116.7	81.6	20.7	56.5
n	5	5	5	5	5	5	5	5	5	5	5
Mean	696.0	13.62	39.98	57.42	19.56	34.10	9.410	114.84	130.58	35.72	89.74
S.D.	12.0	0.46	1.90	2.53	0.73	0.70	1.323	4.14	35.65	12.83	23.45

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
50353	4.3	0.6	0.0	15.6	12.0
50354	5.1	1.5	0.1	15.8	12.7
50356	4.7	0.7	0.0	16.0	16.0
50357	3.0	1.2	0.0	16.1	14.8
50361	3.9	0.4	0.1	16.5	10.0
n	5	5	5	5	5
Mean	4.20	0.88	0.04	16.00	13.10
S.D.	0.81	0.45	0.05	0.34	2.36

Hematological findings
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
50451	718	13.9	41.2	57.4	19.4	33.7	10.09	110.1	96.8	43.1	48.4
50452	826	15.3	44.1	53.4	18.5	34.7	3.85	124.3	55.6	19.6	30.5
50457	695	13.4	38.4	55.3	19.3	34.9	8.92	109.4	99.3	37.6	57.6
50459	727	13.0	37.9	52.1	17.9	34.3	9.08	114.5	125.7	31.9	88.5
50460	671	13.3	39.2	58.4	19.8	33.9	9.26	134.7	53.9	16.7	34.3
n	5	5	5	5	5	5	5	5	5	5	5
Mean	727.4	13.78	40.16	55.32	18.98	34.30	8.240	118.60	86.26	29.78	51.86
S.D.	59.2	0.91	2.54	2.64	0.77	0.51	2.495	10.79	30.92	11.38	23.19

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
50451	4.9	0.4	0.0	16.2	12.5
50452	4.5	1.0	0.0	15.2	15.1
50457	3.6	0.5	0.0	16.7	12.7
50459	4.8	0.4	0.1	16.2	13.6
50460	2.7	0.2	0.0	16.0	12.1
n	5	5	5	5	5
Mean	4.10	0.50	0.02	16.06	13.20
S.D.	0.94	0.30	0.04	0.55	1.20

Hematological findings
Sex : Female (satellite)

Stage : Day 29
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
50551	729	14.2	40.1	55.0	19.5	35.4	2.70	103.4	51.9	10.3	40.4
50552	848	15.3	41.7	49.2	18.0	36.7	2.19	122.1	45.9	9.0	35.1
50553	780	14.9	41.7	53.5	19.1	35.7	3.71	126.2	46.6	5.1	40.2
50554	863	15.8	43.8	50.8	18.3	36.1	3.74	99.6	38.6	8.1	29.3
50555	807	14.6	40.2	49.8	18.1	36.3	1.27	112.3	72.0	6.4	62.9
n	5	5	5	5	5	5	5	5	5	5	5
Mean	805.4	14.96	41.50	51.66	18.60	36.04	2.722	112.72	51.00	7.78	41.58
S.D.	53.9	0.62	1.50	2.49	0.66	0.51	1.049	11.50	12.66	2.06	12.75

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
50551	0.7	0.5	0.0	15.0	10.4
50552	1.1	0.7	0.0	14.9	14.0
50553	1.0	0.3	0.0	15.2	11.7
50554	0.7	0.5	0.0	14.5	12.2
50555	1.8	0.9	0.0	14.4	12.2
n	5	5	5	5	5
Mean	1.06	0.58	0.00	14.80	12.10
S.D.	0.45	0.23	0.00	0.34	1.29

Hematological findings
Sex : Female (satellite)

Stage : Day 29
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
50651	721	13.4	39.8	55.2	18.6	33.7	3.61	88.9	32.0	5.5	25.6
50652	784	14.5	41.2	52.6	18.5	35.2	3.50	106.3	94.0	11.5	80.6
50653	735	13.9	39.7	54.0	18.9	35.0	3.56	120.7	57.2	9.7	46.0
50654	767	14.9	43.2	56.3	19.4	34.5	3.27	102.0	128.7	19.8	102.9
50655	754	14.3	41.7	55.3	19.0	34.3	4.72	108.2	59.7	10.7	45.2
n	5	5	5	5	5	5	5	5	5	5	5
Mean	752.2	14.20	41.12	54.68	18.88	34.54	3.732	105.22	74.32	11.44	60.06
S.D.	25.0	0.57	1.45	1.42	0.36	0.59	0.567	11.47	37.56	5.21	31.08

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
50651	0.6	0.3	0.0	16.9	13.2
50652	1.4	0.5	0.0	14.8	10.8
50653	1.3	0.2	0.0	16.7	15.0
50654	4.2	1.8	0.0	15.0	13.9
50655	2.7	1.1	0.0	14.6	15.1
n	5	5	5	5	5
Mean	2.04	0.78	0.00	15.60	13.60
S.D.	1.43	0.67	0.00	1.11	1.75

Hematological findings
Sex : Male

Stage : Recovery Day 15
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
10104	844	14.5	40.4	47.9	17.2	35.9	3.88	126.1	103.4	11.8	86.9
10106	824	15.3	42.7	51.8	18.6	35.8	3.77	98.5	104.8	12.2	87.6
10108	923	15.3	42.7	46.3	16.6	35.8	4.18	120.5	92.4	15.0	71.8
10110	858	16.2	46.0	53.6	18.9	35.2	3.92	127.4	85.5	10.0	71.1
10112	852	16.0	45.4	53.3	18.8	35.2	3.13	97.5	60.0	9.9	46.4
n	5	5	5	5	5	5	5	5	5	5	5
Mean	860.2	15.46	43.44	50.58	18.02	35.58	3.776	114.00	89.22	11.78	72.76
S.D.	37.4	0.67	2.28	3.30	1.05	0.35	0.391	14.84	18.18	2.08	16.72

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
10104	3.8	0.8	0.1	15.3	14.6
10106	3.9	1.0	0.1	17.0	17.2
10108	3.3	2.3	0.0	23.5	21.1
10110	3.1	1.2	0.1	15.3	14.6
10112	2.5	1.2	0.0	15.9	16.0
n	5	5	5	5	5
Mean	3.32	1.30	0.06	17.40	16.70
S.D.	0.57	0.58	0.05	3.48	2.69

Hematological findings
Sex : Male

Stage : Recovery Day 15
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
10404	821	14.5	40.9	49.8	17.7	35.5	5.13	131.3	144.7	22.4	117.2
10406	847	14.3	40.2	47.5	16.9	35.6	4.31	116.2	90.6	17.5	68.9
10407	872	15.9	44.9	51.5	18.2	35.4	3.61	111.0	67.2	12.2	50.7
10409	898	15.4	43.8	48.8	17.1	35.2	4.38	98.8	77.5	19.6	54.4
10412	853	14.8	42.0	49.2	17.4	35.2	4.84	119.5	69.8	14.7	51.3
n	5	5	5	5	5	5	5	5	5	5	5
Mean	858.2	14.98	42.36	49.36	17.46	35.38	4.454	115.36	89.96	17.28	68.50
S.D.	28.8	0.66	1.97	1.46	0.51	0.18	0.580	11.89	31.92	4.00	28.21

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
10404	3.9	1.1	0.1	21.9	18.9
10406	3.4	0.8	0.0	22.4	19.0
10407	3.0	1.2	0.1	16.8	16.5
10409	2.5	1.0	0.0	19.8	18.5
10412	2.2	1.6	0.0	17.7	17.5
n	5	5	5	5	5
Mean	3.00	1.14	0.04	19.72	18.08
S.D.	0.68	0.30	0.05	2.48	1.06

Hematological findings
Sex : Female (satellite)

Stage : Recovery Day 15
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
50556	861	15.1	42.9	49.8	17.5	35.2	2.49	112.4	31.8	6.4	23.5
50557	821	15.1	42.1	51.3	18.4	35.9	4.15	99.4	33.5	7.9	24.1
50558	852	15.4	43.0	50.5	18.1	35.8	3.10	98.9	37.9	3.9	33.0
50559	773	14.8	40.8	52.8	19.1	36.3	2.65	88.3	67.9	7.5	58.7
50560	837	14.9	40.5	48.4	17.8	36.8	3.84	121.2	74.0	8.1	63.9
n	5	5	5	5	5	5	5	5	5	5	5
Mean	828.8	15.06	41.86	50.56	18.18	36.00	3.246	104.04	49.02	6.76	40.64
S.D.	34.7	0.23	1.16	1.64	0.61	0.60	0.728	12.85	20.26	1.73	19.32

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
50556	1.3	0.6	0.0	15.8	10.4
50557	1.1	0.4	0.0	14.7	11.6
50558	0.6	0.4	0.0	16.2	11.8
50559	1.4	0.3	0.0	160.0 $	ND
50560	1.2	0.8	0.0	15.8	10.8
n	5	5	5	4	4
Mean	1.12	0.50	0.00	15.63	11.15
S.D.	0.31	0.20	0.00	0.64	0.66

$: Excepted data from calculation, ND : No data

Hematological findings
Sex : Female (satellite)

Stage : Recovery Day 15
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	RBC $10^4/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	Reticulocyte %	Platelet $10^4/\mu L$	WBC $10^2/\mu L$	Neutrophil $10^2/\mu L$	Lymphocyte $10^2/\mu L$
50656	774	14.2	39.9	51.6	18.3	35.6	3.88	100.6	28.8	5.5	21.5
50657	797	15.5	43.8	55.0	19.4	35.4	2.96	117.5	54.8	10.8	41.5
50658	857	15.8	43.0	50.2	18.4	36.7	2.68	110.5	58.2	6.6	49.8
50659	853	16.1	45.4	53.2	18.9	35.5	2.14	112.7	39.8	7.1	30.7
50660	817	14.9	40.9	50.1	18.2	36.4	3.77	119.0	40.0	8.7	29.1
n	5	5	5	5	5	5	5	5	5	5	5
Mean	819.6	15.30	42.60	52.02	18.64	35.92	3.086	112.06	44.32	7.74	34.52
S.D.	35.7	0.76	2.21	2.09	0.50	0.59	0.737	7.28	12.07	2.06	11.13

Animal No.	Monocyte $10^2/\mu L$	Eosinophil $10^2/\mu L$	Basophil $10^2/\mu L$	PT sec	APTT sec
50656	1.2	0.6	0.0	15.1	12.5
50657	1.6	0.9	0.0	14.0	13.1
50658	1.0	0.8	0.0	17.0	11.3
50659	1.6	0.4	0.0	16.5	13.7
50660	1.2	1.0	0.0	16.4	12.7
n	5	5	5	5	5
Mean	1.32	0.74	0.00	15.80	12.66
S.D.	0.27	0.24	0.00	1.23	0.89

Biochemical findings Stage : Day 29
Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
10101	72	28	479	0.2	0.06	7.9	143	49	9	5.4	12.0
10102	70	29	556	0.3	0.06	10.6	169	49	23	4.9	14.2
10103	59	27	437	0.4	0.04	6.4	176	41	31	5.5	11.6
10105	80	32	472	0.2	0.05	10.2	152	41	41	5.2	9.4
10107	80	35	528	0.5	0.06	13.0	149	55	24	5.2	12.7
n	5	5	5	5	5	5	5	5	5	5	5
Mean	72.2	30.2	494.4	0.32	0.054	9.62	157.8	47.0	25.6	5.24	11.98
S.D.	8.7	3.3	47.3	0.13	0.009	2.55	14.0	6.0	11.7	0.23	1.75

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
10101	0.32	145	4.46	104	9.0	5.8	1.05	2.76	51.1	20.6	8.5
10102	0.30	145	4.33	105	9.2	7.2	1.24	2.71	55.3	17.9	10.2
10103	0.29	144	4.60	103	9.4	6.6	0.86	2.54	46.1	23.8	8.2
10105	0.26	145	5.12	105	9.5	7.1	1.00	2.60	50.0	18.2	11.1
10107	0.28	145	4.69	105	9.4	7.4	1.15	2.78	53.4	19.2	9.3
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.290	144.8	4.640	104.4	9.30	6.82	1.060	2.678	51.18	19.94	9.46
S.D.	0.022	0.4	0.301	0.9	0.20	0.64	0.145	0.104	3.50	2.40	1.20

Animal No.	β-G %	γ-G %
10101	14.7	5.1
10102	14.1	2.5
10103	14.9	7.0
10105	16.7	4.0
10107	15.0	3.1
n	5	5
Mean	15.08	4.34
S.D.	0.97	1.78

Biochemical findings
Sex : Male

Stage : Day 29
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
10201	65	26	397	0.2	0.05	4.8	170	52	15	4.9	14.9
10202	60	25	624	0.3	0.05	4.4	161	79	36	5.4	10.2
10203	63	28	409	0.4	0.05	10.1	167	63	31	5.5	13.3
10204	51	22	383	0.5	0.06	4.8	157	65	30	5.2	11.1
10208	72	34	623	0.4	0.06	8.6	160	50	28	5.6	9.7
n	5	5	5	5	5	5	5	5	5	5	5
Mean	62.2	27.0	487.2	0.36	0.054	6.54	163.0	61.8	28.0	5.32	11.84
S.D.	7.7	4.5	124.8	0.11	0.005	2.62	5.3	11.6	7.8	0.28	2.20

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
10201	0.35	143	4.35	104	9.2	6.6	0.97	2.42	49.3	19.5	10.5
10202	0.27	144	4.63	103	9.7	6.6	0.91	2.57	47.6	25.4	8.9
10203	0.33	146	4.63	104	10.0	7.5	0.92	2.63	47.9	24.6	8.9
10204	0.30	147	4.42	107	9.6	6.9	1.12	2.75	52.8	17.1	9.7
10208	0.33	145	4.61	105	9.8	6.5	0.95	2.73	48.7	20.5	10.6
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.316	145.0	4.528	104.6	9.66	6.82	0.974	2.620	49.26	21.42	9.72
S.D.	0.031	1.6	0.133	1.5	0.30	0.41	0.085	0.134	2.09	3.51	0.83

Animal No.	β-G %	γ-G %
10201	15.9	4.8
10202	15.1	3.0
10203	15.4	3.2
10204	16.6	3.8
10208	15.7	4.5
n	5	5
Mean	15.74	3.86
S.D.	0.57	0.79

Biochemical findings Stage : Day 29
Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
10301	53	24	416	0.2	0.04	3.3	150	54	27	5.2	9.6
10303	56	28	300	0.2	0.04	5.1	161	58	28	5.2	10.1
10306	66	30	496	0.3	0.05	5.5	139	71	62	5.4	9.8
10307	68	31	501	0.6	0.05	6.1	153	48	23	5.2	12.0
10308	117	66	380	0.0	0.07	27.5	153	51	14	5.4	13.1
n	5	5	5	5	5	5	5	5	5	5	5
Mean	72.0	35.8	418.6	0.26	0.050	9.50	151.2	56.4	30.8	5.28	10.92
S.D.	26.0	17.1	84.2	0.22	0.012	10.12	7.9	9.0	18.3	0.11	1.55

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
10301	0.30	145	5.06	104	9.6	6.7	0.87	2.41	46.4	25.3	9.4
10303	0.31	146	4.48	105	9.5	5.6	0.97	2.56	49.3	24.6	8.8
10306	0.28	145	4.90	103	9.5	6.9	0.95	2.62	48.6	21.6	10.3
10307	0.29	147	4.35	106	9.3	6.9	0.96	2.55	49.1	22.1	8.5
10308	0.27	146	4.43	106	9.5	6.8	0.92	2.59	47.9	23.5	9.8
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.290	145.8	4.644	104.8	9.48	6.58	0.934	2.546	48.26	23.42	9.36
S.D.	0.016	0.8	0.315	1.3	0.11	0.55	0.040	0.081	1.17	1.58	0.73

Animal No.	β-G %	γ-G %
10301	14.5	4.4
10303	14.0	3.3
10306	15.8	3.7
10307	16.7	3.6
10308	15.6	3.2
n	5	5
Mean	15.32	3.64
S.D.	1.08	0.47

Biochemical findings
Sex : Male

Stage : Day 29
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
10401	77	37	679	0.5	0.04	5.3	124	45	22	5.2	10.9
10402	67	30	446	0.4	0.03	2.9	149	52	19	5.7	11.3
10403	66	31	389	0.0	0.05	9.4	138	58	21	4.9	8.8
10405	94	64	563	2.7	0.09	15.5	144	56	12	5.6	11.2
10408	93	50	402	0.6	0.05	13.2	166	54	15	5.7	13.4
n	5	5	5	5	5	5	5	5	5	5	5
Mean	79.4	42.4	495.8	0.84	0.052	9.26	144.2	53.0	17.8	5.42	11.12
S.D.	13.6	14.5	123.3	1.06	0.023	5.26	15.4	5.0	4.2	0.36	1.63

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
10401	0.31	146	4.35	105	9.6	6.3	1.30	2.94	56.6	10.9	11.6
10402	0.34	145	4.90	104	9.8	6.0	0.94	2.76	48.5	23.8	9.9
10403	0.32	146	4.72	106	9.5	6.4	1.09	2.56	52.2	20.8	8.8
10405	0.28	145	4.68	104	9.7	6.1	0.98	2.78	49.6	20.7	9.4
10408	0.26	146	4.70	103	9.9	7.8	0.93	2.75	48.2	19.7	9.7
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.302	145.6	4.670	104.4	9.70	6.52	1.048	2.758	51.02	19.18	9.88
S.D.	0.032	0.5	0.199	1.1	0.16	0.73	0.154	0.135	3.49	4.88	1.05

Animal No.	β-G %	γ-G %
10401	15.1	5.8
10402	13.9	3.9
10403	14.5	3.7
10405	15.8	4.5
10408	15.2	7.2
n	5	5
Mean	14.90	5.02
S.D.	0.72	1.47

Biochemical findings
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
50153	82	43	171	0.5	0.04	14.4	162	70	45	5.6	15.6
50154	173	62	232	0.7	0.06	18.5	144	55	26	5.7	16.8
50155	69	44	179	1.1	0.03	9.0	147	59	50	5.7	13.8
50156	87	48	373	0.6	0.04	8.7	131	54	24	6.1	19.1
50157	102	49	212	0.8	0.04	9.6	130	47	16	5.8	20.5
n	5	5	5	5	5	5	5	5	5	5	5
Mean	102.6	49.2	233.4	0.74	0.042	12.04	142.8	57.0	32.2	5.78	17.16
S.D.	41.1	7.6	81.9	0.23	0.011	4.29	13.1	8.5	14.6	0.19	2.68

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
50153	0.33	143	4.71	107	10.2	7.2	0.94	2.72	48.5	18.8	10.7
50154	0.39	143	4.53	106	10.1	8.1	0.82	2.58	45.2	22.6	8.5
50155	0.28	145	4.30	109	10.3	7.0	1.15	3.05	53.5	14.2	12.0
50156	0.32	144	4.41	106	10.5	8.2	0.86	2.82	46.3	20.6	8.1
50157	0.35	144	4.34	108	10.3	8.3	0.78	2.55	43.9	21.0	11.1
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.334	143.8	4.458	107.2	10.28	7.76	0.910	2.744	47.48	19.44	10.08
S.D.	0.040	0.8	0.166	1.3	0.15	0.61	0.147	0.203	3.76	3.23	1.70

Animal No.	β-G %	γ-G %
50153	17.5	4.5
50154	19.0	4.7
50155	17.3	3.0
50156	18.7	6.3
50157	18.7	5.3
n	5	5
Mean	18.24	4.76
S.D.	0.78	1.21

Biochemical findings
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 100 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
50253	155	59	238	0.8	0.07	6.6	149	70	26	5.7	16.0
50255	76	44	223	0.9	0.05	23.2	158	79	61	5.5	16.0
50259	133	38	208	0.5	0.05	6.9	119	57	15	5.9	14.8
50260	90	50	243	1.3	0.07	44.4	163	74	49	5.7	18.8
50261	90	52	195	1.9	0.05	16.4	140	100	78	5.5	28.1
n	5	5	5	5	5	5	5	5	5	5	5
Mean	108.8	48.6	221.4	1.08	0.058	19.50	145.8	76.0	45.8	5.66	18.74
S.D.	33.6	8.0	20.1	0.54	0.011	15.56	17.4	15.7	25.6	0.17	5.43

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
50253	0.41	145	4.04	107	10.0	8.3	1.05	2.92	51.2	20.1	8.1
50255	0.38	146	4.51	107	10.2	8.5	1.00	2.76	50.1	20.1	9.7
50259	0.34	145	4.09	110	10.1	8.4	0.78	2.58	43.7	19.0	10.1
50260	0.35	144	4.74	107	10.3	7.7	0.97	2.80	49.2	21.2	9.2
50261	0.41	144	4.18	106	10.9	9.8	0.82	2.48	45.0	20.9	11.6
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.378	144.8	4.312	107.4	10.30	8.54	0.924	2.708	47.84	20.26	9.74
S.D.	0.033	0.8	0.301	1.5	0.35	0.77	0.118	0.176	3.30	0.86	1.28

Animal No.	β-G %	γ-G %
50253	15.8	4.8
50255	17.0	3.1
50259	19.6	7.6
50260	17.1	3.3
50261	18.7	3.8
n	5	5
Mean	17.64	4.52
S.D.	1.50	1.84

Biochemical findings
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 300 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
50353	162	100	218	2.0	0.06	38.7	132	71	97	5.3	18.5
50354	160	51	241	1.0	0.04	9.1	152	59	34	5.4	16.9
50356	78	43	230	0.4	0.04	16.3	131	59	40	5.4	16.8
50357	72	35	432	0.9	0.05	14.3	144	62	17	5.4	13.0
50361	74	33	205	0.7	0.05	17.4	132	75	42	5.6	11.5
n	5	5	5	5	5	5	5	5	5	5	5
Mean	109.2	52.4	265.2	1.00	0.048	19.16	138.2	65.2	46.0	5.42	15.34
S.D.	47.3	27.5	94.2	0.60	0.008	11.38	9.4	7.4	30.2	0.11	2.95

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
50353	0.35	144	4.38	106	10.3	8.8	0.78	2.33	43.9	18.6	11.7
50354	0.35	145	4.31	108	9.7	8.1	0.91	2.57	47.6	21.2	9.4
50356	0.40	143	4.67	103	10.0	8.0	0.87	2.51	46.4	22.0	9.9
50357	0.38	146	4.59	109	9.9	8.4	1.07	2.79	51.6	18.4	9.2
50361	0.33	145	4.71	107	10.2	7.5	0.80	2.49	44.5	23.1	10.0
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.362	144.6	4.532	106.6	10.02	8.16	0.886	2.538	46.80	20.66	10.04
S.D.	0.028	1.1	0.178	2.3	0.24	0.48	0.115	0.166	3.06	2.09	0.99

Animal No.	β-G %	γ-G %
50353	20.2	5.6
50354	16.5	5.3
50356	18.1	3.6
50357	17.0	3.8
50361	18.2	4.2
n	5	5
Mean	18.00	4.50
S.D.	1.43	0.90

Biochemical findings
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
50451	83	47	480	1.8	0.02	9.4	166	63	39	5.7	16.9
50452	79	43	168	1.4	0.03	9.1	170	63	11	5.8	12.0
50457	102	71	291	1.7	0.03	14.1	140	68	60	5.3	23.3
50459	91	62	361	0.8	0.04	13.6	139	67	36	5.9	19.4
50460	77	46	298	0.7	0.03	9.5	149	80	55	5.6	14.0
n	5	5	5	5	5	5	5	5	5	5	5
Mean	86.4	53.8	319.6	1.28	0.030	11.14	152.8	68.2	40.2	5.66	17.12
S.D.	10.2	12.1	113.7	0.51	0.007	2.48	14.5	7.0	19.3	0.23	4.45

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
50451	0.35	143	4.59	105	10.2	7.5	0.98	2.83	49.6	19.2	9.1
50452	0.27	144	4.78	106	9.9	6.8	1.01	2.92	50.3	18.3	10.0
50457	0.41	145	4.60	106	10.5	9.3	0.80	2.35	44.3	19.1	11.7
50459	0.36	144	4.48	105	10.7	8.2	0.77	2.57	43.5	20.5	10.4
50460	0.31	145	4.78	106	10.4	7.7	0.93	2.70	48.3	20.6	9.5
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.340	144.2	4.646	105.6	10.34	7.90	0.898	2.674	47.20	19.54	10.14
S.D.	0.053	0.8	0.131	0.5	0.30	0.93	0.108	0.224	3.11	0.99	1.00

Animal No.	β-G %	γ-G %
50451	17.2	4.9
50452	17.1	4.3
50457	19.7	5.2
50459	19.3	6.3
50460	18.1	3.5
n	5	5
Mean	18.28	4.84
S.D.	1.19	1.04

Biochemical findings
Sex : Female (satellite)

Stage : Day 29
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
50551	53	21	218	0.4	0.07	7.7	111	59	11	5.6	13.2
50552	52	23	180	0.2	0.07	8.4	138	51	6	7.0	17.9
50553	64	21	271	0.6	0.07	12.2	134	56	9	5.9	12.3
50554	64	21	243	1.0	0.06	11.4	131	43	4	5.6	13.9
50555	53	22	285	0.0	0.08	9.8	160	61	15	5.5	13.8
n	5	5	5	5	5	5	5	5	5	5	5
Mean	57.2	21.6	239.4	0.44	0.070	9.90	134.8	54.0	9.0	5.92	14.22
S.D.	6.2	0.9	42.1	0.38	0.007	1.91	17.5	7.2	4.3	0.62	2.15

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
50551	0.38	145	5.58	105	10.2	7.6	1.16	3.01	53.7	19.2	6.5
50552	0.36	145	4.64	105	10.4	6.2	1.34	4.01	57.3	18.9	7.4
50553	0.32	146	4.47	105	10.6	7.1	1.18	3.20	54.2	16.3	7.6
50554	0.35	146	4.06	106	9.7	7.6	1.20	3.06	54.6	19.7	7.3
50555	0.30	143	3.85	105	10.5	6.9	1.28	3.09	56.2	14.8	10.9
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.342	145.0	4.520	105.2	10.28	7.08	1.232	3.274	55.20	17.78	7.94
S.D.	0.032	1.2	0.671	0.4	0.36	0.58	0.076	0.417	1.50	2.12	1.71

Animal No.	β-G %	γ-G %
50551	13.9	6.7
50552	12.5	3.9
50553	15.9	6.0
50554	13.9	4.5
50555	13.5	4.6
n	5	5
Mean	13.94	5.14
S.D.	1.24	1.16

Biochemical findings
Sex : Female (satellite)

Stage : Day 29
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
50651	53	29	198	0.3	0.04	4.1	122	60	16	5.5	15.4
50652	52	27	255	0.4	0.05	6.8	134	93	15	6.5	15.2
50653	48	22	180	0.7	0.03	11.4	126	69	18	6.6	17.3
50654	63	40	260	0.9	0.04	21.4	137	71	15	6.1	16.3
50655	74	40	151	0.8	0.04	4.8	113	52	17	5.7	11.8
n	5	5	5	5	5	5	5	5	5	5	5
Mean	58.0	31.6	208.8	0.62	0.040	9.70	126.4	69.0	16.2	6.08	15.20
S.D.	10.5	8.1	47.5	0.26	0.007	7.13	9.6	15.4	1.3	0.48	2.07

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
50651	0.42	144	4.62	105	10.0	5.8	1.34	3.15	57.2	17.2	7.6
50652	0.33	144	4.34	103	10.6	6.2	1.28	3.65	56.2	16.5	7.8
50653	0.38	145	4.23	105	10.5	6.0	1.30	3.73	56.5	17.1	8.3
50654	0.38	145	4.04	105	10.4	7.5	1.08	3.17	51.9	16.3	9.5
50655	0.35	145	4.40	106	10.3	6.8	1.11	3.00	52.6	15.7	10.8
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.372	144.6	4.326	104.8	10.36	6.46	1.222	3.340	54.88	16.56	8.80
S.D.	0.034	0.5	0.214	1.1	0.23	0.69	0.118	0.327	2.44	0.61	1.34

Animal No.	β-G %	γ-G %
50651	12.6	5.4
50652	14.5	5.0
50653	12.9	5.2
50654	15.8	6.5
50655	16.6	4.3
n	5	5
Mean	14.48	5.28
S.D.	1.75	0.80

Biochemical findings
Sex : Male

Stage : Recovery Day 15
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
10104	79	25	337	0.2	0.09	38.6	151	74	21	5.5	14.9
10106	80	30	458	0.2	0.06	8.4	145	52	23	5.3	15.9
10108	58	27	317	0.3	0.06	7.9	163	50	42	5.4	13.1
10110	90	40	331	0.7	0.09	17.0	168	77	37	5.6	15.7
10112	53	26	287	0.3	0.06	5.3	162	54	18	5.2	14.1
n	5	5	5	5	5	5	5	5	5	5	5
Mean	72.0	29.6	346.0	0.34	0.072	15.44	157.8	61.4	28.2	5.40	14.74
S.D.	15.8	6.1	65.5	0.21	0.016	13.68	9.5	13.0	10.6	0.16	1.16

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
10104	0.31	142	4.55	102	9.4	6.3	0.93	2.65	48.1	23.3	8.4
10106	0.33	142	4.57	104	8.8	6.1	0.92	2.53	47.8	20.6	10.0
10108	0.32	143	5.01	103	9.2	5.6	0.95	2.62	48.6	24.2	9.6
10110	0.33	142	4.68	104	9.2	5.8	0.93	2.70	48.3	17.7	10.5
10112	0.26	143	4.59	104	8.6	6.2	0.94	2.52	48.4	23.2	9.2
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.310	142.4	4.680	103.4	9.04	6.00	0.934	2.604	48.24	21.80	9.54
S.D.	0.029	0.5	0.191	0.9	0.33	0.29	0.011	0.078	0.30	2.66	0.80

Animal No.	β-G %	γ-G %
10104	16.3	3.9
10106	15.5	6.1
10108	14.6	3.0
10110	16.7	6.8
10112	15.3	3.9
n	5	5
Mean	15.68	4.74
S.D.	0.83	1.62

Biochemical findings
Sex : Male

Stage : Recovery Day 15
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
10404	76	33	481	0.3	0.06	4.2	183	55	35	5.4	12.2
10406	61	25	286	0.2	0.04	6.8	165	54	20	5.6	14.9
10407	63	31	339	0.4	0.05	6.2	148	52	26	5.4	15.2
10409	55	27	351	0.4	0.05	3.0	157	52	11	5.2	14.0
10412	65	24	383	0.6	0.07	5.8	173	70	19	5.6	13.7
n	5	5	5	5	5	5	5	5	5	5	5
Mean	64.0	28.0	368.0	0.38	0.054	5.20	165.2	56.6	22.2	5.44	14.00
S.D.	7.7	3.9	72.2	0.15	0.011	1.56	13.6	7.6	8.9	0.17	1.18

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
10404	0.26	142	4.78	102	8.9	6.5	0.82	2.44	45.1	23.5	8.4
10406	0.34	143	4.86	104	9.1	5.8	1.00	2.80	50.0	23.4	9.2
10407	0.29	144	4.56	104	8.9	6.9	0.95	2.64	48.8	21.6	8.2
10409	0.32	142	4.71	104	8.9	5.8	0.96	2.55	49.0	23.4	9.1
10412	0.30	144	4.35	104	9.6	6.4	1.09	2.92	52.2	19.5	9.1
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.302	143.0	4.652	103.6	9.08	6.28	0.964	2.670	49.02	22.28	8.80
S.D.	0.030	1.0	0.202	0.9	0.30	0.48	0.098	0.192	2.57	1.75	0.46

Animal No.	β-G %	γ-G %
10404	16.4	6.6
10406	13.8	3.6
10407	15.2	6.2
10409	14.7	3.8
10412	16.2	3.0
n	5	5
Mean	15.26	4.64
S.D.	1.08	1.64

Biochemical findings
Sex : Female (satellite)

Stage : Recovery Day 15
Dose : EGEHE 0 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
50556	53	21	209	0.8	0.09	22.1	174	90	21	6.3	14.1
50557	54	20	193	0.5	0.09	12.1	168	73	13	6.0	16.7
50558	53	24	173	0.5	0.08	10.7	165	63	11	5.8	15.5
50559	51	22	304	1.0	0.09	10.4	130	60	10	5.5	13.9
50560	52	23	139	1.1	0.10	14.4	146	71	11	6.1	16.2
n	5	5	5	5	5	5	5	5	5	5	5
Mean	52.6	22.0	203.6	0.78	0.090	13.94	156.6	71.4	13.2	5.94	15.28
S.D.	1.1	1.6	61.9	0.28	0.007	4.83	18.2	11.7	4.5	0.30	1.25

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
50556	0.29	142	4.65	105	9.8	5.4	1.34	3.60	57.2	18.2	7.9
50557	0.31	142	4.49	105	9.5	5.3	1.26	3.35	55.8	16.6	7.8
50558	0.31	142	4.50	105	9.7	6.1	1.27	3.24	55.9	14.8	8.2
50559	0.37	140	4.28	104	9.3	6.3	1.16	2.95	53.7	14.2	10.2
50560	0.35	141	4.58	103	9.6	5.9	1.08	3.17	52.0	22.3	6.5
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.326	141.4	4.500	104.4	9.58	5.80	1.222	3.262	54.92	17.22	8.12
S.D.	0.033	0.9	0.139	0.9	0.19	0.44	0.102	0.239	2.06	3.25	1.33

Animal No.	β-G %	γ-G %
50556	13.5	3.2
50557	14.2	5.6
50558	14.8	6.3
50559	15.5	6.4
50560	13.7	5.5
n	5	5
Mean	14.34	5.40
S.D.	0.82	1.29

Biochemical findings
Sex : Female (satellite)

Stage : Recovery Day 15
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	AST IU/L	ALT IU/L	ALP IU/L	γ-GTP IU/L	T-Bil mg/dL	TBA μmol/L	Glucose mg/dL	T-Cho mg/dL	TG mg/dL	TP g/dL	UN mg/dL
50656	52	20	228	0.3	0.07	6.8	138	57	10	5.8	12.9
50657	68	30	115	0.2	0.07	6.6	112	80	10	6.0	16.5
50658	64	26	292	0.4	0.07	18.2	126	55	10	5.5	17.1
50659	63	25	177	0.8	0.06	7.6	127	41	6	6.0	13.7
50660	48	22	184	0.6	0.08	22.3	121	60	6	6.3	17.5
n	5	5	5	5	5	5	5	5	5	5	5
Mean	59.0	24.6	199.2	0.46	0.070	12.30	124.8	58.6	8.4	5.92	15.54
S.D.	8.5	3.8	65.7	0.24	0.007	7.41	9.5	14.0	2.2	0.29	2.09

Animal No.	Crea mg/dL	Na mEq/L	K mEq/L	Cl mEq/L	Ca mg/dL	IP mg/dL	A/G	Albumin g/dL	Albumin %	α1-G %	α2-G %
50656	0.36	143	4.35	104	9.4	5.5	1.11	3.06	52.7	17.1	8.3
50657	0.36	143	4.40	104	9.3	5.8	1.11	3.15	52.5	18.3	8.1
50658	0.34	140	4.45	103	9.5	7.2	1.19	2.99	54.3	12.1	10.0
50659	0.30	140	4.72	104	9.5	6.9	0.97	2.95	49.2	16.4	8.4
50660	0.31	141	4.50	103	9.7	6.4	1.04	3.21	51.0	19.9	7.2
n	5	5	5	5	5	5	5	5	5	5	5
Mean	0.334	141.4	4.484	103.6	9.48	6.36	1.084	3.072	51.94	16.76	8.40
S.D.	0.028	1.5	0.143	0.5	0.15	0.72	0.083	0.108	1.93	2.92	1.01

Animal No.	β-G %	γ-G %
50656	15.5	6.4
50657	13.8	7.3
50658	17.6	6.0
50659	15.4	10.6
50660	14.8	7.1
n	5	5
Mean	15.42	7.48
S.D.	1.39	1.82

Necropsy findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 10101
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 10102
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 10103
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 10105
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 10107
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 10109
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 10111
Finding absent :	Liver, Other organs & tissues	

Necropsy findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10201
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10202
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10203
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10204
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10205
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10206
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10207
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10208
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10209
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10210
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10211
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 10212
Finding absent :	Liver, Other organs & tissues	

Necropsy findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10301
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10302
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10303
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10304
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10305
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10306
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10307
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10308
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10309
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10310
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10311
Finding absent :	Liver, Other organs & tissues	
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 10312
Finding absent :	Liver, Other organs & tissues	

Necropsy findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10401
Finding absent : Liver, Other organs & tissues

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10402
Liver
Findings : Finding present
Dark brown
Non-graded change

Finding absent : Other organs & tissues

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10403
Finding absent : Liver, Other organs & tissues

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10405
Liver
Findings : Finding present
Dark brown
Non-graded change

Finding absent : Other organs & tissues

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10408
Finding absent : Liver, Other organs & tissues

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10410
Liver
Findings : Finding present
Dark brown
Non-graded change

Finding absent : Other organs & tissues

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10411
Liver
Findings : Finding present
Dark brown
Non-graded change

Finding absent : Other organs & tissues

Necropsy findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50151 Non-pregnancy

Uterus
Findings : Finding present
Retention, fluid, colorless, serous and transparent
Non-graded change
Dilatation, lumen
Non-graded change

Vagina
Findings : Finding present
Atresia
Non-graded change

Finding absent : Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50152
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50153
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50154
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50155

Kidney
Findings : Finding present
Yellowish white focus, unilateral
Non-graded change
Finding Comment : left kidney, 7 x 3 mm

Finding absent : Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50156
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50157
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50158
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50159
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50160
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50161
Finding absent : Kidney, Other organs & tissues

Necropsy findings

	Sex : Female		Stage : Day 5 after delivery	Species : Rat
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 50162		
Finding absent :	Kidney, Other organs & tissues			

Necropsy findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50251	Unsuccessful mating
Finding absent :	All organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50252	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50253	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50254	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50255	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50256	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50257	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50258	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50259	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50260	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50261	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 100 mg/kg	Animal No. : 50262	
Finding absent :	Kidney, Other organs & tissues		

Necropsy findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50351
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50352
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50353
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50354
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50355
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50356
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50357
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50358 Non-pregnancy
Vagina
Findings : Finding present
Atresia
Non-graded change
Retention, fluid, pale yellow, viscous and cloudy
Non-graded change

Finding absent : Uterus, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50359
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50360
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50361
Finding absent : Kidney, Other organs & tissues

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50362
Finding absent : Kidney, Other organs & tissues

Necropsy findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50451	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50452	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50453	Non-pregnancy
Finding absent :	Uterus, Vagina, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50454	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50455	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50456	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50457	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50458	Non-pregnancy
Finding absent :	Uterus, Vagina, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50459	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50460	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50461	
Finding absent :	Kidney, Other organs & tissues		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50462	
Finding absent :	Kidney, Other organs & tissues		

Necropsy findings
Sex : Female (satellite) Stage : Day 29 Species : Rat

Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 50551
Finding absent :	Liver, Other organs & tissues	
Estrous cycle : Proestrus		
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 50552
Finding absent :	Liver, Other organs & tissues	
Estrous cycle : Diestrus		
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 50553
Finding absent :	Liver, Other organs & tissues	
Estrous cycle : Proestrus		
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 50554
Finding absent :	Liver, Other organs & tissues	
Estrous cycle : Proestrus		
Test article : EGEHE	Dose : 0 mg/kg	Animal No. : 50555
Finding absent :	Liver, Other organs & tissues	
Estrous cycle : Metestrus		

Necropsy findings
Sex : Female (satellite) Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50651
Finding absent : Liver, Other organs & tissues
Estrous cycle : Diestrus

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50652
Finding absent : Liver, Other organs & tissues
Estrous cycle : Proestrus

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50653
Liver
Findings : Finding present
Dark brown
Non-graded change

Finding absent : Other organs & tissues
Estrous cycle : Diestrus

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50654
Liver
Findings : Finding present
Dark brown
Non-graded change

Finding absent : Other organs & tissues
Estrous cycle : Diestrus

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50655
Finding absent : Liver, Other organs & tissues
Estrous cycle : Proestrus

Necropsy findings
Sex : Male Stage : Recovery Day 15 Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10104

Epididymis
Findings : Finding present
Yellowish white focus, cauda, unilateral
Non-graded change
Finding Comment : right epididymis, 5 x 3, mm

Finding absent : Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10106
Finding absent : Epididymis, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10108
Finding absent : Epididymis, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10110
Finding absent : Epididymis, Other organs & tissues

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10112
Finding absent : Epididymis, Other organs & tissues

Necropsy findings
Sex : Male Stage : Recovery Day 15 Species : Rat

Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 10404
Finding absent :	Epididymis, Other organs & tissues	
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 10406
Finding absent :	Epididymis, Other organs & tissues	
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 10407
Finding absent :	Epididymis, Other organs & tissues	
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 10409
Finding absent :	Epididymis, Other organs & tissues	
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 10412
Finding absent :	Epididymis, Other organs & tissues	

Necropsy findings
Sex : Female (satellite) Stage : Recovery Day 15 Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50556
Finding absent : All organs & tissues
Estrous cycle : Metestrus

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50557
Finding absent : All organs & tissues
Estrous cycle : Diestrus

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50558
Finding absent : All organs & tissues
Estrous cycle : Proestrus

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50559
Finding absent : All organs & tissues
Estrous cycle : Estrus

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50560
Finding absent : All organs & tissues
Estrous cycle : Diestrus

Necropsy findings
Sex : Female (satellite) Stage : Recovery Day 15 Species : Rat

Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50656
Finding absent :	All organs & tissues	
Estrous cycle : Proestrus		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50657
Finding absent :	All organs & tissues	
Estrous cycle : Metestrus		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50658
Finding absent :	All organs & tissues	
Estrous cycle : Diestrus		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50659
Finding absent :	All organs & tissues	
Estrous cycle : Diestrus		
Test article : EGEHE	Dose : 1000 mg/kg	Animal No. : 50660
Finding absent :	All organs & tissues	
Estrous cycle : Diestrus		

Organ weight
Sex : Male
Stage : Day 29
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Body weight	Liver		Kidney		Heart		Spleen	
		AB	RE	AB	RE	AB	RE	AB	RE
	g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
10101	406	9.05	2.23	2.64	0.65	1.25	0.31	643	158.37
10102	439	10.39	2.37	2.90	0.66	1.53	0.35	908	206.83
10103	513	13.74	2.68	3.31	0.65	1.48	0.29	703	137.04
10105	430	12.38	2.88	2.87	0.67	1.28	0.30	640	148.84
10107	487	11.60	2.38	3.25	0.67	1.37	0.28	876	179.88
10109	495	13.68	2.76	3.16	0.64	1.49	0.30	872	176.16
10111	481	13.74	2.86	3.55	0.74	1.39	0.29	711	147.82
n	7	7	7	7	7	7	7	7	7
Mean	464.4	12.083	2.594	3.097	0.669	1.399	0.303	764.7	164.991
S.D.	39.4	1.845	0.263	0.310	0.033	0.107	0.023	116.5	24.075

Animal No.	Thymus		Adrenal		Pituitary gland		Thyroid		Testis	
	AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	g	g/100g
10101	325	80.05	62	15.27	11.1	2.73	18.0	4.43	3.06	0.75
10102	331	75.40	74	16.86	11.3	2.57	17.3	3.94	3.31	0.75
10103	315	61.40	66	12.87	12.0	2.34	22.2	4.33	3.18	0.62
10105	468	108.84	64	14.88	12.6	2.93	23.5	5.47	3.02	0.70
10107	401	82.34	57	11.70	11.8	2.42	22.9	4.70	3.41	0.70
10109	421	85.05	68	13.74	10.5	2.12	20.8	4.20	3.09	0.62
10111	556	115.59	75	15.59	12.0	2.49	22.5	4.68	2.98	0.62
n	7	7	7	7	7	7	7	7	7	7
Mean	402.4	86.953	66.6	14.416	11.61	2.514	21.03	4.536	3.150	0.680
S.D.	88.5	18.965	6.4	1.757	0.70	0.264	2.46	0.490	0.159	0.060

Animal No.	Epididymis		Prostate		Seminal vesicle		Brain	
	AB	RE	AB	RE	AB	RE	AB	RE
	g	g/100g	mg	mg/100g	g	g/100g	g	g/100g
10101	1.12	0.28	693	170.69	2.75	0.68	2.01	0.50
10102	1.13	0.26	814	185.42	2.01	0.46	2.29	0.52
10103	1.20	0.23	550	107.21	1.85	0.36	2.27	0.44
10105	1.30	0.30	679	157.91	2.26	0.53	2.14	0.50
10107	1.34	0.28	772	158.52	2.29	0.47	2.37	0.49
10109	1.31	0.26	554	111.92	2.24	0.45	2.26	0.46
10111	1.35	0.28	535	111.23	1.93	0.40	2.23	0.46
n	7	7	7	7	7	7	7	7
Mean	1.250	0.270	656.7	143.271	2.190	0.479	2.224	0.481
S.D.	0.098	0.022	113.0	32.365	0.302	0.104	0.117	0.029

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Male
Stage : Day 29
Dose : EGEHE 100 mg/kg
Species : Rat

Animal No.	Body weight	Liver		Kidney		Heart		Spleen	
		AB	RE	AB	RE	AB	RE	AB	RE
	g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
10201	432	10.66	2.47	2.63	0.61	1.17	0.27	637	147.45
10202	516	15.31	2.97	3.35	0.65	1.77	0.34	702	136.05
10203	499	13.89	2.78	3.26	0.65	1.47	0.29	784	157.11
10204	487	12.68	2.60	3.33	0.68	1.53	0.31	957	196.51
10205	481	14.09	2.93	3.59	0.75	1.51	0.31	854	177.55
10206	458	12.18	2.66	3.33	0.73	1.38	0.30	628	137.12
10207	450	10.87	2.42	3.17	0.70	1.31	0.29	613	136.22
10208	474	11.63	2.45	2.82	0.59	1.57	0.33	739	155.91
10209	450	12.71	2.82	3.07	0.68	1.44	0.32	601	133.56
10210	435	11.66	2.68	3.53	0.81	1.33	0.31	673	154.71
10211	471	11.35	2.41	3.07	0.65	1.39	0.30	665	141.19
10212	402	10.99	2.73	3.19	0.79	1.29	0.32	726	180.60
n	12	12	12	12	12	12	12	12	12
Mean	462.9	12.335	2.660	3.195	0.691	1.430	0.308	714.9	154.498
S.D.	31.6	1.456	0.195	0.274	0.068	0.156	0.019	106.5	20.512

Animal No.	Thymus		Adrenal		Pituitary gland		Thyroid		Testis	
	AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	g	g/100g
10201	393	90.97	61	14.12	10.3	2.38	21.7	5.02	3.64	0.84
10202	376	72.87	54	10.47	13.7	2.66	21.6	4.19	3.14	0.61
10203	652	130.66	77	15.43	15.5	3.11	23.9	4.79	3.37	0.68
10204	290	59.55	56	11.50	15.3	3.14	19.0	3.90	3.90	0.80
10205	472	98.13	77	16.01	11.8	2.45	19.1	3.97	3.56	0.74
10206	489	106.77	68	14.85	11.2	2.45	22.8	4.98	3.42	0.75
10207	292	64.89	55	12.22	8.3	1.84	17.4	3.87	2.87	0.64
10208	456	96.20	68	14.35	10.8	2.28	23.6	4.98	3.11	0.66
10209	278	61.78	48	10.67	9.6	2.13	23.5	5.22	2.54	0.56
10210	349	80.23	55	12.64	11.9	2.74	21.0	4.83	3.51	0.81
10211	315	66.88	69	14.65	11.1	2.36	19.1	4.06	3.28	0.70
10212	290	72.14	77	19.15	13.5	3.36	20.1	5.00	3.50	0.87
n	12	12	12	12	12	12	12	12	12	12
Mean	387.7	83.423	63.8	13.838	11.92	2.575	21.07	4.568	3.320	0.722
S.D.	112.5	21.569	10.2	2.494	2.20	0.447	2.14	0.519	0.365	0.096

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Male

Stage : Day 29
Dose : EGEHE 100 mg/kg

Species : Rat

	Epididymis		Prostate		Seminal vesicle		Brain	
	AB	RE	AB	RE	AB	RE	AB	RE
Animal No.	g	g/100g	mg	mg/100g	g	g/100g	g	g/100g
10201	1.42	0.33	985	228.01	2.72	0.63	2.02	0.47
10202	1.23	0.24	971	188.18	2.22	0.43	2.08	0.40
10203	1.29	0.26	692	138.68	2.58	0.52	2.25	0.45
10204	1.51	0.31	829	170.23	2.80	0.57	2.09	0.43
10205	1.45	0.30	774	160.91	2.12	0.44	2.16	0.45
10206	1.25	0.27	572	124.89	1.87	0.41	2.23	0.49
10207	1.13	0.25	576	128.00	2.01	0.45	2.23	0.50
10208	1.25	0.26	641	135.23	2.02	0.43	2.28	0.48
10209	1.01	0.22	679	150.89	2.22	0.49	2.12	0.47
10210	1.32	0.30	610	140.23	1.75	0.40	2.13	0.49
10211	1.25	0.27	785	166.67	1.89	0.40	2.24	0.48
10212	1.41	0.35	687	170.90	1.90	0.47	2.10	0.52
n	12	12	12	12	12	12	12	12
Mean	1.293	0.280	733.4	158.568	2.175	0.470	2.161	0.469
S.D.	0.141	0.038	139.7	29.329	0.349	0.072	0.083	0.033

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Male
Stage : Day 29
Dose : EGEHE 300 mg/kg
Species : Rat

Animal No.	Body weight	Liver		Kidney		Heart		Spleen	
		AB	RE	AB	RE	AB	RE	AB	RE
	g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
10301	468	13.78	2.94	3.22	0.69	1.39	0.30	739	157.91
10302	456	13.09	2.87	3.43	0.75	1.40	0.31	670	146.93
10303	478	12.48	2.61	3.18	0.67	1.55	0.32	734	153.56
10304	443	12.35	2.79	3.13	0.71	1.35	0.30	752	169.75
10305	443	12.08	2.73	3.26	0.74	1.37	0.31	596	134.54
10306	440	12.20	2.77	3.07	0.70	1.33	0.30	708	160.91
10307	431	11.43	2.65	3.02	0.70	1.30	0.30	741	171.93
10308	401	11.21	2.80	2.88	0.72	1.36	0.34	671	167.33
10309	464	12.48	2.69	3.22	0.69	1.38	0.30	798	171.98
10310	427	11.64	2.73	3.50	0.82	1.29	0.30	679	159.02
10311	501	13.67	2.73	3.78	0.75	1.40	0.28	742	148.10
10312	489	14.08	2.88	4.00	0.82	1.55	0.32	942	192.64
n	12	12	12	12	12	12	12	12	12
Mean	453.4	12.541	2.766	3.308	0.730	1.389	0.307	731.0	161.217
S.D.	28.3	0.938	0.097	0.322	0.049	0.083	0.015	84.5	15.047

Animal No.	Thymus		Adrenal		Pituitary gland		Thyroid		Testis	
	AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	g	g/100g
10301	305	65.17	57	12.18	13.7	2.93	27.0	5.77	3.60	0.77
10302	186	40.79	90	19.74	13.1	2.87	21.4	4.69	2.95	0.65
10303	505	105.65	54	11.30	9.9	2.07	23.0	4.81	2.38	0.50
10304	297	67.04	84	18.96	11.6	2.62	16.0	3.61	3.52	0.79
10305	324	73.14	73	16.48	11.5	2.60	18.6	4.20	3.56	0.80
10306	336	76.36	58	13.18	15.8	3.59	17.5	3.98	3.49	0.79
10307	355	82.37	55	12.76	12.0	2.78	16.0	3.71	2.87	0.67
10308	327	81.55	59	14.71	11.6	2.89	25.5	6.36	2.93	0.73
10309	232	50.00	62	13.36	11.7	2.52	24.5	5.28	3.30	0.71
10310	304	71.19	74	17.33	10.3	2.41	21.2	4.96	3.38	0.79
10311	467	93.21	81	16.17	9.4	1.88	20.7	4.13	3.62	0.72
10312	488	99.80	70	14.31	12.3	2.52	21.8	4.46	3.45	0.71
n	12	12	12	12	12	12	12	12	12	12
Mean	343.8	75.523	68.1	15.040	11.91	2.640	21.10	4.663	3.254	0.719
S.D.	97.9	18.962	12.3	2.703	1.74	0.438	3.58	0.832	0.386	0.085

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Male

Stage : Day 29
Dose : EGEHE 300 mg/kg

Species : Rat

	Epididymis		Prostate		Seminal vesicle		Brain	
	AB	RE	AB	RE	AB	RE	AB	RE
Animal No.	g	g/100g	mg	mg/100g	g	g/100g	g	g/100g
10301	1.37	0.29	596	127.35	1.76	0.38	2.26	0.48
10302	1.15	0.25	611	133.99	2.00	0.44	2.15	0.47
10303	0.88	0.18	716	149.79	1.86	0.39	2.03	0.42
10304	1.16	0.26	611	137.92	2.32	0.52	2.26	0.51
10305	1.26	0.28	659	148.76	1.95	0.44	2.29	0.52
10306	1.31	0.30	683	155.23	2.10	0.48	2.24	0.51
10307	1.19	0.28	598	138.75	1.97	0.46	2.23	0.52
10308	1.27	0.32	543	135.41	2.03	0.51	2.08	0.52
10309	1.23	0.27	537	115.73	1.57	0.34	2.28	0.49
10310	1.19	0.28	601	140.75	1.81	0.42	2.20	0.52
10311	1.69	0.34	822	164.07	2.50	0.50	2.20	0.44
10312	1.29	0.26	675	138.04	2.30	0.47	2.30	0.47
n	12	12	12	12	12	12	12	12
Mean	1.249	0.276	637.7	140.483	2.014	0.446	2.210	0.489
S.D.	0.185	0.040	79.3	12.784	0.262	0.056	0.085	0.034

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Male
Stage : Day 29
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Body weight	Liver		Kidney		Heart		Spleen	
		AB	RE	AB	RE	AB	RE	AB	RE
	g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
10401	396	12.46	3.15	2.85	0.72	1.25	0.32	714	180.30
10402	451	13.75	3.05	3.00	0.67	1.50	0.33	624	138.36
10403	415	11.99	2.89	2.83	0.68	1.30	0.31	661	159.28
10405	409	13.04	3.19	3.26	0.80	1.28	0.31	534	130.56
10408	407	13.97	3.43	3.23	0.79	1.38	0.34	691	169.78
10410	448	14.35	3.20	3.66	0.82	1.41	0.31	849	189.51
10411	453	14.80	3.27	4.09	0.90	1.46	0.32	745	164.46
n	7	7	7	7	7	7	7	7	7
Mean	425.6	13.480	3.169	3.274	0.769	1.369	0.320	688.3	161.750
S.D.	24.2	1.022	0.169	0.460	0.083	0.095	0.012	98.7	21.262

Animal No.	Thymus		Adrenal		Pituitary gland		Thyroid		Testis	
	AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	g	g/100g
10401	259	65.40	58	14.65	12.5	3.16	18.2	4.60	2.75	0.69
10402	385	85.37	78	17.29	13.0	2.88	20.9	4.63	3.28	0.73
10403	232	55.90	53	12.77	10.6	2.55	17.8	4.29	3.10	0.75
10405	228	55.75	68	16.63	11.1	2.71	17.4	4.25	3.39	0.83
10408	343	84.28	69	16.95	10.6	2.60	22.9	5.63	3.07	0.75
10410	303	67.63	69	15.40	12.1	2.70	15.5	3.46	3.06	0.68
10411	290	64.02	60	13.25	13.7	3.02	26.5	5.85	3.68	0.81
n	7	7	7	7	7	7	7	7	7	7
Mean	291.4	68.336	65.0	15.277	11.94	2.803	19.89	4.673	3.190	0.749
S.D.	58.0	12.146	8.4	1.802	1.21	0.225	3.80	0.827	0.295	0.056

Animal No.	Epididymis		Prostate		Seminal vesicle		Brain	
	AB	RE	AB	RE	AB	RE	AB	RE
	g	g/100g	mg	mg/100g	g	g/100g	g	g/100g
10401	1.05	0.27	638	161.11	1.97	0.50	2.19	0.55
10402	1.14	0.25	715	158.54	2.26	0.50	2.14	0.47
10403	1.09	0.26	340	81.93	1.74	0.42	2.06	0.50
10405	1.20	0.29	737	180.20	2.10	0.51	2.16	0.53
10408	1.26	0.31	700	171.99	2.01	0.49	2.27	0.56
10410	1.27	0.28	636	141.96	1.87	0.42	2.19	0.49
10411	1.39	0.31	563	124.28	2.30	0.51	2.29	0.51
n	7	7	7	7	7	7	7	7
Mean	1.200	0.281	618.4	145.716	2.036	0.479	2.186	0.516
S.D.	0.117	0.023	136.2	33.722	0.202	0.041	0.078	0.033

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Female
Stage : Day 5 after delivery
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Body weight g	Liver AB g	Liver RE g/100g	Kidney AB g	Kidney RE g/100g	Heart AB g	Heart RE g/100g	Spleen AB mg	Spleen RE mg/100g
50151	295 $	7.24 $	2.45 $	2.23 $	0.76 $	0.92 $	0.31 $	480 $	162.71 $
50152	306	10.57	3.45	2.40	0.78	1.13	0.37	673	219.93
50153	330	11.39	3.45	2.06	0.62	1.00	0.30	837	253.64
50154	332	10.44	3.14	2.13	0.64	0.98	0.30	570	171.69
50155	343	9.81	2.86	1.92	0.56	1.01	0.29	685	199.71
50156	279	9.87	3.54	2.00	0.72	1.03	0.37	581	208.24
50157	318	9.65	3.03	2.16	0.68	1.03	0.32	650	204.40
50158	307	9.74	3.17	2.26	0.74	1.03	0.34	459	149.51
50159	279	9.28	3.33	2.24	0.80	0.91	0.33	679	243.37
50160	353	12.25	3.47	2.21	0.63	1.07	0.30	578	163.74
50161	286	9.63	3.37	2.15	0.75	0.93	0.33	624	218.18
50162	330	10.68	3.24	2.35	0.71	1.02	0.31	564	170.91
n	11	11	11	11	11	11	11	11	11
Mean	314.8	10.301	3.277	2.171	0.694	1.013	0.324	627.3	200.302
S.D.	25.6	0.888	0.211	0.143	0.074	0.061	0.028	96.3	33.293

Animal No.	Thymus AB mg	Thymus RE mg/100g	Adrenal AB mg	Adrenal RE mg/100g	Pituitary gland AB mg	Pituitary gland RE mg/100g	Thyroid AB mg	Thyroid RE mg/100g	Ovary AB mg	Ovary RE mg/100g
50151	273 $	92.54 $	87 $	29.49 $	15.4 $	5.22 $	20.6 $	6.98 $	99 $	33.56 $
50152	179	58.50	66	21.57	17.2	5.62	14.3	4.67	124	40.52
50153	217	65.76	73	22.12	15.2	4.61	16.5	5.00	138	41.82
50154	245	73.80	75	22.59	20.1	6.05	12.4	3.73	109	32.83
50155	379	110.50	59	17.20	14.0	4.08	24.8	7.23	93	27.11
50156	173	62.01	62	22.22	13.7	4.91	23.6	8.46	109	39.07
50157	239	75.16	73	22.96	17.0	5.35	14.4	4.53	115	36.16
50158	155	50.49	75	24.43	16.8	5.47	16.1	5.24	124	40.39
50159	231	82.80	72	25.81	16.5	5.91	16.8	6.02	105	37.63
50160	274	77.62	72	20.40	16.1	4.56	16.8	4.76	109	30.88
50161	169	59.09	67	23.43	13.4	4.69	15.2	5.31	99	34.62
50162	240	72.73	68	20.61	19.1	5.79	25.5	7.73	113	34.24
n	11	11	11	11	11	11	11	11	11	11
Mean	227.4	71.678	69.3	22.122	16.28	5.185	17.85	5.698	112.5	35.934
S.D.	63.1	16.104	5.3	2.266	2.13	0.648	4.56	1.491	12.6	4.538

AB : Absolute weight, RE : Relative weight by body weight
Animal No. 50151 : Non-pregnancy
$: Excepted data from calculation

Organ weight
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 0 mg/kg

Species : Rat

	Uterus		Brain	
	AB	RE	AB	RE
Animal No.	mg	mg/100g	g	g/100g
50151	2696 $	913.90 $	2.25 $	0.76 $
50152	823	268.95	2.21	0.72
50153	846	256.36	1.93	0.58
50154	599	180.42	2.01	0.61
50155	661	192.71	1.98	0.58
50156	705	252.69	2.06	0.74
50157	669	210.38	1.96	0.62
50158	615	200.33	2.04	0.66
50159	715	256.27	1.96	0.70
50160	679	192.35	2.00	0.57
50161	620	216.78	2.08	0.73
50162	746	226.06	2.03	0.62
n	11	11	11	11
Mean	698.0	223.027	2.024	0.648
S.D.	80.9	30.990	0.077	0.064

AB : Absolute weight, RE : Relative weight by body weight
Animal No. 50151 : Non-pregnancy
$: Excepted data from calculation

Organ weight
Sex : Female
Stage : Day 5 after delivery
Dose : EGEHE 100 mg/kg
Species : Rat

Animal No.	Body weight g	Liver AB g	Liver RE g/100g	Kidney AB g	Kidney RE g/100g	Heart AB g	Heart RE g/100g	Spleen AB mg	Spleen RE mg/100g
50251	279 $	7.49 $	2.68 $	1.89 $	0.68 $	1.04 $	0.37 $	530 $	189.96 $
50252	291	9.38	3.22	2.10	0.72	0.86	0.30	677	232.65
50253	297	9.56	3.22	1.98	0.67	0.94	0.32	766	257.91
50254	307	9.80	3.19	2.14	0.70	0.97	0.32	726	236.48
50255	309	11.05	3.58	1.95	0.63	0.93	0.30	622	201.29
50256	336	11.27	3.35	2.30	0.68	1.04	0.31	620	184.52
50257	323	10.84	3.36	2.54	0.79	1.01	0.31	583	180.50
50258	309	11.20	3.62	2.11	0.68	1.09	0.35	680	220.06
50259	269	8.62	3.20	1.83	0.68	0.90	0.33	621	230.86
50260	324	10.93	3.37	2.07	0.64	0.91	0.28	634	195.68
50261	308	10.56	3.43	2.18	0.71	1.01	0.33	461	149.68
50262	332	10.15	3.06	2.60	0.78	1.02	0.31	663	199.70
n	11	11	11	11	11	11	11	11	11
Mean	309.5	10.305	3.327	2.164	0.698	0.971	0.315	641.2	208.121
S.D.	19.4	0.869	0.171	0.236	0.051	0.069	0.019	79.5	30.906

Animal No.	Thymus AB mg	Thymus RE mg/100g	Adrenal AB mg	Adrenal RE mg/100g	Pituitary gland AB mg	Pituitary gland RE mg/100g	Thyroid AB mg	Thyroid RE mg/100g	Ovary AB mg	Ovary RE mg/100g
50251	318 $	113.98 $	56 $	20.07 $	12.9 $	4.62 $	16.1 $	5.77 $	102 $	36.56 $
50252	331	113.75	78	26.80	17.7	6.08	18.7	6.43	109	37.46
50253	263	88.55	87	29.29	13.0	4.38	17.3	5.82	100	33.67
50254	243	79.15	61	19.87	18.5	6.03	15.9	5.18	108	35.18
50255	318	102.91	72	23.30	18.3	5.92	21.3	6.89	132	42.72
50256	186	55.36	73	21.73	17.0	5.06	20.7	6.16	120	35.71
50257	172	53.25	66	20.43	18.3	5.67	22.1	6.84	129	39.94
50258	299	96.76	86	27.83	17.9	5.79	18.5	5.99	102	33.01
50259	209	77.70	61	22.68	14.0	5.20	16.6	6.17	100	37.17
50260	166	51.23	66	20.37	15.5	4.78	18.3	5.65	138	42.59
50261	155	50.32	62	20.13	15.6	5.06	16.2	5.26	109	35.39
50262	333	100.30	100	30.12	14.0	4.22	21.4	6.45	154	46.39
n	11	11	11	11	11	11	11	11	11	11
Mean	243.2	79.025	73.8	23.868	16.35	5.290	18.82	6.076	118.3	38.112
S.D.	69.4	23.360	12.7	3.913	2.01	0.657	2.24	0.570	17.8	4.266

AB : Absolute weight, RE : Relative weight by body weight
Animal No. 50251 : Unsuccessful mating
$: Excepted data from calculation

Organ weight
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 100 mg/kg

Species : Rat

	Uterus		Brain	
	AB	RE	AB	RE
Animal No.	mg	mg/100g	g	g/100g
50251	1042 $	373.48 $	2.10 $	0.75 $
50252	718	246.74	1.86	0.64
50253	660	222.22	2.06	0.69
50254	721	234.85	2.02	0.66
50255	545	176.38	2.02	0.65
50256	724	215.48	1.98	0.59
50257	688	213.00	2.04	0.63
50258	728	235.60	2.05	0.66
50259	691	256.88	2.01	0.75
50260	773	238.58	1.96	0.60
50261	737	239.29	2.02	0.66
50262	667	200.90	2.12	0.64
n	11	11	11	11
Mean	695.6	225.447	2.013	0.652
S.D.	59.6	22.960	0.066	0.043

AB : Absolute weight, RE : Relative weight by body weight
Animal No. 50251 : Unsuccessful mating
$: Excepted data from calculation

Organ weight
Sex : Female
Stage : Day 5 after delivery
Dose : EGEHE 300 mg/kg
Species : Rat

Animal No.	Body weight g	Liver AB g	Liver RE g/100g	Kidney AB g	Kidney RE g/100g	Heart AB g	Heart RE g/100g	Spleen AB mg	Spleen RE mg/100g
50351	316	11.12	3.52	2.50	0.79	1.15	0.36	839	265.51
50352	303	10.00	3.30	2.29	0.76	0.91	0.30	604	199.34
50353	309	12.41	4.02	2.06	0.67	1.08	0.35	677	219.09
50354	277	10.24	3.70	1.87	0.68	0.91	0.33	623	224.91
50355	302	10.62	3.52	2.27	0.75	1.14	0.38	812	268.87
50356	305	10.48	3.44	2.15	0.70	0.93	0.30	710	232.79
50357	276	9.95	3.61	1.88	0.68	0.90	0.33	806	292.03
50358	276 $	6.98 $	2.53 $	1.88 $	0.68 $	0.86 $	0.31 $	467 $	169.20 $
50359	291	11.14	3.83	2.14	0.74	1.01	0.35	1009	346.74
50360	329	11.09	3.37	2.06	0.63	1.12	0.34	624	189.67
50361	286	8.79	3.07	1.89	0.66	0.95	0.33	704	246.15
50362	297	11.09	3.73	2.21	0.74	0.97	0.33	683	229.97
n	11	11	11	11	11	11	11	11	11
Mean	299.2	10.630	3.555	2.120	0.709	1.006	0.336	735.5	246.825
S.D.	16.1	0.923	0.264	0.196	0.050	0.099	0.024	121.1	44.849

Animal No.	Thymus AB mg	Thymus RE mg/100g	Adrenal AB mg	Adrenal RE mg/100g	Pituitary gland AB mg	Pituitary gland RE mg/100g	Thyroid AB mg	Thyroid RE mg/100g	Ovary AB mg	Ovary RE mg/100g
50351	304	96.20	87	27.53	21.8	6.90	22.7	7.18	177	56.01
50352	207	68.32	84	27.72	15.4	5.08	12.2	4.03	108	35.64
50353	260	84.14	74	23.95	19.0	6.15	14.2	4.60	110	35.60
50354	320	115.52	75	27.08	14.1	5.09	22.0	7.94	118	42.60
50355	251	83.11	70	23.18	17.7	5.86	15.6	5.17	135	44.70
50356	308	100.98	78	25.57	16.6	5.44	16.0	5.25	109	35.74
50357	322	116.67	65	23.55	15.0	5.43	14.9	5.40	101	36.59
50358	479 $	173.55 $	69 $	25.00 $	13.0 $	4.71 $	14.6 $	5.29 $	97 $	35.14 $
50359	250	85.91	73	25.09	17.4	5.98	14.8	5.09	126	43.30
50360	232	70.52	80	24.32	16.1	4.89	16.2	4.92	107	32.52
50361	230	80.42	77	26.92	16.7	5.84	17.4	6.08	98	34.27
50362	231	77.78	71	23.91	14.2	4.78	12.2	4.11	111	37.37
n	11	11	11	11	11	11	11	11	11	11
Mean	265.0	89.052	75.8	25.347	16.73	5.585	16.20	5.434	118.2	39.485
S.D.	41.1	16.434	6.3	1.703	2.25	0.634	3.43	1.210	22.2	6.760

AB : Absolute weight, RE : Relative weight by body weight
Animal No. 50358 : Non-pregnancy
$: Excepted data from calculation

Organ weight
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 300 mg/kg

Species : Rat

	Uterus		Brain	
	AB	RE	AB	RE
Animal No.	mg	mg/100g	g	g/100g
50351	656	207.59	1.97	0.62
50352	628	207.26	1.99	0.66
50353	632	204.53	2.06	0.67
50354	716	258.48	1.94	0.70
50355	649	214.90	2.09	0.69
50356	677	221.97	1.95	0.64
50357	639	231.52	1.79	0.65
50358	835 $	302.54 $	2.16 $	0.78 $
50359	758	260.48	1.98	0.68
50360	719	218.54	2.11	0.64
50361	597	208.74	2.10	0.73
50362	668	224.92	1.95	0.66
n	11	11	11	11
Mean	667.2	223.539	1.994	0.667
S.D.	47.3	19.629	0.094	0.031

AB : Absolute weight, RE : Relative weight by body weight
Animal No. 50358 : Non-pregnancy
$: Excepted data from calculation

Organ weight
Sex : Female
Stage : Day 5 after delivery
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Body weight g	Liver AB g	Liver RE g/100g	Kidney AB g	Kidney RE g/100g	Heart AB g	Heart RE g/100g	Spleen AB mg	Spleen RE mg/100g
50451	262	11.20	4.27	2.02	0.77	0.83	0.32	443	169.08
50452	291	12.19	4.19	2.11	0.73	0.91	0.31	533	183.16
50453	251 $	9.18 $	3.66 $	2.14 $	0.85 $	0.85 $	0.34 $	432 $	172.11 $
50454	295	13.41	4.55	2.27	0.77	0.96	0.33	577	195.59
50455	276	12.15	4.40	2.10	0.76	1.03	0.37	524	189.86
50456	316	12.59	3.98	2.49	0.79	0.97	0.31	548	173.42
50457	265	12.02	4.54	1.93	0.73	0.77	0.29	583	220.00
50458	269 $	10.29 $	3.83 $	2.05 $	0.76 $	0.81 $	0.30 $	431 $	160.22 $
50459	262	11.19	4.27	1.98	0.76	0.84	0.32	560	213.74
50460	277	12.92	4.66	2.06	0.74	0.93	0.34	519	187.36
50461	327	14.61	4.47	2.59	0.79	1.21	0.37	637	194.80
50462	238	9.83	4.13	2.01	0.84	0.73	0.31	504	211.76
n	10	10	10	10	10	10	10	10	10
Mean	280.9	12.211	4.346	2.156	0.768	0.918	0.327	542.8	193.877
S.D.	26.9	1.317	0.214	0.223	0.033	0.139	0.026	52.1	17.021

Animal No.	Thymus AB mg	Thymus RE mg/100g	Adrenal AB mg	Adrenal RE mg/100g	Pituitary gland AB mg	Pituitary gland RE mg/100g	Thyroid AB mg	Thyroid RE mg/100g	Ovary AB mg	Ovary RE mg/100g
50451	151	57.63	55	20.99	15.0	5.73	14.4	5.50	91	34.73
50452	288	98.97	81	27.84	14.4	4.95	16.1	5.53	100	34.36
50453	313 $	124.70 $	67 $	26.69 $	10.5 $	4.18 $	17.6 $	7.01 $	92 $	36.65 $
50454	204	69.15	78	26.44	14.9	5.05	26.2	8.88	107	36.27
50455	193	69.93	64	23.19	15.7	5.69	17.5	6.34	93	33.70
50456	278	87.97	68	21.52	16.4	5.19	17.6	5.57	99	31.33
50457	148	55.85	83	31.32	12.3	4.64	14.2	5.36	100	37.74
50458	294 $	109.29 $	73 $	27.14 $	12.9 $	4.80 $	16.4 $	6.10 $	74 $	27.51 $
50459	259	98.85	74	28.24	17.4	6.64	12.7	4.85	90	34.35
50460	182	65.70	87	31.41	16.1	5.81	14.1	5.09	87	31.41
50461	366	111.93	97	29.66	18.4	5.63	19.7	6.02	102	31.19
50462	276	115.97	67	28.15	12.5	5.25	21.9	9.20	100	42.02
n	10	10	10	10	10	10	10	10	10	10
Mean	234.5	83.195	75.4	26.876	15.31	5.458	17.44	6.234	96.9	34.710
S.D.	70.1	22.354	12.3	3.794	1.94	0.566	4.18	1.539	6.3	3.350

AB : Absolute weight, RE : Relative weight by body weight
Animal Nos. 50453 and 50458 : Non-pregnancy
$: Excepted data from calculation

Organ weight
Sex : Female

Stage : Day 5 after delivery
Dose : EGEHE 1000 mg/kg

Species : Rat

	Uterus		Brain	
	AB	RE	AB	RE
Animal No.	mg	mg/100g	g	g/100g
50451	715	272.90	2.08	0.79
50452	641	220.27	1.89	0.65
50453	906 $	360.96 $	1.99 $	0.79 $
50454	656	222.37	2.09	0.71
50455	627	227.17	1.91	0.69
50456	687	217.41	2.10	0.66
50457	653	246.42	1.88	0.71
50458	468 $	173.98 $	2.01 $	0.75 $
50459	580	221.37	2.07	0.79
50460	545	196.75	2.02	0.73
50461	536	163.91	1.89	0.58
50462	662	278.15	2.02	0.85
n	10	10	10	10
Mean	630.2	226.672	1.995	0.716
S.D.	59.1	33.640	0.092	0.079

AB : Absolute weight, RE : Relative weight by body weight
Animal Nos. 50453 and 50458 : Non-pregnancy
$: Excepted data from calculation

Organ weight
Sex : Female (satellite)
Stage : Day 29
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Body weight g	Liver AB g	Liver RE g/100g	Kidney AB g	Kidney RE g/100g	Heart AB g	Heart RE g/100g	Spleen AB mg	Spleen RE mg/100g
50551	271	7.04	2.60	2.02	0.75	0.80	0.30	553	204.06
50552	246	6.61	2.69	1.77	0.72	0.82	0.33	424	172.36
50553	256	6.52	2.55	1.72	0.67	0.91	0.36	517	201.95
50554	249	5.45	2.19	1.92	0.77	0.81	0.33	449	180.32
50555	231	6.37	2.76	2.04	0.88	0.81	0.35	461	199.57
n	5	5	5	5	5	5	5	5	5
Mean	250.6	6.398	2.558	1.894	0.758	0.830	0.334	480.8	191.652
S.D.	14.6	0.586	0.221	0.144	0.078	0.045	0.023	52.8	14.347

Animal No.	Thymus AB mg	Thymus RE mg/100g	Adrenal AB mg	Adrenal RE mg/100g	Pituitary gland AB mg	Pituitary gland RE mg/100g	Thyroid AB mg	Thyroid RE mg/100g	Ovary AB mg	Ovary RE mg/100g
50551	367	135.42	82	30.26	10.6	3.91	14.8	5.46	92	33.95
50552	234	95.12	71	28.86	13.1	5.33	14.0	5.69	106	43.09
50553	358	139.84	78	30.47	15.0	5.86	22.6	8.83	92	35.94
50554	293	117.67	76	30.52	12.6	5.06	9.5	3.82	75	30.12
50555	405	175.32	61	26.41	14.5	6.28	15.0	6.49	49	21.21
n	5	5	5	5	5	5	5	5	5	5
Mean	331.4	132.674	73.6	29.304	13.16	5.288	15.18	6.058	82.8	32.862
S.D.	67.7	29.635	8.1	1.755	1.74	0.903	4.71	1.828	21.9	8.040

Animal No.	Uterus AB mg	Uterus RE mg/100g	Brain AB g	Brain RE g/100g
50551	1162	428.78	1.99	0.73
50552	491	199.59	1.95	0.79
50553	898	350.78	2.10	0.82
50554	1150	461.85	1.97	0.79
50555	722	312.55	1.87	0.81
n	5	5	5	5
Mean	884.6	350.710	1.976	0.788
S.D.	286.8	103.369	0.083	0.035

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Female (satellite)
Stage : Day 29
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Body weight g	Liver AB g	Liver RE g/100g	Kidney AB g	Kidney RE g/100g	Heart AB g	Heart RE g/100g	Spleen AB mg	Spleen RE mg/100g
50651	243	8.35	3.44	1.74	0.72	0.78	0.32	412	169.55
50652	257	9.40	3.66	1.98	0.77	0.79	0.31	575	223.74
50653	227	7.99	3.52	1.72	0.76	0.74	0.33	427	188.11
50654	249	9.61	3.86	1.87	0.75	0.77	0.31	651	261.45
50655	244	8.44	3.46	1.84	0.75	0.77	0.32	380	155.74
n	5	5	5	5	5	5	5	5	5
Mean	244.0	8.758	3.588	1.830	0.750	0.770	0.318	489.0	199.718
S.D.	11.0	0.706	0.175	0.105	0.019	0.019	0.008	117.6	42.915

Animal No.	Thymus AB mg	Thymus RE mg/100g	Adrenal AB mg	Adrenal RE mg/100g	Pituitary gland AB mg	Pituitary gland RE mg/100g	Thyroid AB mg	Thyroid RE mg/100g	Ovary AB mg	Ovary RE mg/100g
50651	325	133.74	57	23.46	9.9	4.07	15.0	6.17	78	32.10
50652	479	186.38	74	28.79	14.2	5.53	17.6	6.85	97	37.74
50653	267	117.62	75	33.04	18.1	7.97	18.8	8.28	76	33.48
50654	352	141.37	86	34.54	16.4	6.59	14.7	5.90	79	31.73
50655	367	150.41	70	28.69	15.9	6.52	18.6	7.62	88	36.07
n	5	5	5	5	5	5	5	5	5	5
Mean	358.0	145.904	72.4	29.704	14.90	6.136	16.94	6.964	83.6	34.224
S.D.	77.7	25.628	10.5	4.341	3.12	1.445	1.96	0.992	8.8	2.601

Animal No.	Uterus AB mg	Uterus RE mg/100g	Brain AB g	Brain RE g/100g
50651	657	270.37	1.95	0.80
50652	994	386.77	1.95	0.76
50653	690	303.96	1.99	0.88
50654	566	227.31	1.93	0.78
50655	1044	427.87	1.97	0.81
n	5	5	5	5
Mean	790.2	323.256	1.958	0.806
S.D.	214.5	82.694	0.023	0.046

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Male
Stage : Recovery Day 15
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Body weight	Liver		Kidney		Heart		Spleen	
		AB	RE	AB	RE	AB	RE	AB	RE
	g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
10104	505	12.83	2.54	3.17	0.63	1.45	0.29	779	154.26
10106	500	11.45	2.29	3.09	0.62	1.44	0.29	909	181.80
10108	480	11.54	2.40	2.87	0.60	1.43	0.30	682	142.08
10110	487	11.95	2.45	2.74	0.56	1.42	0.29	884	181.52
10112	507	12.74	2.51	3.45	0.68	1.43	0.28	748	147.53
n	5	5	5	5	5	5	5	5	5
Mean	495.8	12.102	2.438	3.064	0.618	1.434	0.290	800.4	161.438
S.D.	11.8	0.652	0.099	0.275	0.044	0.011	0.007	94.9	18.958

Animal No.	Thymus		Adrenal		Pituitary gland		Thyroid		Testis	
	AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	g	g/100g
10104	327	64.75	57	11.29	14.4	2.85	20.1	3.98	3.36	0.67
10106	472	94.40	72	14.40	13.2	2.64	21.8	4.36	3.65	0.73
10108	451	93.96	50	10.42	11.3	2.35	27.1	5.65	3.35	0.70
10110	304	62.42	62	12.73	13.3	2.73	15.2	3.12	2.21	0.45
10112	279	55.03	70	13.81	12.6	2.49	26.1	5.15	3.68	0.73
n	5	5	5	5	5	5	5	5	5	5
Mean	366.6	74.112	62.2	12.530	12.96	2.612	22.06	4.452	3.250	0.656
S.D.	88.6	18.668	9.1	1.671	1.13	0.197	4.81	0.991	0.602	0.118

Animal No.	Epididymis		Prostate		Seminal vesicle		Brain	
	AB	RE	AB	RE	AB	RE	AB	RE
	g	g/100g	mg	mg/100g	g	g/100g	g	g/100g
10104	1.35	0.27	720	142.57	2.45	0.49	2.28	0.45
10106	1.41	0.28	1147	229.40	2.74	0.55	2.10	0.42
10108	1.44	0.30	952	198.33	2.20	0.46	2.13	0.44
10110	1.02	0.21	834	171.25	2.53	0.52	2.24	0.46
10112	1.34	0.26	866	170.81	2.76	0.54	2.42	0.48
n	5	5	5	5	5	5	5	5
Mean	1.312	0.264	903.8	182.472	2.536	0.512	2.234	0.450
S.D.	0.168	0.034	159.3	32.817	0.230	0.037	0.128	0.022

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Male
Stage : Recovery Day 15
Dose : EGEHE 1000 mg/kg
Species : Rat

Animal No.	Body weight	Liver		Kidney		Heart		Spleen	
		AB	RE	AB	RE	AB	RE	AB	RE
	g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
10404	495	12.42	2.51	3.58	0.72	1.40	0.28	694	140.20
10406	464	11.77	2.54	2.97	0.64	1.34	0.29	680	146.55
10407	457	11.33	2.48	3.34	0.73	1.43	0.31	712	155.80
10409	441	10.85	2.46	2.77	0.63	1.30	0.29	665	150.79
10412	483	13.23	2.74	3.08	0.64	1.46	0.30	700	144.93
n	5	5	5	5	5	5	5	5	5
Mean	468.0	11.920	2.546	3.148	0.672	1.386	0.294	690.2	147.654
S.D.	21.3	0.933	0.113	0.317	0.049	0.065	0.011	18.2	5.924

Animal No.	Thymus		Adrenal		Pituitary gland		Thyroid		Testis	
	AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	g	g/100g
10404	354	71.52	75	15.15	12.9	2.61	19.1	3.86	3.12	0.63
10406	262	56.47	58	12.50	13.6	2.93	20.4	4.40	3.13	0.67
10407	294	64.33	59	12.91	12.2	2.67	19.4	4.25	3.23	0.71
10409	337	76.42	57	12.93	12.3	2.79	21.0	4.76	3.30	0.75
10412	403	83.44	70	14.49	12.9	2.67	22.0	4.55	2.54	0.53
n	5	5	5	5	5	5	5	5	5	5
Mean	330.0	70.436	63.8	13.596	12.78	2.734	20.38	4.364	3.064	0.658
S.D.	54.5	10.469	8.2	1.154	0.56	0.128	1.18	0.339	0.302	0.084

Animal No.	Epididymis		Prostate		Seminal vesicle		Brain	
	AB	RE	AB	RE	AB	RE	AB	RE
	g	g/100g	mg	mg/100g	g	g/100g	g	g/100g
10404	1.41	0.28	363	73.33	2.23	0.45	2.22	0.45
10406	1.35	0.29	793	170.91	2.10	0.45	2.05	0.44
10407	1.20	0.26	891	194.97	2.55	0.56	2.29	0.50
10409	1.34	0.30	827	187.53	2.80	0.63	2.24	0.51
10412	1.08	0.22	634	131.26	2.28	0.47	2.37	0.49
n	5	5	5	5	5	5	5	5
Mean	1.276	0.270	701.6	151.600	2.392	0.512	2.234	0.478
S.D.	0.134	0.032	211.6	50.211	0.281	0.080	0.118	0.031

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Female (satellite)
Stage : Recovery Day 15
Dose : EGEHE 0 mg/kg
Species : Rat

Animal No.	Body weight	Liver		Kidney		Heart		Spleen	
		AB	RE	AB	RE	AB	RE	AB	RE
	g	g	g/100g	g	g/100g	g	g/100g	mg	mg/100g
50556	281	7.31	2.60	2.04	0.73	0.93	0.33	400	142.35
50557	265	6.91	2.61	1.88	0.71	0.87	0.33	454	171.32
50558	250	6.23	2.49	1.72	0.69	0.84	0.34	525	210.00
50559	273	7.11	2.60	1.83	0.67	0.94	0.34	664	243.22
50560	259	6.31	2.44	1.69	0.65	0.82	0.32	477	184.17
n	5	5	5	5	5	5	5	5	5
Mean	265.6	6.774	2.548	1.832	0.690	0.880	0.332	504.0	190.212
S.D.	12.0	0.482	0.078	0.140	0.032	0.053	0.008	100.1	38.359

Animal No.	Thymus		Adrenal		Pituitary gland		Thyroid		Ovary	
	AB	RE	AB	RE	AB	RE	AB	RE	AB	RE
	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g	mg	mg/100g
50556	244	86.83	61	21.71	15.7	5.59	20.5	7.30	142	50.53
50557	297	112.08	67	25.28	15.4	5.81	24.8	9.36	99	37.36
50558	307	122.80	91	36.40	17.9	7.16	12.7	5.08	66	26.40
50559	332	121.61	85	31.14	23.2	8.50	11.5	4.21	105	38.46
50560	311	120.08	64	24.71	14.2	5.48	15.1	5.83	74	28.57
n	5	5	5	5	5	5	5	5	5	5
Mean	298.2	112.680	73.6	27.848	17.28	6.508	16.92	6.356	97.2	36.264
S.D.	32.9	15.046	13.5	5.876	3.57	1.302	5.60	2.026	29.9	9.566

Animal No.	Uterus		Brain	
	AB	RE	AB	RE
	mg	mg/100g	g	g/100g
50556	454	161.57	1.93	0.69
50557	582	219.62	2.02	0.76
50558	1092	436.80	2.12	0.85
50559	608	222.71	2.08	0.76
50560	854	329.73	2.03	0.78
n	5	5	5	5
Mean	718.0	274.086	2.036	0.768
S.D.	254.3	109.359	0.072	0.057

AB : Absolute weight, RE : Relative weight by body weight

Organ weight
Sex : Female (satellite)

Stage : Recovery Day 15
Dose : EGEHE 1000 mg/kg

Species : Rat

Animal No.	Body weight g	Liver AB g	Liver RE g/100g	Kidney AB g	Kidney RE g/100g	Heart AB g	Heart RE g/100g	Spleen AB mg	Spleen RE mg/100g
50656	266	7.48	2.81	1.96	0.74	0.91	0.34	504	189.47
50657	253	7.23	2.86	1.97	0.78	0.83	0.33	509	201.19
50658	265	6.63	2.50	1.96	0.74	0.86	0.32	620	233.96
50659	260	6.59	2.53	1.98	0.76	0.89	0.34	650	250.00
50660	265	6.56	2.48	1.94	0.73	0.89	0.34	459	173.21
n	5	5	5	5	5	5	5	5	5
Mean	261.8	6.898	2.636	1.962	0.750	0.876	0.334	548.4	209.566
S.D.	5.4	0.427	0.183	0.015	0.020	0.031	0.009	82.1	31.724

Animal No.	Thymus AB mg	Thymus RE mg/100g	Adrenal AB mg	Adrenal RE mg/100g	Pituitary gland AB mg	Pituitary gland RE mg/100g	Thyroid AB mg	Thyroid RE mg/100g	Ovary AB mg	Ovary RE mg/100g
50656	281	105.64	74	27.82	14.7	5.53	17.8	6.69	98	36.84
50657	330	130.43	85	33.60	18.0	7.11	14.0	5.53	76	30.04
50658	335	126.42	61	23.02	14.8	5.58	9.8	3.70	126	47.55
50659	306	117.69	89	34.23	12.9	4.96	13.1	5.04	93	35.77
50660	297	112.08	64	24.15	13.1	4.94	12.3	4.64	92	34.72
n	5	5	5	5	5	5	5	5	5	5
Mean	309.8	118.452	74.6	28.564	14.70	5.624	13.40	5.120	97.0	36.984
S.D.	22.6	10.152	12.4	5.202	2.04	0.884	2.91	1.105	18.2	6.451

Animal No.	Uterus AB mg	Uterus RE mg/100g	Brain AB g	Brain RE g/100g
50656	1066	400.75	2.01	0.76
50657	353	139.53	2.11	0.83
50658	443	167.17	2.04	0.77
50659	434	166.92	1.82	0.70
50660	421	158.87	1.98	0.75
n	5	5	5	5
Mean	543.4	206.648	1.992	0.762
S.D.	294.3	109.087	0.108	0.047

AB : Absolute weight, RE : Relative weight by body weight

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10101

Liver
Findings : Finding present
Microgranuloma
Slight

Heart
Findings : Finding present
Inflammation, focal
Slight

Kidney
Findings : Finding present
Basophilic change, renal tubule
Slight

Prostate
Findings : Finding present
Inflammation, interstitium
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Urinary bladder, Testis, Epididymis, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10102

Prostate
Findings : Finding present
Inflammation, interstitium
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Testis, Epididymis, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10103

Lung
Findings : Finding present
Aggregation, macrophage, alveolar
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Parathyroid
Findings : Finding absent
Animal Comment : right parathyroid : missing

Eyeball
Findings : Finding present
Rosette, retina
Slight

Finding absent : Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Adrenal, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10105

Liver
Findings : Finding present
Vacuolation, hepatocyte, periportal
Slight

Heart
Findings : Finding present
Inflammation, focal
Slight

Prostate
Findings : Finding present
Inflammation, interstitium
Slight

Harderian gland
Findings : Finding present
Infiltration, inflammatory cell, focal
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Kidney, Urinary bladder, Testis, Epididymis, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10107

Liver
Findings : Finding present
Microgranuloma
Slight

Kidney
Findings : Finding present
Basophilic change, renal tubule
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10109

Liver
Findings : Finding present
Microgranuloma
Slight
Vacuolation, hepatocyte, periportal
Slight

Heart
Findings : Finding present
Inflammation, focal
Slight

Harderian gland
Findings : Finding present
Infiltration, inflammatory cell, focal
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Kidney, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10111

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10201
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10202
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10203
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10204
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10205
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10206
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10207
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10208
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10209
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10210
Finding absent : Liver

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10211

Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 10212

Finding absent : Liver

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10301
Finding absent : Liver

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10302
Liver
Findings : Finding present
Microgranuloma
Slight
Vacuolation, hepatocyte, periportal
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10303
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10304
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10305
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10306
Finding absent : Liver

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10307
Finding absent : Liver

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10308
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10309
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10310
Finding absent : Liver

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10311

Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 10312

Finding absent : Liver

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10401

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight
Microgranuloma
Slight

Kidney
Findings : Finding present
Basophilic change, renal tubule
Slight

Pituitary gland
Findings : Finding present
Cyst, pars distalis
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10402

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight
Microgranuloma
Slight

Heart
Findings : Finding present
Inflammation, focal
Slight

Kidney
Findings : Finding present
Basophilic change, renal tubule
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10403

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Parathyroid
Findings : Finding absent
Animal Comment : left parathyroid : missing

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10405

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Harderian gland
Findings : Finding present
Infiltration, inflammatory cell, focal
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Male Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10408

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight
Microgranuloma
Slight

Pituitary gland
Findings : Finding present
Cyst, pars distalis
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10410

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight
Microgranuloma
Mild

Prostate
Findings : Finding present
Inflammation, interstitium
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Testis, Epididymis, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10411

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight
Microgranuloma
Mild

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Testis, Epididymis, Prostate, Seminal vesicle, Coagulating gland, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50151 Non-pregnancy

Liver
Findings : Finding present
Microgranuloma
Slight

Uterine horn
Findings : Finding present
Infiltration, inflammatory cell
Mild

Uterine cervix
Findings : Finding present
Infiltration, inflammatory cell
Mild

Vagina
Findings : Finding present
Septum
Mild

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50152

Parathyroid
Findings : Finding absent
Animal Comment : left parathyroid : missing

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50153

Kidney
Findings : Finding present
Infiltration, inflammatory cell, renal pelvic mucosa
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50154

Liver
Findings : Finding present
Microgranuloma
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50155

Kidney
Findings : Finding present
Infarct
Mild

Thyroid
Findings : Finding present
Cyst
Slight

Eyeball
Findings : Finding present
Atrophy, retina, focal
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50156

Pituitary gland
Findings : Finding present
Cyst, pars distalis
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50157

Liver
Findings : Finding present
Microgranuloma
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50158

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50159

Liver
Findings : Finding present
Microgranuloma
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50160

Eyeball
Findings : Finding present
Atrophy, retina, focal
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50161

Pancreas
Findings : Finding present
Atrophy, acinar cell, focal
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50162

Parathyroid
Findings : Finding absent
Animal Comment : left parathyroid : missing

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50251 Unsuccessful mating
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50252
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50253
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50254
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50255
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50256
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50257
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50258
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50259
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50260
Liver
Findings : Finding present
Necrosis, focal
Slight

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50261
Finding absent : Liver

Test article : EGEHE Dose : 100 mg/kg Animal No. : 50262
Finding absent : Liver

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50351
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50352
Finding absent : Liver

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50353
Liver
Findings : Finding present
Necrosis, focal
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50354
Finding absent : Liver

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50355
Finding absent : Liver

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50356
Finding absent : Liver

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50357
Finding absent : Liver

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50358 Non-pregnancy
Vagina
Findings : Finding present
Septum
Mild
Infiltration, inflammatory cell
Mild

Finding absent : Liver

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50359
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 300 mg/kg Animal No. : 50360
Liver
Findings : Finding present
Microgranuloma
Slight

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 50361	
Finding absent :	Liver		
Test article : EGEHE	Dose : 300 mg/kg	Animal No. : 50362	
Finding absent :	Liver		

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50451

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight

Peyer's patch
Findings : Finding present
Mineralization
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50452

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight
Microgranuloma
Slight

Harderian gland
Findings : Finding present
Infiltration, inflammatory cell
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50453 Non-pregnancy

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50454

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight
Microgranuloma
Slight

Peyer's patch
Findings : Finding present
Mineralization
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50455

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50456

Lung
Findings : Finding present
Aggregation, macrophage, alveolar
Slight

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight
Microgranuloma
Slight

Finding absent : Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50457

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50458 Non-pregnancy

Liver
Findings : Finding present
Microgranuloma
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50459

Liver
Findings : Finding present
Microgranuloma
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50460

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight

Peyer's patch
Findings : Finding present
Mineralization
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50461

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Femur
Findings : Finding present
Osteosclerosis
Mild

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Mammary gland

Histopathological findings
Sex : Female Stage : Day 5 after delivery Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50462

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight

Parathyroid
Findings : Finding absent
Animal Comment : left parathyroid : missing

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female (satellite) Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50551

Liver
Findings : Finding present
Vacuolation, hepatocyte, periportal
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50552

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50553

Liver
Findings : Finding present
Microgranuloma
Slight

Parathyroid
Findings : Finding absent
Animal Comment : left parathyroid : missing

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female (satellite) Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50554

Lung
Findings : Finding present
Aggregation, macrophage, alveolar
Slight

Kidney
Findings : Finding present
Basophilic change, renal tubule
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50555

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female (satellite) Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50651

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Liver, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50652

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50653

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight

Thyroid
Findings : Finding present
Ultimobranchial body
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Female (satellite) Stage : Day 29 Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50654

Lung
Findings : Finding present
Aggregation, macrophage, alveolar
Slight

Liver
Findings : Finding present
Hypertrophy, hepatocyte, centrilobular
Slight
Microgranuloma
Slight

Kidney
Findings : Finding present
Cyst
Slight
Basophilic change, renal tubule
Slight

Finding absent : Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50655

Liver
Findings : Finding present
Microgranuloma
Slight

Finding absent : Lung, Trachea, Submandibular gland, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Pancreas, Heart, Kidney, Urinary bladder, Ovary, Uterine horn, Uterine cervix, Vagina, Cerebrum, Cerebellum, Pons, Spinal cord, Sciatic nerve, Spleen, Thymus, Bone marrow, femur, Submandibular lymph node, Mesenteric lymph node, Peyer's patch, Pituitary gland, Thyroid, Parathyroid, Adrenal, Eyeball, Harderian gland, Skeletal muscle, Femur, Mammary gland

Histopathological findings
Sex : Male Stage : Recovery Day 15 Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10104

Epididymis
Findings : Finding present
Granuloma, spermatic
Slight

Finding absent : Liver

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10106

Liver
Findings : Finding present
Microgranuloma
Slight
Vacuolation, hepatocyte, periportal
Slight

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10108

Finding absent : Liver

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10110

Liver
Findings : Finding present
Microgranuloma
Mild

Test article : EGEHE Dose : 0 mg/kg Animal No. : 10112

Liver
Findings : Finding present
Microgranuloma
Slight

Histopathological findings
Sex : Male Stage : Recovery Day 15 Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10404

Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10406

Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10407

Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10409

Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 10412

Finding absent : Liver

Histopathological findings
Sex : Female (satellite) Stage : Recovery Day 15 Species : Rat

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50556
Finding absent : Liver

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50557
Finding absent : Liver

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50558
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50559
Finding absent : Liver

Test article : EGEHE Dose : 0 mg/kg Animal No. : 50560
Liver
Findings : Finding present
Microgranuloma
Slight

Histopathological findings
Sex : Female (satellite) Stage : Recovery Day 15 Species : Rat

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50656
Finding absent : Liver

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50657
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50658
Finding absent : Liver

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50659
Liver
Findings : Finding present
Microgranuloma
Slight

Test article : EGEHE Dose : 1000 mg/kg Animal No. : 50660
Liver
Findings : Finding present
Microgranuloma
Slight

Estrous cycles and copulation
Generation : F0 Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	/Before mating (day) 1	2	3	4	5	6	7	8	9	10	11	12	13	14	Length of estrous cycle (days)			Mean	Number of estrus	Animal with acyclic or irregular cycle
50151	D	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50152	P	E	M	D	P	E	M	D	P	E	M	D	D	D	4	4		4.0	3	-
50153	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50154	E	M	D	P	E	M	D	P	E	E	M	D	P	E	4	4	5	4.3	4	-
50155	E	M	D	P	E	M	D	P	E	M	D	P	E	M	4	4	4	4.0	4	-
50156	M	D	P	E	M	D	P	E	M	D	P	E	M	D	4	4		4.0	3	-
50157	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50158	E	M	D	P	E	M	D	P	E	M	D	P	E	M	4	4	4	4.0	4	-
50159	E	M	D	P	E	M	D	P	E	M	D	P	E	M	4	4	4	4.0	4	-
50160	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50161	E	M	D	P	E	M	D	P	E	M	D	P	E	M	4	4	4	4.0	4	-
50162	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-

P : Proestrus, E : Estrus, M : Metestrus, D : Diestrus
+ : Animal with acyclic or irregular cycle, - : Animal with normal and regular cycle

Estrous cycles and copulation

Generation : F0 Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	/Before mating (day) 1	2	3	4	5	6	7	8	9	10	11	12	13	14	Length of estrous cycle (days)			Mean	Number of estrus	Animal with acyclic or irregular cycle
50251	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50252	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50253	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50254	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50255	D	P	E	M	D	P	E	M	D	P	E	M	D	D	4	4		4.0	3	-
50256	E	M	D	P	E	M	D	P	E	M	D	P	E	M	4	4	4	4.0	4	-
50257	E	E	M	D	D	P	E	M	D	P	E	E	M	D	6	4		5.0	3	-
50258	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50259	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50260	M	D	P	E	M	D	D	E	M	D	P	E	M	D	4	4		4.0	3	-
50261	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50262	D	P	E	M	D	P	E	E	M	D	P	E	E	M	4	5		4.5	3	-

P : Proestrus, E : Estrus, M : Metestrus, D : Diestrus

+ : Animal with acyclic or irregular cycle, - : Animal with normal and regular cycle

Estrous cycles and copulation

Generation : F0 Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	/Before mating (day) 1	2	3	4	5	6	7	8	9	10	11	12	13	14	Length of estrous cycle (days)			Mean	Number of estrus	Animal with acyclic or irregular cycle
50351	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50352	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50353	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50354	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50355	M	D	P	E	M	D	P	E	M	D	P	E	M	D	4	4		4.0	3	-
50356	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50357	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50358	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50359	P	E	E	M	D	P	E	E	M	D	D	E	E	M	5	5		5.0	3	-
50360	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50361	D	P	E	M	D	P	E	M	D	P	E	M	D	D	4	4		4.0	3	-
50362	E	M	D	P	E	M	D	P	E	M	D	P	E	M	4	4	4	4.0	4	-

P : Proestrus, E : Estrus, M : Metestrus, D : Diestrus

+ : Animal with acyclic or irregular cycle, - : Animal with normal and regular cycle

Estrous cycles and copulation

Generation : F0 Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	/Before mating (day) 1	2	3	4	5	6	7	8	9	10	11	12	13	14	Length of estrous cycle (days)			Mean	Number of estrus	Animal with acyclic or irregular cycle
50451	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50452	D	P	E	M	D	D	P	E	M	D	P	E	M	D	5	4		4.5	3	-
50453	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50454	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50455	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50456	M	D	P	E	M	D	P	E	M	D	P	E	M	D	4	4		4.0	3	-
50457	M	D	P	E	M	D	P	E	M	D	P	E	M	D	4	4		4.0	3	-
50458	P	E	M	D	P	E	M	D	P	E	M	D	P	E	4	4	4	4.0	4	-
50459	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50460	D	P	E	M	D	P	E	M	D	P	E	M	D	P	4	4		4.0	3	-
50461	M	D	P	E	M	D	D	E	M	D	P	E	M	D	4	4		4.0	3	-
50462	E	M	D	P	E	M	D	P	E	M	D	P	E	M	4	4	4	4.0	4	-

P : Proestrus, E : Estrus, M : Metestrus, D : Diestrus

+ : Animal with acyclic or irregular cycle, - : Animal with normal and regular cycle

Estrous cycles and copulation
Generation : F0 Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	/1st mating (times) 1	2	3	4	5	6	7	8	9	10	11	12	13	14
50151	E													
	Y													
50152	D	D	D	D	D	D	D	D	D	E				
	N	N	N	N	N	N	N	N	N	Y				
50153	E													
	Y													
50154	E													
	Y													
50155	D	P	E											
	N	N	Y											
50156	P	E												
	N	Y												
50157	E													
	Y													
50158	D	P	E	M	D	P	E							
	N	N	N	N	N	N	Y							
50159	D	P	E											
	N	N	Y											
50160	M	D	P	E										
	N	N	N	Y										
50161	D	P	E											
	N	N	Y											
50162	M	D	P	E										
	N	N	N	Y										

Upper / P : Proestrus, E : Estrus, M : Metestrus, D : Diestrus
Lower / Y : Completion in copulation, N : Incompletion in copulation

Estrous cycles and copulation

Generation : F0 Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	/1st mating (times) 1	2	3	4	5	6	7	8	9	10	11	12	13	14
50251	M	D	P	E	M	D	D	D	D	D	D	D	D	D
	N	N	N	N	N	N	N	N	N	N	N	N	N	N
50252	M	D	P	E										
	N	N	N	Y										
50253	E													
	Y													
50254	M	D	P	E										
	N	N	N	Y										
50255	E													
	Y													
50256	D	P	E											
	N	N	Y											
50257	D	P	E											
	N	N	Y											
50258	M	D	P	E										
	N	N	N	Y										
50259	E													
	Y													
50260	P	E												
	N	Y												
50261	E													
	Y													
50262	D	P	E											
	N	N	Y											

Upper / P : Proestrus, E : Estrus, M : Metestrus, D : Diestrus

Lower / Y : Completion in copulation, N : Incompletion in copulation

Estrous cycles and copulation

Generation : F0 Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	/1st mating (times) 1	2	3	4	5	6	7	8	9	10	11	12	13	14
50351	M	D	P	E										
	N	N	N	Y										
50352	M	D	P	E										
	N	N	N	Y										
50353	E													
	Y													
50354	E													
	Y													
50355	P	E												
	N	Y												
50356	E													
	Y													
50357	E													
	Y													
50358	E													
	Y													
50359	D	P	P	E										
	N	N	N	Y										
50360	M	D	P	E										
	N	N	N	Y										
50361	E													
	Y													
50362	D	P	E											
	N	N	Y											

Upper / P : Proestrus, E : Estrus, M : Metestrus, D : Diestrus

Lower / Y : Completion in copulation, N : Incompletion in copulation

Estrous cycles and copulation
Generation : F0 Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	/1st mating (times) 1	2	3	4	5	6	7	8	9	10	11	12	13	14
50451	E													
	Y													
50452	P	E												
	N	Y												
50453	E													
	Y													
50454	M	D	P	E										
	N	N	N	Y										
50455	M	D	P	E										
	N	N	N	Y										
50456	P	E												
	N	Y												
50457	P	E												
	N	Y												
50458	M	D	D	D	D	D	D	D	D	D	D	D	E	
	N	N	N	N	N	N	N	N	N	N	N	N	Y	
50459	E													
	Y													
50460	E													
	Y													
50461	P	E												
	N	Y												
50462	D	P	E											
	N	N	Y											

Upper / P : Proestrus, E : Estrus, M : Metestrus, D : Diestrus
Lower / Y : Completion in copulation, N : Incompletion in copulation

Reproductive performance
Generation : F0 Sex : Male Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Day of conceiving	1st mating			2nd mating			Total	
		Paired animal	Copulation	Fertility	Paired animal	Copulation	Fertility	Copulation	Fertility
10101	1	50151	+	-	///	///	///	+	-
10102	10	50152	+	+	///	///	///	+	+
10103	1	50153	+	+	///	///	///	+	+
10104	1	50154	+	+	///	///	///	+	+
10105	3	50155	+	+	///	///	///	+	+
10106	2	50156	+	+	///	///	///	+	+
10107	1	50157	+	+	///	///	///	+	+
10108	7	50158	+	+	///	///	///	+	+
10109	3	50159	+	+	///	///	///	+	+
10110	4	50160	+	+	///	///	///	+	+
10111	3	50161	+	+	///	///	///	+	+
10112	4	50162	+	+	///	///	///	+	+
n	12		12	12		0	0	12	12
Mean	3.3								
S.D.	2.7								
No. of positives			12	11				12	11
%			100.0	91.7				100.0	91.7

/// : No need to input/measure

Reproductive performance
Generation : F0 Sex : Male Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Day of conceiving	1st mating			2nd mating			Total	
		Paired animal	Copulation	Fertility	Paired animal	Copulation	Fertility	Copulation	Fertility
10201	-	50251	-	///	///	///	///	-	///
10202	4	50252	+	+	///	///	///	+	+
10203	1	50253	+	+	///	///	///	+	+
10204	4	50254	+	+	///	///	///	+	+
10205	1	50255	+	+	///	///	///	+	+
10206	3	50256	+	+	///	///	///	+	+
10207	3	50257	+	+	///	///	///	+	+
10208	4	50258	+	+	///	///	///	+	+
10209	1	50259	+	+	///	///	///	+	+
10210	2	50260	+	+	///	///	///	+	+
10211	1	50261	+	+	///	///	///	+	+
10212	3	50262	+	+	///	///	///	+	+
n	11		12	11		0	0	12	11
Mean	2.5								
S.D.	1.3								
No. of positives			11	11				11	11
%			91.7	100.0				91.7	100.0

/// : No need to input/measure

Reproductive performance
Generation : F0 Sex : Male Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Day of conceiving	1st mating			2nd mating			Total	
		Paired animal	Copulation	Fertility	Paired animal	Copulation	Fertility	Copulation	Fertility
10301	4	50351	+	+	///	///	///	+	+
10302	4	50352	+	+	///	///	///	+	+
10303	1	50353	+	+	///	///	///	+	+
10304	1	50354	+	+	///	///	///	+	+
10305	2	50355	+	+	///	///	///	+	+
10306	1	50356	+	+	///	///	///	+	+
10307	1	50357	+	+	///	///	///	+	+
10308	1	50358	+	-	///	///	///	+	-
10309	4	50359	+	+	///	///	///	+	+
10310	4	50360	+	+	///	///	///	+	+
10311	1	50361	+	+	///	///	///	+	+
10312	3	50362	+	+	///	///	///	+	+
n	12		12	12		0	0	12	12
Mean	2.3								
S.D.	1.4								
No. of positives			12	11				12	11
%			100.0	91.7				100.0	91.7

/// : No need to input/measure

Reproductive performance
Generation : F0 Sex : Male Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Day of conceiving	1st mating			2nd mating			Total	
		Paired animal	Copulation	Fertility	Paired animal	Copulation	Fertility	Copulation	Fertility
10401	1	50451	+	+	///	///	///	+	+
10402	2	50452	+	+	///	///	///	+	+
10403	1	50453	+	-	///	///	///	+	-
10404	4	50454	+	+	///	///	///	+	+
10405	4	50455	+	+	///	///	///	+	+
10406	2	50456	+	+	///	///	///	+	+
10407	2	50457	+	+	///	///	///	+	+
10408	13	50458	+	-	///	///	///	+	-
10409	1	50459	+	+	///	///	///	+	+
10410	1	50460	+	+	///	///	///	+	+
10411	2	50461	+	+	///	///	///	+	+
10412	3	50462	+	+	///	///	///	+	+
n	12		12	12		0	0	12	12
Mean	3.0								
S.D.	3.3								
No. of positives			12	10				12	10
%			100.0	83.3				100.0	83.3

/// : No need to input/measure

Reproductive performance
Generation : F0 Sex : Female Dose : EGEHE 0 mg/kg Species : Rat

Animal No.	Day of conceiving	1st mating			2nd mating			Total	
		Paired animal	Copulation	Fertility	Paired animal	Copulation	Fertility	Copulation	Fertility
50151	1	10101	+	-	///	///	///	+	-
50152	10	10102	+	+	///	///	///	+	+
50153	1	10103	+	+	///	///	///	+	+
50154	1	10104	+	+	///	///	///	+	+
50155	3	10105	+	+	///	///	///	+	+
50156	2	10106	+	+	///	///	///	+	+
50157	1	10107	+	+	///	///	///	+	+
50158	7	10108	+	+	///	///	///	+	+
50159	3	10109	+	+	///	///	///	+	+
50160	4	10110	+	+	///	///	///	+	+
50161	3	10111	+	+	///	///	///	+	+
50162	4	10112	+	+	///	///	///	+	+
n	12		12	12		0	0	12	12
Mean	3.3								
S.D.	2.7								
No. of positives			12	11				12	11
%			100.0	91.7				100.0	91.7

/// : No need to input/measure

Reproductive performance
Generation : F0 Sex : Female Dose : EGEHE 100 mg/kg Species : Rat

Animal No.	Day of conceiving	1st mating			2nd mating			Total	
		Paired animal	Copulation	Fertility	Paired animal	Copulation	Fertility	Copulation	Fertility
50251	-	10201	-	///	///	///	///	-	///
50252	4	10202	+	+	///	///	///	+	+
50253	1	10203	+	+	///	///	///	+	+
50254	4	10204	+	+	///	///	///	+	+
50255	1	10205	+	+	///	///	///	+	+
50256	3	10206	+	+	///	///	///	+	+
50257	3	10207	+	+	///	///	///	+	+
50258	4	10208	+	+	///	///	///	+	+
50259	1	10209	+	+	///	///	///	+	+
50260	2	10210	+	+	///	///	///	+	+
50261	1	10211	+	+	///	///	///	+	+
50262	3	10212	+	+	///	///	///	+	+
n	11		12	11		0	0	12	11
Mean	2.5								
S.D.	1.3								
No. of positives			11	11				11	11
%			91.7	100.0				91.7	100.0

/// : No need to input/measure

Reproductive performance
Generation : F0 Sex : Female Dose : EGEHE 300 mg/kg Species : Rat

Animal No.	Day of conceiving	1st mating			2nd mating			Total	
		Paired animal	Copulation	Fertility	Paired animal	Copulation	Fertility	Copulation	Fertility
50351	4	10301	+	+	///	///	///	+	+
50352	4	10302	+	+	///	///	///	+	+
50353	1	10303	+	+	///	///	///	+	+
50354	1	10304	+	+	///	///	///	+	+
50355	2	10305	+	+	///	///	///	+	+
50356	1	10306	+	+	///	///	///	+	+
50357	1	10307	+	+	///	///	///	+	+
50358	1	10308	+	-	///	///	///	+	-
50359	4	10309	+	+	///	///	///	+	+
50360	4	10310	+	+	///	///	///	+	+
50361	1	10311	+	+	///	///	///	+	+
50362	3	10312	+	+	///	///	///	+	+
n	12		12	12		0	0	12	12
Mean	2.3								
S.D.	1.4								
No. of positives			12	11				12	11
%			100.0	91.7				100.0	91.7

/// : No need to input/measure

Reproductive performance
Generation : F0 Sex : Female Dose : EGEHE 1000 mg/kg Species : Rat

Animal No.	Day of conceiving	1st mating			2nd mating			Total	
		Paired animal	Copulation	Fertility	Paired animal	Copulation	Fertility	Copulation	Fertility
50451	1	10401	+	+	///	///	///	+	+
50452	2	10402	+	+	///	///	///	+	+
50453	1	10403	+	-	///	///	///	+	-
50454	4	10404	+	+	///	///	///	+	+
50455	4	10405	+	+	///	///	///	+	+
50456	2	10406	+	+	///	///	///	+	+
50457	2	10407	+	+	///	///	///	+	+
50458	13	10408	+	-	///	///	///	+	-
50459	1	10409	+	+	///	///	///	+	+
50460	1	10410	+	+	///	///	///	+	+
50461	2	10411	+	+	///	///	///	+	+
50462	3	10412	+	+	///	///	///	+	+
n	12		12	12		0	0	12	12
Mean	3.0								
S.D.	3.3								
No. of positives			12	10				12	10
%			100.0	83.3				100.0	83.3

/// : No need to input/measure

Delivery data
Generation : F0 Dose : EGEHE 0 mg/kg Species : Rat

Dam No.	Gestation period (day)	Number of implantation	Birth index (%)	Number of offspring	Number of live newborns			Number of dead newborns											
								Dead				Cannibalism				Total			
					M	F	Total	M	F	U	Total	M	F	U	Total	M	F	U	Total
50152	22	18(10/8)	100.0	18	11	7	18	0	0	0	0	0	0	0	0	0	0	0	0
50153	22	16(7/9)	87.5	14	8	6	14	0	0	0	0	0	0	0	0	0	0	0	0
50154	22	18(10/8)	94.4	17	6	11	17	0	0	0	0	0	0	0	0	0	0	0	0
50155	22	15(9/6)	86.7	15	9	4	13	2	0	0	2	0	0	0	0	2	0	0	2
50156	22	13(9/4)	92.3	12	8	4	12	0	0	0	0	0	0	0	0	0	0	0	0
50157	22	15(9/6)	100.0	15	7	8	15	0	0	0	0	0	0	0	0	0	0	0	0
50158	22	17(8/9)	100.0	17	12	5	17	0	0	0	0	0	0	0	0	0	0	0	0
50159	22	15(8/7)	93.3	14	6	8	14	0	0	0	0	0	0	0	0	0	0	0	0
50160	23	18(10/8)	88.9	16	5	11	16	0	0	0	0	0	0	0	0	0	0	0	0
50161	22	14(9/5)	100.0	14	9	5	14	0	0	0	0	0	0	0	0	0	0	0	0
50162	22	16(7/9)	87.5	14	9	5	14	0	0	0	0	0	0	0	0	0	0	0	0
n	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
Mean	22.09	15.9	93.69	15.1	8.2	6.7	14.9	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2
S.D.	0.30	1.7	5.57	1.8	2.1	2.5	1.9	0.6	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.6

(/) : Number of implantation Right/Left, M : Male, F : Female, U : Unable to be sexed

Delivery data
Generation : F0 Dose : EGEHE 100 mg/kg Species : Rat

Dam No.	Gestation period (day)	Number of implantation	Birth index (%)	Number of offspring	Number of live newborns			Number of dead newborns											
								Dead				Cannibalism				Total			
					M	F	Total	M	F	U	Total	M	F	U	Total	M	F	U	Total
50252	22	12(7/5)	91.7	11	3	8	11	0	0	0	0	0	0	0	0	0	0	0	0
50253	22	15(6/9)	100.0	15	6	9	15	0	0	0	0	0	0	0	0	0	0	0	0
50254	22	16(11/5)	93.8	15	8	7	15	0	0	0	0	0	0	0	0	0	0	0	0
50255	22	15(6/9)	93.3	14	7	7	14	0	0	0	0	0	0	0	0	0	0	0	0
50256	22	17(10/7)	100.0	17	8	9	17	0	0	0	0	0	0	0	0	0	0	0	0
50257	23	16(7/9)	87.5	14	9	5	14	0	0	0	0	0	0	0	0	0	0	0	0
50258	23	12(8/4)	91.7	11	8	3	11	0	0	0	0	0	0	0	0	0	0	0	0
50259	22	14(9/5)	71.4	10	4	6	10	0	0	0	0	0	0	0	0	0	0	0	0
50260	22	15(7/8)	100.0	15	5	10	15	0	0	0	0	0	0	0	0	0	0	0	0
50261	23	15(7/8)	100.0	15	6	9	15	0	0	0	0	0	0	0	0	0	0	0	0
50262	22	15(7/8)	93.3	14	7	7	14	0	0	0	0	0	0	0	0	0	0	0	0
n	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
Mean	22.27	14.7	92.97	13.7	6.5	7.3	13.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
S.D.	0.47	1.6	8.35	2.1	1.9	2.1	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

(/) : Number of implantation Right/Left, M : Male, F : Female, U : Unable to be sexed

Delivery data
Generation : F0 Dose : EGEHE 300 mg/kg Species : Rat

Dam No.	Gestation period (day)	Number of implantation	Birth index (%)	Number of offspring	Number of live newborns			Number of dead newborns											
								Dead				Cannibalism				Total			
					M	F	Total	M	F	U	Total	M	F	U	Total	M	F	U	Total
50351	23	18(7/11)	50.0	11	5	4	9	0	2	0	2	0	0	0	0	0	2	0	2
50352	22	16(9/7)	93.8	15	7	8	15	0	0	0	0	0	0	0	0	0	0	0	0
50353	23	16(8/8)	100.0	16	4	12	16	0	0	0	0	0	0	0	0	0	0	0	0
50354	22	13(8/5)	100.0	13	7	6	13	0	0	0	0	0	0	0	0	0	0	0	0
50355	23	14(12/2)	85.7	12	7	5	12	0	0	0	0	0	0	0	0	0	0	0	0
50356	22	16(8/8)	100.0	16	7	9	16	0	0	0	0	0	0	0	0	0	0	0	0
50357	22	15(9/6)	100.0	15	6	9	15	0	0	0	0	0	0	0	0	0	0	0	0
50359	23	16(5/11)	87.5	14	5	9	14	0	0	0	0	0	0	0	0	0	0	0	0
50360	22	18(8/10)	100.0	18	8	10	18	0	0	0	0	0	0	0	0	0	0	0	0
50361	23	14(10/4)	100.0	14	9	5	14	0	0	0	0	0	0	0	0	0	0	0	0
50362	23	15(9/6)	100.0	15	6	9	15	0	0	0	0	0	0	0	0	0	0	0	0
n	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
Mean	22.55	15.5	92.45	14.5	6.5	7.8	14.3	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2
S.D.	0.52	1.6	15.08	2.0	1.4	2.5	2.4	0.0	0.6	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.6

(/) : Number of implantation Right/Left, M : Male, F : Female, U : Unable to be sexed

Delivery data
Generation : F0 Dose : EGEHE 1000 mg/kg Species : Rat

Dam No.	Gestation period (day)	Number of implantation	Birth index (%)	Number of offspring	Number of live newborns			Number of dead newborns											
								Dead				Cannibalism				Total			
					M	F	Total	M	F	U	Total	M	F	U	Total	M	F	U	Total
50451	22	12(6/6)	91.7	11	4	7	11	0	0	0	0	0	0	0	0	0	0	0	0
50452	23	13(6/7)	38.5	11	2	3	5	2	4	0	6	0	0	0	0	2	4	0	6
50454	22	17(11/6)	100.0	17	8	9	17	0	0	0	0	0	0	0	0	0	0	0	0
50455	22	15(6/9)	100.0	15	9	6	15	0	0	0	0	0	0	0	0	0	0	0	0
50456	23	18(6/12)	88.9	16	5	11	16	0	0	0	0	0	0	0	0	0	0	0	0
50457	22	16(13/3)	87.5	16	5	9	14	1	1	0	2	0	0	0	0	1	1	0	2
50459	22	13(4/9)	100.0	13	8	5	13	0	0	0	0	0	0	0	0	0	0	0	0
50460	22	15(9/6)	93.3	14	10	4	14	0	0	0	0	0	0	0	0	0	0	0	0
50461	23	12(7/5)	83.3	10	6	4	10	0	0	0	0	0	0	0	0	0	0	0	0
50462	22	13(5/8)	92.3	12	5	7	12	0	0	0	0	0	0	0	0	0	0	0	0
n	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Mean	22.30	14.4	87.55	13.5	6.2	6.5	12.7	0.3	0.5	0.0	0.8	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.8
S.D.	0.48	2.1	18.15	2.5	2.5	2.6	3.5	0.7	1.3	0.0	1.9	0.0	0.0	0.0	0.0	0.7	1.3	0.0	1.9

(/) : Number of implantation Right/Left, M : Male, F : Female, U : Unable to be sexed

Delivery data
Generation : F0 Dose : EGEHE 0 mg/kg Species : Rat

Dam No.	Number of corpora lutea	Implantation index (%)
50151	Non-Pregnancy	
50152	18(10/8)	100.0
50153	18(8/10)	88.9
50154	18(10/8)	100.0
50155	15(9/6)	100.0
50156	13(9/4)	100.0
50157	15(9/6)	100.0
50158	17(8/9)	100.0
50159	17(9/8)	88.2
50160	18(10/8)	100.0
50161	14(9/5)	100.0
50162	17(8/9)	94.1
n	11	11
Mean	16.4	97.38
S.D.	1.8	4.71

(/) : Right/Left

Delivery data
Generation : F0 Dose : EGEHE 100 mg/kg Species : Rat

Dam No.	Number of corpora lutea	Implantation index (%)
50252	12(7/5)	100.0
50253	17(7/10)	88.2
50254	17(11/6)	94.1
50255	15(6/9)	100.0
50256	17(10/7)	100.0
50257	16(7/9)	100.0
50258	12(8/4)	100.0
50259	14(9/5)	100.0
50260	16(8/8)	93.8
50261	15(7/8)	100.0
50262	15(7/8)	100.0
n	11	11
Mean	15.1	97.83
S.D.	1.8	4.01

(/) : Right/Left

Delivery data
Generation : F0 Dose : EGEHE 300 mg/kg Species : Rat

Dam No.	Number of corpora lutea	Implantation index (%)
50351	19(8/11)	94.7
50352	16(9/7)	100.0
50353	16(8/8)	100.0
50354	13(8/5)	100.0
50355	16(12/4)	87.5
50356	18(9/9)	88.9
50357	16(9/7)	93.8
50358	Non-Pregnancy	
50359	18(6/12)	88.9
50360	19(8/11)	94.7
50361	14(10/4)	100.0
50362	15(9/6)	100.0
n	11	11
Mean	16.4	95.32
S.D.	2.0	5.06

(/) : Right/Left

Delivery data
Generation : F0 Dose : EGEHE 1000 mg/kg Species : Rat

Dam No.	Number of corpora lutea	Implantation index (%)
50451	12(6/6)	100.0
50452	13(6/7)	100.0
50453	Non-Pregnancy	
50454	17(11/6)	100.0
50455	17(7/10)	88.2
50456	18(6/12)	100.0
50457	16(13/3)	100.0
50458	Non-Pregnancy	
50459	13(4/9)	100.0
50460	16(9/7)	93.8
50461	12(7/5)	100.0
50462	13(5/8)	100.0
n	10	10
Mean	14.7	98.20
S.D.	2.3	4.02

(/) : Right/Left

Delivery data (external examination of offspring)
Generation : F0

Unit : Number of anomalous offspring (incidence %)
Dose : EGEHE 0 mg/kg

Day after birth : 0
Species : Rat

Dam No.	Number of offspring examined	/Findings
50152	18	No anomaly
50153	14	No anomaly
50154	17	No anomaly
50155	13	No anomaly
50156	12	No anomaly
50157	15	No anomaly
50158	17	No anomaly
50159	14	No anomaly
50160	16	No anomaly
50161	14	No anomaly
50162	14	No anomaly
Total	164	
n	11	
Mean		
S.D.		

Mean : Average of incidence (%)

Delivery data (external examination of offspring)
Generation : F0

Unit : Number of anomalous offspring (incidence %)
Dose : EGEHE 100 mg/kg

Day after birth : 0
Species : Rat

Dam No.	Number of offspring examined	/Findings
50252	11	No anomaly
50253	15	No anomaly
50254	15	No anomaly
50255	14	No anomaly
50256	17	No anomaly
50257	14	No anomaly
50258	11	No anomaly
50259	10	No anomaly
50260	15	No anomaly
50261	15	No anomaly
50262	14	No anomaly
Total	151	
n	11	
Mean		
S.D.		

Mean : Average of incidence (%)

Delivery data (external examination of offspring)
Generation : F0

Unit : Number of anomalous offspring (incidence %)
Dose : EGEHE 300 mg/kg

Day after birth : 0
Species : Rat

Dam No.	Number of offspring examined	/Findings
50351	9	No anomaly
50352	15	No anomaly
50353	16	No anomaly
50354	13	No anomaly
50355	12	No anomaly
50356	16	No anomaly
50357	15	No anomaly
50359	14	No anomaly
50360	18	No anomaly
50361	14	No anomaly
50362	15	No anomaly
Total	157	
n	11	
Mean		
S.D.		

Mean : Average of incidence (%)

Delivery data (external examination of offspring)
Generation : F0

Unit : Number of anomalous offspring (incidence %)
Dose : EGEHE 1000 mg/kg

Day after birth : 0
Species : Rat

Dam No.	Number of offspring examined	/Findings
50451	11	No anomaly
50452	5	No anomaly
50454	17	No anomaly
50455	15	No anomaly
50456	16	No anomaly
50457	14	No anomaly
50459	13	No anomaly
50460	14	No anomaly
50461	10	No anomaly
50462	12	No anomaly
Total	127	
n	10	
Mean		
S.D.		

Mean : Average of incidence (%)

Clinical sign of offspring
Generation : F0 Dose : EGEHE 0 mg/kg Species : Rat

Dam No.		Number of offspring	/Day after birth 0	1	2	3	4
50152	Alive :	Male	11	11	11	11	11
		Female	7	7	7	7	7
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	11/7	11/7	11/7	11/7	11/7
50153	Alive :	Male	8	8	8	8	8
		Female	6	6	6	6	6
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	8/6	8/6	8/6	8/6	8/6
50154	Alive :	Male	6	6	6	6	6
		Female	11	11	11	11	11
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	6/11	6/11	6/11	6/11	6/11
50155	Alive :	Male	9	9	9	9	9
		Female	4	4	4	4	4
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	9/4	9/4	9/4	9/4	9/4
50156	Alive :	Male	8	8	8	8	8
		Female	4	4	4	4	4
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	8/4	8/4	8/4	8/4	8/4
50157	Alive :	Male	7	7	7	7	7
		Female	8	8	8	8	7
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/1/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	7/8	7/8	7/8	7/8	7/7

(/) : Number of offspring Male/Female/Unable to be sexed

Clinical sign of offspring
Generation : F0 Dose : EGEHE 0 mg/kg Species : Rat

Dam No.		Number of offspring	/Day after birth 0	1	2	3	4
50158	Alive :	Male	12	12	12	12	12
		Female	5	5	5	5	5
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	12/5	12/5	12/5	12/5	12/5
50159	Alive :	Male	6	6	6	6	6
		Female	8	8	8	8	8
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	6/8	6/8	6/8	6/8	6/8
50160	Alive :	Male	5	5	5	5	5
		Female	11	11	11	11	11
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	5/11	5/11	5/11	5/11	5/11
50161	Alive :	Male	9	9	9	9	9
		Female	5	5	5	5	5
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	9/5	9/5	9/5	9/5	9/5
50162	Alive :	Male	9	9	9	9	8
		Female	5	5	5	5	5
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	1/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	9/5	9/5	9/5	9/5	8/5

(/) : Number of offspring Male/Female/Unable to be sexed

Clinical sign of offspring
Generation : F0 Dose : EGEHE 100 mg/kg Species : Rat

Dam No.		Number of offspring	/Day after birth 0	1	2	3	4
50252	Alive :	Male	3	3	3	3	3
		Female	8	8	8	8	8
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	3/8	3/8	3/8	3/8	3/8
50253	Alive :	Male	6	6	6	6	6
		Female	9	9	9	9	9
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	6/9	6/9	6/9	6/9	6/9
50254	Alive :	Male	8	8	8	8	8
		Female	7	7	7	7	7
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	8/7	8/7	8/7	8/7	8/7
50255	Alive :	Male	7	7	7	7	7
		Female	7	7	7	7	7
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	7/7	7/7	7/7	7/7	7/7
50256	Alive :	Male	8	8	8	8	8
		Female	9	9	9	9	9
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	8/9	8/9	8/9	8/9	8/9
50257	Alive :	Male	9	9	9	9	9
		Female	5	5	5	5	5
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	9/5	9/5	9/5	9/5	9/5

(/) : Number of offspring Male/Female/Unable to be sexed

Clinical sign of offspring
Generation : F0 Dose : EGEHE 100 mg/kg Species : Rat

Dam No.		Number of offspring	/Day after birth 0	1	2	3	4
50258	Alive :	Male	8	8	8	8	8
		Female	3	3	3	3	3
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	8/3	8/3	8/3	8/3	8/3
50259	Alive :	Male	4	4	4	4	4
		Female	6	6	6	6	6
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	4/6	4/6	4/6	4/6	4/6
50260	Alive :	Male	5	5	5	5	5
		Female	10	10	10	10	10
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	5/10	5/10	5/10	5/10	5/10
50261	Alive :	Male	6	6	6	6	6
		Female	9	9	9	9	9
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	6/9	6/9	6/9	6/9	6/9
50262	Alive :	Male	7	7	7	7	7
		Female	7	7	7	7	7
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	7/7	7/7	7/7	7/7	7/7

(/) : Number of offspring Male/Female/Unable to be sexed

Clinical sign of offspring
Generation : F0 Dose : EGEHE 300 mg/kg Species : Rat

Dam No.		Number of offspring	/Day after birth 0	1	2	3	4
50351	Alive :	Male	5	5	5	5	5
		Female	4	4	4	4	4
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	5/4	5/4	5/4	5/4	5/4
50352	Alive :	Male	7	7	7	7	7
		Female	8	8	8	8	8
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	7/8	7/8	7/8	7/8	7/8
50353	Alive :	Male	4	4	4	4	4
		Female	12	12	12	12	12
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	4/12	4/12	4/12	4/12	4/12
50354	Alive :	Male	7	7	7	7	7
		Female	6	6	6	6	6
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	7/6	7/6	7/6	7/6	7/6
50355	Alive :	Male	7	7	7	7	7
		Female	5	5	5	5	5
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	7/5	7/5	7/5	7/5	7/5
50356	Alive :	Male	7	7	7	7	7
		Female	9	9	9	9	9
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	7/9	7/9	7/9	7/9	7/9

(/) : Number of offspring Male/Female/Unable to be sexed

Clinical sign of offspring
Generation : F0 Dose : EGEHE 300 mg/kg Species : Rat

Dam No.		Number of offspring	/Day after birth 0	1	2	3	4
50357	Alive :	Male	6	6	6	6	6
		Female	9	9	9	9	9
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	6/9	6/9	6/9	6/9	6/9
50359	Alive :	Male	5	5	5	5	5
		Female	9	9	9	9	9
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	5/9	5/9	5/9	5/9	5/9
50360	Alive :	Male	8	8	8	8	8
		Female	10	10	10	10	9
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/1/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	8/10	8/10	8/10	8/10	8/9
50361	Alive :	Male	9	9	9	9	9
		Female	5	5	5	5	5
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	9/5	9/5	9/5	9/5	9/5
50362	Alive :	Male	6	6	6	6	6
		Female	9	9	9	9	9
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	6/9	6/9	6/9	6/9	6/9

(/) : Number of offspring Male/Female/Unable to be sexed

Clinical sign of offspring
Generation : F0 Dose : EGEHE 1000 mg/kg Species : Rat

Dam No.		Number of offspring	/Day after birth 0	1	2	3	4
50451	Alive :	Male	4	4	4	4	4
		Female	7	7	7	7	6
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/1/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	4/7	4/7	4/7	4/7	4/6
50452	Alive :	Male	2	2	2	2	1
		Female	3	3	3	3	3
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	1/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	2/3	2/3	2/3	2/3	1/3
50454	Alive :	Male	8	8	8	8	8
		Female	9	9	9	9	8
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/1/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	8/9	8/9	8/9	8/9	8/8
50455	Alive :	Male	9	9	9	9	8
		Female	6	6	6	6	6
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	1/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	9/6	9/6	9/6	9/6	8/6
50456	Alive :	Male	5	5	5	5	5
		Female	11	11	11	11	11
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	5/11	5/11	5/11	5/11	5/11
50457	Alive :	Male	5	5	5	5	5
		Female	9	9	9	9	9
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	5/9	5/9	5/9	5/9	5/9

(/) : Number of offspring Male/Female/Unable to be sexed

Clinical sign of offspring
Generation : F0 Dose : EGEHE 1000 mg/kg Species : Rat

Dam No.		Number of offspring	/Day after birth 0	1	2	3	4
50459	Alive :	Male	8	8	8	8	8
		Female	5	5	5	5	5
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	8/5	8/5	8/5	8/5	8/5
50460	Alive :	Male	10	10	10	10	9
		Female	4	4	4	4	4
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	1/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	10/4	10/4	10/4	10/4	9/4
50461	Alive :	Male	6	6	6	6	6
		Female	4	4	4	4	4
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	6/4	6/4	6/4	6/4	6/4
50462	Alive :	Male	5	5	5	5	5
		Female	7	7	7	7	7
	Dead :	Dead	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Unknown	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Cannibalism	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0
		Signs					
		No abnormality	5/7	5/7	5/7	5/7	5/7

(/) : Number of offspring Male/Female/Unable to be sexed

Litter size and viability index of offspring

Generation : F0 Dose : EGEHE 0 mg/kg Species : Rat

		/Day after birth				
		0	0	0	4	4
		All pups	Live pups	Viability	Live pups	Viability
Dam No.	Sex	Male/Female	Male/Female	index (%)	Male/Female	index (%)
50152	Total	18	18	100.0	18	100.0
		(11/7)	(11/7)		(11/7)	
50153	Total	14	14	100.0	14	100.0
		(8/6)	(8/6)		(8/6)	
50154	Total	17	17	100.0	17	100.0
		(6/11)	(6/11)		(6/11)	
50155	Total	15	13	86.7	13	100.0
		(11/4)	(9/4)		(9/4)	
50156	Total	12	12	100.0	12	100.0
		(8/4)	(8/4)		(8/4)	
50157	Total	15	15	100.0	14	93.3
		(7/8)	(7/8)		(7/7)	
50158	Total	17	17	100.0	17	100.0
		(12/5)	(12/5)		(12/5)	
50159	Total	14	14	100.0	14	100.0
		(6/8)	(6/8)		(6/8)	
50160	Total	16	16	100.0	16	100.0
		(5/11)	(5/11)		(5/11)	
50161	Total	14	14	100.0	14	100.0
		(9/5)	(9/5)		(9/5)	
50162	Total	14	14	100.0	13	92.9
		(9/5)	(9/5)		(8/5)	
Total		166	164		162	
Male/Female		92/74	90/74		89/73	
n		11	11	11	11	11
Mean				98.79		98.75
S.D.				4.01		2.79

Litter size and viability index of offspring

Generation : F0 Dose : EGEHE 100 mg/kg Species : Rat

Dam No.	Sex	/Day after birth 0 All pups Male/Female	0 Live pups Male/Female	0 Viability index (%)	4 Live pups Male/Female	4 Viability index (%)
50252	Total	11	11	100.0	11	100.0
		(3/8)	(3/8)		(3/8)	
50253	Total	15	15	100.0	15	100.0
		(6/9)	(6/9)		(6/9)	
50254	Total	15	15	100.0	15	100.0
		(8/7)	(8/7)		(8/7)	
50255	Total	14	14	100.0	14	100.0
		(7/7)	(7/7)		(7/7)	
50256	Total	17	17	100.0	17	100.0
		(8/9)	(8/9)		(8/9)	
50257	Total	14	14	100.0	14	100.0
		(9/5)	(9/5)		(9/5)	
50258	Total	11	11	100.0	11	100.0
		(8/3)	(8/3)		(8/3)	
50259	Total	10	10	100.0	10	100.0
		(4/6)	(4/6)		(4/6)	
50260	Total	15	15	100.0	15	100.0
		(5/10)	(5/10)		(5/10)	
50261	Total	15	15	100.0	15	100.0
		(6/9)	(6/9)		(6/9)	
50262	Total	14	14	100.0	14	100.0
		(7/7)	(7/7)		(7/7)	
Total		151	151		151	
Male/Female		71/80	71/80		71/80	
n		11	11	11	11	11
Mean				100.00		100.00
S.D.				0.00		0.00

Litter size and viability index of offspring

Generation : F0 Dose : EGEHE 300 mg/kg Species : Rat

Dam No.	Sex	/Day after birth 0 All pups Male/Female	0 Live pups Male/Female	0 Viability index (%)	4 Live pups Male/Female	4 Viability index (%)
50351	Total	11	9	81.8	9	100.0
		(5/6)	(5/4)		(5/4)	
50352	Total	15	15	100.0	15	100.0
		(7/8)	(7/8)		(7/8)	
50353	Total	16	16	100.0	16	100.0
		(4/12)	(4/12)		(4/12)	
50354	Total	13	13	100.0	13	100.0
		(7/6)	(7/6)		(7/6)	
50355	Total	12	12	100.0	12	100.0
		(7/5)	(7/5)		(7/5)	
50356	Total	16	16	100.0	16	100.0
		(7/9)	(7/9)		(7/9)	
50357	Total	15	15	100.0	15	100.0
		(6/9)	(6/9)		(6/9)	
50359	Total	14	14	100.0	14	100.0
		(5/9)	(5/9)		(5/9)	
50360	Total	18	18	100.0	17	94.4
		(8/10)	(8/10)		(8/9)	
50361	Total	14	14	100.0	14	100.0
		(9/5)	(9/5)		(9/5)	
50362	Total	15	15	100.0	15	100.0
		(6/9)	(6/9)		(6/9)	
Total		159	157		156	
Male/Female		71/88	71/86		71/85	
n		11	11	11	11	11
Mean				98.35		99.49
S.D.				5.49		1.69

Litter size and viability index of offspring

Generation : F0 Dose : EGEHE 1000 mg/kg Species : Rat

Dam No.	Sex	/Day after birth 0 All pups Male/Female	0 Live pups Male/Female	0 Viability index (%)	4 Live pups Male/Female	4 Viability index (%)
50451	Total	11	11	100.0	10	90.9
		(4/7)	(4/7)		(4/6)	
50452	Total	11	5	45.5	4	80.0
		(4/7)	(2/3)		(1/3)	
50454	Total	17	17	100.0	16	94.1
		(8/9)	(8/9)		(8/8)	
50455	Total	15	15	100.0	14	93.3
		(9/6)	(9/6)		(8/6)	
50456	Total	16	16	100.0	16	100.0
		(5/11)	(5/11)		(5/11)	
50457	Total	16	14	87.5	14	100.0
		(6/10)	(5/9)		(5/9)	
50459	Total	13	13	100.0	13	100.0
		(8/5)	(8/5)		(8/5)	
50460	Total	14	14	100.0	13	92.9
		(10/4)	(10/4)		(9/4)	
50461	Total	10	10	100.0	10	100.0
		(6/4)	(6/4)		(6/4)	
50462	Total	12	12	100.0	12	100.0
		(5/7)	(5/7)		(5/7)	
Total		135	127		122	
Male/Female		65/70	62/65		59/63	
n		10	10	10	10	10
Mean				93.30		95.12
S.D.				17.25		6.45

Body weight of offspring
Generation : F0 Dose : EGEHE 0 mg/kg Unit : g Species : Rat
/Day after birth

		0		4	
Dam No.	Sex	n	B.W.	n	B.W.
50152	Male	11	5.95	11	9.14
	Female	7	5.50	7	8.44
50153	Male	8	6.80	8	11.74
	Female	6	6.67	6	11.45
50154	Male	6	6.30	6	10.65
	Female	11	5.91	11	9.70
50155	Male	9	6.02	9	10.47
	Female	4	5.63	4	9.70
50156	Male	8	6.63	8	11.15
	Female	4	6.43	4	10.83
50157	Male	7	6.16	7	9.73
	Female	8	5.65	7	9.34
50158	Male	12	6.36	12	9.68
	Female	5	5.80	5	9.02
50159	Male	6	6.65	6	10.82
	Female	8	5.94	8	9.81
50160	Male	5	7.28	5	11.06
	Female	11	6.69	11	10.71
50161	Male	9	6.86	9	10.99
	Female	5	6.44	5	10.60
50162	Male	9	6.43	8	11.26
	Female	5	6.06	5	11.00
n	Male	90		89	
	Female	74		73	
Mean	Male		6.495		10.608
	Female		6.065		10.055
S.D.	Male		0.398		0.788
	Female		0.427		0.931

Body weight of offspring
Generation : F0 Dose : EGEHE 100 mg/kg Unit : g Species : Rat
/Day after birth

		0		4	
Dam No.	Sex	n	B.W.	n	B.W.
50252	Male	3	7.17	3	12.47
	Female	8	6.79	8	11.55
50253	Male	6	6.73	6	10.45
	Female	9	5.97	9	9.42
50254	Male	8	6.34	8	9.98
	Female	7	6.07	7	10.09
50255	Male	7	5.99	7	10.10
	Female	7	5.60	7	9.43
50256	Male	8	6.56	8	9.64
	Female	9	6.09	9	9.60
50257	Male	9	7.79	9	12.54
	Female	5	7.58	5	12.30
50258	Male	8	7.74	8	12.31
	Female	3	7.37	3	12.23
50259	Male	4	6.95	4	11.05
	Female	6	6.72	6	10.73
50260	Male	5	6.66	5	10.82
	Female	10	6.29	10	10.61
50261	Male	6	7.50	6	11.95
	Female	9	7.14	9	11.88
50262	Male	7	7.17	7	11.14
	Female	7	6.34	7	10.37
n	Male	71		71	
	Female	80		80	
Mean	Male		6.964		11.132
	Female		6.542		10.746
S.D.	Male		0.575		1.050
	Female		0.629		1.093

Body weight of offspring
Generation : F0 Dose : EGEHE 300 mg/kg Unit : g Species : Rat
/Day after birth

		0		4	
Dam No.	Sex	n	B.W.	n	B.W.
50351	Male	5	7.66	5	14.28
	Female	4	7.00	4	13.13
50352	Male	7	5.97	7	9.99
	Female	8	5.60	8	9.74
50353	Male	4	6.78	4	10.73
	Female	12	7.38	12	11.76
50354	Male	7	6.44	7	10.93
	Female	6	6.05	6	10.48
50355	Male	7	7.40	7	13.06
	Female	5	7.00	5	12.50
50356	Male	7	6.41	7	10.14
	Female	9	5.73	9	8.78
50357	Male	6	6.57	6	9.63
	Female	9	6.21	9	9.33
50359	Male	5	7.02	5	12.62
	Female	9	6.36	9	11.20
50360	Male	8	5.39	8	7.48
	Female	10	5.02	9	6.54
50361	Male	9	7.34	9	10.67
	Female	5	6.98	5	10.24
50362	Male	6	7.63	6	12.58
	Female	9	6.88	9	11.39
n	Male	71		71	
	Female	86		85	
Mean	Male		6.783		11.101
	Female		6.383		10.463
S.D.	Male		0.717		1.903
	Female		0.735		1.855

Body weight of offspring
Generation : F0 Dose : EGEHE 1000 mg/kg Unit : g Species : Rat
/Day after birth

		0		4	
Dam No.	Sex	n	B.W.	n	B.W.
50451	Male	4	5.93	4	10.05
	Female	7	5.69	6	9.43
50452	Male	2	5.95	1	11.70
	Female	3	7.03	3	11.80
50454	Male	8	4.96	8	7.58
	Female	9	4.81	8	6.93
50455	Male	9	5.49	8	10.29
	Female	6	5.15	6	9.38
50456	Male	5	6.04	5	10.06
	Female	11	5.80	11	9.70
50457	Male	5	5.44	5	9.38
	Female	9	5.00	9	8.81
50459	Male	8	6.08	8	9.96
	Female	5	5.58	5	9.32
50460	Male	10	5.78	9	10.41
	Female	4	5.63	4	9.93
50461	Male	6	7.45	6	12.73
	Female	4	6.78	4	11.80
50462	Male	5	5.40	5	8.20
	Female	7	5.40	7	8.44
n	Male	62		59	
	Female	65		63	
Mean	Male		5.852		10.036
	Female		5.687		9.554
S.D.	Male		0.664		1.493
	Female		0.718		1.454

Necropsy findings of offspring
Generation : F0 Dose : EGEHE 0 mg/kg Species : Rat

Dam No.	Number of live offspring examined on Day 4	/Findings	Number of dead offspring examined on Day 0-4	/Findings
50152	18	Absent	0	
50153	14	Absent	0	
50154	17	Absent	0	
50155	13	Absent	2	Absent (Day 0)
50156	12	Absent	0	
50157	14	Absent	1	Absent[a] (Day 4)
50158	17	Absent	0	
50159	14	Absent	0	
50160	16	Absent	0	
50161	14	Absent	0	
50162	13	Absent	1	Kidney, Dilatation, renal pelvis, bilateral (Day 4)
Total	162		4	
n	11		3	

a : Showed autolysis in abdominal cavity

Necropsy findings of offspring
Generation : F0 Dose : EGEHE 100 mg/kg Species : Rat

Dam No.	Number of live offspring examined on Day 4	/Findings	Number of dead offspring examined on Day 0-4	/Findings
50252	11	Absent	0	
50253	15	Absent	0	
50254	15	Absent	0	
50255	14	Absent	0	
50256	17	Absent	0	
50257	14	Absent	0	
50258	11	Absent	0	
50259	10	Absent	0	
50260	15	Absent	0	
50261	15	Absent	0	
50262	14	Absent	0	
Total	151		0	
n	11		0	

Necropsy findings of offspring
Generation : F0 Dose : EGEHE 300 mg/kg Species : Rat

Dam No.	Number of live offspring examined on Day 4	/Findings	Number of dead offspring examined on Day 0-4	/Findings
50351	9	Absent	2	Absent (Day 0)
50352	15	Absent	0	
50353	16	Absent	0	
50354	13	Absent	0	
50355	12	Absent	0	
50356	16	Absent	0	
50357	15	Absent	0	
50359	14	Absent	0	
50360	17	Absent	0	
50361	14	Absent	0	
50362	15	Absent	0	
Total	156		2	
n	11		1	

Necropsy findings of offspring
Generation : F0 Dose : EGEHE 1000 mg/kg Species : Rat

Dam No.	Number of live offspring examined on Day 4	/Findings	Number of dead offspring examined on Day 0-4	/Findings
50451	10	Absent	0	
50452	4	Absent	6	Absent (Day 0)
50454	16	Absent	1	Absent (Day 4)
50455	14	Absent	0	
50456	16	2; Kidney, Dilatation, renal pelvis, unilateral, 14; Absent	0	
50457	14	Absent	2	Absent (Day 0)
50459	13	Absent	0	
50460	13	Absent	0	
50461	10	Absent	0	
50462	12	Absent	0	
Total	122		9	
n	10		3	

最終報告書

試験名

投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験

著 者
[redacted]

試験終了日
2017 年 12 月 13 日

試験施設
株式会社日曹分析センター
〒250-0216　神奈川県小田原市高田 345

試験委託者
株式会社化合物安全性研究所
安全性研究部
〒004-0839 北海道札幌市清田区真栄 363 番地 24

試験番号
NCAS 17-209

TRUE COPY OF ORIGINAL
12/14/17 [redacted]

GLP 適合陳述書

試験番号： NCAS 17-209

試験名： 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験

この試験は、以下の GLP に従って実施した。
「新規化学物質等に係る試験を実施する試験施設に関する基準について」(平成 23 年 3 月 31 日 薬食発 0331 第 8 号、平成 23・03・29 製局第 6 号、環保企発第 110331010 号)

この試験はここに述べられた方法により行われ、この最終報告書は試験実施により得られた生データを正確に反映したものである。

試験責任者： [redacted] 2017 年 12 月 13 日

株式会社日曹分析センター 小田原事業所

信頼性保証書

試験番号： NCAS 17-209

試 験 名： 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験

上記試験の信頼性保証の監査または査察を適用 GLP および信頼性保証部門（QAU）の SOP に基づいて実施した。監査または査察の結果は、以下の日付で試験責任者および運営管理者に報告した。

監査または査察項目	日付（月/日/年）		
	監査または査察日	報告日	
		試験責任者	運営管理者
試験計画書	8/22/2017	8/22/2017	8/22/2017
実験操作			
・ IR スペクトル測定	8/28/2017	8/31/2017	8/31/2017
・ 標準溶液の調製	8/30, 31/2017	8/31/2017	8/31/2017
・ 模擬投与液の調製	8/30, 31/2017	8/31/2017	8/31/2017
・ 測定溶液の調製	8/30, 31/2017	8/31/2017	8/31/2017
・ GC 測定	8/30, 31/2017	8/31/2017	8/31/2017
・ 投与液の受領	9/13/2017	9/13/2017	9/13/2017
生データおよび関連試験資料	12/4-6/2017	12/6/2017	12/6/2017
報告書草案	12/4-6/2017	12/6/2017	12/6/2017
最終報告書	12/13/2017	12/13/2017	12/13/2017

QAU は、この試験が試験計画書および SOP に従って行われ、報告された方法や手段が実際に使われたものであり、結果は記録されたデータを正確に反映していることを確認した。

QAU 責任者 [redacted] 2017 年 12 月 13 日

（株）日曹分析センター

試験情報

試験番号： NCAS 17-209
試験名： 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験
報告書番号： NCAS 17-209

試験委託者： 株式会社化合物安全性研究所
安全性研究部
〒004-0839 北海道札幌市清田区真栄 363 番地 24
TEL 011-885-5031、FAX 011-885-5313
試験施設： 株式会社日曹分析センター 小田原事業所
〒250-0216 神奈川県小田原市高田 345
TEL 080-5969-3620、FAX 0465-42-3586

試験責任者：
試験従事者：

試験開始日： 2017 年 8 月 22 日
実験開始日： 2017 年 8 月 28 日
実験終了日： 2017 年 11 月 14 日
試験終了日： 2017 年 12 月 13 日

適用ガイドライン：なし
関連する試験：
試験番号 NCAS 17-208NG：投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの分析法検討および分析法確認試験
試験番号 SR17140：2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのラットにおける反復投与毒性・生殖発生毒性併合試験

試資料保管：
本試験に関する全ての文書は、当試験施設の資料室に該当通知後 10 年間保管する。その後の保管場所については、試験委託者と協議して決定する。被験物質は該当の通知後 10 年間または品質低下を起こさない期間のいずれか短い期間保管する。

SOP および試験計画書からの逸脱：
SOP および試験計画書からの逸脱はなかった。

試験成績の信頼性に影響を及ぼしたと思われる環境要因：
試験成績の信頼性に影響を及ぼしたと思われる環境要因はなかった。

目次

表紙 1
GLP 適合陳述書 2
信頼性保証書 3
試験情報 4
目次 5
目次(図・表) 6
概要 8
緒言 8
実験材料および方法 9
1. 測定対象物質 9
2. 標準物質 9
2.1. 標準物質 1 9
2.2. 標準物質 2 9
3. 試薬および機器 9
4. 投与液 10
5. 実験方法 10
5.1. 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの同一性・安定性確認 10
5.2. GC 条件 10
5.3. 検量線 11
5.4. 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性確認 11
5.5. 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度測定 13
6. 機器使用前点検 13
7. 統計処理 13
結果、考察および結論 14
1. 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの同一性・安定性確認 14
1.1. 同一性 14
1.2. 安定性 14
2. 検量線および機器使用前点検 14
3. 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性確認 14
3.1. 模擬投与液調製直後試料 14
3.2. 保存安定性確認試料 14
4. 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度測定 15
4.1. 2017 年 9 月 11 日に調製された投与液の測定結果 15
4.2. 2017 年 10 月 8 日に調製された投与液の測定結果 15
5. 中間報告 15

目次(図・表)

表 1 機器使用前点検結果 16
表 2 標準溶液の測定結果（測定日：2017 年 8 月 30 日） 16
表 3 標準溶液の測定結果（測定日：2017 年 9 月 8 日） 16
表 4 標準溶液の測定結果（測定日：2017 年 9 月 13 日） 17
表 5 標準溶液の測定結果（測定日：2017 年 10 月 10 日） 17
表 6 調製直後の安定性確認用模擬投与液の濃度測定結果（測定日：2017 年 8 月 30 日） .. 18
表 7 保存後の安定性確認用模擬投与液の濃度測定結果（測定日：2017 年 9 月 8 日） 18
表 8 2017 年 9 月 11 日調製投与液の濃度測定結果（測定日：2017 年 11 月 13 日） 19
表 9 2017 年 10 月 8 日調製投与液の濃度測定結果（測定日：2017 年 10 月 10 日） 19

図 1 試験委託者より提供された標準物質の IR スペクトル 20
図 2 模擬投与液調製前に測定した標準物質 (ロット番号：DSR0115) の IR スペクトル (測定日：2017 年 8 月 28 日) 20
図 3 模擬投与液調製前に測定した標準物質 (ロット番号：ECP4663) の IR スペクトル (測定日：2017 年 8 月 28 日) 21
図 4 毒性試験における投与終了後に測定した標準物質 (ロット番号：DSR0115) の IR スペクトル (測定日：2017 年 11 月 14 日) 21
図 5 毒性試験における投与終了後に測定した標準物質 (ロット番号：ECP4663) の IR スペクトル (測定日：2017 年 11 月 14 日) 22
図 6 機器使用前点検のクロマトグラムの一例（測定日：2017 年 8 月 30 日） 22
図 7 アセトンのクロマトグラム（測定日：2017 年 8 月 30 日） 23
図 8 標準溶液（濃度 1.958 mg/L）の代表的なクロマトグラム（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-5） 23
図 9 標準溶液（濃度 9.792 mg/L）の代表的なクロマトグラム（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-4） 24
図 10 標準溶液（濃度 48.96 mg/L）の代表的なクロマトグラム（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-3） 24
図 11 標準溶液（濃度 244.8 mg/L）の代表的なクロマトグラム（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-2） 25
図 12 標準溶液（濃度 1224 mg/L）の代表的なクロマトグラム（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-1） 25
図 13 調製直後安定性確認 20 mg/mL 模擬投与液のクロマトグラムの一例（測定日：2017 年 8 月 30 日、試料 ID：0830-20mgml-0D-001） 26
図 14 調製直後安定性確認 200 mg/mL 模擬投与液のクロマトグラムの一例（測定日：2017 年 8 月 30 日、試料 ID：0830-200mgml-0D-001） 26

図 15　保存後安定性確認 20 mg/mL 模擬投与液のクロマトグラムの一例
（測定日：2017 年 9 月 8 日、試料 ID：0830-20mgml-9D-001） 27
図 16　保存後安定性確認 200 mg/mL 模擬投与液のクロマトグラムの一例
（測定日：2017 年 9 月 8 日、試料 ID：0830-200mgml-9D-001） 27
図 17　2017 年 9 月 11 日調製 20 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 9 月 13 日、試料 ID：0913-20mgml-001） 28
図 18　2017 年 9 月 11 日調製 60 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 9 月 13 日、試料 ID：0913-60mgml-001） 28
図 19　2017 年 9 月 11 日調製 200 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 9 月 13 日、試料 ID：0913-200mgml-001） 29
図 20　2017 年 10 月 8 日調製 20 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 10 月 10 日、試料 ID：1010-20mgml-001） 29
図 21　2017 年 10 月 8 日調製 60 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 10 月 10 日、試料 ID：1010-60mgml-001） 30
図 22　2017 年 10 月 8 日調製 200 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 10 月 10 日、試料 ID：1010-200mgml-001） 30

添付資料 1: 中間報告書 No.1 31
添付資料 2: 中間報告書 No.2 32
添付資料 3: 中間報告書 No.3 33

概要

株式会社化合物安全性研究所の委託により、投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験を行った。

2017 年 8 月 28 日に測定した標準物質 (ロット番号 DSR0115 および ECP4663) の IR スペクトルは、試験委託者より提供された 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの IR スペクトルと吸収波数がほぼ一致し、同一性が確認された。また、実験終了時 (2017 年 11 月 14 日) に測定した標準物質の IR スペクトルと比較したところ、主な吸収波数が一致したので実験期間中の標準物質は安定であったと判断した。

投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性確認を行った結果、調製した模擬投与液中における 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの室温 (22.5～23.1℃) 保存 9 日間 (調製日を 0 日として起算) の安定性が確認された。

試験委託者より受領した投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノール濃度確認試験を行った。濃度測定は GC により行い、結果は以下の通りであった。

試験項目		設定濃度 mg/mL	投与液濃度 mg/mL	真度 (%)	相対標準偏差 (%)
2017 年 9 月 11 日 調製	20 mg/mL 投与液	20	18.0	90.0	0.6
	60 mg/mL 投与液	60	59.2	98.7	9.9
	200 mg/mL 投与液	200	191	95.5	1.9
2017 年 10 月 8 日 調製	20 mg/mL 投与液	20	19.0	95.0	1.0
	60 mg/mL 投与液	60	65.7	109.5	5.7
	200 mg/mL 投与液	200	214	107.0	4.9

毒性試験施設で調製した 20、60 および 200 mg/mL 投与液の濃度測定結果は、判定基準である設定濃度に対して 100±10%以内、相対標準偏差 10%以下であることが確認され、設定濃度に調製されたと判断し、得られた結果は有効とした。

緒言

株式会社化合物安全性研究所の委託により、測定対象物質である 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの同一性試験および安定性試験を実施し、また、投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験を実施したのでここに報告する。

実験材料および方法

1. 測定対象物質

化合物名： 2-[(2-エチルヘキサン-1-イル)オキシ]エタノール
CAS No.： 1559-35-9
分子式： $C_{10}H_{22}O_2$
分子量： 174.28
構造式：

2. 標準物質

2.1. 標準物質 1

化合物名： 2-[(2-エチルヘキサン-1-イル)オキシ]エタノール
純度： 99.7%（高純度品のため、定量計算では純度補正を実施しなかった。）
ロット番号： DSR0115
NCAS 検索番号： STD-1544
入手先： 株式会社化合物安全性研究所
入手日： 2017 年 7 月 6 日
入手量： 20 g
保存条件： 冷蔵、暗所
構造式や分子量等の情報は 1 項に記載した。

2.2. 標準物質 2

化合物名： 2-[(2-エチルヘキサン-1-イル)オキシ]エタノール
純度： 99.5%（高純度品のため、定量計算では純度補正を実施しなかった。）
ロット番号： ECP4663
NCAS 検索番号： STD-1550
入手先： 株式会社化合物安全性研究所
入手予定日： 2017 年 8 月 23 日
入手量： 10 g
保存条件： 冷蔵、暗所
備考： ロット番号 ECP4663 は、5.1 項の試験でのみ使用した。
構造式や分子量等の情報は 1 項に記載した。

3. 試薬および機器

トウモロコシ油： CP (Reagent)、ナカライテスク株式会社
アセトン： HPLC 用、和光純薬工業(株)
室温保管庫： SH-170F1NC、コクヨ
サーモレコーダー：TR-71U、(株) ティアンドデイ

天秤：　XP205、メトラー・トレド(株)
ガスクロマトグラフ (GC)：Agilent 7890GC、Agilent Technologies
水素発生装置：　NM-H100、(株)エアーテック
フーリエ変換赤外分光光度計 (FT-IR)：Spectrum One、PerkinElmer

4. 投与液

2017 年 9 月 13 日および 2017 年 10 月 10 日に、毒性試験施設で調製した 20、60 および 200 mg/mL の投与液を受領した。受領した試料は即日分析した。残余試料は室温 (1～30 °C) で保存し、試験終了後、試験委託者の了解を得て処分した。

2017 年 9 月 13 日入手投与液：　2017 年 9 月 11 日調製 (初回調製)
2017 年 10 月 10 日入手投与液：　2017 年 10 月 8 日調製 (雄の最終回調製)

5. 実験方法

5.1. 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの同一性・安定性確認

5.1.1 FT-IR 測定条件

測定法：　KBr 液膜法
測定波数：4000～400 cm^{-1}
積算回数：4
分解能：　4 cm^{-1}

5.1.2 同一性

5.4 項で実施された安定性試験における模擬投与液調製前 (2017 年 8 月 28 日) に、FT-IR (KBr 液膜法) を用いて、標準物質 2 ロットの IR スペクトルを測定し、試験委託者より提供されたスペクトルとの比較により同一性を確認した。

5.1.3 安定性

試験委託者が実施する毒性試験 (委託者試験番号 SR17140) における投与終了日以降 (2017 年 11 月 14 日) に、FT-IR を用いて標準物質 2 ロットの IR スペクトルを測定し、5.1.2 項のスペクトルと比較した。スペクトルが一致した場合に、実験期間中の標準物質は安定であったと判断した。

5.2. GC 条件

GC：	Agilent 7890 GC
カラム：	InertCap Pure WAX, 30 m×0.25 mm i.d., 膜厚 0.25 μm, GL Sciences
カラム温度：	初期温度 60 °C, 60→240 °C (20 °C /min), 最終温度 240 °C (5 分間保持)
注入口：	スプリットレス
注入口温度：	240 °C
検出器：	FID
検出器温度：	280 °C
検出器ガス：	水素 30 mL/min, 空気 400 mL/min

メークアップガス：窒素 25 mL/min
キャリアガス： ヘリウム 1 mL/min
注入量： 1 μL

5.3. 検量線

5.3.1 標準溶液の調製

下表に従い、1200 mg/L 標準溶液を調製した。

調製日	標準溶液 No.	標準物質秤取量(mg)	調製量(mL)	使用溶媒	調製濃度(mg/L)
2017 年 8 月 30 日	0830-SS-1	24.48	20	アセトン	1224
2017 年 9 月 8 日	0908-SS-1	24.34			1217
2017 年 9 月 13 日	0913-SS-1	24.14			1207
2017 年 10 月 10 日	1010-SS-1	24.24			1212

各調製日ごとに、1200 mg/L 標準溶液をアセトンで以下に示したように希釈し、各標準溶液を調製した。また、標準溶液 No.の『mmdd』は調製月日を意味する。

標準溶液 No.	使用標準溶液 No.	採取量(mL)	調製量(mL)
mmdd-SS-2	mmdd-SS-1	2	10
mmdd-SS-3	mmdd-SS-2	2	10
mmdd-SS-4	mmdd-SS-3	2	10
mmdd-SS-5	mmdd-SS-4	2	10

5.3.2 検量線試料の分析と回帰式の算出

5.3.1 項で調製した各標準溶液（mmdd-SS-1～5）とアセトン（ブランク試料）を 5.2 項記載の条件の GC で分析し、クロマトグラムより 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのピーク面積を求めた。

2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのピーク面積を縦軸に、標準溶液濃度 (mg/L) を横軸にとり、Microsoft Excel 2010 (SP2 MSO) を用いて検量線（重み付け：1/x）の回帰式および相関係数 (r) を求めた。さらに、検量線の各点について逆回帰値を算出し、設定値に対する真度 (%) を算出した。

検量線の判定基準は、相関係数が 0.990 以上、真度が最低濃度試料で±20%以内、それ以外の検量線試料で±15%以内とした。

5.4. 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性確認

5.4.1 概要

模擬投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度測定を行い、模擬投与液調製後、室温（1～30℃）保存 9 日間（調製日を 0 日として起算）の安定性を確認した。調製された模擬投与液の測定は以下の時点で行った。

・模擬投与液調製初日（調製直後試料）
・初日調製から 9 日経過後（保存安定性確認試料）

5.4.2 安定性確認用模擬投与液の調製方法

標準物質を次表のように秤取し、それぞれトウモロコシ油で 10 mL に定容して、20 およ

び 200 mg/mL の模擬投与液を調製した。

安定性確認用模擬投与液の調製は初日のみ実施した。調製直後に安定性確認用模擬投与液の前処理を実施し、2-[(2-エチルヘキサン-1-イル)オキシ]エタノール濃度測定を行った（2017 年 8 月 30 日実施）。残りの安定性確認用模擬投与液は室温下（室温保管庫）で 9 日間保存した（保存安定性確認試料）。保存後の試料は前処理を実施し、2-[(2-エチルヘキサン-1-イル)オキシ]エタノール濃度測定を行った（2017 年 9 月 8 日実施）。

標準物質秤取量 (mg)	トウモロコシ油定容量 (mL)	安定性確認用模擬投与液調製濃度 (mg/mL)
203.30	10	20.33
2006.3	10	200.6

5.4.3 前処理および濃度測定

5.4.2 項で調製した調製直後および 9 日間保存後の安定性確認用模擬投与液は、以下に従って前処理を行い測定溶液とした。

・20 mg/mL 模擬投与液

20 mg/mL 模擬投与液を 1 mL 採取し、アセトンで 100 mL に定容し、20 mg/mL 測定溶液とした（100 倍希釈）。これを 2 連で調製した。

・200 mg/mL 模擬投与液

200 mg/mL 模擬投与液を 0.5 mL 採取し、アセトンで 100 mL に定容し、200 mg/mL 測定溶液とした（200 倍希釈）。これを 2 連で調製した。

上記で調製した測定溶液を 5.2 項記載の条件の GC で分析し、クロマトグラムより 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのピーク面積を求めた。同日に作成した検量線の回帰式にピーク面積を代入し測定溶液濃度を算出した。測定溶液の検出濃度に希釈率をかけて、安定性確認用模擬投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノール濃度の定量値を算出した。

$$\text{各模擬投与液中の2-[(2-エチルヘキサン-1-イル)オキシ]エタノール濃度の定量値 (mg/mL)} = \frac{\text{検出濃度 (mg/L)} \times \text{希釈倍率}}{1000}$$

5.4.4 解析および評価

調製直後試料の平均濃度が設定濃度に対して 100±10%以内であれば、設定濃度に調製されたと判断し、得られた結果は有効とした。

調製直後および保存後の試料の測定で得られた濃度から次式より測定対象物質の変化率 (%) を算出した。判定基準は変化率 (%) が 100±10%以内の場合、安定であると判断した。

$$\text{変化率 (\%)} = \frac{\text{保存安定性確認試料の平均濃度}}{\text{調製直後試料の平均濃度}} \times 100$$

5.5. 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度測定

4 項で受領した各投与液を以下に従って希釈し、測定溶液とした。それぞれ 2 連で実施した。

• 20 mg/mL 投与液

20 mg/mL 投与液を 1 mL 採取し、アセトンで 100 mL に定容し、20 mg/mL 測定溶液とした（100 倍希釈）。

• 60 mg/mL 投与液

60 mg/mL 投与液を 1 mL 採取し、アセトンで 100 mL に定容し、60 mg/mL 測定溶液とした（100 倍希釈）。

• 200 mg/mL 投与液

200 mg/mL 投与液を 0.5 mL 採取し、アセトンで 100 mL に定容し、200 mg/mL 測定溶液とした（200 倍希釈）。

上記で調製した測定溶液を 5.2 項記載の条件の GC で分析し、クロマトグラムより 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのピーク面積を求めた。同日に作成した検量線の回帰式にピーク面積を代入し測定溶液濃度を算出した。下式に従い測定溶液の検出濃度より投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノール濃度を算出した（有効数字 4 桁）。この濃度の平均値が、設定濃度に対し 100±10%以内、相対標準偏差が 10%以下であれば設定濃度に調製されたと判断し、得られた結果は有効とした。各投与液の平均濃度を最終的な投与液濃度とした（有効数字 3 桁）。

$$\text{各投与液中の2-[(2-エチルヘキサン-1-イル)オキシ]エタノール濃度の定量値 (mg/mL)} = \frac{\text{検出濃度 (mg/L)} \times \text{希釈倍率}}{1000}$$

6. 機器使用前点検

GC 測定の前に、5.3.1 項に従って調製した最高濃度の検量線試料（mmdd-SS-1）を 3 回測定し、2-[(2-エチルヘキサン-1-イル)オキシ]エタノールのピーク面積を求めた。ピーク面積値の相対標準偏差が 10%以下の場合、異常なしと判断して測定を開始した。

7. 統計処理

結果の統計処理は、Microsoft Excel 2010 (SP2 MSO) を使用した。計算は Excel の最大精度をもって行なわれた。

結果、考察および結論

1. 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの同一性・安定性確認

1.1. 同一性

試験委託者より提供された IR スペクトルを図 1 に、本試験における模擬投与液調製前（2017 年 8 月 28 日）に測定した標準物質 2 ロットの IR スペクトルを図 2 および図 3 に示す。両者の吸収波数はほぼ一致しており、同一性が確認された。

1.2. 安定性

安定性確認時（2017 年 11 月 14 日）の標準物質 2 ロットの IR スペクトルを図 4 および図 5 に示す。同一性確認時における標準物質 2 ロットの IR スペクトルと比較した結果、主な吸収波数はほぼ一致したため、実験期間中の標準物質は安定であったと判断した。

2. 検量線および機器使用前点検

各測定日における機器使用前点検結果を表 1 に、機器使用前点検の代表的なクロマトグラムを図 6 に示す。各測定日における最高濃度の検量線試料（mmdd-SS-1）を 3 回測定して求めたピーク面積の相対標準偏差はすべて 10%以内であったので、異常なしと判断し濃度測定を実施した。

アセトン (ブランク試料) の代表的なクロマトグラムを図 7 に示す。各測定日において、2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの検出時間付近に定量を妨害するピークがないことを確認した。

各測定日における標準溶液の測定結果を表 2～表 5 に、標準溶液の代表的なクロマトグラムを図 8～図 12 に示す。各測定日における検量線の相関係数はすべて 0.990 以上、検量線試料の真度は±15%以内であり、検量線の判定基準を満たした。

3. 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性確認

3.1. 模擬投与液調製直後試料

調製直後の安定性確認用模擬投与液の濃度測定結果を表 6 に、代表的なクロマトグラムを図 13 および図 14 に示す。調製直後試料における 20 mg/mL 模擬投与液の 2 連測定の平均濃度は 20.75 mg/mL であり、理論濃度 (20.33 mg/mL) に対して 102.1%であった。また、200 mg/mL 模擬投与液の 2 連測定の平均濃度は 207.1 mg/mL であり、理論濃度 (200.6 mg/mL) に対して 103.2%であった。以上より、各模擬投与液は理論濃度に調製されたと判断し、得られた結果は有効とした。

3.2. 保存安定性確認試料

保存安定性確認試料の濃度測定結果を表 7 に、代表的なクロマトグラムを図 15 および図 16 に示す。保存後の 20 mg/mL 模擬投与液の 2 連測定の平均濃度は 20.35 mg/mL、200 mg/mL 模擬投与液の 2 連測定の平均濃度は 204.4 mg/mL であった。変化率は 20 mg/mL 模擬投与液で 98.1%、200 mg/mL 模擬投与液で 98.7%となり、安定性の判定基準（変化率が 100±10%）

を満たした。従って、20 mg/mL および 200 mg/mL 模擬投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールは、室温（1～30 °C）保存 9 日間（調製日を 0 日として起算）まで安定であることが確認された。なお、保存期間中の温度は、22.5～23.1 °C（室温）であった。

4. 投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度測定

4.1. 2017 年 9 月 11 日に調製された投与液の測定結果

2017 年 9 月 11 日に調製された投与液を測定した結果（測定日：2017 年 9 月 13 日）を表 8 に、20、60 および 200 mg/mL 投与液の代表的な測定溶液のクロマトグラムを図 17～図 19 に示す。毒性試験施設で調製した 20、60 および 200 mg/mL の投与液における 2 連測定の平均濃度は、それぞれ 18.0、59.2 および 191 mg/mL であった。これらの真度はそれぞれ 90.0%、98.7%および 95.5%であり、設定濃度±10%以内であることが確認された。また、相対標準偏差はそれぞれ 0.6%、9.9%および 1.9%であり、10%以内であった。以上の結果、各濃度の投与液は設定濃度に調製されたと判断し、得られた結果は有効とした。

4.2. 2017 年 10 月 8 日に調製された投与液の測定結果

2017 年 10 月 8 日に調製された投与液を測定した結果（測定日：2017 年 10 月 10 日）を表 9 に、20、60 および 200 mg/mL 投与液の代表的な測定溶液のクロマトグラムを図 20～図 22 に示す。毒性試験施設で調製した 20、60 および 200 mg/mL の投与液における 2 連測定の平均濃度は、それぞれ 19.0、65.7 および 214 mg/mL であった。これらの真度はそれぞれ 95.0%、109.5%および 107.0%であり、設定濃度±10%以内であることが確認された。また、相対標準偏差はそれぞれ 1.0%、5.7%および 4.9%であり、10%以内であった。以上の結果、各濃度の投与液は設定濃度に調製されたと判断し、得られた結果は有効とした。

5. 中間報告

各結果について、中間報告として作成した分析証明書を添付資料 1～添付資料 3 に示す。

表 1　機器使用前点検結果

測定日	試料 ID	ピーク面積	ピーク面積平均値	相対標準偏差 (%)
2017 年 8 月 30 日	0830-SS-1-001	13091.041	12992.126	1.7
	0830-SS-1-002	13146.444		
	0830-SS-1-003	12738.893		
2017 年 9 月 8 日	0908-SS-1-001	13603.836	13271.014	2.4
	0908-SS-1-002	13249.035		
	0908-SS-1-003	12960.170		
2017 年 9 月 13 日	0913-SS-1-001	11904.129	12599.144	6.3
	0913-SS-1-002	13470.860		
	0913-SS-1-003	12422.444		
2017 年 10 月 10 日	1010-SS-1-001	12640.516	13120.197	3.5
	1010-SS-1-002	13168.719		
	1010-SS-1-003	13551.355		

表 2　標準溶液の測定結果（測定日：2017 年 8 月 30 日）

試料 ID	標準溶液濃度 (mg/L)	ピーク面積	逆回帰値 (mg/L)	真度 (%)
0830-SS-1	1224	12564.305	1231	0.6
0830-SS-2	244.8	2444.641	239.8	-2.0
0830-SS-3	48.96	472.587	46.64	-4.7
0830-SS-4	9.792	93.211	9.479	-3.2
0830-SS-5	1.958	18.277	2.140	9.3
0830-blank	—	Not detected	—	—

Correlation coefficient：　0.9999
Slope：　10.21
Intercept：　-3.568

表 3　標準溶液の測定結果（測定日：2017 年 9 月 8 日）

試料 ID	標準溶液濃度 (mg/L)	ピーク面積	逆回帰値 (mg/L)	真度 (%)
0908-SS-1	1217	13181.074	1216	-0.1
0908-SS-2	243.4	2658.379	245.4	0.8
0908-SS-3	48.68	521.282	48.26	-0.9
0908-SS-4	9.736	102.664	9.640	-1.0
0908-SS-5	1.947	19.548	1.973	1.3
0908-blank	—	Not detected	—	—

Correlation coefficient：　1.0000
Slope：　10.84
Intercept：　-1.836

表 4　標準溶液の測定結果（測定日：2017 年 9 月 13 日）

試料 ID	標準溶液濃度 (mg/L)	ピーク面積	逆回帰値 (mg/L)	真度 (%)
0913-SS-1	1207	13727.056	1211	0.3
0913-SS-2	241.4	2708.078	239.2	-0.9
0913-SS-3	48.28	531.101	47.23	-2.2
0913-SS-4	9.656	104.102	9.571	-0.9
0913-SS-5	1.931	18.311	2.006	3.9
0913-blank	—	Not detected	—	—

Correlation coefficient : 1.0000
Slope : 11.34
Intercept : -4.434

表 5　標準溶液の測定結果（測定日：2017 年 10 月 10 日）

試料 ID	標準溶液濃度 (mg/L)	ピーク面積	逆回帰値 (mg/L)	真度 (%)
1010-SS-1	1212	11883.116	1192	-1.7
1010-SS-2	242.4	2576.122	258.3	6.6
1010-SS-3	48.48	526.609	52.69	8.7
1010-SS-4	9.696	98.550	9.744	0.5
1010-SS-5	1.939	18.034	1.665	-14.1
1010-blank	—	Not detected	—	—

Correlation coefficient : 0.9994
Slope : 9.967
Intercept : 1.434

表 6　調製直後の安定性確認用模擬投与液の濃度測定結果（測定日：2017 年 8 月 30 日）

試料 ID	模擬投与液理論濃度 (mg/mL)	希釈倍率	ピーク面積	検出濃度 (mg/L)	定量値 (mg/mL)	定量値の平均濃度 (mg/mL)	平均回収率 (%)
0830-20mgml-0D-001	20.33	100	2119.378	207.9	20.79	20.75	102.1
0830-20mgml-0D-002			2110.669	207.1	20.71		
0830-200mgml-0D-001	200.6	200	10515.179	1030	206.0	207.1	103.2
0830-200mgml-0D-002			10624.446	1041	208.2		

表 7　保存後の安定性確認用模擬投与液の濃度測定結果（測定日：2017 年 9 月 8 日）

試料 ID	調製直後試料の平均濃度 (mg/mL)	希釈倍率	ピーク面積	検出濃度 (mg/L)	定量値 (mg/mL)	定量値の平均濃度 (mg/mL)	変化率 (%)
0830-20mgml-9D-001	20.75	100	2154.199	198.9	19.89	20.35	98.1
0830-20mgml-9D-002			2252.421	208.0	20.80		
0830-200mgml-9D-001	207.1	200	11329.369	1045	209.1	204.4	98.7
0830-200mgml-9D-002			10819.624	998.3	199.7		

$$\text{変化率 (\%)} = \frac{\text{保存安定性確認試料の平均濃度}}{\text{調製直後試料の平均濃度}} \times 100$$

表 8　2017 年 9 月 11 日調製投与液の濃度測定結果（測定日：2017 年 9 月 13 日）

投与液濃度 (mg/mL)	測定試料 ID	希釈倍率	ピーク面積	検出濃度 (mg/L)	定量値 (mg/mL)	定量値の平均値 (mg/mL)	真度 (%)	相対標準偏差 (%)
20	0913-20mgml-001	100	2043.102	180.6	18.06	18.0	90.0	0.6
	0913-20mgml-002		2026.284	179.1	17.91			
60	0913-60mgml-001	100	6243.148	550.9	55.09	59.2	98.7	9.9
	0913-60mgml-002		7182.729	633.8	63.38			
200	0913-200mgml-001	200	10694.165	943.4	188.7	191	95.5	1.9
	0913-200mgml-002		10986.708	969.2	193.8			

表 9　2017 年 10 月 8 日調製投与液の濃度測定結果（測定日：2017 年 10 月 10 日）

投与液濃度 (mg/mL)	測定試料 ID	希釈倍率	ピーク面積	検出濃度 (mg/L)	定量値 (mg/mL)	定量値の平均値 (mg/mL)	真度 (%)	相対標準偏差 (%)
20	1010-20mgml-001	100	1878.082	188.3	18.83	19.0	95.0	1.0
	1010-20mgml-002		1904.724	191.0	19.10			
60	1010-60mgml-001	100	6810.390	683.1	68.31	65.7	109.5	5.7
	1010-60mgml-002		6283.156	630.3	63.03			
200	1010-200mgml-001	200	10272.133	1030.5	206.1	214	107.0	4.9
	1010-200mgml-002		11016.996	1105.2	221.0			

図 1　試験委託者より提供された標準物質の IR スペクトル

図 2　模擬投与液調製前に測定した標準物質 (ロット番号：DSR0115) の IR スペクトル
(測定日：2017 年 8 月 28 日)

図 3　模擬投与液調製前に測定した標準物質 (ロット番号:ECP4663) の IR スペクトル
(測定日：2017 年 8 月 28 日)

図 4　毒性試験における投与終了後に測定した標準物質 (ロット番号：DSR0115) の IR スペクトル
(測定日：2017 年 11 月 14 日)

図 5　毒性試験における投与終了後に測定した標準物質 (ロット番号：ECP4663) の IR スペクトル
(測定日：2017 年 11 月 14 日)

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.231	7.382	1.142	0.06
	4.614	13091.041	2403.060	99.94

図 6　機器使用前点検のクロマトグラムの一例（測定日：2017 年 8 月 30 日）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)

図 7　アセトンのクロマトグラム（測定日：2017 年 8 月 30 日）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.524	18.277	3.513	100.00

図 8　標準溶液（濃度 1.958 mg/L）の代表的なクロマトグラム
（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-5）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.523	93.211	17.219	100.00

図 9　標準溶液（濃度 9.792 mg/L）の代表的なクロマトグラム
（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-4）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.526	472.587	90.540	100.00

図 10　標準溶液（濃度 48.96 mg/L）の代表的なクロマトグラム
（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-3）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.537	2444.641	470.598	100.00

図 11　標準溶液（濃度 244.8 mg/L）の代表的なクロマトグラム
（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-2）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.224	6.872	1.083	0.05
	4.603	12564.305	2316.896	99.95

図 12　標準溶液（濃度 1224 mg/L）の代表的なクロマトグラム
（測定日：2017 年 8 月 30 日、試料 ID：0830-SS-1）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.535	2119.378	411.310	100.00

図 13　調製直後安定性確認 20 mg/mL 模擬投与液のクロマトグラムの一例
（測定日：2017 年 8 月 30 日、試料 ID：0830-20mgml-0D-001）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.221	6.281	1.200	0.06
	4.590	10515.179	2003.657	99.94

図 14　調製直後安定性確認 200 mg/mL 模擬投与液のクロマトグラムの一例
（測定日：2017 年 8 月 30 日、試料 ID：0830-200mgml-0D-001）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.509	2154.199	437.733	100.00

図 15　保存後安定性確認 20 mg/mL 模擬投与液のクロマトグラムの一例
（測定日：2017 年 9 月 8 日、試料 ID：0830-20mgml-9D-001）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.196	6.451	1.054	0.06
	4.572	11329.369	2148.004	99.94

図 16　保存後安定性確認 200 mg/mL 模擬投与液のクロマトグラムの一例
（測定日：2017 年 9 月 8 日、試料 ID：0830-200mgml-9D-001）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.485	2043.102	424.022	100.00

図 17　2017 年 9 月 11 日調製 20 mg/mL 投与液のクロマトグラムの一例
(測定日：2017 年 9 月 13 日、試料 ID：0913-20mgml-001)

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.169	3.907	0.691	0.06
	4.517	6243.148	1305.115	99.94

図 18　2017 年 9 月 11 日調製 60 mg/mL 投与液のクロマトグラムの一例
(測定日：2017 年 9 月 13 日、試料 ID：0913-60mgml-001)

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.177	6.789	1.178	0.06
	4.550	10694.165	2084.438	99.94

図 19　2017 年 9 月 11 日調製 200 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 9 月 13 日、試料 ID：0913-200mgml-001）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.473	1878.082	390.008	100.00

図 20　2017 年 10 月 8 日調製 20 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 10 月 10 日、試料 ID：1010-20mgml-001）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.163	3.865	0.730	0.06
	4.516	6810.390	1471.417	99.94

図 21　2017 年 10 月 8 日調製 60 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 10 月 10 日、試料 ID：1010-60mgml-001）

<Result>

Name	Time(min)	Aera(pA*s)	Height	Area(%)
	4.166	6.095	1.067	0.06
	4.537	10272.133	2054.253	99.94

図 22　2017 年 10 月 8 日調製 200 mg/mL 投与液のクロマトグラムの一例
（測定日：2017 年 10 月 10 日、試料 ID：1010-200mgml-001）

添付資料 1: 中間報告書 No.1

試験計画書番号 17-209

Page 1 of 1

中間報告書

No. 1

試験計画書番号　17-209

試験名　投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験

試験項目　投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性確認

・調製直後試料の評価

試料名	理論濃度 (mg/mL)	定量値の平均濃度 (mg/mL)	回収率 (%)	判定基準 (%)
20 mg/mL 模擬投与液 (調製直後試料)	20.33	20.75	102.1	100±10
200 mg/mL 模擬投与液 (調製直後試料)	200.6	207.1	103.2	

各模擬投与液中における 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度を分析した結果、すべてにおいて判定基準を満たしたため、すべての模擬投与液において設定濃度に調製されたことが確認された。

・保存安定性確認試料の評価

試料名	調製直後試料の平均濃度 (mg/mL)	保存安定性確認試料の平均濃度 (mg/mL)	変化率 (%)	判定基準 (%)
20 mg/mL 模擬投与液	20.75	20.35	98.1	100±10
200 mg/mL 模擬投与液	207.1	204.4	98.7	

各模擬投与液中における 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性を評価した結果、調製後室温保存 9 日間において判定基準を満たし、安定性が確認された。

試験責任者：[redacted]　日付 2017年9月8日

株式会社 日曹分析センター (NCAS)

〒250-0216　神奈川県小田原市高田 345 株式会社 日曹分析センター

添付資料 2: 中間報告書 No.2

試験計画書番号 17-209

Page 1 of 1

中間報告書

No. 2

試験計画書番号　17-209

試験名　投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験

試験項目　投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度測定

・投与液（2017 年 9 月 11 日調製）

試料名	設定濃度 (mg/mL)	定量値の平均濃度 (mg/mL)	真度 (%)	相対標準偏差 (%)
20 mg/mL 投与液	20	18.0	90.0	0.6
60 mg/mL 投与液	60	59.2	98.7	9.9
200 mg/mL 投与液	200	191	95.5	1.9

判定基準：真度が 100±10%以内、相対標準偏差が±10%以内

20、60 および 200 mg/mL 投与液中における 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度を分析した結果、すべてにおいて判定基準を満たしたため、すべての投与液において設定濃度に調製されたことが確認された。

試験責任者：[redacted]　日付 2017年 9月 13 日

株式会社 日曹分析センター (NCAS)

〒250-0216　神奈川県小田原市高田 345 株式会社 日曹分析センター

添付資料 3: 中間報告書 No.3

試験計画書番号 17-209

Page 1 of 1

中間報告書

No. 3

試験計画書番号　17-209

試験名　投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの安定性試験および濃度確認試験

試験項目　投与液中の 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度測定

・投与液（2017 年 10 月 8 日調製）

試料名	設定濃度 (mg/mL)	定量値の平均濃度 (mg/mL)	真度 (%)	相対標準偏差 (%)
20 mg/mL 投与液	20	19.0	95.0	1.0
60 mg/mL 投与液	60	65.7	109.5	5.7
200 mg/mL 投与液	200	214	107.0	~~5.0~~ 4.1

判定基準：真度が 100±10%以内、相対標準偏差が±10%以内　誤入力 10/10/2018 YT

20、60 および 200 mg/mL 投与液中における 2-[(2-エチルヘキサン-1-イル)オキシ]エタノールの濃度を分析した結果、すべてにおいて判定基準を満たしたため、すべての投与液において設定濃度に調製されたことが確認された。

試験責任者：[redacted]　日付 2017 4 10月 10 13

株式会社 日曹分析センター (NCAS)

〒250-0216　神奈川県小田原市高田 345 株式会社 日曹分析センター

Photo 1 Liver, Male (animal No. 10102), control group: Normal ×400 (H.E. stain)

Photo 2 Liver, Male (animal No. 10401), 1000 mg/kg group:
Hypertrophy, hepatocyte, centrilobular ×400 (H.E. stain)